0001193125-15-280728.txt : 20150806 0001193125-15-280728.hdr.sgml : 20150806 20150806144621 ACCESSION NUMBER: 0001193125-15-280728 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 24 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150806 DATE AS OF CHANGE: 20150806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ICAD INC CENTRAL INDEX KEY: 0000749660 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 020377419 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09341 FILM NUMBER: 151032560 BUSINESS ADDRESS: STREET 1: 98 SPIT BROOK ROAD, SUITE 100 CITY: NASHUA STATE: NH ZIP: 03062 BUSINESS PHONE: 603-882-5200 MAIL ADDRESS: STREET 1: 98 SPIT BROOK ROAD, SUITE 100 CITY: NASHUA STATE: NH ZIP: 03062 FORMER COMPANY: FORMER CONFORMED NAME: HOWTEK INC DATE OF NAME CHANGE: 19920703 10-Q 1 d89197d10q.htm FORM 10-Q Form 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number 001-09341

 

 

iCAD, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   02-0377419

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

98 Spit Brook Road, Suite 100, Nashua, NH   03062
(Address of principal executive offices)   (Zip Code)

(603) 882-5200

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirement for the past 90 days.    YES  x    NO  ¨.

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    YES  x    NO  ¨.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated filer   ¨    Accelerated filer   x
Non-accelerated filer   ¨  (do not check if a smaller reporting company)    Smaller reporting company   x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)    YES  ¨    NO  x.

As of the close of business on August 4, 2015 there were 15,720,547 shares outstanding of the registrant’s Common Stock, $.01 par value.

 

 

 


Table of Contents

iCAD, Inc.

INDEX

 

          Page  

PART I

  

FINANCIAL INFORMATION

  

Item 1

  

Financial Statements (unaudited)

  
  

Condensed Consolidated Balance Sheets as of June 30, 2015 and December 31, 2014

     3   
  

Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2015 and June  30, 2014

     4   
  

Condensed Consolidated Statements of Cash Flows for the three and six months ended June 30, 2015 and June  30, 2014

     5   
  

Notes to Condensed Consolidated Financial Statements

     6-25   

Item 2

  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     26-39   

Item 3

  

Quantitative and Qualitative Disclosures about Market Risk

     40   

Item 4

  

Controls and Procedures

     40   

PART II

  

OTHER INFORMATION

  

Item 1

  

Legal Proceedings

     41   

Item 1A

  

Risk Factors

     41   

Item 2

  

Unregistered Sales of Equity Securities and Use of Proceeds

     41   

Item 6

  

Exhibits

     42   
  

Signatures

     43   

 

2


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands except for share data)

 

     June 30,     December 31,  
     2015     2014  
Assets     

Current assets:

    

Cash and cash equivalents

   $ 18,208      $ 32,220   

Trade accounts receivable, net of allowance for doubtful accounts of $228 in 2015 and $203 in 2014

     7,764        9,642   

Inventory, net

     3,322        2,214   

Prepaid expenses and other current assets

     422        540   
  

 

 

   

 

 

 

Total current assets

     29,716        44,616   
  

 

 

   

 

 

 

Property and equipment, net of accumulated depreciation of $4,678 in 2015 and $4,861 in 2014

     2,861        4,255   

Other assets

     94        132   

Intangible assets, net of accumulated amortization of $10,492 in 2015 and $14,738 in 2014

     4,674        17,504   

Goodwill

     14,198        27,263   
  

 

 

   

 

 

 

Total assets

   $ 51,543      $ 93,770   
  

 

 

   

 

 

 
Liabilities and Stockholders’ Equity     

Current liabilities:

    

Accounts payable

   $ 1,804      $ 2,151   

Accrued and other expenses

     4,235        5,554   

Interest payable

     —          180   

Notes and lease payable - current portion

     1,251        5,044   

Deferred revenue

     8,049        9,120   
  

 

 

   

 

 

 

Total current liabilities

     15,339        22,049   
  

 

 

   

 

 

 

Deferred revenue, long-term portion

     633        1,525   

Other long-term liabilities

     639        795   

Capital lease - long-term portion

     488        1,020   

Notes payable - long-term portion

     —          5,602   
  

 

 

   

 

 

 

Total liabilities

     17,099        30,991   
  

 

 

   

 

 

 

Commitments and Contingencies (Note 8)

    

Stockholders’ equity:

    

Preferred stock, $ .01 par value: authorized 1,000,000 shares; none issued.

     —          —     

Common stock, $ .01 par value: authorized 20,000,000 shares; issued 15,906,378 in 2015 and 15,732,177 in 2014; outstanding 15,720,547 in 2015 and 15,546,346 in 2014

     159        157   

Additional paid-in capital

     210,406        209,100   

Accumulated deficit

     (174,706     (145,063

Treasury stock at cost, 185,831 shares in 2015 and 2014

     (1,415     (1,415
  

 

 

   

 

 

 

Total stockholders’ equity

     34,444        62,779   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 51,543      $ 93,770   
  

 

 

   

 

 

 

See accompanying notes to condensed consolidated financial statements.

 

3


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands except for per share data)

 

     Three Months Ended June 30,     Six Months Ended June 30,  
     2015     2014     2015     2014  

Revenue:

        

Products

   $ 3,096      $ 5,294      $ 7,054      $ 9,503   

Service and supplies

     8,047        4,373        17,309        8,684   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     11,143        9,667        24,363        18,187   

Cost of revenue:

        

Products

     680        1,390        1,621        2,570   

Service and supplies

     2,082        1,104        4,360        2,179   

Amortization and depreciation

     503        343        1,142        674   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total cost of revenue

     3,265        2,837        7,123        5,423   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     7,878        6,830        17,240        12,764   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating expenses:

        

Engineering and product development

     2,272        2,004        4,528        3,866   

Marketing and sales

     3,165        2,872        6,995        5,464   

General and administrative

     2,330        1,865        4,543        3,554   

Amortization and depreciation

     496        255        1,116        506   

Goodwill and long-lived asset impairment

     27,443        —          27,443        —     
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     35,706        6,996        44,625        13,390   
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

     (27,828     (166     (27,385     (626

Loss from extinguishment of debt

     —          (903     (1,723     (903

Gain from change in fair value of warrant

     —          699        —          1,835   

Interest expense

     (70     (614     (577     (1,431

Other income

     5        12        14        16   
  

 

 

   

 

 

   

 

 

   

 

 

 

Other expense, net

     (65     (806     (2,286     (483

Loss before income tax expense

     (27,893     (972     (29,671     (1,109

Tax benefit (expense)

     107        (25     28        (78
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss and comprehensive loss

   $ (27,786   $ (997   $ (29,643   $ (1,187
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share:

        

Basic

   $ (1.77   $ (0.07   $ (1.90   $ (0.09
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted

   $ (1.77   $ (0.07   $ (1.90   $ (0.09
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average number of shares used in computing loss per share:

        

Basic

     15,679        14,074        15,642        12,759   
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted

     15,679        14,074        15,642        12,759   
  

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes to consolidated financial statements.

 

4


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(unaudited)

 

     For the six months ended June 30,  
     2015     2014  
     (in thousands)  

Cash flow from operating activities:

    

Net loss

   $ (29,643   $ (1,187

Adjustments to reconcile net loss to net cash provided by (used for) operating activities:

    

Amortization

     1,362        748   

Depreciation

     896        432   

Bad debt provision

     188        27   

Stock-based compensation expense

     1,064        606   

Amortization of debt discount and debt costs

     323        524   

Interest on settlement obligations

     92        106   

Loss on extinguishment of debt

     1,723        903   

Gain from change in fair value of warrant

     —          (1,835

Goodwill and long-lived asset impairment

     27,443        —     

Loss on disposal of assets

     123        —     

Changes in operating assets and liabilities (net of the effect of the acquisition):

    

Accounts receivable

     1,691        (2,035

Inventory

     (993     22   

Prepaid and other current assets

     65        96   

Accounts payable

     (347     31   

Accrued expenses

     (1,802     (576

Deferred revenue

     (1,962     (198
  

 

 

   

 

 

 

Total adjustments

     29,866        (1,149
  

 

 

   

 

 

 

Net cash provided by (used for) operating activities

     223        (2,336
  

 

 

   

 

 

 

Cash flow from investing activities:

    

Additions to patents, technology and other

     (36     (44

Additions to property and equipment

     (799     (465

Acquisition of VuComp M-Vu Breast Density

     (1,700     —     
  

 

 

   

 

 

 

Net cash used for investing activities

     (2,535     (509
  

 

 

   

 

 

 

Cash flow from financing activities:

    

Issuance of common stock for cash, net

     —          28,214   

Stock option exercises

     327        293   

Warrant exercise

     —          1,575   

Taxes paid related to restricted stock issuance

     (84     (101

Principal payments of capital lease obligations

     (693     (65

Principal repayment of debt financing, net

     (11,250     (4,100
  

 

 

   

 

 

 

Net cash provided by (used for) financing activities

     (11,700     25,816   
  

 

 

   

 

 

 

Increase (decrease) in cash and equivalents

     (14,012     22,971   

Cash and equivalents, beginning of period

     32,220        11,880   
  

 

 

   

 

 

 

Cash and equivalents, end of period

   $ 18,208      $ 34,851   
  

 

 

   

 

 

 

Supplemental disclosure of cash flow information:

    

Interest paid

   $ 471      $ 1,068   
  

 

 

   

 

 

 

Taxes paid

   $ 93      $ 80   
  

 

 

   

 

 

 

See accompanying notes to consolidated financial statements.

 

 

5


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

Note 1 - Basis of Presentation and Significant Accounting Policies

The accompanying condensed consolidated financial statements of iCAD, Inc. and subsidiaries (“iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, these unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at June 30, 2015, the results of operations of the Company for the three and six month period ended June 30, 2015 and 2014, respectively, and cash flows of the Company for the three and six month period ended June 30, 2015 and 2014, respectively. Although the Company believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (“SEC”). The accompanying financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10–K for the fiscal year ended December 31, 2014 filed with the SEC on March 13, 2015. The results for the three and six month period ended June 30, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2015, or any future period.

Revenue Recognition

The Company recognizes revenue primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement.

The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Update No. 2009-13, “Multiple-Deliverable Revenue Arrangements” (“ASU 2009-13”) and ASC Update No. 2009-14, “Certain Arrangements That Contain Software Elements” (“ASU 2009-14”) and ASC 985-605, “Software” (“ASC 985-605”). Revenue for the sale of certain CAD products is recognized in accordance with ASC 840 “Leases” (“ASC 840”). For multiple element arrangements, revenue is allocated to all deliverables based on their relative selling prices. In such circumstances, a hierarchy is used to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value (“VSOE”), (ii) third-party evidence of selling price (“TPE”), and (iii) best estimate of the selling price (“BESP”). VSOE generally exists only when the deliverable is sold separately and is the price actually charged for that deliverable. The process for determining BESP for deliverables without VSOE or TPE considers multiple factors

 

6


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

including relative selling prices; competitive prices in the marketplace, and management judgment; however, these may vary depending upon the unique facts and circumstances related to each deliverable.

The Company uses customer purchase orders that are subject to the Company’s terms and conditions or, in the case of an Original Equipment Manufacturer (“OEM”) are governed by distribution agreements. In accordance with the Company’s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references.

If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer’s post-delivery acceptance provisions, if any, and the installation process.

The Company has determined that iCAD’s digital, and film based sales generally follow the guidance of FASB ASC Topic 605 “Revenue Recognition” (“ASC 605”) as the software has been considered essential to the functionality of the product per the guidance of ASU 2009-14. Typically, the responsibility for the installation process lies with the OEM partner. On occasion, when iCAD is responsible for product installation, the installation element is considered a separate unit of accounting because the delivered product has stand-alone value to the customer. In these instances, the Company allocates revenue to the deliverables based on the framework established within ASU 2009-13. Therefore, the installation and training revenue is recognized as the services are performed according to the BESP of the element. Revenue from the digital and film based equipment, when there is installation, is recognized based on the relative selling price allocation of the BESP, when delivered.

Revenue from certain CAD products is recognized in accordance with ASC 985-605. Sales of this product include training, and the Company has established VSOE for this element. Product revenue is determined based on the residual value in the arrangement, and is recognized when delivered. Revenue for training is deferred and recognized when the training has been completed.

The Company recognizes post contract customer support revenue together with the initial licensing fee for certain MRI products in accordance with ASC 985-605-25-71.

Sales of the Company’s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13.

 

7


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

Product revenue is generally recognized when the product has been delivered and service and source revenue is typically recognized over the life of the service and source agreement. The Company includes the following in service and supplies revenue: the sale of physics and management services, the lease of electronic brachytherapy equipment, development fees, supplies and the right to use the Company’s AxxentHub software. Physics and management services revenue and development fees are considered to be delivered as the services are performed or over the estimated life of the agreement. The Company typically bills items monthly over the life of the agreement except for development fees, which are generally billed in advance or over a 12 month period and the fee for treatment supplies which is generally billed in advance.

The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20, “Services”. The Company provides for estimated warranty costs on original product warranties at the time of sale.

Cost of Revenue

Cost of revenue consists of the costs of products purchased for resale, costs relating to service including personnel costs for physicists, management services and radiation therapists, costs of service contracts to maintain equipment after the warranty period, product installation, training, customer support, certain warranty repair costs, inbound freight and duty, cost of supplies, manufacturing, warehousing, material movement, inspection, scrap, rework, amortization, depreciation and in-house product warranty repairs.

In September 2014, the Company reclassified depreciation previously included in product and service cost of revenue to amortization and depreciation as a separate component of cost of revenue. For the three and six months ended June 30, 2014, approximately $343,000 and $674,000, respectively was reclassified to conform to current period classification. Medical Device Excise tax included in the cost of revenue is approximately $132,000 and $331,000, for the three and six months ended June 30, 2015, respectively and $200,000 and $379,000 for the three and six months ended June 30, 2014, respectively.

Segments

The Company reports the results of two segments, Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of our advanced image analysis and workflow products. The Therapy segment consists of our radiation therapy (“Axxent”) products, physics and management services, development fees, supplies, and the right to use the AxxentHub software platform.

 

8


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

Note 2 - Loss per Common Share

The Company’s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period.

A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts):

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 
     2015      2014      2015      2014  

Net loss

   $ (27,786    $ (997    $ (29,643    $ (1,187
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic and diluted shares used in the calculation of net loss per share

     15,679         14,074         15,642         12,759   

Net loss per share - basic and diluted

   $ (1.77    $ (0.07    $ (1.90    $ (0.09
  

 

 

    

 

 

    

 

 

    

 

 

 

The shares of the Company’s common stock, issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive is as follows:

 

     Period Ended
June 30,
 
     2015      2014  

Stock Options

     1,618,043         1,477,871   

Restricted Stock

     453,392         326,318   
  

 

 

    

 

 

 

Stock options and restricted stock

     2,071,435         1,804,189   
  

 

 

    

 

 

 

Note 3 – Business Combinations

Acquisition of VuComp M-Vu Breast Density Product

On April 29, 2015, pursuant to the terms of the Asset Purchase Agreement with VuComp, the Company purchased VuComp’s M-Vu Breast Density product for $1,700,000 in cash. Under the terms of the agreement, the Company acquired the breast density intellectual property product, which will be integrated with the Company’s PowerLook Advanced Mammography Platform (AMP). PowerLook AMP is a modular solution designed to provide advanced tools for breast disease detection and analysis, including CAD for tomosynthesis. The Company considered the acquisition to be an acquisition of a business as the Company acquired the Breast Density product and certain customer liabilities which were considered to be an integrated set of activities at acquisition. Accordingly the assets were valued in accordance with ASC Topic 805, “Business Combinations” (“ASC 805”).

The amount allocated to the acquired assets, was estimated primarily through the use of discounted cash flow valuation techniques. Appraisal assumptions utilized under this method include a forecast of estimated future net cash flows, as well as discounting the

 

9


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

future net cash flows to their present value. The acquired technology is being amortized over the estimated useful life of approximately eight years and nine months from the closing of the transaction. The following is a summary of the preliminary allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life:

 

     Amount      Estimated Amortizable Life

Developed Technology

     900       8 years 9 months

Goodwill

     800      
  

 

 

    

Purchase price

   $ 1,700      
  

 

 

    

The assets obtained in the acquisition of VuComp’s M-Vu Breast Density product and the anticipated future revenues are included in the Detection segment and, accordingly, the goodwill resulting from the purchase price allocation is included in goodwill of the Detection segment.

Acquisition of DermEbx and Radion

On July 15, 2014, the Company entered into two Asset Purchase Agreements, one with Radion, Inc. (“Radion”) the other with DermEbx, a series of Radion Capital Partners LLC (“DermEbx”) (the “Radion/DermEbx Acquisition”). Pursuant to the Asset Purchase Agreement with DermEbx, the Company purchased substantially all of the assets of DermEbx, including all of DermEbx’s intellectual property and customer contracts. The Company paid the following consideration to DermEbx: (i) $1,600,000 in cash and (ii) 600,000 restricted shares of the Company’s common stock, $0.01 par value per share. The 600,000 restricted shares are subject to the following provisions; 25% was locked up until the date that was two trading days after the Company announced its fourth quarter 2014 earnings, which occurred on March 2, 2015; 30% of the shares shall be locked up for a period of 24 months from the date of the agreement; and 30% of the shares shall be locked up for a period of 36 months from the date of the agreement. In addition the Company delivered the remaining 15%, or 90,000, of the restricted shares to US Bank, N.A., as escrow agent, to be held in escrow for a period of 18 months pursuant to the terms of an escrow agreement. The 90,000 escrow shares will act as the source of payment for the indemnification of the Company by DermEbx under the DermEbx Asset Purchase Agreement.

Pursuant to the terms of the Asset Purchase Agreement with Radion, the Company purchased substantially all of the assets of Radion, including all of Radion’s intellectual property and customer contracts. The Company paid the following consideration to Radion: (i) $2,382,000 in cash which included $182,000 payoff of an existing note payable and (ii) the issuance to Radion of 600,000 restricted shares of the Company’s common

 

10


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

stock. The 600,000 restricted shares are subject to the following provisions; 25% of the shares were locked up until the date that is two trading days after the Company announces its fourth quarter 2014 earnings, which occurred on March 2, 2015; 30% of the shares shall be locked up for a period of 24 months from the date of the agreement; and 30% of the shares shall be locked up for a period of 36 months from the date of the agreement. In addition the Company delivered the remaining 15% or 90,000 of the restricted shares to US Bank, N.A., as escrow agent, to be held in escrow for a period of 18 months pursuant to the terms of an escrow agreement. The 90,000 escrow shares will act as the source of payment for the indemnification of the Company by Radion under the Radion Asset Purchase Agreement.

The Company did not achieve significant synergies from the Radion/DermEbx Acquisition. Prior to the Radion DermEbx Acquisition, the Sellers represented one of the Company’s significant customers in the Therapy segment. The Company recognized approximately $0.8 million of Therapy product revenue and approximately $0.3 million of Therapy service revenue, for a total of $1.1 million related to Sellers, in the quarter ended June 30, 2014 and approximately $1.6 million of Therapy product revenue and approximately $0.5 million of Therapy service revenue, for a total of $2.1 million related to Sellers, in the six months ended June 30, 2014.

The amounts allocated to purchased and developed software, customer relationships, trade names, employee non-compete agreements and backlog were estimated primarily through the use of discounted cash flow valuation techniques. Appraisal assumptions utilized under these methods include a forecast of estimated future net cash flows, as well as discounting the future net cash flows to their present value. Acquired intangible assets are being amortized over the estimated useful lives as set forth in the following table. The following is a summary of the allocation of the total purchase price based on the estimated fair values of the assets acquired and liabilities assumed as of the date of the acquisition and the amortizable lives of the intangible assets:

 

     Amount      Estimated Amortizable Life

Current assets

   $ 3,457      

Property and equipment

     2,625       3 – 7 Years

Identifiable intangible assets

     6,050       5 – 10 Years

Goodwill

     6,270      

Current liabilities

     (4,382   

Long-term liabilities

     (2,164   
  

 

 

    

Purchase price

   $ 11,856      
  

 

 

    

The assets obtained in the Radion/DermEbx Acquisition and the resulting revenues are included in the Therapy segment and, accordingly, the goodwill resulting from the purchase price allocation is included in goodwill of the Therapy segment. As discussed in Note 12, the Company recorded a goodwill impairment charge related to the Therapy segment of $14.0 million in the quarter ended June 30, 2015.

 

11


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

The goodwill is deductible for income tax purposes.

The unaudited proforma operating results for the Company for the three and six months ended June 30, 2014, assuming the Radion/DermEbx Acquisition occurred as of January 1, 2014 are as follows (in thousands except per share amounts):

 

     June 30, 2014  
     Three months      Six months  

Revenue

   $ 11,815       $ 22,408   

Income from operations

     566         685   

Net (loss) income

     (264      32   

Net (loss) income per share-basic

   $ (0.02    $ 0.00   

Net (loss) income per share-diluted

   $ (0.02    $ 0.00   

Basic

     13,959         13,959   

Diluted

     13,959         14,667   

Note 4 – Inventory

The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows:

 

     as of June 30,
2015
     as of December 31,
2014
 

Raw materials

   $ 1,608       $ 955   

Work in process

     223         54   

Finished Goods

     1,491         1,205   
  

 

 

    

 

 

 

Inventory

   $ 3,322       $ 2,214   
  

 

 

    

 

 

 

Note 5 – Long Term Debt

On March 31, 2015, the Company repaid in full the aggregate amount outstanding under the Deerfield Facility Agreement, dated as of December 29, 2011 (as amended, supplemented or otherwise modified to the date hereof, the “Facility Agreement”), by and among the Company, Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., and Deerfield Special Situations Fund, L.P. and, for itself and as assignee of the obligations held by Deerfield Special Situations Fund International Master Fund, L.P. The Facility Agreement and related documents were terminated as of March 31, 2015. The Facility Agreement was to mature on December 29, 2016 and was able to be repaid prior to the maturity date at the Company’s option without penalty or premium. On

 

12


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

March 31, 2015, the Company used cash on hand to pay the $11.25 million outstanding principal amount due under the Facility Agreement and approximately $162,000 in accrued and unpaid interest on such principal amount.

The Company recorded a loss on the extinguishment of debt of approximately $1.7 million at the termination date in the quarter ended March 31, 2015.

The following amounts compose interest expense included in our consolidated statement of operations for the three and six months ended June 30, 2015 and 2014: (in thousands)

 

     Three months ended June 30,  
     2015      2014  

Cash interest expense

   $ —         $ 216   

Non-cash amortization of debt discount

     —           313   

Amortization of debt costs

     —           28   

Amortization of settlement obligations

     47         54   

Interest expense capital lease

     23         3   
  

 

 

    

 

 

 

Total interest expense

   $ 70       $ 614   
  

 

 

    

 

 

 
     Six months ended June 30  
     2015      2014  

Cash interest expense

   $ 162       $ 794   

Non-cash amortization of debt discount

     254         448   

Amortization of debt costs

     13         76   

Amortization of settlement obligations

     92         106   

Interest expense capital lease

     56         7   
  

 

 

    

 

 

 

Total interest expense

   $ 577       $ 1,431   
  

 

 

    

 

 

 

Cash interest expense represents the amount of interest paid in cash under the Facility Agreement which represents the interest of 5.75% on the Facility Agreement through March 31, 2015. Non-cash amortization is the amortization of the discount on the Facility Agreement. The amortization of debt costs relates to the costs incurred with the financing, which is primarily a facility fee and a finder’s fee that were capitalized and are being expensed using the effective interest method. The amortization of the settlement obligation represents the interest associated with the settlement agreements for both Carl Zeiss Meditec AG and Hologic, Inc (see Note 8). Interest expense capital lease represents interest related to the capital lease as described in Note 6.

 

13


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

Note 6 – Lease Commitments

Operating leases

Facilities are leased under operating leases expiring at various dates through September, 2017. Certain of these leases contain renewal options. Rent expense under operating leases was $165,000 and $328,000 for the three and six month period ended June 30, 2015 and $168,000 and $327,000 for the three and six month period ended June 30, 2014, respectively.

Future minimum lease payments as of June 30, 2015 under operating leases are as follows: (in thousands)

 

Fiscal Year

   Operating
Leases
 

2015

   $ 255   

2016

     499   

2017

     255   
  

 

 

 
   $ 1,009   
  

 

 

 

Capital leases

The Company entered into a capital lease agreement for the purchase of certain equipment in August 2013 for approximately $409,000. Under the guidance of ASC Topic 840, “Leases” (“ASC 840”) the Company determined that the lease was a capital lease as it contained a bargain purchase option whereby the Company has the option to buy the equipment for $1 at the end of the lease term. Accordingly, the equipment has been capitalized and a liability has been recorded. The equipment cost of $409,000 is reflected as property and equipment in the balance sheet and is being depreciated over its useful life.

In connection with the Radion/DermEbx Acquisition, the Company assumed two separate equipment lease obligations with payments totaling approximately $2.6 million through May, 2017. The leases were determined to be capital leases and accordingly the equipment was capitalized and a liability of $2.5 million was recorded. As of June 30, 2015, the outstanding liability for the acquired equipment leases was approximately $1.7 million.

 

14


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

Future minimum lease payments under all outstanding capital leases are as follows: (in thousands)

 

Fiscal Year    Capital
Leases
 

2015

   $ 774   

2016

     1,039   

2017

     89   
  

 

 

 

Subtotal minimum lease obligation

     1,902   

Less interest

     (163
  

 

 

 

Total, net

     1,739   

Less current portion

     (1,251
  

 

 

 

Long term portion

   $ 488   
  

 

 

 

Kamal Gogineni is an employee of the Company’s and a beneficial owner of more than 5% of the Company’s common stock. Additionally, Mr. Gogineni is a significant shareholder of Radion Capital Partners (“RCP”). RCP was the lessor under a lease between RCP and DermEbx (the “DermEbx Lease”). In connection with the Company’s Radion/DermEbx acquisition that closed in July 2014, one of the assets and obligations that the Company acquired was the Lease. Pursuant to the Lease, the Company is obligated to pay a total of $855,000 as of June 30, 2015 and the liability is included in the minimum lease payments above, with annual payments of $383,000 for the remainder of 2015, $396,000 in 2016 and $76,000 in 2017.

Note 7 - Stock-Based Compensation

The Company follows the guidance in ASC Topic 718, “Compensation – Stock Compensation, (“ASC 718”).

The Company granted 130,000 and 317,000 options in the three and six months ended June 30, 2015. Options granted under the Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values:

 

     Three Months Ended
June 30,
   Six Months Ended
June 30,
     2015    2014    2015    2014

Average risk-free interest rate

   0.98%    0.85%    0.92%    0.82%

Expected dividend yield

   None    None    None    None

Expected life

   3.5 years    3.5 years    3.5 years    3.5 years

Expected volatility

   60.5% to 73.8%    64.9% to 66.5%    60.5% to 73.8%    64.2% to 66.5%

Weighted average exercise price

   $3.37    $6.72    $6.97    $7.83

Weighted average fair value

   $1.74    $3.17    $3.33    $3.67

 

15


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

The amounts included in the consolidated statement of operations relating to stock based compensation expense are as follows:

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 
     2015      2014      2015      2014  

Cost of revenue

   $ 4       $ 3       $ 8       $ 7   

Engineering and product development

     60         34         111         83   

Marketing and sales

     203         69         333         140   

General and administrative

     353         175         612         376   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 620       $ 281       $ 1,064       $ 606   
  

 

 

    

 

 

    

 

 

    

 

 

 

As of June 30, 2015 unrecognized compensation cost (in thousands) related to unexercisable options and unvested restricted stock and the weighted average remaining period is as follows:

 

Remaining expense

   $ 4,698   

Weighted average term

     1.31 years   

The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands):

 

     Period Ended
June 30,
 

Aggregate intrinsic value

   2015      2014  

Stock options

   $ 485       $ 3,187   

Restricted stock

     1,469         2,092   

Note 8 - Commitments and Contingencies

Foreign Tax Claim

In July 2007, a dissolved former Canadian subsidiary of the Company, CADx Medical Systems Inc. (“CADx Medical”), received a tax re-assessment of approximately $6,800,000 from the Canada Revenue Agency (“CRA”) resulting from CRA’s audit of CADx Medical’s Canadian federal tax return for the year ended December 31, 2002. In February 2010 the CRA reviewed the matter and reduced the tax re-assessment to approximately $703,000, excluding interest and penalties. The Company believes that it is not liable for the re-assessment against CADx Medical and no accrual has been recorded for this matter as of June 30, 2015.

Settlement Obligations

In connection with the acquisition of Xoft in 2010, the Company recorded a royalty obligation pursuant to a settlement agreement entered into between Xoft and Hologic in August 2007. Xoft received a nonexclusive, irrevocable, perpetual, worldwide license,

 

16


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

including the right to sublicense certain Hologic patents, and a non-compete covenant as well as an agreement not to seek further damages with respect to the alleged patent violations. In return, the Company has a remaining obligation to pay a minimum annual royalty payment to Hologic, of $250,000 payable through 2016. In addition to the minimum annual royalty payments, the litigation settlement agreement with Hologic also provided for payment of royalties based upon a specified percentage of future net sales on any products that utilize the licensed rights. The Company has a liability within accrued expenses and long-term settlement cost for future payment and for future minimum royalty obligations totaling $442,000. The Company recorded interest expense of approximately $18,000 and $36,000 in the three and six months ended June 30, 2015 and $25,000 and $50,000 in the three and six months June 30, 2014, respectively, related to this obligation.

In December, 2011, the Company agreed to a settlement related to litigation with Carl Zeiss Meditec AG. The Company is obligated to pay the remaining amount of $0.5 million in June 2017. As of June 30, 2015, the remaining liability recorded within accrued expenses and long-term settlement cost for future payment and for future minimum royalty obligations is $395,000. The Company recorded interest expense of approximately $28,000 and $56,000 in the three and six months ended June 30, 2015 and $28,000 and $56,000 in the three and six months ended June 30, 2014, respectively, related to this obligation.

Other Commitments

The Company is obligated to pay approximately $2.2 million for firm purchase obligations to suppliers for future product deliverables.

Litigation

The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

Note 9 - Fair Value Measurements

The Company follows the provisions of ASC Topic 820, “Fair Value Measurement and Disclosures”, (“ASC 820”). This topic defines fair value, establishes a framework for measuring fair value under US GAAP and enhances disclosures about fair value

 

17


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

 

    Level 1 - Quoted prices in active markets for identical assets or liabilities.

 

    Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

    Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value.

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and certain accrued liabilities and our notes payable. The carrying amounts of our cash and cash equivalents (which are composed primarily of deposit and overnight sweep accounts), accounts receivable, accounts payable and certain accrued liabilities approximate fair value due to the short maturity of these instruments. The carrying value of our notes payable approximates fair value due to the market rate of the stated interest rate.

The Company’s assets that are measured at fair value on a recurring basis relate to the Company’s money market accounts.

The Company’s money market funds are included in cash and cash equivalents in the accompanying balance sheets, and are considered a Level 1 investment as they are valued at quoted market prices in active markets.

The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy.

 

Fair value measurements using: (000’s) as of December 31, 2014

 
     Level 1      Level 2      Level 3      Total  

Assets

           

Money market accounts

   $ 26,530       $ —         $ —         $ 26,530   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Assets

   $ 26,530       $ —         $ —         $ 26,530   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

18


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

Fair value measurements using: (000’s) as of June 30, 2015

 
     Level 1      Level 2      Level 3      Total  

Assets

           

Money market accounts

   $ 13,568       $ —         $ —         $ 13,568   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Assets

   $ 13,568       $ —         $ —         $ 13,568   
  

 

 

    

 

 

    

 

 

    

 

 

 

Items Measured at Fair Value on a Nonrecurring Basis

Certain assets, including long-lived assets and goodwill, are measured at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be impaired. The Company recorded a $27.4 million impairment consisting of $14.0 million related to goodwill and $13.4 million related to long-lived assets as discussed in Note 11 and Note 12 and remeasured long-lived assets and goodwill of the Therapy reporting unit at fair value as of the impairment date as noted in the following table. The fair values of long-lived assets and goodwill were measured using Level 3 inputs.

 

Fair value measurements using: (000’s) as of June 30, 2015

 
     Level 1      Level 2      Level 3      Total  

Non-recurring assets

           

Long-lived and intangible assets

   $ —         $ —         $ 3,195       $ 3,195   

Goodwill

     —           —           5,735         5,735   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Assets

   $ —         $ —         $ 8,930       $ 8,930   
  

 

 

    

 

 

    

 

 

    

 

 

 

Note 10 - Income Taxes

The Company recorded an income tax benefit of $107,000 and $28,000, in the three and six months ended June 30, 2015 as compared to a provision of $25,000 and $78,000 in the three and six months ended June 30, 2014, respectively. The income tax net benefit as of June 30, 2015 primarily relates a state tax provision and a benefit from the reversal of a deferred tax liability relating to tax amortizable goodwill. Due to the Company’s goodwill impairment the tax basis in amortizable goodwill is greater than book basis which results in a deferred tax asset that is subject to a valuation allowance. At June 30, 2015, the Company had no material unrecognized tax benefits and no adjustments to liabilities or tax expense were required under ASC 740, “Income Taxes”. The Company does not expect that the unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any interest or penalties related to uncertain tax positions at June 30, 2015. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company’s three preceding tax years remain subject to examination by federal and state taxing authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not under examination by any federal or state jurisdiction for any tax years.

 

19


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

Note 11 – Long-lived assets

In accordance with FASB ASC Topic 360, “Property, Plant and Equipment”, (“ASC 360”), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group.

ASC 360-10-35 uses “events and circumstances” criteria to determine when, if at all, an asset (or asset group) is evaluated for recoverability. Thus, there is no set interval or frequency for recoverability evaluation. In accordance with ASC 360-10-35-21 the following factors are examples of events or changes in circumstances that indicate the carrying amount of an asset (asset group) may not be recoverable and thus is to be evaluated for recoverability.

 

    A significant decrease in the market price of a long-lived asset (asset group);

 

    A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition;

 

    A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator;

 

    An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group);

 

    A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group).

As a result of external factors and general uncertainty related to reimbursement for the treatment of non-melanoma skin cancer, the Company evaluated the long-lived assets of the Therapy segment and reviewed them for potential impairment. The Company determined the “Asset Group” to be the assets of the Therapy segment, which the Company considered to be the lowest level for which the identifiable cash flows were largely independent of the cash flows of other assets and liabilities.

In accordance with ASC 360-10-35-17, if the carrying amount of an asset or asset group (in use or under development) is evaluated and found not to be fully recoverable (the carrying amount exceeds the estimated gross, undiscounted cash flows from use and disposition), then an impairment loss must be recognized. The impairment loss is measured as the excess of the carrying amount over the assets (or asset group’s) fair value.

In connection with the preparation of the financial statements for the second quarter ended June 30, 2015, the Company completed its analysis pursuant to ASC 360-10-35-17 and determined that the carrying value of the Asset Group was approximately $36.8 million, which exceeded the undiscounted cash flows by approximately $2.8 million. Accordingly the Company completed the Step 2 analysis to determine the fair value of the asset group. The Company recorded long-lived asset impairment charges of approximately $13.4 million in the second quarter ended June 30, 2015 and as a result the long lived assets in the asset group are recorded at their current fair values.

 

20


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

A considerable amount of judgment and assumptions are required in performing the impairment tests, principally in determining the fair value of the asset group and the reporting unit. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair values and, therefore additional impairment charges could be required. Significant negative industry or economic trends, disruptions to the Company’s business, loss of significant customers, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of the assets may adversely impact the assumptions used in the fair value estimates and ultimately result in future impairment charges.

Note 12 - Goodwill

In accordance with FASB ASC Topic 350-20, “Intangibles - Goodwill and Other”, (“ASC 350-20”), the Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the Company is less than the carrying value of the Company.

Factors the Company considers important, which could trigger an impairment of such asset, include the following:

 

    significant underperformance relative to historical or projected future operating results;

 

    significant changes in the manner or use of the assets or the strategy for the Company’s overall business;

 

    significant negative industry or economic trends;

 

    significant decline in the Company’s stock price for a sustained period; and

 

    a decline in the Company’s market capitalization below net book value.

The Company’s Chief Operating Decision Maker (“CODM”) is the Chief Executive Officer (“CEO”). The two segments and reporting units are Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). Each segment generates revenue from the sale of medical equipment and related services and/or sale of supplies.

The Company performed the annual impairment assessment at October 1, 2014 and compared the fair value of each of reporting unit to its carrying value as of this date. Fair value of each reporting unit exceeded the carry value by approximately 315% for the Detection reporting unit and 255% for the Therapy reporting unit. The carrying values of the reporting units were determined based on an allocation of our assets and liabilities through specific allocation of certain assets and liabilities, to the reporting units and an apportionment of the remaining net assets based on the relative size of the reporting units’ revenues and operating expenses compared to the Company as a whole. The determination of reporting units also requires management judgment.

 

21


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

An impairment charge is recorded if such an assessment were to indicate that the fair value of a reporting unit was less than the carrying value. When the Company evaluates potential impairments outside of the annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. The Company utilizes either discounted cash flow models or other valuation models, such as comparative transactions and market multiples, to determine the fair value of the reporting unit. The Company makes assumptions about future cash flows, future operating plans, discount rates, comparable companies, market multiples, purchase price premiums and other factors in those models. Different assumptions and judgment determinations could yield different conclusions that would result in an impairment charge to income in the period that such change or determination was made.

As a result of external factors and general uncertainty related to reimbursement for non-melanoma skin cancer and in conjunction with the long-lived asset impairment testing, the Company performed an impairment assessment of the Therapy reporting unit. As a result the Company recorded a goodwill impairment charge of $14.0 million during the quarter ended June 30, 2015.

The implied fair value of the Therapy reporting unit was determined in the same manner as the manner in which the amount of goodwill recognized in a business combination is determined. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied amount of goodwill. The Company identified the intangible assets that were valued during this process, including technology, customer relationships, trade-names, and the Company’s workforce. The allocation process was performed only for purposes of testing goodwill for impairment.

The Company determined the fair value of the Therapy reporting unit based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. This approach was selected as it measures the income producing assets, primarily technology and customer relationships. This method estimates the fair value based upon the ability to generate future cash flows, which is particularly applicable when future profit margins and growth are expected to vary significantly from historical operating results.

The Company uses internal forecasts to estimate future cash flows and includes an estimate of long-term future growth rates based on the most recent views of the long-term forecast for the reporting unit. Accordingly, actual results can differ from those assumed in the forecasts. The discount rate of approximately 17% is derived from a capital asset pricing model and analyzing published rates for industries relevant to the reporting unit to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in the internally developed forecasts

 

22


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

Other significant assumptions include terminal value margin rates, future capital expenditures, and changes in future working capital requirements. While there are inherent uncertainties related to the assumptions used and to the application of these assumptions to this analysis, the income approach provides a reasonable estimate of the fair value of the Therapy reporting unit.

The Step 2 test resulted in an approximate fair value of goodwill of $5.7 million which resulted in a goodwill impairment loss of $14.0 million.

As discussed in Note 3, the Company acquired VuComp’s M-Vu® Breast Density product for $1.7 million. The product will be integrated into the Company’s Powerlook AMP system, which is a component of the Detection reporting unit. The Company determined that the acquisition was a business combination and accordingly recorded goodwill of $0.8 million.

A roll forward of goodwill activity by reporting unit is as follows:

 

     Detection      Therapy      Total  

Accumulated Goodwill

   $ —         $ —         $ 47,937   

Accumulated impairment

     —           —           (26,828

Fair value allocation

     7,663         13,446         —     

Acquisition of DermEbx and Radion

     —           6,154         6,154   
  

 

 

    

 

 

    

 

 

 

Balance at December 31, 2014

     7,663         19,600         27,263   

Acquisition measurement period adjustments

     —           116         116   

Acquisition of VuComp

     800         —           800   

Impairment

     —           (13,981      (13,981
  

 

 

    

 

 

    

 

 

 

Balance at June 30, 2015

   $ 8,463       $ 5,735       $ 14,198   
  

 

 

    

 

 

    

 

 

 

Note 13 – Segment Reporting

In accordance with FASB Topic ASC 280, “Segments”, operating segments, are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker CODM in deciding how to allocate resources and assess performance.

The Company’s CODM is the CEO. Each segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments, Detection and Therapy.

 

23


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

The Detection segment consists of our advanced image analysis and workflow products, and the Therapy segment consists of our radiation therapy Axxent products, and related services. The primary factors used by our CODM to allocate resources are based on revenues, gross profit, operating income, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring items (“Adjusted EBITDA”) of each segment. Included in segment operating income are stock compensation, amortization of technology and depreciation expense. There are no intersegment revenues.

Our CODM does not use asset information by segment to allocate resources or make operating decisions.

Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands):

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 
     2015      2014      2015      2014  

Segment revenues:

           

Detection

   $ 4,955       $ 4,832       $ 9,743       $ 9,007   

Therapy

     6,188         4,835         14,620         9,180   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Revenue

   $ 11,143       $ 9,667       $ 24,363       $ 18,187   
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment gross profit:

           

Detection

   $ 4,090       $ 3,960       $ 8,037       $ 7,324   

Therapy

     3,788         2,870         9,203         5,440   
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment gross profit

   $ 7,878       $ 6,830       $ 17,240       $ 12,764   
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment operating income (loss):

           

Detection

     2,033         1,897         3,793         3,413   

Therapy

     (27,469      (140      (26,512      (368
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment operating income

   $ (25,436    $ 1,757       $ (22,719    $ 3,045   
  

 

 

    

 

 

    

 

 

    

 

 

 

General, administrative, depreciation and amortization expense

   $ (2,392    $ (1,923    $ (4,666    $ (3,671

Interest expense

     (70      (614      (577      (1,431

Gain on fair value of warrant

     —           699         —           1,835   

Other income

     5         12         14         16   

Loss on debt extinguishment

     —           (903      (1,723      (903
  

 

 

    

 

 

    

 

 

    

 

 

 

Loss before income tax

   $ (27,893    $ (972    $ (29,671    $ (1,109
  

 

 

    

 

 

    

 

 

    

 

 

 

 

24


Table of Contents

iCAD, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

June 30, 2015

 

Note 14 - Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers” (ASU 2014-09), which amends ASC 605 “Revenue Recognition” and creates a new Topic 606 “Revenue from Contracts with Customers.” This update provides guidance on how an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Upon initial application, the provisions of this update are required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this update recognized at the date of initial application. This update also expands the disclosure requirements surrounding revenue recorded from contracts with customers. This update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. In April 2015 the FASB voted to defer effective date of this standard with respect to years, beginning after December 15, 2017. We are currently evaluating the effect of this update on our financial statements and have not yet determined the method of initial application we will use.

 

25


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Certain information included in this Item 2 and elsewhere in this Form 10-Q that are not historical facts contain forward looking statements that involve a number of known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievement expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to, uncertainty of future sales and expense levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, regulatory changes and requirements applicable to our products, product market acceptance, possible technological obsolescence of products, increased competition, integration of the acquired businesses, the impact of litigation and/or government regulation, changes in Medicare reimbursement policies, competitive factors, the effects of a decline in the economy in markets served by the Company and other risks detailed in the Company’s other filings with the Securities and Exchange Commission. The words “believe”, “plan”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, “seek”, “should”, “would”, “could” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made.

Results of Operations

Overview

iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and while enhancing patient care. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments.

The Company has grown primarily through acquisitions including CADx, Qualia Computing, CAD Sciences, Xoft and DermEbx and Radion. The Radion/DermEbx acquisition extends the Company’s position as a larger player in the oncology market, including the components that enable dermatologists and radiation oncologists to develop, launch and manage their electronic brachytherapy (“eBx”) programs for the treatment of non-melanoma skin cancer.

In the Detection segment, our industry-leading solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT).

 

26


Table of Contents

The Company intends to continue the extension of its image analysis and clinical decision support solutions for mammography, MRI and CT imaging. The Company believes that advances in digital imaging techniques, such as 3D mammography, should bolster its efforts to develop additional commercially viable CAD/advanced image analysis and workflow products. In April 2015, the Company acquired VuComp’s M-Vu Breast Density product, which the Company expects to integrate with our mammography products. The purchase price was $1.7 million which was paid in cash at closing.

In the Therapy segment the Company offers an isotope-free cancer treatment platform technology. The Xoft Electronic Brachytherapy System (“Xoft eBx”) can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and skin cancer. We believe the Xoft eBx system platform indications represent strategic opportunities in the United States and International markets to offer differentiated treatment alternatives. In addition, the Xoft eBx system generates additional recurring revenue for the sale of consumables and related accessories which will continue to drive growth in this segment. With the acquisition of the assets of DermEbx and Radion the Company now offers solutions that enable dermatologists and radiation oncologists to develop, launch and manage their eBx programs for the treatment of non-melanoma skin cancer.

In May 2015 the Company announced that one of the regional Medicare Administrative Contractors instructed physicians to report CPT code (17999) rather than the established CPT code (0182T) for electronic brachytherapy for treatment of non-melanoma skin cancers (“NMSC”). This announcement resulted in a significant disruption in our Therapy segment as a result of the reimbursement uncertainty. Revenues for the three and six months ended June 30, 2015 were also negatively impacted as a result of the uncertainty. In addition, the Company implemented expense reductions in response to the general uncertainty with respect to reimbursement levels. The Company is proactively addressing the situation in its dialogue with the regional provider and Centers for Medicare and Medicaid Services (“CMS”); however there is insufficient clarification to fully assess the impact on our customers.

As we have discussed in our risk factors noted in our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2014, our business can be affected by coverage policies adopted by federal and state governmental authorities, such as Medicare and Medicaid, as well as private payers, which often follow the coverage policies of these public programs. Such policies may affect which products customers purchase and the prices customers are willing to pay for those products in a particular jurisdiction. The change in CPT codes for the Company’s electronic brachytherapy treatment of NMSC had a negative impact on the Company’s revenues in the second quarter of 2015.

In connection with the preparation of the financial statements for the second quarter ended June 30, 2015, the Company evaluated the Therapy reporting unit for both long-lived asset and goodwill impairment. As a result of this assessment, the Company has recorded material impairment charges in our Therapy reporting unit.

 

27


Table of Contents

The Company’s headquarters are located in Nashua, New Hampshire, with manufacturing and contract manufacturing facilities in New Hampshire and Massachusetts and an operations, research, development, manufacturing and warehousing facility in San Jose, California, which now includes the operations of Xoft, Radion and DermEbx.

Critical Accounting Policies

The Company’s discussion and analysis of its financial condition, results of operations, and cash flows are based on the Company’s consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates these estimates, including those related to accounts receivable allowance, inventory valuation and obsolescence, intangible assets, income taxes, warranty obligations, contingencies and litigation. Additionally, the Company uses assumptions and estimates in calculations to determine stock-based compensation. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a comprehensive list of the Company’s critical accounting policies, reference should be made to the Annual Report on Form 10-K for the year ended December 31, 2014 filed on March 13, 2015.

 

28


Table of Contents

Three months ended June 30, 2015 compared to the three months ended June 30, 2014

Revenue: (in thousands)

 

     Three months ended June 30,  
     2015      2014      Change      % Change  

Detection revenue

           

Product revenue

   $ 2,955       $ 2,809       $ 146         5.2

Service revenue

     2,000         2,023         (23      (1.1 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Subtotal

     4,955         4,832         123         2.5
  

 

 

    

 

 

    

 

 

    

 

 

 

Therapy revenue

           

Product revenue

     141         2,485         (2,344      (94.3 )% 

Service revenue

     6,047         2,350         3,697         157.3
  

 

 

    

 

 

    

 

 

    

 

 

 

Subtotal

     6,188         4,835         1,353         28.0
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue

   $ 11,143       $ 9,667       $ 1,476         15.3
  

 

 

    

 

 

    

 

 

    

 

 

 

Three months ended June 30, 2015 and 2014:

Total revenue for the three month period ended June 30, 2015 was $11.1 million compared with revenue of $9.7 million for the three month period ended June 30, 2014, an increase of approximately $1.5 million, or 15.3%. The increase in revenue was due to a $1.4 million increase in Therapy revenue and an increase in Detection revenues of approximately $0.1 million.

Detection product revenue increased by approximately $0.1 million from $2.8 million to $3.0 million or 5.2% in the three months ended June 30, 2015 as compared to the three months ended June 30, 2014. The increase is due primarily to an increase in MRI revenue of approximately $0.6 million offset by a decrease in CAD revenue of $0.5 million.

Detection service and supplies revenue was $2.0 million in the three months ended June 30, 2014 and the three months ended June 30, 2015. Service and supplies revenue reflects the sale of service contracts to our installed base of customers. Service and supplies revenue related to our installed base of customers can vary from quarter to quarter.

Therapy product revenue was approximately $0.1 million for the three months ended June 30, 2015 as compared to $2.5 million for the three months ended June 30, 2014. The decrease in product revenue was due primarily to the customer reaction to the uncertainty of reimbursement rates. Revenue from the sale of our Axxent eBx systems can vary significantly due to an increase or decrease in the number of units sold which can cause a significant fluctuation in product revenue in the period.

Therapy service and supplies revenue increased approximately $3.7 million from $2.4 million in the three months ended June 30, 2014 to $6.0 million for the three months ended June 30, 2015. The increase in Therapy service and supplies revenue is due primarily to additional revenues resulting from the acquisition of Radion and DermEbx which represented approximately $3.8 million of revenue in the current quarter. Included in the $3.8 million of revenue are approximately $0.7 million of certain customer deferred revenues which were recognized upon termination of the respective customer agreement.

 

29


Table of Contents

In July 2014, we acquired the assets of DermEbx and Radion, each of which was a Therapy customer. For the three months ended June 30, 2014 we recognized approximately $275,000 of Therapy product revenue and $838,000 of Therapy service and supplies revenue, for a total of approximately $1.1 million, related specifically to these two customers.

Cost of Revenue and Gross Profit: (in thousands)

 

     Three months ended June 30,  
     2015     2014     Change      % Change  

Products

   $ 680      $ 1,390      $ (710      (51.1 )% 

Service & supply

   $ 2,082      $ 1,104        978         88.6

Amortization and depreciation

   $ 503      $ 343        160         46.6
  

 

 

   

 

 

   

 

 

    

 

 

 

Total cost of revenue

   $ 3,265      $ 2,837      $ 428         15.1
  

 

 

   

 

 

   

 

 

    

 

 

 
     Three months ended June 30,  
     2015     2014     Change      % Change  

Detection gross profit

   $ 4,090      $ 3,960      $ 130         3.3

Therapy gross profit

     3,788        2,870        918         32.0
  

 

 

   

 

 

   

 

 

    

 

 

 

Gross profit

     7,878        6,830        1,048         15.3
  

 

 

   

 

 

   

 

 

    

 

 

 

Gross profit %

     70.7     70.7     

Gross profit for the three month period ended June 30, 2015 was $7.9 million, or 70.7% of revenue as compared to $6.8 million or 70.7% of revenue in the three month period ended June 30, 2014. Gross profit percent changes are primarily due to changes in the mix of business, consulting costs related to non-recurring engineering revenue, additional manufacturing investments and amortization of acquired intangibles.

 

    Cost of products decreased by approximately $0.7 million from approximately $1.4 million for the three months ended June 30, 2014 to approximately $0.7 million for the three months ended June 30, 2015, which is due primarily to the overall decrease in product revenue. The cost of product revenue as a percentage of product revenue was approximately 22% for the three months ended June 30, 2015 as compared to 26% for the three months ended June 30, 2014. Cost of product revenue can vary due primarily to product mix.

 

   

The cost of service and supplies increased by $1.0 million from $1.1 million in the three months ended June 30, 2014 to $2.1 million in the three months ended June 30, 2015. This increase is due primarily to the increase related to the acquisition of the assets of DermEbx

 

30


Table of Contents
 

and Radion, and represents primarily personnel costs related to physics, radiation therapist and management services provided following the acquisition. The cost of service and supply revenue as a percentage of service revenue was approximately 26% for the quarter ended June 30, 2015 and 25% for the quarter ended June 30, 2014. During the second quarter of 2015, the Company implemented cost reduction initiatives.

 

    Amortization and depreciation increased by $160,000 from $343,000 in three months ended June 30, 2014 to $503,000 for the three months ended June 30, 2015. The increase in amortization and depreciation is due to amortization and depreciation for the acquired intangibles. In June 2015, the Company impaired intangible assets of the Therapy reporting unit and recorded amortization expense based on the revised values of the assets.

Operating Expenses: (in thousands)

 

     Three months ended June 30,  
     2015      2014      Change      Change %  

Operating expenses:

           

Engineering and product development

   $ 2,272       $ 2,004       $ 268         13.4

Marketing and sales

     3,165         2,872         293         10.2

General and administrative

     2,330         1,865         465         24.9

Amortization and depreciation

     496         255         241         94.5

Goodwill and long-lived asset impairment

     27,443         —           27,443         0.0
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating expenses

   $ 35,706       $ 6,996       $ 28,710         410.4
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating expenses increased by approximately $28.7 million or 410.4% in the three months ended June 30, 2015. The primary driver for the increase was the goodwill and long-lived asset impairment as well as additional personnel costs related to the acquisition of DermEbx and Radion. During the second quarter of 2015, the Company implemented cost reduction initiatives, which we expect to impact operating expenses in the third quarter of 2015.

Engineering and Product Development. Engineering and product development costs for the three month period ended June 30, 2015 increased by $0.3 million or 13.4%, from $2.0 million in 2014 to $2.3 million in 2015. Therapy engineering and product development increased $0.3 million from $1.0 million in the three months ended June 30, 2014 to $1.3 million for the three months ended June 30, 2015. The increase in Therapy engineering and product development costs was due primarily to increases in salaries, consulting and clinical costs. Detection engineering and product development costs remained at $1.0 million for the three months ended June 30, 2014 and the three months ended June 30, 2015.

Marketing and Sales. Marketing and sales expenses increased by $0.3 million or 10.2%, from $2.9 million in the three month period ended June 30, 2014 to $3.2 million in the three month period ended June 30, 2015. Therapy marketing and sales expense increased $0.2 million from $2.0 million in the three months ended June 30, 2014 to $2.2 million for the three months ended June 30, 2015. The increase in Therapy marketing and sales expenses was due primarily to increases in salaries and wages and consulting fees. In June 2015, the Company incurred $235,000 of severance payments in the Therapy segment marketing and sales, which is reflected in salaries and wages. Detection marketing and sales costs increased slightly by $0.1 million from $0.9 million in the three months ended June 30, 2014 to $1.0 million for the three months ended June 30, 2015; this increase is due primarily to $0.1 million of severance payments.

 

31


Table of Contents

General and Administrative. General and administrative expenses increased by $0.5 million from $1.9 million in the three month period ended June 30, 2014 to $2.3 million in the three month periods ended June 30, 2015. The increase was due primarily to increases in personnel legal, accounting, consulting, travel and stock compensation expense.

Amortization and Depreciation. Amortization and depreciation is primarily related to acquired intangible assets and depreciation related to machinery and equipment. Amortization and depreciation increased by $241,000 from $255,000 in the three month period ended June 30, 2014 to $496,000 in the three month period ended June 30, 2015. The increase in expense was due to amortization of the acquired intangible assets related to the acquisition. In June 2015, the Company impaired intangible assets of the Therapy reporting unit and recorded amortization and depreciation expense based on the revised values of the assets.

Goodwill and long-lived asset impairment. In connection with the preparation of the financial statements for the second quarter ended June 30, 2015, the Company evaluated the Therapy reporting unit for both long-lived asset and goodwill impairment and recorded a goodwill impairment charge of $14.0 million and a $13.4 million long-lived asset impairment for a total of $27.4 million.

Other Income and Expense: (in thousands)

 

     Three months ended June 30,  
     2015      2014      Change      Change %  

Loss on extinguishment of debt

   $ —         $ (903      903         (100.0 )% 

Gain from change in fair value of warrants

     —         $ 699         (699      (100.0 )% 

Interest expense

     (70      (614      544         (88.6 )% 

Interest income

     5         12         (7      (58.3 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ (65    $ (806    $ 741         (91.9 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Tax benefit (expense)

     107         (25      132         (528.0 )% 

Loss on extinguishment of debt. The loss of $0.9 million from the extinguishment of debt represents the loss associated with the payoff of the Deerfield revenue purchase agreement, which was terminated in April 2014.

Gain from change in fair value of warrants. The loss of $0.7 million from the change in fair value of the warrants for the period ended June 30, 2014, resulted from change in the fair value of the warrants under the binomial lattice based valuation methodology, due primarily to changes in the Company’s stock price, and volatility which are the key assumptions in determining the value of the warrants. On April 30, 2014, the warrants were exercised in full and the Company issued 450,000 shares of common stock.

Interest expense. Interest expense of $70,000 decreased by $544,000 or 88.6% for the three month period ended June 30, 2015 as compared to interest expense of $614,000 in the three month period ended June 30, 2014. The reduction in interest expense is due primarily to the reduction in interest

 

32


Table of Contents

related to the Deerfield facility agreement that was terminated in March 2015. Interest related to the Hologic and Zeiss settlement obligations was $47,000 in the three months ended June 30, 2015 as compared to $54,000 in the same period in 2014.

Interest income. Interest income of $5,000 and $12,000 for the three month periods ended June 30, 2015, and 2014, respectively, reflects income earned from our money market accounts.

Tax benefit (expense). The Company recorded a tax benefit of $107,000 as compared to tax expense of $25,000 for the three month periods ended June 30, 2015, and 2014, respectively. The tax benefit is due primarily to the reversal of a deferred tax liability of approximately $117,000, offset by tax expense of approximately $10,000. The deferred liability was the result of tax amortizable goodwill that was recognized due to the impairment of goodwill. Tax expense is due primarily to state non-income and franchise based taxes.

Six months ended June 30, 2015 compared to the six months ended June 30, 2014

Revenue: (in thousands)

 

     Six months ended June 30,  
     2015      2014      Change      % Change  

Detection revenue

           

Product revenue

   $ 5,828       $ 4,873       $ 955         19.6

Service revenue

     3,915         4,134         (219      (5.3 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 

Subtotal

     9,743         9,007         736         8.2
  

 

 

    

 

 

    

 

 

    

 

 

 

Therapy revenue

           

Product revenue

     1,226         4,630         (3,404      (73.5 )% 

Service revenue

     13,394         4,550         8,844         194.4
  

 

 

    

 

 

    

 

 

    

 

 

 

Subtotal

     14,620         9,180         5,440         59.3
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue

   $ 24,363       $ 18,187       $ 6,176         34.0
  

 

 

    

 

 

    

 

 

    

 

 

 

Six months ended June 30, 2015 and 2014:

Total revenue for the six month period ended June 30, 2015 was $24.4 million compared with revenue of $18.2 million for the six month period ended June 30, 2014, an increase of approximately $6.2 million, or 34.0%. The increase in revenue was due to a $5.4 million increase in Therapy revenue and an increase in Detection revenues of approximately $0.7 million.

Detection product revenue increased by approximately $1.0 million from $4.9 million to $5.8 million or 19.6% in the six months ended June 30, 2015 as compared to the six months ended June 30, 2014. The increase is due primarily to an increase in CAD revenue of approximately $0.2 million and an increase in MRI revenue of $0.8 million.

Detection service and supplies revenue decreased approximately $0.2 million from $4.1 million in the six months ended June 30, 2014 to $3.9 million in the six months ended June 30, 2015.

 

33


Table of Contents

Service and supplies revenue reflects the sale of service contracts to our installed base of customers. The decrease in service and supplies revenue is due primarily to the decrease in OEM service contracts. Service and supplies revenue related to our installed base of customers can vary from quarter to quarter.

Therapy product revenue was approximately $1.2 million for the six months ended June 30, 2015 as compared to $4.6 million for the six months ended June 30, 2014. The decrease in product revenue was due primarily to the customer reaction to the uncertainty of reimbursement rates. Revenue from the sale of our Axxent eBx systems can vary significantly due to an increase or decrease in the number of units sold which can cause a significant fluctuation in product revenue in the period.

Therapy service and supplies revenue increased approximately $8.8 million from $4.6 million in the six months ended June 30, 2014 to $13.4 million for the six months ended June 30, 2015. The increase in Therapy service and supplies revenue is due to additional revenues resulting from the acquisition of the assets of Radion and DermEbx which represented approximately $8.6 million of revenue for the six months ended June 30, 2015. Included in the $8.6 million of revenue are approximately $0.7 million of certain customer deferred revenues which were recognized upon termination of the respective customer agreement.

In July 2014, we acquired the assets of DermEbx and Radion, each of which was a Therapy customer. For the six months ended June 30, 2014 we recognized approximately $1.6 million of Therapy product revenue and $0.5 million of Therapy service and supplies revenue, for a total of approximately $2.1 million, related specifically to these two customers.

Cost of Revenue and Gross Profit: (in thousands)

 

    Six months ended June 30,  
        2015             2014         Change     % Change  

Products

  $ 1,621      $ 2,570      $ (949     (36.9 )% 

Service & supply

    4,360        2,179        2,181        100.1

Amortization and depreciation

    1,142        674        468        69.4
 

 

 

   

 

 

   

 

 

   

 

 

 

Total cost of revenue

  $ 7,123      $ 5,423      $ 1,700        31.3
 

 

 

   

 

 

   

 

 

   

 

 

 

 

    Six months ended June 30,  
    2015     2014     Change     % Change  

Detection gross profit

  $ 8,037      $ 7,324      $ 713        9.7

Therapy gross profit

    9,203        5,440        3,763        69.2
 

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

    17,240        12,764        4,476        35.1
 

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit %

    70.8     70.2    

Gross profit for the six month period ended June 30, 2015 was $17.2 million, or 70.8% of revenue as compared to $12.8 million or 70.2% of revenue in the six month period ended June 30, 2014. Gross profit percent changes are primarily due to changes in the mix of business, consulting costs related to non-recurring engineering revenue, additional manufacturing investments and amortization of acquired intangibles.

 

    Cost of products decreased by approximately $0.9 million from approximately $2.6 million for the six months ended June 30, 2014 to approximately $1.6 million for the six months ended June 30, 2015, which is due primarily to the overall decrease in product revenue. The cost of product revenue as a percentage of product revenue was approximately 23% for the six months ended June 30, 2015 as compared to 27% for the six months ended June 30, 2014. Cost of product revenue can vary due primarily to product mix.

 

34


Table of Contents
    The cost of service and supplies increased by $2.2 million from $2.2 million in the six months ended June 30, 2014 to $4.4 million in the six months ended June 30, 2015. This increase is due primarily to the increase related to the acquisition of the assets of DermEbx and Radion, and represents primarily personnel costs related to physics, radiation therapist and management services provided following the acquisition. The cost of service and supply revenue as a percentage of service revenue was approximately 25% in each of the quarters ended June 30, 2015 and June 30, 2014.

 

    Amortization and depreciation increased by $0.4 million from $0.7 million for the six months ended June 30, 2014 to $1.1 million for the six months ended June 30, 2015. The increase in amortization and depreciation is due to amortization and depreciation for the acquired intangibles. In June 2015, the Company impaired intangible assets of the Therapy reporting unit and recorded amortization and depreciation expense based on the revised values of the assets.

Operating Expenses: (in thousands)

 

     Six months ended June 30,  
     2015      2014      Change      Change %  

Operating expenses:

           

Engineering and product development

   $ 4,528       $ 3,866       $ 662         17.1

Marketing and sales

     6,995         5,464         1,531         28.0

General and administrative

     4,543         3,554         989         27.8

Amortization and depreciation

     1,116         506         610         120.6

Goodwill and long-lived asset impairment

     27,443         —           27,443         0.0
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating expenses

   $ 44,625       $ 13,390       $ 31,235         233.3
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating expenses increased by approximately $31.2 million or 233.3%, in the six months ended June 30, 2015. The primary driver for the increase was the goodwill and long-lived asset impairment as well as additional personnel costs related to the acquisition of DermEbx and Radion. In the second quarter of 2015, the Company implemented cost reduction initiatives and as a result we expect operating expenses, net of impairment to decrease from the current levels.

Engineering and Product Development. Engineering and product development costs for the six month period ended June 30, 2015 increased by $0.6 million, or 17.1%, from $3.9 million in 2014 to $4.5 million in 2015. Therapy engineering and product development increased $0.6 million from $1.9 million in the six months ended June 30, 2014 to $2.5 million for the six months ended June 30, 2015. The increase in Therapy engineering and product development costs was due primarily to increases in salaries, consulting and clinical costs. Detection engineering and product development costs remained at $1.9 million for the six months ended June 30, 2014 and the six months ended June 30, 2015.

 

35


Table of Contents

Marketing and Sales. Marketing and sales expenses increased by $1.5 million or 28.0%, from $5.5 million in the six month period ended June 30, 2014 to $7.0 million in the six month period ended June 30, 2015. Therapy marketing and sales expense increased $1.3 million from $3.7 million in the six months ended June 30, 2014 to $5.0 million for the six months ended June 30, 2015. The increase in Therapy marketing and sales expenses was due primarily to increases in salaries and wages, consulting, trade shows and travel. These increases reflect continued investment in the Therapy segment. For the six months ended June 30, 2015, the Company incurred $0.5 million of severance payments in the Therapy segment marketing and sales. Detection marketing and sales costs increased slightly by $0.2 million from $1.8 million in the six months ended June 30, 2014 to $2.0 million for the six months ended June 30, 2015, this increase is due primarily to $0.1 million of severance payments in the second quarter of 2015.

General and Administrative. General and administrative expenses increased by $0.9 million from $3.6 million in the six month period ended June 30, 2014 to $4.5 million in the six month periods ended June 30, 2015. The increase was due primarily to increases in personnel, legal, accounting, consulting, travel and stock compensation expense.

Amortization and Depreciation. Amortization and depreciation is primarily related to acquired intangible assets and depreciation related to machinery and equipment. Amortization and depreciation increased by $0.6 million from $0.5 million in the six month period ended June 30, 2014 to $1.1 million in the six month period ended June 30, 2015. The increase in expense was due to amortization of the acquired intangible assets related to the DermEbx/ Radion acquisition. In June 2015, the Company impaired intangible assets of the Therapy reporting unit and recorded amortization and depreciation expense based on the revised values of the assets.

Goodwill and long-lived asset impairment. In connection with the preparation of the financial statements for the second quarter ended June 30, 2015, the Company evaluated the Therapy reporting unit for both long-lived asset and goodwill impairment and recorded an impairment charge of $14.0 million related to goodwill and an impairment charge of $13.4 related to long-lived assets for a total of $27.4 million.

Other Income and Expense: (in thousands)

 

     Six months ended June 30,  
     2015      2014      Change      Change %  

Loss on extinguishment of debt

   $ (1,723    $ (903      (820      90.8

Gain from change in fair value of warrants

     —           1,835         (1,835      (100.0 )% 

Interest expense

     (577      (1,431      854         (59.7 )% 

Interest income

     14         16         (2      (12.5 )% 
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ (2,286    $ (483    $ (1,803      373.3
  

 

 

    

 

 

    

 

 

    

 

 

 

Tax benefit (expense)

     28         (78      106         (135.9 )% 

 

36


Table of Contents

Loss on extinguishment of debt. The loss of $1.7 million from the extinguishment of debt represents the loss associated with the payoff of the Deerfield facility agreement, which has now been terminated. On March 31, 2015, the Company paid $11.25 million which represented the entire obligation. The loss on extinguishment represents the unamortized discount on the Facility agreement, and the write-off of the deferred debt costs. The Facility Agreement was to mature on December 29, 2016 and was able to be repaid at the Company’s option without penalty or premium. The loss of $0.9 million from the extinguishment of debt represents the loss associated with the payoff of the Deerfield revenue purchase agreement, which was terminated in April 2014.

Gain from change in fair value of warrants. The gain of $1.8 million from the change in fair value of the warrants for the period ended June 30, 2014, resulted from change in the fair value of the warrants under the binomial lattice based valuation methodology, due primarily to changes in the Company’s stock price, and volatility which are the key assumptions in determining the value of the warrants. On April 30, 2014, the warrants were exercised in full and the Company issued 450,000 shares of common stock.

Interest expense. Interest expense of $0.6 million decreased by $0.9 million or 59.7% for the six month period ended June 30, 2015 as compared to interest expense of $1.4 million in the six month period ended June 30, 2014. The reduction in interest expense is due primarily to the reduction in interest related to the Deerfield facility agreement that was terminated on March 31, 2015. Interest related to the Hologic and Zeiss settlement obligations was $92,000 in the six months ended June 30, 2015 as compared to $0.1 million in the same period in 2014.

Interest income. Interest income of $14,000 and $16,000 for the six month periods ended June 30, 2015, and 2014, respectively, reflects income earned from our money market accounts.

Tax benefit (expense). The Company recorded a tax benefit of $28,000 as compared to tax expense of $78,000 for the six month period ended June 30, 2015, and 2014, respectively. The tax benefit is due primarily to a deferred tax liability of approximately $117,000, offset by tax expense of approximately $89,000. The deferred liability was the result of tax amortizable goodwill that was recognized due to the impairment of goodwill. Tax expense is due primarily to state non-income and franchise based taxes.

Liquidity and Capital Resources

We believe that our current liquidity and capital resources are sufficient to sustain operations through at least the next 12 months, primarily due to cash on hand. Our projected cash needs include planned capital expenditures, lease and settlement commitments, and other long-term obligations.

As of June 30, 2015, the Company current assets of $29.7 million which includes $18.2 of cash and cash equivalents, current liabilities of $15.3 million and working capital of $14.4 million. The ratio of current assets to current liabilities was 1.93:1. On March 31, 2015 the Company paid $11.2 million to repay the Deerfield facility agreement. In April 2015, we paid $1.7 million to acquire VuComp’s M-Vu Breast Density product which was paid in cash at closing.

 

     For the six months ended June 30,  
     2015      2014  

Net cash provided by (used for) operating activities

   $ 223       $ (2,336

Net cash used for investing activities

     (2,535      (509

Net cash provided by (used for) financing activities

     (11,700      25,816   
  

 

 

    

 

 

 

Increase (decrease) in cash and equivalents

   $ (14,012    $ 22,971   
  

 

 

    

 

 

 

 

37


Table of Contents

Net cash provided by operating activities for the six month period ended June 30, 2015 was $223,000, compared to net cash used for operating activities of $2.3 million for the six month period ended June 30, 2014. The cash provided by operating activities for the six month period ended June 30, 2015 resulted primarily from sources of cash due to working capital changes resulting from decreases in accounts receivable offset by an increase in inventory and decreases in accounts payable and accrued expenses. We expect that cash used for or provided by operating activities may fluctuate in future periods as a result of a number of factors, including fluctuations in our operating results, specifically the timing of when we recognize revenue, our accounts receivable collections and the timing of other payments.

The net cash used for investing activities for the six month period ended June 30, 2015 was $2.5 million. The Company used approximately $799,000 for purchases of property and equipment, and $1.7 million to acquire VuComp M-Vu Breast Density software. Cash used for investing activities of $509,000 in the six month period ended June 30, 2014 consisted primarily of purchases of property and equipment.

Net cash used for financing activities for the six month period ended June 30, 2015 was $11.7 million as compared to net cash provided by financing activities of $25.8 million for the six month period ended June 30, 2014. The net cash used of $11.7 million represents primarily the repayment of the Deerfield facility agreement. The cash provided by financing activities reflects the underwritten offering in March 2014 of 2.76 million shares at approximately $11.00 per share, with net proceeds of $28.2 million after deducting offering expenses and underwriting discounts.

 

38


Table of Contents

Contractual Obligations

The following table summarizes, for the periods presented, our future estimated cash payments under existing contractual obligations (in thousands).

 

Contractual Obligations

   Payments due by period  
     Total      Less than 1
year
     1-3 years      3-5 years      5+ years  

Operating Lease Obligations

   $ 1,009       $ 507       $ 502       $ —         $ —     

Capital Lease Obligations

     1,739       $ 1,251       $ 488         —           —     

Settlement Obligations

     1,425         275         800         50         300   

Other Commitments

     2,233         2,233         —           —           —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total Contractual Obligations

   $ 6,406       $ 4,266       $ 1,790       $ 50       $ 300   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Operating lease obligations are the minimum payments due under these obligations. Capital lease obligations represent the principal payments due under the respective leases.

Settlement obligations represent the minimum payments attributable to the obligations related primarily to Zeiss and Hologic.

Other commitments represent firm purchase obligations to suppliers for future product deliverables.

Recent Accounting Pronouncements

See Note 14 to the Condensed Consolidated Financial Statements.

 

39


Table of Contents
Item 3. Quantitative and Qualitative Disclosures about Market Risk

We believe we are not subject to material foreign currency exchange rate fluctuations, as substantially all of our sales and expenses are denominated in the U.S. dollar. We do not hold derivative securities and have not entered into contracts embedded with derivative instruments, such as foreign currency and interest rate swaps, options, forwards, futures, collars or warrants, either to hedge existing risks or for speculative purposes.

 

Item 4. Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on this evaluation, as of June 30, 2015, the principal executive officer and principal financial officer concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934 (“Exchange Act”) were effective at the reasonable level of assurance.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. We conduct periodic evaluations to enhance, where necessary our procedures and controls.

Our principal executive officer and principal financial officer conducted an evaluation of our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) to determine whether any changes in internal control over financial reporting occurred during the quarter ended June 30, 2015, that have materially affected or which are reasonably likely to materially affect internal control over financial reporting. Based on that evaluation, there has been no such change during such period.

 

40


Table of Contents
PART II OTHER INFORMATION

Item 1. Legal Proceedings

Please refer to the detailed discussion regarding litigation set forth in Note 8 of the Notes to Condensed Consolidated Financial Statements in this Form 10-Q.

The Company is involved in various legal matters that are in the process of litigation or settled in the ordinary course of business. Although the final results of all such matters and claims cannot be predicted with certainty, we believe that the ultimate resolution of all such matters and claims will not have a material adverse effect on our financial condition. However, such matters could have a material adverse effect on our operating results and cash flows for a particular period.

Item 1A. Risk Factors:

We operate in a changing environment that involves numerous known and unknown risks and uncertainties that could materially adversely affect our operations. Our risk factors are described in Part I, Item 1A of our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2014 as filed with the SEC on March 13, 2015. There have been no material changes in the risks affecting iCAD since the filing of our Form 10K.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Month of purchase

   Total number
of shares
purchased (1)
     Average
price paid per
share
     Total number of
shares
purchased as
part of publicly
announced plans
or programs
     Maximum dollar
value of shares
that may yet be
purchased under
the plans or
programs
 

April 1 - April 30, 2015

     4,118       $ 4.72       $ —         $ —     

May 1 - May 31, 2015

     1,084       $ 3.70       $ —         $ —     

June 1 - June 30, 2015

     —         $ —         $ —         $ —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     5,202       $ 4.51       $ —         $ —     
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(1) Represents shares of common stock surrendered by employees to the Company to pay employee withholding taxes due upon the vesting of restricted stock.

 

41


Table of Contents
Item 6. Exhibits

 

Exhibit
No.

  

Description

    3.1    Certificate of Incorporation of the Registrant as amended through June 16, 2015.
  31.1    Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *
  31.2    Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *
  32.1    Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *
  32.2    Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *
101    The following materials formatted in XBRL (eXtensible Business Reporting Language); (i) Consolidated Balance Sheets as of June 30, 2015 and December 31, 2014, (ii) Consolidated Statements of Operations for the three and six months ended June 30, 2015 and 2014, (iii) Consolidated Statements of Cash Flows for the three and six months ended June 30, 2015 and 2014, and (iv) Notes to Consolidated Financial Statements.

 

42


Table of Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

iCAD, Inc.

(Registrant)
Date:

August 6, 2015

By:

/s/ Kenneth M. Ferry

Kenneth M. Ferry
Chief Executive Officer,
Director
Date:

August 6, 2015

By:

/s/    Kevin C. Burns        

Kevin C. Burns
President, Chief Operating Officer
Chief Financial Officer and Treasurer

 

43

EX-3.1 2 d89197dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

CERTIFICATE OF INCORPORATION

OF

HOWTEK, INC.

FIRST: The name of the Corporation is Howtek, Inc.

SECOND: The address of its registered office in the State of Delaware is 100 West 10th St., Wilmington, Delaware, County of New Castle. The name of its registered agent at such address is The Corporation Trust Company.

THIRD: The nature of the business or purposes to be conducted or promoted area:

To engage in research and development, purchase, sale, import, export, license, distribution, manufacture or rental of any program, product, machine, apparatus, appliance, merchandise and property of every kind and description, ideas, systems, procedures and services of any nature, including, without limiting the generality of the foregoing, all types of products which possess an internal intelligence for recognizing and correlating any type of data or information to be processed, pattern interpretation, recognition and memory systems and equipment, optical scanning, printing, (including, but not limited to, impact dot matrix and jet stream), analog and digital computers, components, all types of electrical, mechanical, electromechanical and electronic products and systems.

To engage in any lawful act or activity for which corporations may be organized under the General Corporation Laws of the State of Delaware.

FOURTH: The total number of shares of stock which the corporation shall have authority to issue is 1,000 all of which shares are to be Common Stock of no par value.


FIFTH: The name and mailing address of the incorporator is Leonard I. Weinstock, 355 Lexington Avenue, New York, New York 10017.

SIXTH: Election of directors need not be by ballot.

SEVENTH: The Board of Directors is authorized to make, alter, or repeal the By-laws of the corporation.

EIGHTH: Whenever a compromise or arrangement is proposed between this corporation and its creditors or any class of them and/or between this corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of this corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed for this corporation under the provisions of section 291 or Title 8 of the Delaware Code or on the application of trustees in dissolution or of any receiver or receivers appointed for this corporation under the provisions of section 279 of Title 8 of the Delaware Code order a meeting of the creditors or class of creditors, and/or of the stockholders or a class of stockholders of this corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three-fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of this corporation as consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders or class of stockholders, of this corporation, as the case may be, and also on this corporation.

THE UNDERSIGNED, being the incorporator herein before named, for the purpose of incorporating a corporation pursuant to the General Corporation Law of the State of Delaware, does make this Certificate this 21st day of February, 1984, and affirms that the statements contained herein are true under the penalties of perjury.

 

LOGO

 

Leonard I. Weinstock
Incorporator

 

–2–


CERTIFICATE OF AMENDMENT

OF

CERTIFICATE OF INCORPORATION

OF

                    HOWTEK, INC.                    

HOWTEK, INC. (hereinafter the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:

FIRST: That the Board of Directors of said Corporation, by unanimous written consent of its members, filed with the minutes of the Board, adopted resolutions proposing and declaring advisable the following amendments to the Certificate of Incorporation of said Corporation:

RESOLVED, that the Certificate of Incorporation of HOWTEK, INC. be amended by changing Article FOURTH thereof so that, as amended, said Article shall be and read as follows:

“FOURTH: The aggregate number of shares of stock which this Corporation shall have authority to issue is one million (1,000,000) shares, all of which shares are to be Common Stock par value $.01 per share.”

SECOND: That in lieu of a meeting and vote of stockholders, the stockholders have given unanimous written consent to said amendment in accordance with the provisions of Section 228 of the General Corporation Law of the State of Delaware.


THIRD: That the aforesaid amendment was duly adopted in accordance with the applicable provisions of Sections 242 and 228 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, the Corporation has caused this certificate to be signed by Robert Howard, its President and attested by Beth Weinstein, its Secretary, as of the 31st day of May, 1984.

 

HOWTEK, INC.
By:  

LOGO

 

  Robert Howard, President

 

ATTEST:

LOGO

 

Beth Weinstein, Secretary


CERTIFICATE OF AMENDMENT

OF

CERTIFICATE OF INCORPORATION

OF

                    HOWTEK, INC.                    

HOWTEK, INC. (hereinafter the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:

FIRST: That the Board of Directors of said Corporation, by unanimous written consent of its members, filed with the minutes of the Board, adopted resolutions proposing and declaring advisable the following amendments to the Certificate of Incorporation of said Corporation:

RESOLVED, that the Certificate of Incorporation of HOWTEK INC., be amended by changing Article FOURTH thereof so that, as amended, said Article shall be and read as follows:

“FOURTH: The aggregate number of shares of stock which this Corporation shall have authority to issue is ten million (10,000,000) shares, all of which shares are to be Common Stock par value $.01 per share.”

SECOND: That in lieu of a meeting and vote of stockholders, the stockholders have given unanimous written consent to said amendment in accordance with the provisions of Section 228 of the General Corporation Law of the State of Delaware.


THIRD: That the aforesaid amendment was duly adopted in accordance with the applicable provisions of Sections 242 and 228 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, the Corporation has caused this certificate to be signed by Robert Howard, its President and attested by Beth Weinstein, its Secretary, as of the 22nd day of August, 1984.

 

HOWTEK, INC.
By:  

LOGO

 

  Robert Howard, President

 

ATTEST:

LOGO

 

Beth Weinstein, Secretary


Certificate of Restoration and Revival of

Certificate of Incorporation

of

It is hereby certified that:

1. ) The name of the corporation (hereinafter called the “corporation”) is Howtek, Inc.

2. ) The corporation was organized under the provisions of the General Corporation Law of the State of Delaware.

3. ) The address, including the street, city and county, of the registered office of the corporation in the State of Delaware and the name of the registered agent at such address are as Follows:

The Corporation Trust Company

Corporation Trust Center

1209 Orange Street

Wilmington, DE 19801

New Castle County

4. ) The corporation hereby procures a restoration and revival of its certificate of incorporation, which became inoperative by law on March 1, 1987 for failure to file annual reports and non-payment of taxes payable to the State of Delaware.

5. ) The certificate of incorporation of the corporation, which provides for and will continue to provide for, perpetual duration, shall, upon the filing of this Certificate of Restoration and Revival of the Certificate of Incorporation in the Department of State of the State of Delaware, be restored and revived and shall become fully operative on February 28, 1987.

6. ) This certificate of restoration and revival of the Certificate of Incorporation is filed by authority of the duly elected directors as prescribed by Section 312 of the General Corporation Law of the State of Delaware.

Signed and attested to on July 31, 1987.

 

LOGO

 

Vice President – Finance

 

Attest:

LOGO

 

Secretary

 

Delaware Cert. Res. & Rev.-9/85-1


[illegible]          [illegible]
[illegible] HOWTEK, INC.          SCREEN TAX
*    *    *    *    *    *    *        TAX HISTORY          *    *    *    *    *    *    *    
[illegible]    TAXES    INTEREST    PENALTY    CHECK CHGS    PETITION/[illegible]
DATES & STATUS

1986

 

DUE

   2,380.00       50.00       08/03/1987
 

ADJUSTMENT PAID

   2,380.00       50.00      
     08/03/1987    000706826         

1985

 

DUE

   1,260.00    15.65    50.00       08/03/1987
 

ADJUSTMENT PAID

   1,260.00    15.65    50.00      

4

     04/25/1986    R27 5032         

1984

 

DUE

   915.22            
 

ADJUSTMENT PAID

   915.22            
     03/01/1985    060013661         

FRANCHISE TAX BALANCE:

   10.55CR         

plf

VOID 3-1-87

PETITION GRANTED AUGUST 4, 1987

BILL TO RENEW


CERTIFICATE OF AMENDMENT

OF

CERTIFICATE OF INCORPORATION

OF

HOWTEK, INC.

 

 

Adopted in accordance with the provisions

of Section 242 of the General Corporation

Law of the State of Delaware

 

 

WE, Robert Howard, Chairman of the Board and President, and Robert J. Mittman, Assistant Secretary, of Howtek, Inc. (the “Corporation”), a corporation existing under the laws of the State of Delaware, do hereby certify as follows:

1. That Article FOURTH of the Certificate of Incorporation of the Corporation has been amended to read in its entirety as follows:

FOURTH: The total number of shares of stock which the Corporation shall have authority to issue is twenty-five million (25,000,000) shares, all of which shares are to be shares of Common Stock, par value $.01 per share.


2. That the Certificate of Incorporation of the Corporation has been amended by adding a new Article Ninth, reading in its entirety as follows:

NINTH: No director of the Corporation shall be personally liable to the Corporation or its stockholders for any monetary damages for breaches of fiduciary duty as a director, provided that this provision shall not eliminate or limit the liability of a director (i) for any breach of the director’s duty of loyalty to the Corporation or its stockholders; (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) under Section 174 of the General Corporation Law of the State of Delaware; or (iv) for any transaction from which the director derived an improper personal benefit. No repeal or modification of this Article NINTH shall adversely affect any right or protection of a director of the Corporation existing at the time of such repeal or modification with respect to any acts or omissions of such director occurring in whole or in part prior to the effective date of such repeal or modification.

3. That such amendments have been duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware by the affirmative vote of the holders of a majority of the stock entitled to vote at a meeting of stockholders.

 

–2–


IN WITNESS WHEREOF, we have signed this Certificate this 21st day of October, 1987.

 

LOGO

 

Robert Howard, Chairman of the Board and President

 

ATTEST:

LOGO

 

Robert J. Mittman
Assistant Secretary

 

–3–


    STATE OF DELAWARE
    SECRETARY OF STATE
    DIVISION OF CORPORATIONS
    FILED 09:00 AM 10/01/1999
    991414443 – 2029045

CERTIFICATE OF AMENDMENT

OF THE

CERTIFICATE OF INCORPORATION

OF

HOWTEK, INC.

 

 

Adopted in accordance with the provisions of Section 242

of the General Corporation Law of the State of Delaware

 

 

The undersigned, being the President of HOWTEK, INC. (the “Corporation”), a corporation existing under the laws of the State of Delaware, does hereby certify as follows:

FIRST: That the Certificate of Incorporation of the Corporation has been amended as follows by striking out the whole of Article FOURTH thereof as it now exists and inserting in lieu and instead thereof a new Article FOURTH, reading as follows:

“FOURTH: The total number of shares of capital stock which the Corporation shall have authority to issue is Twenty-Six Million (26,000,000) shares, of which Twenty-Five Million (25,000,000) shares shall be Common stock, par value $.01 per share, and One Million (1,000,000) shares shall be Preferred Stock, par value $.01 per share.

The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Corporation is hereby expressly authorized to provide, by resolution or resolutions duly adopted by it prior to issuance, for the creation of each such series and to fix the designation and the powers, preferences, rights, qualifications, limitations and restrictions relating to the shares of each such series. The authority of the Board of Directors with respect to each series of Preferred Stock shall include, but not be limited to, determining the following:

(a) the designation of the series and the number of shares to constitute such series (which number may be increased or decreased from time to time unless otherwise provided by the Board of Directors);


(b) the dividend rate (or method of determining such rate), any conditions on which and times at which dividends are payable, the preference or relation which such dividends shall bear to the dividends payable on any other class or classes or of any other series of capital stock including the Preferred Stock, and whether such dividends shall be cumulative or non-cumulative;

(c) whether the series will be redeemable (at the option of the Corporation or the holders of such shares or both, or upon the happening of a specified event) and, if so, the redemption prices and the conditions and times upon which redemption may take place and whether for cash, property or rights, including securities of the Corporation or another corporation;

(d) whether the shares of such series shall be subject to the operation of a retirement or sinking fund and, if so, the extent to and manner in which any such retirement or sinking fund shall be applied to the purchase or redemption of the shares of such series for retirement or other corporate purposes and the terms and provisions relating to the operation thereof;

(e) the conversion or exchange rights (at the option of the Corporation or the holders of such shares or both, or upon the happening of a specified event), if any, including the conversion or exchange, times, prices, rates, adjustments and other terms of conversion or exchange;

(f) whether the shares of such series shall have voting rights in addition to any voting rights provided as a matter of law and, if so, the terms of such voting rights, which may be general or limited;

 

–2–


(g) the conditions or restrictions, if any, upon the creation of indebtedness of the Corporation or upon the issue or reissue or sale of any additional stock, including additional shares of such series or of any other series of Preferred Stock or of any other class;

(h) the rights of the holders upon voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Corporation or upon any dissolution of the assets of the Corporation (including preferences over the Common Stock or other class or classes or series of capital stock including the Preferred Stock);

(i) the preemptive rights, if any, to subscribe to additional issues of stock or securities of the Corporation;

(j) the limitations and restrictions, if any, to be effective while any shares of such series are outstanding upon the payment of dividends or the making of other distributions on, and upon the purchase, redemption or other acquisition by the Corporation of, the Common Stock or shares of stock of any other class or any other series of Preferred Stock; and

(k) such other special rights and privileges, if any, for the benefit of the holders of the Preferred Stock, as shall not be inconsistent with the provisions of the Corporation’s Certificate of Incorporation, as amended, or applicable law.

All shares of Preferred Stock of the same series shall be identical in all respects, except that shares of any one series issued at different times may differ as to dates, if any, from which dividends thereon may accumulate. All shares of Preferred Stock redeemed, purchased or otherwise acquired by the Corporation (including share surrendered for conversion) shall be cancelled and thereupon restored to the status of authorized but unissued shares of Preferred Stock undesignated as to series.”

 

–3–


SECOND: That such amendment has been duly adopted by the affirmative vote of the holders of a majority of the stock entitled to vote at a meeting of stockholders in accordance with the provisions of the General Corporation Law of the State of Delaware.

Dated: September 28, 1999.

 

HOWTEK, INC.
By:  

LOGO

 

  W. Scott Parr, President

 

–4–


   STATE OF DELAWARE
   SECRETARY OF STATE
   DIVISION OF CORPORATIONS
   FILED 09:00 AM 12/28/1999
   991565517 – 2029045

 

HOWTEK, INC.

CERTIFICATE OF DESIGNATION

OF

7.0% SERIES A CONVERTIBLE PREFERRED STOCK

SETTING FORTH THE POWERS,

PREFERENCES, RIGHTS, QUALIFICATIONS,

LIMITATIONS AND RESTRICTIONS OF

SUCH SERIES OF PREFERRED STOCK

 

 

Pursuant to Section 151 of the General Corporation Law of the State of Delaware, Howtek, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, in accordance with the provisions of Section 103 thereof, DOES HEREBY CERTIFY:

That pursuant to the authority of Directors of the Board of Directors of the Corporation by Article Fourth of the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”), and in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware, the Board of Directors of the Corporation adopted the following resolution creating a series of preferred stock designated as 7.0% Series A Convertible Preferred Stock.

RESOLVED that, pursuant to the authority vested in the Board of Directors of the Corporation in accordance with the General Corporation Law of the State of Delaware and the provisions of the Certificate of Incorporation, a series of the class of authorized Preferred Stock, liquidation preference $100 per share, of the Corporation is hereby created and that the designation and number of shares thereof and the voting powers, preferences and relative, participating, optional and other special rights of the shares of such series, and the qualifications, limitations and restrictions thereof, are as follows:

Section 1. Designation, Number and Rank. (a) The shares of such series shall be designated “7.0% Series a Convertible Preferred Stock” (the “Series A Preferred Stock”). The number of shares initially constituting the Series A Preferred Stock shall be 10,000, par value $.01 per share, which number may be decreased (but not increased) by the Board of Directors without a vote of stockholders; provided, however, that such number may not be decreased below the number of then outstanding shares of Series A Preferred Stock.


(b) The Series A Preferred Stock shall, with respect to dividend rights and rights on liquidation, dissolution or winding up, rank prior to the common stock, par value $.01 per share, of the Corporation (the “Common Stock”) and any other issue of preferred stock hereinafter created by the Corporation which does not expressly provide that it ranks senior to or pari passu with the Series A Preferred Stock as to dividends, liquidation preference or otherwise.

Section 2. Dividends and Distributions. (a) The holders of shares of Series A Preferred Stock, in preference to the holders of shares of Common Stock and of any shares of other capital stock of the Corporation (other than shares of any other issue of preferred stock hereinafter created by the Corporation that expressly provides that it ranks senior to or pari passu with the Series A Preferred Stock as to dividends and distributions), shall be entitled to receive, out of the assets of the Corporation legally available therefor, cumulative dividends of $7.00 per annum per share, payable annually, subject to appropriate adjustment by the Board of Directors of the Corporation in the event of any stock split, dividend or similar division of shares of Series A Preferred Stock or reverse split or similar combination of the Series A Preferred Stock. Dividends shall be payable annually, in arrears, on the last day of December in each year, commencing December 31, 1999.

(b) Dividends payable pursuant to paragraph (a) of this Section 2 shall begin to accrue and be cumulative from the date of issuance, whether or not earned or declared. The amount of dividends so payable shall be determined on the basis of twelve 30-day months and a 360-day year. Accrued but unpaid dividends shall not bear interest. Dividends paid on the shares of Series A Preferred Stock in an amount less than the total amount of such dividends at the time accrued and payable on such shares shall be allocated pro rata on a share-by-share basis among all such shares at the time outstanding. The Board of Directors may fix a record date for the determination of holders of shares of Series A Preferred Stock entitled to receive payment of a dividend declared hereon, which record date shall be no more than sixty days prior to the date fixed for the payment thereof.

 

–2–


(c) Dividends payable pursuant to paragraph (a) of this Section 2 shall be payable at the Corporation’s option in either cash or in that number of shares of Common Stock determined by dividing the total amount of dividends due by the Fair Market Value of the Common Stock. For purposes of this paragraph (c) and Section 7(d) “Fair Market Value” shall mean the average of the closing sales price of the Common Stock as reported on Nasdaq (or such other exchange or quotation medium on which the Common Stock is then traded) for the ten (10) day trading period ending on the third trading date immediately preceding the payment date. In the event of payment of dividends in shares of Common Stock no fractional shares shall be issued but cash shall be paid in lieu of the issuance of the fractional shares based upon the Fair Market Value of such fractional shares.

(d) No dividends or other distributions shall be paid or set apart for payment on, and no purchase, redemption or other acquisition shall be made by the Corporation of any shares of Common Stock unless and until all accrued and unpaid dividends on the Series A Preferred Stock, including the full dividend for the then-current annual dividend period, shall have been paid or declared and set apart for payment.

(e) The holders of shares of Series A Preferred Stock shall not be entitled to receive any dividends or other distributions except as provided herein.

Section 3. Voting Rights. In addition to any voting rights provided in the Corporation’s Certificate of Incorporation or By-Laws, the Series A Preferred Stock shall vote together with the Common Stock as a single class on all actions to be voted on by the stockholders of the Corporation. Each share of Series A Preferred Stock shall entitle the holder thereof to such number of votes per share on each such action as shall equal the number of whole shares of Common Stock into which each share of Series A Preferred Stock is then convertible. The holders of Series A Preferred Stock shall be entitled to notice of any stockholder’s meeting in accordance with the By-Laws of the Corporation.

 

–3–


Section 4. Redemption at the Option of the Corporation.

(a) Provided the Corporation has not received a notice of conversion pursuant to Section 7 hereof, the Corporation may at any time after the date of issuance, at the option of the Board of Directors, redeem in whole or in part the Series A Preferred Stock by paying in cash therefor a sum equal to $100 per share, together with any accrued and unpaid dividends thereon (the “Redemption Price”). The Redemption Price shall be subject to appropriate adjustment by the Board of Directors of the Corporation in the event of any stock split, dividend or similar division of shares of Series A Preferred Stock or reverse split or similar combination of the Series A Preferred Stock. At least fifteen (15) but no more than thirty (30) days prior to the Redemption Date (as hereinafter defined) set forth therein, written notice shall be mailed, first class postage prepaid, to each holder of record (at the close of business on the business day next preceding the day on which notice is given) of the Series A Preferred Stock to be redeemed, at the address last shown on the records of the Corporation for such holder, notifying such holder of the redemption to be effected, specifying the number of shares to be redeemed from such holder, the date of such redemption (the “Redemption Date”), the Redemption Price, the place at which payment may be obtained and calling upon such holder to surrender to the Corporation, in the manner and at the place designated, his, her or its certificate or certificates representing the shares to be redeemed (the “Redemption Notice”). Any redemption effected pursuant to this Section 4 shall be made on a pro rata basis among the holders of the Series A Preferred Stock in proportion to the number of shares of Series A Preferred Stock then held by them. Each holder of Series A Preferred Stock to be redeemed shall surrender to the Corporation the certificate or certificates representing such shares, in the manner and at the place designated in the Redemption Notice, and thereupon the Redemption Price of such shares shall be payable to the order of the person whose name appears on such certificate or certificates as the owner thereof and each surrendered certificate shall be cancelled.

(b) From and after the applicable Redemption Date, unless there shall have been a default in payment of the Redemption Price, all rights of the holders of shares of series A Preferred Stock designated for redemption in the Redemption Notice as holders of Series A Preferred Stock (except the right

 

–4–


to receive the Redemption Price without interest upon surrender of their certificate or certificates) shall cease with respect to such shares.

Section 5. Reacquired Shares. Any shares of Series A Preferred Stock converted, redeemed, purchased or otherwise acquired by the Corporation in any manner whatsoever shall be retired and cancelled promptly after the acquisition thereof and shall upon cancellation be restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the Board of Directors as shares of preferred stock of one or more other series but not as shares of Series A Preferred Stock.

Section 6. Liquidation, Dissolution or Winding Up.

(a) If the Corporation shall commence a voluntary case under the Federal bankruptcy laws or any other applicable Federal or state bankruptcy, insolvency or similar law, or consent to the entry of an order for relief in an involuntary case under such law or to the appointment of a receiver, liquidator, assignee, custodian, trustee, sequestrator (or other similar official) of the Corporation or of any substantial part of its property, or make an assignment for the benefit of its creditors, or admit in writing its inability to pay its debts generally as they become due, or if a decree or order for relief in respect of the Corporation shall be entered by a court having jurisdiction in the premises in an involuntary case under the Federal bankruptcy laws or any other applicable federal or state bankruptcy, insolvency or similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or other similar official) of the Corporation or of any substantial part of its property, or ordering the winding up or liquidation of its affairs, and any such decree or order shall be unstayed and in effect for a period of 180 consecutive days and on account of any such event the Corporation shall liquidate, dissolve or wind up, or if the Corporation shall otherwise liquidate, dissolve or wind up, no distribution shall be made (i) to the holders of shares of Common Stock unless, prior thereto, the holders of shares of Series A Preferred Stock shall have received $100 with respect to each share (as adjusted for any stock dividends, combinations or splits with respect to such shares) plus all declared or accumulated but unpaid dividends on such shares.

(b) Neither the consolidation, merger or other business combination of the Corporation with or into any other person or persons nor the sale of all or substantially all the

 

–5–


assets of the Corporation shall be deemed to be a liquidation, dissolution or winding up of the Corporation for purposes of this Section 6.

Section 7. Conversion. The holders of the Series A Preferred Stock shall have conversion rights as follows:

(a) Each share of Series A Preferred Stock, if not redeemed by the Corporation, is convertible into that number of shares of Common Stock determined by dividing the aggregate liquidation preference of the number of Series A Preferred Stock being converted by $1.00 (the “Conversion Rate”). The Conversion Rate shall be subject to appropriate adjustment by the Board of Directors of the Corporation in the event of any stock split, dividend or similar division of the Common Stock or reverse split or similar combination of the Common Stock prior to conversion.

(b) Before any holder of Series A Preferred Stock shall be entitled to convert the same into shares of Common Stock, he shall surrender the certificate or certificates therefor, duly endorsed, at the office of the Corporation or of any transfer agent for the Series A Preferred Stock together with such other documents and evidence of payment of any required taxes on the part of the holder as the Corporation may request, and shall give written notice to the Corporation at its principal corporate office, of the election to convert the same and shall state therein the name or names in which the certificate or certificates for shares of Common Stock are to be issued. The Corporation shall, as soon as practicable thereafter, issue and deliver at such office to such holder of Series A Preferred Stock, or to the nominee or nominees of such holder, a certificate or certificates for the number of shares of Common Stock to which such holder shall be entitled as aforesaid. Such conversion shall be deemed to have been made immediately prior to the close of business on the date of such surrender of the shares of Series A Preferred Stock to be converted, and the person or persons entitled to receive the shares of Common Stock issuable upon such conversion shall be treated for all purposes as the record holder or holders of such shares of Common Stock as of such date.

(c) In case any shares of Series A Preferred Stock are to be redeemed pursuant to Section 4, such right of conversion shall cease and terminate as to the shares of Series A Preferred Stock to be redeemed at the close of business on the

 

–6–


business day next preceding the date fixed for redemption unless the Corporation shall default in the payment of the Redemption Price.

(d) Upon conversion, the holder of shares of Series A Preferred Stock shall be entitled to receive any accrued and unpaid dividends on the shares of Series A Preferred Stock surrendered for conversion to the date of such conversion. Such dividends shall be payable at the Corporation’s option in either cash or in that number of shares of Common Stock determined by dividing the total amount of dividends due by the Fair Market Value of the Common Stock. In the event of payment of dividends in shares of Common Stock no fractional shares shall be issued but cash shall be paid in lieu of the issuance of the fractional shares based upon the Fair Market Value of such fractional shares.

(e) Once the Corporation has received the written notice of the holder of the election to convert, the right of the Corporation to redeem such shares of Series A Preferred Stock shall terminate.

(f) The Corporation will pay any and all issue or other taxes that may be payable in respect of any issuance or delivery of shares of Common Stock on conversion of the Series A Preferred Stock. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance or delivery of Common Stock in a name other than that of the holder of Series A Preferred Stock, and no such issuance or delivery shall be made unless and until the person requesting such issuance has paid to the Corporation the amount of such tax or has established, to the satisfaction of the Corporation, that such tax has been paid.

(g) The Corporation shall at all times reserve and keep available for issuance upon the conversion of the Series A Preferred Stock, such number of its authorized but unissued shares of Common Stock as will from time to time be sufficient to permit the conversion of all outstanding shares of Series A Preferred Stock, and shall take all action required to increase

 

–7–


the authorized number of shares of Common Stock if necessary to permit the conversion of all outstanding shares of Series A Preferred Stock.

Section 8. Certain Covenants. Any registered holder of Series A Preferred Stock may proceed to protect and enforce its rights and the rights of such holders by any available remedy by proceeding at law or in equity to protect and enforce any such rights, whether for the specific enforcement of any provision in this Certificate of Designation or in aid of the exercise of any power granted herein, or to enforce any other proper remedy.

IN WITNESS WHEREOF, a duly authorized officer of the Corporation has caused this Certificate to be duly executed on this 22nd day of December, 1999.

 

HOWTEK, INC.
By:  

LOGO

 

Name:   W. Scott Parr
Title:   President

 

–8–


STATE OF DELAWARE     
SECRETARY OF STATE     
DIVISION OF CORPORATIONS     
FILED 09:00 AM 10/19/2000     
001528794 – 2029045     

 

 

CERTIFICATE OF DESIGNATION

OF

7.0% SERIES B CONVERTIBLE PREFERRED STOCK

SETTING FORTH THE POWERS,

PREFERENCES, RIGHTS, QUALIFICATIONS,

LIMITATIONS AND RESTRICTIONS OF

SUCH SERIES OF PREFERRED STOCK

 

 

Pursuant to Section 151 of the General Corporation Law of the State of Delaware, Howtek, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, in accordance with the provisions of Section 103 thereof, DOES HEREBY CERTIFY:

That pursuant to the authority of Directors of the Board of Directors of the Corporation by Article Fourth of the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”), and in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware, the Board of Directors of the Corporation adopted the following resolution creating a series of preferred stock designated as 7.0% Series B Convertible Preferred Stock.

RESOLVED that, pursuant to the authority vested in the Board of Directors of the Corporation in accordance with the General Corporation Law of the State of Delaware and the provisions of the Certificate of Incorporation, a series of the class of authorized Preferred Stock, liquidation preference $1,000 per share, of the Corporation is hereby created and that the designation and number of shares thereof and the voting powers, preferences and relative, participating, optional and other special rights of the shares of such series, and the qualifications, limitations and restrictions thereof, are as follows:

Section 1. Designation, Number and Rank. (a) The shares of such series shall be designated “7.0% Series B Convertible Preferred Stock” (the “Series B Preferred Stock”). The number of shares initially constituting the Series B Preferred Stock shall be 2,000, par value $.01 per share, which number may be decreased (but not increased) by the Board of Directors without a vote of stockholders; provided, however, that such number may not be decreased below the number of then outstanding shares of Series B Preferred Stock.


(a) The Series B Preferred Stock shall, with respect to dividend rights and rights on liquidation, dissolution or winding up, be equivalent to the rights of the Company’s 7% Series A Convertible Preferred Stock and pari passu to any other issue of preferred stock hereinafter created by the Corporation which does not expressly provide that it ranks either junior to or senior to the Series B Preferred Stock as to dividends, liquidation preference or otherwise and shall rank prior in right to the common stock, par value $.01 per share, of the Corporation (the “Common Stock”).

Section 2. Dividends and Distributions. (a) The holders of shares of Series B Preferred Stock, in preference to the holders of shares of Common Stock and of any shares of other capital stock of the Corporation (other than shares of the 7% Series A Convertible Preferred Stock or any other issue of preferred stock hereinafter created by the Corporation unless the issue of preferred stock hereinafter created expressly provides that it ranks junior to or senior to the Series B Preferred Stock as to dividends and distributions), shall be entitled to receive, out of the assets of the Corporation legally available therefor, cumulative dividends of $70.00 per annum per share, payable annually, subject to appropriate adjustment by the Board of Directors of the Corporation in the event of any stock split, dividend or similar division of shares of Series B Preferred Stock or reverse split or similar combination of the Series B Preferred Stock. Dividends shall be payable annually, in arrears, on the last day of December in each year, commencing December 31, 2000, provided, however, if any such date shall fall on a day other than a business day, then such payment shall, at the Corporation’s option, be made on either the first business day preceding or the first business day following the date on which such payment shall have so fallen due.

(b) Dividends payable pursuant to paragraph (a) of this Section 2 shall begin to accrue and be cumulative from the date of issuance, whether or not earned or declared. The amount of dividends so payable shall be determined on the basis of twelve 30-day months and a 360-day year. Accrued but unpaid dividends shall not bear interest. Dividends paid on the shares of Series B Preferred Stock in an amount less than the total

 

–2–


amount of such dividends at the time accrued and payable on such shares shall be allocated pro rata on a share-by-share basis among all such shares at the time outstanding. The Board of Directors may fix a record date for the determination of holders of shares of Series B Preferred Stock entitled to receive payment of a dividend declared hereon, which record date shall be no more than sixty days prior to the date fixed for the payment thereof.

(c) Dividends payable pursuant to paragraph (a) of this Section 2 shall be payable at the Corporation’s option in either cash or in that number of shares of Common Stock determined by dividing the total amount of dividends due by the Fair Market Value of the Common Stock. For purposes of this paragraph (c) “Fair Market Value” shall mean the average of the closing sales price of the Common Stock as reported on Nasdaq (or such other exchange or quotation medium on which the Common Stock is then traded) for the ten (10) day trading period immediately preceding the record date for such dividend, or the payment date if no record date shall have been established. In the event of payment of interest in shares of Common Stock no fractional shares shall be issued but cash shall be paid in lieu of the issuance of the fractional share based upon the Fair Market Value of such fractional shares.

(d) No dividends or other cash distributions shall be paid or set apart for payment on any shares of Common Stock unless and until all accrued and unpaid dividends on the Series B Preferred Stock, including the full dividend for the then – current annual dividend period, shall have been paid or declared and set apart for payment.

(e) The holders of shares of Series B Preferred Stock shall not be entitled to receive any dividends or other distributions except as provided herein.

Section 3. Voting Rights. Except as provided in the Corporation’s Certificate of Incorporation or By-Laws or as provided in the Delaware General Corporation Law, the Series B Preferred Stock shall have no voting rights.

 

–3–


Section 4. Redemption at the Option of the Corporation.

(a) Provided (i) the Corporation has not received a notice of conversion pursuant to Section 7 hereof and (ii) the closing sales prices of the Common Stock as reported by Nasdaq (or such other exchange or quotation medium on which the Common Stock is then traded) has been 125% or more of the then Conversion Rate (as hereinafter defined) for any five consecutive trading days (the “Trigger Period”), the Corporation may at any time after the date of issuance, at the option of the Board of Directors, redeem in whole or in part the Series B Preferred Stock by paying in cash therefor a sum equal to $1,000 per share, together with any accrued and unpaid dividends thereon (the “Redemption Price”). Written notice of redemption may be given no more than twenty (20) days after the last day of the Trigger Period and shall be mailed, first class postage prepaid, to each holder of record (at the close of business on the business day next preceding the day on which notice is given) of the Series B Preferred Stock to be redeemed, at the address last shown on the records of the Corporation for such holder. Each such notice of redemption shall specify the date fixed for redemption, which date shall not be less than fifteen (15) days nor more than sixty (60) days after the date notice of redemption is first given, the redemption price, the place or places of payment, the then effective Conversion Rate (as hereinafter defined), that the right of holders of shares of Series B Preferred Stock being redeemed to exercise their conversion right shall terminate as to such shares at the close of business on the day that immediately precedes the date that is fixed for redemption (provided that no default by the Corporation in the payment of the applicable redemption price shall have occurred and be continuing), that payment will be made upon presentation and surrender of the shares of Series B Preferred Stock, that accrued but unpaid dividends to the date fixed for redemption (whether or not declared) will be paid on the date fixed for redemption, and that on and after the redemption date, dividends will cease to accrue on such shares.

(b) Any notice which is mailed as herein provided shall be conclusively presumed to have been duly given, whether or not the holder of the Series B Preferred Stock receives such notice; and failure to give such notice by mail, or any defect in such notice, to the holders of any shares designated for redemption shall not affect the validity of the proceedings for the redemption of any other shares of Series B Preferred Stock. On or after the date fixed for redemption as stated in such notice, each holder of the shares of Series B Preferred Stock shall surrender the certificate (or certificates) evidencing such shares to the Corporation at the place designated in such

 

–4–


notice and shall thereupon be entitled to receive payment of the applicable Redemption Price. If, on the date fixed for redemption, funds necessary for the redemption shall be available therefor and shall have been irrevocably deposited or set aside, then, notwithstanding that the certificates evidencing any shares so called for redemption shall not have been surrendered, the dividends with respect to the shares so called shall cease to accrue after the date fixed for redemption, the shares shall no longer be deemed outstanding, the holders thereof shall cease to be stockholders, and all rights whatsoever with respect to the shares so called for redemption (except the right of the holders to receive the applicable Redemption Price, without interest, upon surrender of their certificates therefor) shall terminate. Any monies deposited by the Corporation pursuant to the foregoing provision and unclaimed at the end of one year from the date fixed for redemption shall, to the extent permitted by law, be returned to the Corporation, after which the holders of shares of Series B Preferred Stock so called for redemption shall look only to the Corporation for the payment thereof.

(c) Notwithstanding the provisions of paragraph (b) of this Section 5, no redemption of the Series B Preferred Stock may be made unless at the date fixed for redemption the shares of Common Stock that may be issued upon conversion of the Series B Preferred Stock have either been registered under the Securities Act of 1933 (the “Act”) or may be publicly sold under either Rule 144 promulgated under the Act or another applicable exemption from registration under the Act.

Section 5. Reacquired Shares. Any shares of Series B Preferred Stock converted, redeemed, purchased or otherwise acquired by the Corporation in any manner whatsoever shall be retired and canceled promptly after the acquisition thereof. All such shares of Series B Preferred Stock shall upon their cancellation, and, if required, upon the filing of an appropriate certificate with the Secretary of State of the State of Delaware, become authorized but unissued shares of Preferred Stock of the Corporation and may be reissued as part of another series of Preferred Stock of the Corporation.

 

–5–


Section 6. Liquidation, Dissolution or Winding Up.

(a) If the Corporation shall commence a voluntary case under the Federal bankruptcy laws or any other applicable Federal or state bankruptcy, insolvency or similar law, or consent to the entry of an order for relief in an involuntary case under such law or to the appointment of a receiver, liquidator, assignee, custodian, trustee, sequestrator (or other similar official) of the Corporation or of any substantial part of its property, or make an assignment for the benefit of its creditors, or admit in writing its inability to pay its debts generally as they become due, or if a decree or order for relief in respect of the Corporation shall be entered by a court having jurisdiction in the premises in an involuntary case under the Federal bankruptcy laws or any other applicable federal or state bankruptcy, insolvency or similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or other similar official) of the Corporation or of any substantial part of its property, or ordering the winding up or liquidation of its affairs, and any such decree or order shall be unstayed and in effect for a period of 180 consecutive days and on account of any such event the Corporation shall liquidate, dissolve or wind up, or if the Corporation shall otherwise liquidate, dissolve or wind up, no distribution shall be made (i) to the holders of shares of Common Stock unless, prior thereto, the holders of shares of Series B Preferred Stock shall have received $1,000 with respect to each share (as adjusted for any stock dividends, combinations or splits with respect to such shares) plus all declared or accumulated but unpaid dividends on such shares.

(b) Neither the consolidation, merger or other business combination of the Corporation with or into any other entity nor the sale of all or substantially all the assets of the Corporation shall be deemed to be a liquidation, dissolution or winding up of the Corporation for purposes of this Section 6.

Section 7. Conversion. The holders of the Series B Preferred Stock shall have conversion rights as follows (the “Conversion Rights”):

(a) Right to Convert. Each share of Series B Preferred Stock, if not redeemed by the Corporation, is convertible into that number of shares of Common Stock determined by dividing the aggregate liquidation preference of the number of Series B Preferred Stock being converted by $2.00 (the “Conversion Rate”). The Conversion Rate shall be subject to appropriate adjustment by the Board of Directors of the Corporation in the event of any stock split, dividend or similar division of the Common Stock, or the Series B Preferred Stock,

 

–6–


as the case may be, or reverse split or similar combination of the Common Stock, or the Series B Preferred Stock, as the case may be, prior to conversion.

(b) Mechanics of Conversion. Before any holder of Series B Preferred Stock shall be entitled to convert the same into shares of Common Stock, he shall surrender the certificate or certificates therefor, duly endorsed, at the office of the Corporation or of any transfer agent for the Series B Preferred Stock, and shall give written notice to the Corporation at its principal corporate office, of the election to convert the same and shall state therein the name or names in which the certificate or certificates for shares of Common Stock are to be issued. The Corporation shall, as soon as practicable thereafter, subject to the receipt by the Corporation from the converting holder of any representations or other documentation the Corporation may reasonably request in order to comply with the federal securities laws with respect to the issue of the Common Stock upon such conversion, to issue and deliver at such office to such holder of Series B Preferred Stock, or to the nominee or nominees of such holder, a certificate or certificates for the number of shares of Common Stock to which such holder shall be entitled as aforesaid. Such conversion shall be deemed to have been made immediately prior to the close of business on the date of such surrender of the shares of Series B Preferred Stock to be converted, and the person or persons entitled to receive the shares of Common Stock issuable upon such conversion shall be treated for all purposes as the record holder or holders of such shares of Common Stock as of such date.

(c) In case any shares of Series B Preferred Stock are to be redeemed pursuant to Section 4, such right of conversion shall cease and terminate as to the shares of Series B Preferred Stock to be redeemed at the close of business on the business day next preceding the date fixed for redemption unless the Corporation shall default in the payment of the Redemption Price.

(d) Upon conversion, the holder of shares of Series B Preferred Stock shall be entitled to receive, at the Corporation’s option, in cash, or shares of Common Stock, any accrued and unpaid dividends on the shares of Series B Preferred Stock surrendered for conversion to the date of such conversion.

 

–7–


(e) Once the Corporation has received the written notice of the holder of the election to convert, the right of the Corporation to redeem such shares of Series B Preferred Stock shall terminate.

(f) The Corporation shall at all times reserve and keep available for issuance upon the conversion of the Series B Preferred Stock, such number of its authorized but unissued shares of Common Stock as will from time to time be sufficient to permit the conversion of all outstanding shares of Series B Preferred Stock, and shall take all action required to increase the authorized number of shares of Common Stock if necessary to permit the conversion of all outstanding shares of Series B Preferred Stock.

Section 8. Certain Covenants. Any registered holder of Series B Preferred Stock may proceed to protect and enforce its rights and the rights of such holders by any available remedy by proceeding at law or in equity to protect and enforce any such rights, whether for the specific enforcement of any provision in this Certificate of Designation or in aid of the exercise of any power granted herein, or to enforce any other proper remedy.

IN WITNESS WHEREOF, a duly authorized officer of the Corporation has caused this Certificate to be duly executed on this 19th day of October, 2000.

 

HOWTEK, INC.
By:  

/s/ W. Scott Parr

Name:   W. Scott Parr
Title:   President

 

–8–


   

STATE OF DELAWARE

SECRETARY OF STATE

DIVISION OF CORPORATIONS

FILED 09:00 AM 06/28/2002

020422294 – 2029045

CERTIFICATE OF AMENDMENT

OF

CERTIFICATE OF INCORPORATION

OF

HOWTEK, INC.

 

 

Adopted in accordance with the provisions of Section 242

of the General Corporation Law of the State of Delaware

 

 

THE UNDERSIGNED, being a duly authorized officer of Howtek, Inc., a corporation existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows:

FIRST: That the Certificate of Incorporation of the Corporation has been amended as follows by striking out the first sentence of Article FOURTH as it now exists and inserting in lieu and instead thereof a new first sentence of Article FOURTH, reading as follows:

“The total number of shares of capital stock which the Corporation shall have authority to issue is Fifty One Million (51,000,000), of which Fifty Million (50,000,000) shares shall be Common Stock, par value $.01 per share (“Common Stock”), and One Million (1,000,000) shares shall be Preferred Stock, par value $.01 per share (“Preferred Stock”).”

SECOND: That such amendment has been duly adopted in accordance with the provisions of the General Corporation Law of the State of Delaware by the affirmative vote of the holders of a majority of the stock entitled to vote at a meeting of stockholders.

IN WITNESS WHEREOF, the undersigned has executed this Certificate this 28th day of June, 2002.

 

/s/ W. Scott Parr

Name:   W. Scott Parr
Title:   President and CEO


   

STATE OF DELAWARE

SECRETARY OF STATE

DIVISION OF CORPORATIONS

FILED 09:10 AM 06/28/2002

020424085 – 2029045

CERTIFICATE OF AMENDMENT

OF

CERTIFICATE OF INCORPORATION

OF

HOWTEK, INC.

 

 

Adopted in accordance with the provisions of Section 242

of the General Corporation Law of the State of Delaware

 

 

THE UNDERSIGNED, being a duly authorized officer of Howtek, Inc., a corporation existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows:

1. That the Certificate of Incorporation of the Corporation has been amended as follows by striking out Article FIRST as it now exists and inserting in lieu and instead thereof a new Article FIRST reading as follows:

 

“FIRST:    The name of the Corporation is:
   icad, inc.”

2. That the Certificate of Incorporation of the Corporation has been further amended as follows by inserting a new Article TENTH reading as follows:

“TENTH: 1. Indemnification.

The Corporation shall, and does hereby, indemnify to the fullest extent permitted or authorized by the Delaware General Corporation Law or judicial or administrative decisions, as the same exists or may hereafter be amended or interpreted differently in the future (but, in the case of any such amendment or interpretation, only to the extent that such amendment or interpretation permits the Corporation tO provide broader indemnification rights than permitted


prior thereto), each person (including the current and future heirs, beneficiaries, personal representatives and estate of such person) who was or is a party, or is threatened to be made a party, or was or is a witness, to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”) and whether the basis of such Proceeding is an allegation of an action in an official capacity of such person related to the Corporation or any other capacity while such person is serving as an officer, director, employee or agent of the Corporation, against any liability (which for purposes of this Article shall include any judgment, settlement, penalty or fine) or cost, charge or expense (including attorneys’ fees) asserted against him or incurred by him by reason of the fact that such indemnified person (1) is or was a director, officer or employee of the Corporation or (2) is or was an agent of the Corporation as to whom the Corporation, by action of its Board of Directors, has agreed to grant such indemnity or (3) is or was serving, at the request of the Corporation, as a director, officer or employee of another corporation, partnership, joint venture, trust or other enterprise (including serving as a fiduciary of any employee benefit plan) or (4) is or was serving as an agent of such other corporation, partnership, joint venture, trust or other enterprise described in clause (3) hereof as to whom the Corporation, by action of its Board of Directors, has agreed to grant such indemnity. Each director, officer, employee or agent of the Corporation to whom indemnification rights under this Section 1 of this Article have been granted shall be referred to as an “Indemnified Person.”

Notwithstanding the foregoing, except as specified in Section 3 of this Article, the Corporation shall not be required to indemnify an Indemnified Person in connection with a Proceeding (or any part thereof) initiated by such Indemnified Person, unless such authorization for such Proceeding (or any part thereof) was not denied by the Board of Directors of the

 

2


Corporation prior to sixty (60) days after receipt of notice thereof from such Indemnified Person stating his intent to initiate such Proceeding and any such indemnification shall be made only upon such terms and conditions as the Board of Directors may deem appropriate.

2. Advance of Costs, Charges and Expenses.

Costs, charges and expenses (including attorneys’ fees) incurred by an officer, director, employee or agent who is an Indemnified Person in defending a Proceeding shall be paid by the Corporation to the fullest extent permitted or authorized by the Delaware General Corporation Law or judicial or administrative decisions, as the same exists or may hereafter be amended or interpreted differently in the future (but, in the case of any such future amendment or interpretation, only to the extent that such amendment or interpretation permits the Corporation to provide broader rights to advance costs, charges and expenses than permitted prior thereto), in advance of the final disposition of such Proceeding, upon receipt of an undertaking by or on behalf of the Indemnified Person to repay all amounts so advanced in the event that it shall ultimately be determined by final judicial decision that such person is not entitled to be indemnified by the Corporation as authorized in this Article and upon such other terms and conditions, in the case of an agent as to whom the Corporation has agreed to grant such indemnity, as the Board of Directors may deem appropriate. The Corporation may, upon approval of the Indemnified Person, authorize the Corporation’s counsel to represent such person in any Proceeding, whether or not the Corporation is a party to such Proceeding. Such authorization may be made by the Board of Directors by majority vote, including directors who are parties to such Proceeding.

 

3


3. Procedure for Indemnification.

Any indemnification or advance under this Article shall be made promptly and in any event within sixty (60) days upon the written request of the Indemnified Person (except in the case of a claim for an advancement of costs, charges or expenses, in which case the applicable period shall be twenty (20) days). The right to indemnification or advances as granted by this Article shall be enforceable by the Indemnified Person in any court of competent jurisdiction if the Corporation denies such request under this Article, in whole or in part, or if no disposition thereof is made within sixty (60) days or twenty (20) days, as may be applicable. Such Indemnified Person’s costs and expenses incurred in connection with successfully establishing his right to indemnification or advancement of costs, charges or expenses, in whole or in part, in any such action shall also be indemnified by the Corporation It shall be a defense to any such action that the claimant has not met the standard of conduct, if any, required by the Delaware General Corporation Law or judicial or administrative decisions, as the same exists or may hereafter be amended or interpreted differently in the future (but, in the case of any such future amendment or interpretation, only to the extent that such amendment or interpretation does not impose a more stringent standard of conduct than permitted prior thereto), but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its Board of Directors or any committee thereof, its independent legal counsel, and its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant or advancement for the claimant is proper in the circumstances because he has met the applicable standard of conduct, if any, nor the fact that there has been an actual determination by the Corporation (including its Board of Directors or any committee thereof, its independent legal counsel, or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.

 

4


4. Non-Exclusivity; Survival of Indemnification.

The indemnification and advancement provided by this Article shall not be deemed exclusive of any other rights to which those Indemnified Persons may be entitled under any agreement, vote of stockholders or disinterested directors or recommendation of counsel or otherwise, both as to actions in such person’s official capacity and as to actions in any other capacity while holding such office or position, and shall continue as to an Indemnified Person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, beneficiaries, personal representatives and the estate of such person. All rights to indemnification and advancement under this Article shall be deemed to be a contract between the Corporation and each Indemnified Person who serves or served in such capacity at any time while this Article is in effect. Any repeal or modification of this Article or any repeal or modification of relevant provisions of the Delaware General Corporation Law or any other applicable laws shall not in any way diminish any rights to indemnification of such Indemnified Person, or the obligations of the Corporation arising hereunder, for claims relating to matters occurring prior to such repeal or modification.

5. Savings Clause.

If this Article or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify and advance costs to each Indemnified Person as to costs, charges and expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement with respect to any Proceeding, including an action by or in the right of the Corporation, to the full extent permitted by any applicable portion of this Article that shall not have been invalidated and as permitted by the Delaware General Corporation Law.”

 

5


3. That the Certificate of Incorporation of the Corporation has been further amended as follows by inserting a new Article ELEVENTH reading as follows:

“ELEVENTH: 1. The number of directors comprising the Board of Directors shall be such number as may be from time to time fixed by resolution of the Board of Directors. The directors shall be classified in respect to the time for which they shall severally hold office, by dividing them into three classes. The number of directors in each class shall be as nearly equal as possible. At each annual election, any vacancy in any class may be filled and the successors to the directors of the class whose terms shall expire in that year shall be elected to hold office for the term of three years, and the term of office of one class of directors shall expire in each year. In the event the number of directors is increased, election may be made to a class of directors with terms expiring in three years or less in order to maintain proportionate equality between the classes.

2. The directors shall be elected by the holders of shares of stock of the Corporation entitled to vote on the election of directors, and directors shall be elected by a plurality vote. The directors shall be divided into three classes, designated as Class I, Class II and Class III as set forth in Section 1 of this Article ELEVENTH. The Class I directors shall serve until the annual meeting of stockholders held in 2003, the Class II directors until the annual meeting of stockholders held in 2004, and the Class III directors until the annual meeting of stockholders held in 2005 and, in each case, until their successor(s) are duly elected and qualified. At each annual meeting of stockholders commencing with the annual meeting to be held during the calendar year 2003 each of the successors to the Directors of the Class whose

 

6


term shall have expired that year shall be elected for a three-year term. If the number of directors is changed, any increase or decrease shall be apportioned among the classes so as to maintain the number of directors in each class as nearly equal as possible, and any additional director of any class elected to fill a vacancy resulting from an increase in such class shall hold office for a term that shall coincide with the remaining term of that class, but in no case will a decrease in the number of directors shorten the term of any incumbent director. A director shall hold office until the annual meeting for the year in which his term expires and until the successor shall be elected and shall qualify, subject, however to prior death, resignation, retirement, disqualification or removal from office. Any vacancy occurring in the Board of Directors, including any vacancy created by reason of an increase in the number of directors, shall be filled for the unexpired term by the concurring vote of a majority of the directors then in office, whether or not a quorum, and any director so chosen shall hold office for the remainder of the full term of the class of directors in which the new directorship was created or the vacancy occurred and until such director’s successor shall have been elected and qualified.’’

4. That such amendments have been duly adopted in accordance with the provisions of the General Corporation Law of the State of Delaware by the affirmative vote of the holders of a majority of the stock entitled to vote at a meeting of stockholders.

Dated: June 28, 2002

 

HOWTEK, INC.
By:  

/s/ W. Scott Parr

  Name:   W. Scott Parr
  Title:   President and CEO

 

7


 

State of Delaware

Secretary of State

Division of Corporations

Delivered 04:41 PM 12/10/2003

FILED 04:22 PM 12/10/2003

SRV 030794156 – 2029045 FILE

CERTIFICATE OF OWNERSHIP AND MERGER

OF

ISSI ACQUISITION CORP.

AND

HOWTEK DEVICES CORPORATION.

INTO

ICAD, INC.

 

 

Adopted in accordance with the provisions of

Section 253 of the Delaware General Corporation Law

 

 

iCAD, Inc. a Delaware corporation, desiring to merge with ISSI ACQUISITION CORP., a Delaware corporation, and HOWTEK DEVICES CORPORATION, a Delaware corporation, pursuant to the provisions of Section 253 of the Delaware General Corporation Law, hereby certifies as follows:

1. iCAD, Inc. is a corporation formed under the laws of the State of Delaware (the “Corporation”).

2. The Corporation is the owner of all of the outstanding shares of each class of stock of each of ISSI ACQUISITION CORP., a corporation formed under the laws of the State of Delaware, and HOWTEK DEVICES CORPORATION, a corporation formed under the laws of the State of Delaware (the “Subsidiaries”).

3. On December 4, 2003, the Board of Directors of the Corporation adopted the following resolutions to merge the Subsidiaries into the Corporation:

“WHEREAS, (the Corporation owns 100% of the issued and outstanding common stock of ISSI ACQUISITION CORP., a Delaware corporation (“ISSI”); and


WHEREAS, the Corporation owns 100% of the issued and outstanding common stock of HOWTEK DEVICES CORPORATION, a Delaware corporation (“Howtek”); and

WHEREAS, it is in the best interests of the Corporation to enter into an Agreement and Plan of Merger with ISSI and Howtek providing for the merger of ISSI and Howtek with and into the Corporation in order that all the estate, property, rights, privileges and franchises of ISSI and Howtek shall vest in and be possessed by the Corporation;

NOW, THEREFORE, be it:

RESOLVED, that ISSI and Howtek shall merge into the Corporation and upon the effective date of such merger each of ISSI and Howtek shall cease to exist and shall no longer exercise their respective powers, privileges and franchises subject to the laws of the State of Delaware; The Corporation shall succeed to the property and assets of and exercise all the powers, privileges and franchises of each of ISSI and Howtek and shall assume and be liable for all of the debts and liabilities, if any, of each of ISSI and Howtek; and further

RESOLVED, that the President, or any executive officer of the Corporation designated by the Board of Directors, is hereby authorized to execute, in the name of the Corporation, a Certificate of Ownership and Merger, and to file such Certificate in the Office of the Secretary of State of the State of Delaware, and to do all the other acts and things that may be necessary to carry out and effectuate the purpose of these resolutions.”

IN WITNESS WHEREOF, ICAD, INC. has caused this Certificate to be executed by its duly authorized officer thereunto duly authorized this 4th day of December 2003.

 

iCAD, Inc.
(a Delaware corporation)

By:

 

/S/ W. Scott Parr

 

Name:

 

W. Scott Parr

 

Title:

 

President and CEO


State of Delaware

Secretary of State

Division of Corporations

Delivered 05:38 PM 07/18/2007

FILED 05:12 PM 07/18/2007

SRV 070828054 – 2029045 FILE

  

CERTIFICATE OF AMENDMENT

OF CERTIFICATE OF INCORPORATION

OF

ICAD, INC.

Adopted in accordance with the provisions of Section 242

of the General Corporation Law of the State of Delaware

The undersigned, being a duly authorized officer of iCAD, Inc. (the “Corporation”), a corporation existing under the laws of the State of Delaware, does hereby certify as follows:

1. The Certificate of Incorporation of the Corporation is hereby amended by striking out the first sentence of Article FOURTH thereof and by substituting in lieu thereof a new first sentence reading as follows:

“FOURTH: The total number of shares of capital stock which the Corporation shall have authority to issue is Eighty Six Million (86,000,000), of which Eighty Five Million (85,000,000) shares shall be Common Stock, par value $.01 per share (“Common Stock”), and One Million (1,000,000) shares shall be Preferred Stock, par value $.01 per share (“Preferred Stock”).

2. The Certificate of Incorporation of the Corporation is hereby amended by striking out Article ELEVENTH thereof in its entirety and by substituting in lieu thereof the following new Article ELEVENTH:

“ELEVENTH: The number of directors of the Corporation shall be fixed only by resolution of the board of directors of the Corporation from time to time. Each director who is serving as a director on the date of this Amendment to the Certificate of Incorporation shall hold office until the next annual meeting of stockholders after such date and until his or her successor has been duly elected and qualified, notwithstanding that such director may have been elected for a term that extended beyond the date of such next annual meeting of stockholders. At each annual meeting of stockholders after the date of this Amendment to the Certificate of Incorporation, directors elected at such annual meeting shall hold office until the next annual meeting of stockholders”

2. That such amendments have been duly adopted in accordance with the provisions of the General Corporation Law of the State of Delaware by the affirmative vote of the holders of a majority of the stock entitled to vote at a meeting of stockholders.

 

Dated: July 18, 2007        
    iCAD, INC.
    By:  

LOGO

 

      Name:   Darlene Deptula-Hicks
      Title:   EVP/CFO


CERTIFICATE OF AMENDMENT

OF CERTIFICATE OF INCORPORATION

OF

ICAD, INC.

Adopted in accordance with the provisions of Section 242

of the General Corporation Law of the State of Delaware

The undersigned, being a duly authorized officer of iCAD, Inc. (the “Corporation”), a corporation existing under the laws of the State of Delaware, does hereby certify as follows:

1. The Certificate of Incorporation of the Corporation is hereby amended by striking out the first sentence of Article FOURTH thereof and by substituting in lieu thereof a new first sentence reading as follows:

“FOURTH: The total number of shares of capital stock which the Corporation shall have authority to issue is Eighty Six Million (86,000,000), of which Eighty Five Million (85,000,000) shares shall be Common Stock, par value $.01 per share (“Common Stock”), and One Million (1,000,000) shares shall be Preferred Stock, par value $.01 per share (“Preferred Stock”). The presently issued and outstanding shares of Common Stock, exclusive of treasury stock, shall be combined in the ratio of one (1) share of Common Stock for each five (5) shares of Common Stock currently issued and outstanding. Such combination shall not change the number of shares of capital stock which the Corporations shall have authority to issue as set forth in this Certificate of Amendment of Certificate of Incorporation nor shall it affect the rights or preferences of the holders of Common Stock now issued and outstanding.”

2. That such amendment has been duly adopted in accordance with the provisions of the General Corporation Law of the State of Delaware by the affirmative vote of the holders of a majority of the stock entitled to vote at a meeting of stockholders.

3. That such amendment shall be effective on August 15, 2012 at 4:15 P.M. Eastern Daylight Time.

Dated: August 10, 2012

 

iCAD, INC.
By:  

/s/ Kevin C. Burns

  Name:   Kevin C. Burns
  Title:   Executive Vice President of Finance, Chief Financial Officer


CERTIFICATE OF AMENDMENT

OF CERTIFICATE OF INCORPORATION

OF

ICAD, INC.

Adopted in accordance with the provisions of Section 242

of the General Corporation Law of the State of Delaware

The undersigned, being a duly authorized officer of iCAD, Inc. (the “Corporation”), a corporation existing under the laws of the State of Delaware, does hereby certify as follows:

1. The Certificate of Incorporation of the Corporation is hereby amended by striking out the first sentence of Article FOURTH thereof and by substituting in lieu thereof a new first sentence reading as follows:

“FOURTH: The total number of shares of capital stock which the Corporation shall have authority to issue is Twenty One Million (21,000,000), of which Twenty Million (20,000,000) shares shall be Common Stock, par value $.01 per share (“Common Stock”), and One Million (1,000,000) shares shall be Preferred Stock, par value $.01 per share (“Preferred Stock”).

2. That such amendment has been duly adopted in accordance with the provisions of the General Corporation Law of the State of Delaware by the affirmative vote of the holders of a majority of the stock entitled to vote at a meeting of stockholders.

Dated: May 31, 2013

iCAD, INC.

By:

  /s/ Kevin Burns
  Kevin Burns, Executive Vice President of Finance and Chief Financial Officer


CERTIFICATE OF AMENDMENT

OF CERTIFICATE OF INCORPORATION

OF

iCAD, INC.

Adopted in accordance with the provisions of Section 242

of the General Corporation Law of the State of Delaware

The undersigned, being a duly authorized officer of iCAD, Inc. (the “Corporation”), a corporation existing under the laws of the State of Delaware, does hereby certify as follows:

1. The Certificate of Incorporation of the Corporation is hereby amended by striking out the first sentence of Article FOURTH thereof and by substituting in lieu thereof a new first sentence reading as follows:

“FOURTH: The total number of shares of capital stock which the Corporation shall have authority to issue is Thirty One Million (31,000,000), of which Thirty Million (30,000,000) shares shall be Common Stock, par value $0.01 per share (“Common Stock”), and One Million (1,000,000) shares shall be Preferred Stock, par value $.01 per share (“Preferred Stock”).

2. That such amendment has been duly adopted in accordance with the provisions of the General Corporation Law of the State of Delaware by the affirmative vote of the holders of a majority of the stock entitled to vote at a meeting of stockholders.

Dated: June 16, 2015

iCAD, INC.

By:

  /s/ Kevin Burns
  Kevin Burns, President, Chief Operating Officer, Chief Financial Officer and Treasurer
EX-31.1 3 d89197dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Kenneth M. Ferry, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2015 of iCAD, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and;

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 6, 2015

 

/s/ Kenneth M. Ferry

Kenneth M. Ferry
Chief Executive Officer
EX-31.2 4 d89197dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Kevin C. Burns, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2015 of iCAD, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and;

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 6, 2015

 

/s/ Kevin C. Burns

Kevin Burns
Chief Financial Officer
EX-32.1 5 d89197dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of iCAD, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2015 (the “Report”), I, Kenneth M. Ferry, as Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Kenneth M. Ferry

Kenneth M. Ferry
Chief Executive Officer

Date: August 6, 2015

EX-32.2 6 d89197dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of iCAD, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2015 (the “Report”), I, Kevin C. Burns, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Kevin C. Burns

Kevin C. Burns
Chief Financial Officer

Date: August 6, 2015

EX-101.INS 7 icad-20150630.xml XBRL INSTANCE DOCUMENT 15720547 900000 800000 1700000 0.01 4382000 2164000 2625000 3457000 11856000 6050000 6270000 409000 1 3187000 34851000 2092000 0.0575 185831 20000000 15720547 0.01 1000000 0 15906378 0.01 255000 26828000 499000 210406000 1009000 34444000 1251000 1739000 0 639000 255000 10492000 4235000 8049000 1804000 89000 228000 -174706000 2200000 17099000 51543000 633000 159000 1039000 0 4678000 15339000 774000 1251000 488000 1902000 1608000 94000 4698000 51543000 5700000 4674000 3322000 7764000 2861000 485000 1415000 29716000 47937000 1491000 14198000 223000 422000 163000 18208000 442000 500000 395000 5735000 3195000 8930000 13568000 13568000 13568000 5735000 3195000 36800000 5735000 2.55 2800000 8463000 3.15 0.05 1469000 13568000 8930000 855000 2600000 76000 396000 383000 1700000 800000 11880000 185831 20000000 15546346 0.01 1000000 0 15732177 0.01 209100000 5602000 62779000 5044000 795000 14738000 5554000 9120000 2151000 203000 -145063000 30991000 93770000 1525000 157000 4861000 22049000 180000 1020000 955000 132000 93770000 17504000 2214000 9642000 4255000 1415000 44616000 1205000 27263000 54000 540000 32220000 26530000 26530000 26530000 19600000 7663000 26530000 P8Y10M24D 1700000 P7Y P10Y P3Y P5Y 600000 600000 1600000 90000 0.15 P18M 182000 2382000 90000 0.15 P18M 2016-12-29 11250000 162000 -0.09 -2336000 -0.09 1804189 12759000 12759000 12759000 -0.09 65000 465000 -1187000 16000 18187000 4100000 1068000 44000 -96000 8684000 -626000 -22000 80000 12764000 -483000 2035000 -903000 -1109000 9503000 78000 606000 -1835000 5423000 -198000 5464000 524000 327000 22971000 13390000 1431000 -509000 25816000 1575000 3866000 2179000 379000 794000 28214000 -576000 293000 674000 3554000 7000 448000 2570000 31000 748000 -1149000 506000 432000 27000 3045000 76000 106000 101000 3671000 140000 83000 376000 7000 50000 56000 9180000 5440000 -368000 2100000 500000 1600000 9007000 7324000 3413000 326318 1477871 0.665 0.642 P3Y6M 0.0082 0 7.83 3.67 0.00 0.00 32000 22408000 685000 13959000 14667000 Q2 -1.90 223000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> As of June&#xA0;30, 2015 unrecognized compensation cost (in thousands) related to unexercisable options and unvested restricted stock and the weighted average remaining period is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Remaining expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,698</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Weighted average term</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.31&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> In accordance with FASB ASC Topic 350-20, &#x201C;Intangibles - Goodwill and Other&#x201D;, (&#x201C;ASC 350-20&#x201D;), the Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the Company is less than the carrying value of the Company.</p> </div> 2 2015 false <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 18pt"> <i>Revenue Recognition</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company recognizes revenue primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (&#x201C;FASB&#x201D;) Accounting Standards Codification (&#x201C;ASC&#x201D;) Update No.&#xA0;2009-13, &#x201C;Multiple-Deliverable Revenue Arrangements&#x201D; (&#x201C;ASU 2009-13&#x201D;) and ASC Update No.&#xA0;2009-14, &#x201C;Certain Arrangements That Contain Software Elements&#x201D; (&#x201C;ASU 2009-14&#x201D;) and ASC 985-605, &#x201C;Software&#x201D; (&#x201C;ASC 985-605&#x201D;). Revenue for the sale of certain CAD products is recognized in accordance with ASC 840 &#x201C;Leases&#x201D; (&#x201C;ASC 840&#x201D;). For multiple element arrangements, revenue is allocated to all deliverables based on their relative selling prices. In such circumstances, a hierarchy is used to determine the selling price to be used for allocating revenue to deliverables as follows: (i)&#xA0;vendor-specific objective evidence of fair value (&#x201C;VSOE&#x201D;), (ii)&#xA0;third-party evidence of selling price (&#x201C;TPE&#x201D;), and (iii)&#xA0;best estimate of the selling price (&#x201C;BESP&#x201D;). VSOE generally exists only when the deliverable is sold separately and is the price actually charged for that deliverable. The process for determining BESP for deliverables without VSOE or TPE considers multiple factors including relative selling prices; competitive prices in the marketplace, and management judgment; however, these may vary depending upon the unique facts and circumstances related to each deliverable.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company uses customer purchase orders that are subject to the Company&#x2019;s terms and conditions or, in the case of an Original Equipment Manufacturer (&#x201C;OEM&#x201D;) are governed by distribution agreements. In accordance with the Company&#x2019;s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer&#x2019;s post-delivery acceptance provisions, if any, and the installation process.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company has determined that iCAD&#x2019;s digital, and film based sales generally follow the guidance of FASB ASC Topic&#xA0;605 &#x201C;Revenue Recognition&#x201D; (&#x201C;ASC 605&#x201D;) as the software has been considered essential to the functionality of the product per the guidance of ASU 2009-14. Typically, the responsibility for the installation process lies with the OEM partner. On occasion, when iCAD is responsible for product installation, the installation element is considered a separate unit of accounting because the delivered product has stand-alone value to the customer. In these instances, the Company allocates revenue to the deliverables based on the framework established within ASU 2009-13. Therefore, the installation and training revenue is recognized as the services are performed according to the BESP of the element. Revenue from the digital and film based equipment, when there is installation, is recognized based on the relative selling price allocation of the BESP, when delivered.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> Revenue from certain CAD products is recognized in accordance with ASC 985-605. Sales of this product include training, and the Company has established VSOE for this element. Product revenue is determined based on the residual value in the arrangement, and is recognized when delivered. Revenue for training is deferred and recognized when the training has been completed.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company recognizes post contract customer support revenue together with the initial licensing fee for certain MRI products in accordance with ASC 985-605-25-71.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> Sales of the Company&#x2019;s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13. Product revenue is generally recognized when the product has been delivered and service and source revenue is typically recognized over the life of the service and source agreement. The Company includes the following in service and supplies revenue: the sale of physics and management services, the lease of electronic brachytherapy equipment, development fees, supplies and the right to use the Company&#x2019;s AxxentHub software. Physics and management services revenue and development fees are considered to be delivered as the services are performed or over the estimated life of the agreement. The Company typically bills items monthly over the life of the agreement except for development fees, which are generally billed in advance or over a 12 month period and the fee for treatment supplies which is generally billed in advance.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20, &#x201C;Services&#x201D;. The Company provides for estimated warranty costs on original product warranties at the time of sale.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Note 3 &#x2013; Business Combinations</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Acquisition of VuComp M-Vu Breast Density Product</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> On April&#xA0;29, 2015, pursuant to the terms of the Asset Purchase Agreement with VuComp, the Company purchased VuComp&#x2019;s M-Vu Breast Density product for $1,700,000 in cash. Under the terms of the agreement, the Company acquired the breast density intellectual property product, which will be integrated with the Company&#x2019;s PowerLook Advanced Mammography Platform (AMP). PowerLook AMP is a modular solution designed to provide advanced tools for breast disease detection and analysis, including CAD for tomosynthesis. The Company considered the acquisition to be an acquisition of a business as the Company acquired the Breast Density product and certain customer liabilities which were considered to be an integrated set of activities at acquisition. Accordingly the assets were valued in accordance with ASC Topic 805, &#x201C;<i>Business Combinations</i>&#x201D; (&#x201C;ASC 805&#x201D;).</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The amount allocated to the acquired assets, was estimated primarily through the use of discounted cash flow valuation techniques. Appraisal assumptions utilized under this method include a forecast of estimated future net cash flows, as well as discounting the future net cash flows to their present value. The acquired technology is being amortized over the estimated useful life of approximately eight years and nine months from the closing of the transaction. The following is a summary of the preliminary allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Amount</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">Estimated&#xA0;Amortizable&#xA0;Life</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Developed Technology</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">900</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center"> 8&#xA0;years&#xA0;9&#xA0;months</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">800</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Purchase price</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,700</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The assets obtained in the acquisition of VuComp&#x2019;s M-Vu Breast Density product and the anticipated future revenues are included in the Detection segment and, accordingly, the goodwill resulting from the purchase price allocation is included in goodwill of the Detection segment.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Acquisition of DermEbx and Radion</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> On July&#xA0;15, 2014, the Company entered into two Asset Purchase Agreements, one with Radion, Inc. (&#x201C;Radion&#x201D;) the other with DermEbx, a series of Radion Capital Partners LLC (&#x201C;DermEbx&#x201D;) (the &#x201C;Radion/DermEbx Acquisition&#x201D;). Pursuant to the Asset Purchase Agreement with DermEbx, the Company purchased substantially all of the assets of DermEbx, including all of DermEbx&#x2019;s intellectual property and customer contracts. The Company paid the following consideration to DermEbx: (i)&#xA0;$1,600,000 in cash and (ii)&#xA0;600,000 restricted shares of the Company&#x2019;s common stock, $0.01 par value per share. The 600,000 restricted shares are subject to the following provisions; 25% was locked up until the date that was two trading days after the Company announced its fourth quarter 2014 earnings, which occurred on March&#xA0;2, 2015; 30% of the shares shall be locked up for a period of 24 months from the date of the agreement; and 30% of the shares shall be locked up for a period of 36 months from the date of the agreement. In addition the Company delivered the remaining 15%, or 90,000, of the restricted shares to US Bank, N.A., as escrow agent, to be held in escrow for a period of 18 months pursuant to the terms of an escrow agreement. The 90,000 escrow shares will act as the source of payment for the indemnification of the Company by DermEbx under the DermEbx Asset Purchase Agreement.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Pursuant to the terms of the Asset Purchase Agreement with Radion, the Company purchased substantially all of the assets of Radion, including all of Radion&#x2019;s intellectual property and customer contracts. The Company paid the following consideration to Radion: (i)&#xA0;$2,382,000 in cash which included $182,000 payoff of an existing note payable and (ii)&#xA0;the issuance to Radion of 600,000 restricted shares of the Company&#x2019;s common stock. The 600,000 restricted shares are subject to the following provisions; 25% of the shares were locked up until the date that is two trading days after the Company announces its fourth quarter 2014 earnings, which occurred on March&#xA0;2, 2015; 30% of the shares shall be locked up for a period of 24 months from the date of the agreement; and 30% of the shares shall be locked up for a period of 36 months from the date of the agreement. In addition the Company delivered the remaining 15% or 90,000 of the restricted shares to US Bank, N.A., as escrow agent, to be held in escrow for a period of 18 months pursuant to the terms of an escrow agreement. The 90,000 escrow shares will act as the source of payment for the indemnification of the Company by Radion under the Radion Asset Purchase Agreement.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company did not achieve significant synergies from the Radion/DermEbx Acquisition. Prior to the Radion DermEbx Acquisition, the Sellers represented one of the Company&#x2019;s significant customers in the Therapy segment. The Company recognized approximately $0.8 million of Therapy product revenue and approximately $0.3 million of Therapy service revenue, for a total of $1.1 million related to Sellers, in the quarter ended June&#xA0;30, 2014 and approximately $1.6 million of Therapy product revenue and approximately $0.5 million of Therapy service revenue, for a total of $2.1 million related to Sellers, in the six months ended June&#xA0;30, 2014.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The amounts allocated to purchased and developed software, customer relationships, trade names, employee non-compete agreements and backlog were estimated primarily through the use of discounted cash flow valuation techniques. Appraisal assumptions utilized under these methods include a forecast of estimated future net cash flows, as well as discounting the future net cash flows to their present value. Acquired intangible assets are being amortized over the estimated useful lives as set forth in the following table. The following is a summary of the allocation of the total purchase price based on the estimated fair values of the assets acquired and liabilities assumed as of the date of the acquisition and the amortizable lives of the intangible assets:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Amount</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">Estimated&#xA0;Amortizable&#xA0;Life</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="2"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,457</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Property and equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,625</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="center"> 3&#xA0;&#x2013;&#xA0;7&#xA0;Years</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Identifiable intangible assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,050</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="center"> 5&#xA0;&#x2013;&#xA0;10&#xA0;Years</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,270</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Current liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(4,382</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Long-term liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,164</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Purchase price</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,856</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The assets obtained in the Radion/DermEbx Acquisition and the resulting revenues are included in the Therapy segment and, accordingly, the goodwill resulting from the purchase price allocation is included in goodwill of the Therapy segment. As discussed in Note 12, the Company recorded a goodwill impairment charge related to the Therapy segment of $14.0 million in the quarter ended June&#xA0;30, 2015.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The goodwill is deductible for income tax purposes.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The unaudited proforma operating results for the Company for the three and six months ended June&#xA0;30, 2014, assuming the Radion/DermEbx Acquisition occurred as of January&#xA0;1, 2014 are as follows (in thousands except per share amounts):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>June&#xA0;30, 2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Three&#xA0;months</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Six&#xA0;months</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,815</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,408</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Income from operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">566</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">685</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net (loss) income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(264</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net (loss) income per share-basic</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.02</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net (loss) income per share-diluted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.02</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Basic</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,959</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,959</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Diluted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,959</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,667</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> <div> In accordance with FASB Topic ASC 280, &#x201C;<i style="FONT-SIZE: 13px; FONT-FAMILY: 'Times New Roman'; FONT-VARIANT: normal; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); WIDOWS: 1; LETTER-SPACING: normal; LINE-HEIGHT: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">Segments</i>&#x201D;, operating segments, are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker CODM in deciding how to allocate resources and assess performance. </div> -1.90 <div> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> Future minimum lease payments under all outstanding capital leases are as follows: (in thousands)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="88%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">Fiscal Year</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center">Capital<br /> Leases</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">774</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,039</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">89</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Subtotal minimum lease obligation</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,902</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Less interest</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(163</td> <td nowrap="nowrap" valign="bottom">)&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Total, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,739</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Less current portion</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,251</td> <td nowrap="nowrap" valign="bottom">)&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Long term portion</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">488</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 2071435 10-Q 0000749660 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The shares of the Company&#x2019;s common stock, issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Period Ended</b><br /> <b>June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Stock Options</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,618,043</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,477,871</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Restricted Stock</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">453,392</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">326,318</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Stock options and restricted stock</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,071,435</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,804,189</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>Note 1 - Basis of Presentation and Significant Accounting Policies</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The accompanying condensed consolidated financial statements of iCAD, Inc. and subsidiaries (&#x201C;iCAD&#x201D; or the &#x201C;Company&#x201D;) have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201C;US GAAP&#x201D;). In the opinion of management, these unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at June&#xA0;30, 2015, the results of operations of the Company for the three and six month period ended June&#xA0;30, 2015 and 2014, respectively, and cash flows of the Company for the three and six month period ended June&#xA0;30, 2015 and 2014, respectively. Although the Company believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US&#xA0;GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (&#x201C;SEC&#x201D;). The accompanying financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10&#x2013;K for the fiscal year ended December&#xA0;31, 2014 filed with the SEC on March&#xA0;13, 2015. The results for the three and six month period ended June&#xA0;30, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#xA0;31, 2015, or any future period.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 18pt"> <i>Revenue Recognition</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company recognizes revenue primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (&#x201C;FASB&#x201D;) Accounting Standards Codification (&#x201C;ASC&#x201D;) Update No.&#xA0;2009-13, &#x201C;Multiple-Deliverable Revenue Arrangements&#x201D; (&#x201C;ASU 2009-13&#x201D;) and ASC Update No.&#xA0;2009-14, &#x201C;Certain Arrangements That Contain Software Elements&#x201D; (&#x201C;ASU 2009-14&#x201D;) and ASC 985-605, &#x201C;Software&#x201D; (&#x201C;ASC 985-605&#x201D;). Revenue for the sale of certain CAD products is recognized in accordance with ASC 840 &#x201C;Leases&#x201D; (&#x201C;ASC 840&#x201D;). For multiple element arrangements, revenue is allocated to all deliverables based on their relative selling prices. In such circumstances, a hierarchy is used to determine the selling price to be used for allocating revenue to deliverables as follows: (i)&#xA0;vendor-specific objective evidence of fair value (&#x201C;VSOE&#x201D;), (ii)&#xA0;third-party evidence of selling price (&#x201C;TPE&#x201D;), and (iii)&#xA0;best estimate of the selling price (&#x201C;BESP&#x201D;). VSOE generally exists only when the deliverable is sold separately and is the price actually charged for that deliverable. The process for determining BESP for deliverables without VSOE or TPE considers multiple factors including relative selling prices; competitive prices in the marketplace, and management judgment; however, these may vary depending upon the unique facts and circumstances related to each deliverable.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company uses customer purchase orders that are subject to the Company&#x2019;s terms and conditions or, in the case of an Original Equipment Manufacturer (&#x201C;OEM&#x201D;) are governed by distribution agreements. In accordance with the Company&#x2019;s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer&#x2019;s post-delivery acceptance provisions, if any, and the installation process.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company has determined that iCAD&#x2019;s digital, and film based sales generally follow the guidance of FASB ASC Topic&#xA0;605 &#x201C;Revenue Recognition&#x201D; (&#x201C;ASC 605&#x201D;) as the software has been considered essential to the functionality of the product per the guidance of ASU 2009-14. Typically, the responsibility for the installation process lies with the OEM partner. On occasion, when iCAD is responsible for product installation, the installation element is considered a separate unit of accounting because the delivered product has stand-alone value to the customer. In these instances, the Company allocates revenue to the deliverables based on the framework established within ASU 2009-13. Therefore, the installation and training revenue is recognized as the services are performed according to the BESP of the element. Revenue from the digital and film based equipment, when there is installation, is recognized based on the relative selling price allocation of the BESP, when delivered.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> Revenue from certain CAD products is recognized in accordance with ASC 985-605. Sales of this product include training, and the Company has established VSOE for this element. Product revenue is determined based on the residual value in the arrangement, and is recognized when delivered. Revenue for training is deferred and recognized when the training has been completed.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company recognizes post contract customer support revenue together with the initial licensing fee for certain MRI products in accordance with ASC 985-605-25-71.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> Sales of the Company&#x2019;s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13. Product revenue is generally recognized when the product has been delivered and service and source revenue is typically recognized over the life of the service and source agreement. The Company includes the following in service and supplies revenue: the sale of physics and management services, the lease of electronic brachytherapy equipment, development fees, supplies and the right to use the Company&#x2019;s AxxentHub software. Physics and management services revenue and development fees are considered to be delivered as the services are performed or over the estimated life of the agreement. The Company typically bills items monthly over the life of the agreement except for development fees, which are generally billed in advance or over a 12 month period and the fee for treatment supplies which is generally billed in advance.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20, &#x201C;Services&#x201D;. The Company provides for estimated warranty costs on original product warranties at the time of sale.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 18pt"> <i>Cost of Revenue</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> Cost of revenue consists of the costs of products purchased for resale, costs relating to service including personnel costs for physicists, management services and radiation therapists, costs of service contracts to maintain equipment after the warranty period, product installation, training, customer support, certain warranty repair costs, inbound freight and duty, cost of supplies, manufacturing, warehousing, material movement, inspection, scrap, rework, amortization, depreciation and in-house product warranty repairs.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> In September 2014, the Company reclassified depreciation previously included in product and service cost of revenue to amortization and depreciation as a separate component of cost of revenue. For the three and six months ended June&#xA0;30, 2014, approximately $343,000 and $674,000, respectively was reclassified to conform to current period classification. Medical Device Excise tax included in the cost of revenue is approximately $132,000 and $331,000, for the three and six months ended June&#xA0;30, 2015, respectively and $200,000 and $379,000 for the three and six months ended June&#xA0;30, 2014, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 18pt"> <i>Segments</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company reports the results of two segments, Cancer Detection (&#x201C;Detection&#x201D;) and Cancer Therapy (&#x201C;Therapy&#x201D;). The Detection segment consists of our advanced image analysis and workflow products. The Therapy segment consists of our radiation therapy (&#x201C;Axxent&#x201D;) products, physics and management services, development fees, supplies, and the right to use the AxxentHub software platform.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Note 12 - Goodwill</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In accordance with FASB ASC Topic 350-20, &#x201C;Intangibles - Goodwill and Other&#x201D;, (&#x201C;ASC 350-20&#x201D;), the Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the Company is less than the carrying value of the Company.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Factors the Company considers important, which could trigger an impairment of such asset, include the following:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">significant underperformance relative to historical or projected future operating results;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">significant changes in the manner or use of the assets or the strategy for the Company&#x2019;s overall business;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">significant negative industry or economic trends;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">significant decline in the Company&#x2019;s stock price for a sustained period; and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">a decline in the Company&#x2019;s market capitalization below net book value.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company&#x2019;s Chief Operating Decision Maker (&#x201C;CODM&#x201D;) is the Chief Executive Officer (&#x201C;CEO&#x201D;). The two segments and reporting units are Cancer Detection (&#x201C;Detection&#x201D;) and Cancer Therapy (&#x201C;Therapy&#x201D;). Each segment generates revenue from the sale of medical equipment and related services and/or sale of supplies.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company performed the annual impairment assessment at October&#xA0;1, 2014 and compared the fair value of each of reporting unit to its carrying value as of this date. Fair value of each reporting unit exceeded the carry value by approximately 315% for the Detection reporting unit and 255% for the Therapy reporting unit. The carrying values of the reporting units were determined based on an allocation of our assets and liabilities through specific allocation of certain assets and liabilities, to the reporting units and an apportionment of the remaining net assets based on the relative size of the reporting units&#x2019; revenues and operating expenses compared to the Company as a whole. The determination of reporting units also requires management judgment.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> An impairment charge is recorded if such an assessment were to indicate that the fair value of a reporting unit was less than the carrying value. When the Company evaluates potential impairments outside of the annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. The Company utilizes either discounted cash flow models or other valuation models, such as comparative transactions and market multiples, to determine the fair value of the reporting unit. The Company makes assumptions about future cash flows, future operating plans, discount rates, comparable companies, market multiples, purchase price premiums and other factors in those models. Different assumptions and judgment determinations could yield different conclusions that would result in an impairment charge to income in the period that such change or determination was made.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> As a result of external factors and general uncertainty related to reimbursement for non-melanoma skin cancer and in conjunction with the long-lived asset impairment testing, the Company performed an impairment assessment of the Therapy reporting unit. As a result the Company recorded a goodwill impairment charge of $14.0 million during the quarter ended June&#xA0;30, 2015.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The implied fair value of the Therapy reporting unit was determined in the same manner as the manner in which the amount of goodwill recognized in a business combination is determined. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied amount of goodwill. The Company identified the intangible assets that were valued during this process, including technology, customer relationships, trade-names, and the Company&#x2019;s workforce. The allocation process was performed only for purposes of testing goodwill for impairment.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company determined the fair value of the Therapy reporting unit based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. This approach was selected as it measures the income producing assets, primarily technology and customer relationships. This method estimates the fair value based upon the ability to generate future cash flows, which is particularly applicable when future profit margins and growth are expected to vary significantly from historical operating results.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company uses internal forecasts to estimate future cash flows and includes an estimate of long-term future growth rates based on the most recent views of the long-term forecast for the reporting unit. Accordingly, actual results can differ from those assumed in the forecasts. The discount rate of approximately 17% is derived from a capital asset pricing model and analyzing published rates for industries relevant to the reporting unit to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in the internally developed forecasts Other significant assumptions include terminal value margin rates, future capital expenditures, and changes in future working capital requirements. While there are inherent uncertainties related to the assumptions used and to the application of these assumptions to this analysis, the income approach provides a reasonable estimate of the fair value of the Therapy reporting unit.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Step 2 test resulted in an approximate fair value of goodwill of $5.7 million which resulted in a goodwill impairment loss of $14.0 million.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> As discussed in Note 3, the Company acquired VuComp&#x2019;s M-Vu&#xAE; Breast Density product for $1.7 million. The product will be integrated into the Company&#x2019;s Powerlook AMP system, which is a component of the Detection reporting unit. The Company determined that the acquisition was a business combination and accordingly recorded goodwill of $0.8 million.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> A roll forward of goodwill activity by reporting unit is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Detection</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Therapy</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accumulated Goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,937</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Accumulated impairment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(26,828</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Fair value allocation</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7,663</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,446</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Acquisition of DermEbx and Radion</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7,663</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19,600</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">27,263</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Acquisition measurement period adjustments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">116</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">116</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Acquisition of VuComp</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">800</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">800</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Impairment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(13,981</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(13,981</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at June&#xA0;30, 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,463</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,735</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,198</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> A roll forward of goodwill activity by reporting unit is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Detection</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Therapy</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accumulated Goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,937</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Accumulated impairment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(26,828</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Fair value allocation</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7,663</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,446</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Acquisition of DermEbx and Radion</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7,663</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">19,600</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">27,263</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Acquisition measurement period adjustments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">116</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">116</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Acquisition of VuComp</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">800</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">800</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Impairment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(13,981</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(13,981</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at June&#xA0;30, 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,463</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,735</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,198</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> Accelerated Filer <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The fair values of long-lived assets and goodwill were measured using Level 3 inputs.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" colspan="16" nowrap="nowrap" align="center"> <p style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 200.2pt" align="center"><b>Fair value measurements using: (000&#x2019;s) as of June&#xA0;30, 2015</b></p> </td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;2</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Non-recurring assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Long-lived and intangible assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,195</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,195</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,735</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,735</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total Assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,930</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,930</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Note 11 &#x2013; Long-lived assets</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In accordance with FASB ASC Topic 360, &#x201C;Property, Plant and Equipment&#x201D;, (&#x201C;ASC 360&#x201D;), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> ASC 360-10-35 uses &#x201C;events and circumstances&#x201D; criteria to determine when, if at all, an asset (or asset group) is evaluated for recoverability. Thus, there is no set interval or frequency for recoverability evaluation. In accordance with ASC 360-10-35-21 the following factors are examples of events or changes in circumstances that indicate the carrying amount of an asset (asset group) may not be recoverable and thus is to be evaluated for recoverability.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">A significant decrease in the market price of a long-lived asset (asset group);</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group);</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> As a result of external factors and general uncertainty related to reimbursement for the treatment of non-melanoma skin cancer, the Company evaluated the long-lived assets of the Therapy segment and reviewed them for potential impairment. The Company determined the &#x201C;Asset Group&#x201D; to be the assets of the Therapy segment, which the Company considered to be the lowest level for which the identifiable cash flows were largely independent of the cash flows of other assets and liabilities.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In accordance with ASC 360-10-35-17, if the carrying amount of an asset or asset group (in use or under development) is evaluated and found not to be fully recoverable (the carrying amount exceeds the estimated gross, undiscounted cash flows from use and disposition), then an impairment loss must be recognized. The impairment loss is measured as the excess of the carrying amount over the assets (or asset group&#x2019;s) fair value.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In connection with the preparation of the financial statements for the second quarter ended June&#xA0;30, 2015, the Company completed its analysis pursuant to ASC 360-10-35-17 and determined that the carrying value of the Asset Group was approximately $36.8 million, which exceeded the undiscounted cash flows by approximately $2.8 million. Accordingly the Company completed the Step 2 analysis to determine the fair value of the asset group. The Company recorded long-lived asset impairment charges of approximately $13.4 million in the second quarter ended June&#xA0;30, 2015 and as a result the long lived assets in the asset group are recorded at their current fair values.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> A considerable amount of judgment and assumptions are required in performing the impairment tests, principally in determining the fair value of the asset group and the reporting unit. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair values and, therefore additional impairment charges could be required. Significant negative industry or economic trends, disruptions to the Company&#x2019;s business, loss of significant customers, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of the assets may adversely impact the assumptions used in the fair value estimates and ultimately result in future impairment charges.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Note 9 - Fair Value Measurements</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company follows the provisions of ASC Topic 820, &#x201C;<i>Fair Value Measurement and Disclosures</i>&#x201D;, (&#x201C;ASC 820&#x201D;). This topic defines fair value, establishes a framework for measuring fair value under US&#xA0;GAAP and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Level 1 - Quoted prices in active markets for identical assets or liabilities.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and certain accrued liabilities and our notes payable. The carrying amounts of our cash and cash equivalents (which are composed primarily of deposit and overnight sweep accounts), accounts receivable, accounts payable and certain accrued liabilities approximate fair value due to the short maturity of these instruments. The carrying value of our notes payable approximates fair value due to the market rate of the stated interest rate.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company&#x2019;s assets that are measured at fair value on a recurring basis relate to the Company&#x2019;s money market accounts.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company&#x2019;s money market funds are included in cash and cash equivalents in the accompanying balance sheets, and are considered a Level 1 investment as they are valued at quoted market prices in active markets.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The following table sets forth the Company&#x2019;s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" colspan="16" nowrap="nowrap" align="center"> <p style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 218.4pt" align="center"><b>Fair value measurements using: (000&#x2019;s) as of December&#xA0;31, 2014</b></p> </td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;2</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Money market accounts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,530</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,530</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total Assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,530</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,530</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" colspan="16" nowrap="nowrap" align="center"> <p style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 200.2pt" align="center"><b>Fair value measurements using: (000&#x2019;s) as of June&#xA0;30, 2015</b></p> </td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;2</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Money market accounts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,568</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,568</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total Assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,568</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,568</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Items Measured at Fair Value on a Nonrecurring Basis</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Certain assets, including long-lived assets and goodwill, are measured at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be impaired. The Company recorded a $27.4 million impairment consisting of $14.0 million related to goodwill and $13.4 million related to long-lived assets as discussed in Note 11 and Note 12 and remeasured long-lived assets and goodwill of the Therapy reporting unit at fair value as of the impairment date as noted in the following table. The fair values of long-lived assets and goodwill were measured using Level 3 inputs.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" colspan="16" nowrap="nowrap" align="center"> <p style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 200.2pt" align="center"><b>Fair value measurements using: (000&#x2019;s) as of June&#xA0;30, 2015</b></p> </td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;2</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Non-recurring assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Long-lived and intangible assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,195</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,195</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,735</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,735</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total Assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,930</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,930</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Note 5 &#x2013; Long Term Debt</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> On March&#xA0;31, 2015, the Company repaid in full the aggregate amount outstanding under the Deerfield Facility Agreement, dated as of December&#xA0;29, 2011 (as amended, supplemented or otherwise modified to the date hereof, the &#x201C;Facility Agreement&#x201D;), by and among the Company, Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., and Deerfield Special Situations Fund, L.P. and, for itself and as assignee of the obligations held by Deerfield Special Situations Fund International Master Fund, L.P. The Facility Agreement and related documents were terminated as of March&#xA0;31, 2015. The Facility Agreement was to mature on December&#xA0;29, 2016 and was able to be repaid prior to the maturity date at the Company&#x2019;s option without penalty or premium. On March&#xA0;31, 2015, the Company used cash on hand to pay the $11.25 million outstanding principal amount due under the Facility Agreement and approximately $162,000 in accrued and unpaid interest on such principal amount.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company recorded a loss on the extinguishment of debt of approximately $1.7 million at the termination date in the quarter ended March&#xA0;31, 2015.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The following amounts compose interest expense included in our consolidated statement of operations for the three and six months ended June&#xA0;30, 2015 and 2014: (in thousands)</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center"> Three&#xA0;months&#xA0;ended&#xA0;June&#xA0;30,</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash interest expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">216</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Non-cash amortization of debt discount</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">313</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Amortization of debt costs</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Amortization of settlement obligations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">47</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">54</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Interest expense capital lease</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">23</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Total interest expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">70</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">614</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="8"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center"> Six&#xA0;months&#xA0;ended&#xA0;June&#xA0;30</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash interest expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">162</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">794</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Non-cash amortization of debt discount</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">254</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">448</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Amortization of debt costs</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">76</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Amortization of settlement obligations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">92</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">106</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Interest expense capital lease</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">56</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Total interest expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">577</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,431</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> Cash interest expense represents the amount of interest paid in cash under the Facility Agreement which represents the interest of 5.75% on the Facility Agreement through March&#xA0;31, 2015. Non-cash amortization is the amortization of the discount on the Facility Agreement. The amortization of debt costs relates to the costs incurred with the financing, which is primarily a facility fee and a finder&#x2019;s fee that were capitalized and are being expensed using the effective interest method. The amortization of the settlement obligation represents the interest associated with the settlement agreements for both Carl Zeiss Meditec AG and Hologic, Inc (see Note 8). Interest expense capital lease represents interest related to the capital lease as described in Note 6.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Note 13 &#x2013; Segment Reporting</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In accordance with FASB Topic ASC 280, &#x201C;<i>Segments</i>&#x201D;, operating segments, are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker CODM in deciding how to allocate resources and assess performance.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company&#x2019;s CODM is the CEO. Each segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments, Detection and Therapy.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Detection segment consists of our advanced image analysis and workflow products, and the Therapy segment consists of our radiation therapy Axxent products, and related services. The primary factors used by our CODM to allocate resources are based on revenues, gross profit, operating income, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring items (&#x201C;Adjusted EBITDA&#x201D;) of each segment. Included in segment operating income are stock compensation, amortization of technology and depreciation expense. There are no intersegment revenues.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Our CODM does not use asset information by segment to allocate resources or make operating decisions.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 125px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended<br /> June&#xA0;30,</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended<br /> June&#xA0;30,</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Segment revenues:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Detection</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,955</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,832</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,743</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,007</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Therapy</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,188</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,835</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,620</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,180</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total Revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,143</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,667</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,363</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,187</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Segment gross profit:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Detection</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,090</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,960</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,037</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,324</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Therapy</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,788</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,870</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,203</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,440</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Segment gross profit</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,878</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,830</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,240</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,764</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Segment operating income (loss):</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Detection</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,033</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,897</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,793</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Therapy</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(27,469</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(140</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(26,512</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(368</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Segment operating income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(25,436</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,757</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(22,719</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,045</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> General, administrative, depreciation and amortization expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,392</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,923</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4,666</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,671</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Interest expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(70</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(614</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(577</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,431</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Gain on fair value of warrant</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">699</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,835</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Other income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Loss on debt extinguishment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(903</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,723</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(903</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Loss before income tax</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(27,893</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(972</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(29,671</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,109</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> 0.17 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> A summary of the Company&#x2019;s calculation of net loss per share is as follows (in thousands except per share amounts):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;Months&#xA0;Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Six&#xA0;Months&#xA0;Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Net loss</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><b>$</b></td> <td valign="bottom" align="right"><b>(27,786</b></td> <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><b>$</b></td> <td valign="bottom" align="right"><b>(997</b></td> <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><b>$</b></td> <td valign="bottom" align="right"><b>(29,643</b></td> <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><b>$</b></td> <td valign="bottom" align="right"><b>(1,187</b></td> <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Basic and diluted shares used in the calculation of net loss per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,679</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,074</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,642</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,759</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net loss per share - basic and diluted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.77</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.07</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.90</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.09</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 0pt"> The amounts included in the consolidated statement of operations relating to stock based compensation expense are as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;Months&#xA0;Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Six&#xA0;Months&#xA0;Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cost of revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Engineering and product development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">60</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">34</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">111</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">83</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Marketing and sales</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">203</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">333</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">140</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> General and administrative</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">353</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">175</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">612</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">376</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">620</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">281</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,064</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">606</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> <b>as&#xA0;of&#xA0;June&#xA0;30,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> <b>as&#xA0;of&#xA0;December&#xA0;31,<br /> 2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,608</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">955</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Work in process</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">223</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">54</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Finished Goods</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,491</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,205</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Inventory</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,322</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,214</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> --12-31 ICAD INC <div> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> Under the guidance of ASC Topic 840, &#x201C;<i>Leases</i>&#x201D; (&#x201C;ASC 840&#x201D;) the Company determined that the lease was a capital lease as it contained a bargain purchase option whereby the Company has the option to buy the equipment for $1 at the end of the lease term. Accordingly, the equipment has been capitalized and a liability has been recorded.</p> </div> <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Note 6 &#x2013; Lease Commitments</b></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> <u>Operating leases</u></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> Facilities are leased under operating leases expiring at various dates through September, 2017. Certain of these leases contain renewal options. Rent expense under operating leases was $165,000 and $328,000 for the three and six month period ended June&#xA0;30, 2015 and $168,000 and $327,000 for the three and six month period ended June&#xA0;30, 2014, respectively.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> Future minimum lease payments as of June&#xA0;30, 2015 under operating leases are as follows: (in thousands)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="88%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom" nowrap="nowrap"> <p style="border-bottom:1.00pt solid #000000; width:36.60pt; font-size:8pt; font-family:Times New Roman"> Fiscal Year</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Operating<br /> Leases</td> <td valign="bottom">&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">255</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">499</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">255</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,009</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> <u>Capital leases</u></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> The Company entered into a capital lease agreement for the purchase of certain equipment in August 2013 for approximately $409,000. Under the guidance of ASC Topic 840, &#x201C;<i>Leases</i>&#x201D; (&#x201C;ASC 840&#x201D;) the Company determined that the lease was a capital lease as it contained a bargain purchase option whereby the Company has the option to buy the equipment for $1 at the end of the lease term. Accordingly, the equipment has been capitalized and a liability has been recorded. The equipment cost of $409,000 is reflected as property and equipment in the balance sheet and is being depreciated over its useful life.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> In connection with the Radion/DermEbx Acquisition, the Company assumed two separate equipment lease obligations with payments totaling approximately $2.6 million through May, 2017. The leases were determined to be capital leases and accordingly the equipment was capitalized and a liability of $2.5 million was recorded. As of June&#xA0;30, 2015, the outstanding liability for the acquired equipment leases was approximately $1.7 million.</p> <p style="font-size:1px;margin-top:6px;margin-bottom:0px"> &#xA0;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> Future minimum lease payments under all outstanding capital leases are as follows: (in thousands)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="88%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">Fiscal Year</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center">Capital<br /> Leases</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">774</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,039</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">89</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Subtotal minimum lease obligation</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,902</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Less interest</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(163</td> <td nowrap="nowrap" valign="bottom">)&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Total, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,739</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Less current portion</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,251</td> <td nowrap="nowrap" valign="bottom">)&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Long term portion</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">488</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> Kamal Gogineni is an employee of the Company&#x2019;s and a beneficial owner of more than 5% of the Company&#x2019;s common stock. Additionally, Mr.&#xA0;Gogineni is a significant shareholder of Radion Capital Partners (&#x201C;RCP&#x201D;). RCP was the lessor under a lease between RCP and DermEbx (the &#x201C;DermEbx Lease&#x201D;). In connection with the Company&#x2019;s Radion/DermEbx acquisition that closed in July 2014, one of the assets and obligations that the Company acquired was the Lease. Pursuant to the Lease, the Company is obligated to pay a total of $855,000 as of June&#xA0;30, 2015 and the liability is included in the minimum lease payments above, with annual payments of $383,000 for the remainder of 2015, $396,000 in 2016 and $76,000 in 2017.</p> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Note 4 &#x2013; Inventory</b></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> <b>as&#xA0;of&#xA0;June&#xA0;30,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> <b>as&#xA0;of&#xA0;December&#xA0;31,<br /> 2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,608</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">955</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Work in process</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">223</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">54</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Finished Goods</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,491</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,205</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Inventory</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,322</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,214</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The following table sets forth the Company&#x2019;s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" colspan="16" nowrap="nowrap" align="center"> <p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 218.4pt" align="center"><b>Fair value measurements using: (000&#x2019;s) as of December&#xA0;31, 2014</b></p> </td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;2</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Money market accounts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,530</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,530</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total Assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,530</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,530</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" colspan="16" nowrap="nowrap" align="center"> <p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 200.2pt" align="center"><b>Fair value measurements using: (000&#x2019;s) as of June&#xA0;30, 2015</b></p> </td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;2</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Money market accounts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,568</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,568</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total Assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,568</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,568</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 15642000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Note 10 - Income Taxes</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company recorded an income tax benefit of $107,000 and $28,000, in the three and six months ended June&#xA0;30, 2015 as compared to a provision of $25,000 and $78,000 in the three and six months ended June&#xA0;30, 2014, respectively. The income tax net benefit as of June&#xA0;30, 2015 primarily relates a state tax provision and a benefit from the reversal of a deferred tax liability relating to tax amortizable goodwill. Due to the Company&#x2019;s goodwill impairment the tax basis in amortizable goodwill is greater than book basis which results in a deferred tax asset that is subject to a valuation allowance. At June&#xA0;30, 2015, the Company had no material unrecognized tax benefits and no adjustments to liabilities or tax expense were required under ASC 740, &#x201C;Income Taxes&#x201D;. The Company does not expect that the unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any interest or penalties related to uncertain tax positions at June&#xA0;30, 2015. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company&#x2019;s three preceding tax years remain subject to examination by federal and state taxing authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not under examination by any federal or state jurisdiction for any tax years.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 18pt"> <i>Cost of Revenue</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> Cost of revenue consists of the costs of products purchased for resale, costs relating to service including personnel costs for physicists, management services and radiation therapists, costs of service contracts to maintain equipment after the warranty period, product installation, training, customer support, certain warranty repair costs, inbound freight and duty, cost of supplies, manufacturing, warehousing, material movement, inspection, scrap, rework, amortization, depreciation and in-house product warranty repairs.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> In September 2014, the Company reclassified depreciation previously included in product and service cost of revenue to amortization and depreciation as a separate component of cost of revenue. For the three and six months ended June&#xA0;30, 2014, approximately $343,000 and $674,000, respectively was reclassified to conform to current period classification. Medical Device Excise tax included in the cost of revenue is approximately $132,000 and $331,000, for the three and six months ended June&#xA0;30, 2015, respectively and $200,000 and $379,000 for the three and six months ended June&#xA0;30, 2014, respectively.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended<br /> June&#xA0;30,</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended<br /> June&#xA0;30,</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Segment revenues:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Detection</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,955</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,832</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,743</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,007</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Therapy</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,188</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,835</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,620</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,180</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total Revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,143</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,667</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,363</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,187</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Segment gross profit:</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Detection</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,090</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,960</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,037</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,324</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Therapy</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,788</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,870</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,203</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,440</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Segment gross profit</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,878</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,830</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,240</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,764</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Segment operating income (loss):</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Detection</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,033</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,897</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,793</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Therapy</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(27,469</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(140</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(26,512</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(368</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Segment operating income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(25,436</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,757</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(22,719</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,045</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> General, administrative, depreciation and amortization expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,392</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,923</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4,666</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,671</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Interest expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(70</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(614</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(577</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,431</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Gain on fair value of warrant</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">699</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,835</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Other income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Loss on debt extinguishment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(903</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,723</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(903</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Loss before income tax</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(27,893</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(972</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(29,671</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,109</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <strong>Long-lived assets <!-- xbrl,body --></strong> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> In accordance with FASB ASC Topic 360, &#x201C;Property, Plant and Equipment&#x201D;, (&#x201C;ASC 360&#x201D;), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> ASC 360-10-35 uses &#x201C;events and circumstances&#x201D; criteria to determine when, if at all, an asset (or asset group) is evaluated for recoverability. Thus, there is no set interval or frequency for recoverability evaluation. In accordance with ASC 360-10-35-21 the following factors are examples of events or changes in circumstances that indicate the carrying amount of an asset (asset group) may not be recoverable and thus is to be evaluated for recoverability.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">A significant decrease in the market price of a long-lived asset (asset group);</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group);</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> As a result of external factors and general uncertainty related to reimbursement for the treatment of non-melanoma skin cancer, the Company evaluated the long-lived assets of the Therapy segment and reviewed them for potential impairment. The Company determined the &#x201C;Asset Group&#x201D; to be the assets of the Therapy segment, which the Company considered to be the lowest level for which the identifiable cash flows were largely independent of the cash flows of other assets and liabilities.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> In accordance with ASC 360-10-35-17, if the carrying amount of an asset or asset group (in use or under development) is evaluated and found not to be fully recoverable (the carrying amount exceeds the estimated gross, undiscounted cash flows from use and disposition), then an impairment loss must be recognized. The impairment loss is measured as the excess of the carrying amount over the assets (or asset group&#x2019;s) fair value.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> In connection with the preparation of the financial statements for the second quarter ended June&#xA0;30, 2015, the Company completed its analysis pursuant to ASC 360-10-35-17 and determined that the carrying value of the Asset Group was approximately $36.8 million, which exceeded the undiscounted cash flows by approximately $2.8 million. Accordingly the Company completed the Step 2 analysis to determine the fair value of the asset group. The Company recorded long-lived asset impairment charges of approximately $13.4 million in the second quarter ended June&#xA0;30, 2015 and as a result the long lived assets in the asset group are recorded at their current fair values.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 0pt"> A considerable amount of judgment and assumptions are required in performing the impairment tests, principally in determining the fair value of the asset group and the reporting unit. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair values and, therefore additional impairment charges could be required. Significant negative industry or economic trends, disruptions to the Company&#x2019;s business, loss of significant customers, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of the assets may adversely impact the assumptions used in the fair value estimates and ultimately result in future impairment charges.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Note 8 - Commitments and Contingencies</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> <b>Foreign Tax Claim</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> In July 2007, a dissolved former Canadian subsidiary of the Company, CADx Medical Systems Inc. (&#x201C;CADx Medical&#x201D;), received a tax re-assessment of approximately $6,800,000 from the Canada Revenue Agency (&#x201C;CRA&#x201D;) resulting from CRA&#x2019;s audit of CADx Medical&#x2019;s Canadian federal tax return for the year ended December&#xA0;31, 2002. In February 2010 the CRA reviewed the matter and reduced the tax re-assessment to approximately $703,000, excluding interest and penalties. The Company believes that it is not liable for the re-assessment against CADx Medical and no accrual has been recorded for this matter as of June&#xA0;30, 2015.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 18pt"> <b>Settlement Obligations</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> In connection with the acquisition of Xoft in 2010, the Company recorded a royalty obligation pursuant to a settlement agreement entered into between Xoft and Hologic in August 2007. Xoft received a nonexclusive, irrevocable, perpetual, worldwide license, including the right to sublicense certain Hologic patents, and a non-compete covenant as well as an agreement not to seek further damages with respect to the alleged patent violations. In return, the Company has a remaining obligation to pay a minimum annual royalty payment to Hologic, of $250,000 payable through 2016. In addition to the minimum annual royalty payments, the litigation settlement agreement with Hologic also provided for payment of royalties based upon a specified percentage of future net sales on any products that utilize the licensed rights. The Company has a liability within accrued expenses and long-term settlement cost for future payment and for future minimum royalty obligations totaling $442,000. The Company recorded interest expense of approximately $18,000 and $36,000 in the three and six months ended June&#xA0;30, 2015 and $25,000 and $50,000 in the three and six months June&#xA0;30, 2014, respectively, related to this obligation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> In December, 2011, the Company agreed to a settlement related to litigation with Carl Zeiss Meditec AG. The Company is obligated to pay the remaining amount of $0.5 million in June 2017. As of June&#xA0;30, 2015, the remaining liability recorded within accrued expenses and long-term settlement cost for future payment and for future minimum royalty obligations is $395,000. The Company recorded interest expense of approximately $28,000 and $56,000 in the three and six months ended June&#xA0;30, 2015 and $28,000 and $56,000 in the three and six months ended June&#xA0;30, 2014, respectively, related to this obligation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 18pt"> <b>Other Commitments</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company is obligated to pay approximately $2.2 million for firm purchase obligations to suppliers for future product deliverables.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 18pt"> <b>Litigation</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.</p> </div> 15642000 <div> <strong>Fair Value Measurements <!-- xbrl,body --></strong> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company follows the provisions of ASC Topic 820, &#x201C;<i>Fair Value Measurement and Disclosures</i>&#x201D;, (&#x201C;ASC 820&#x201D;). This topic defines fair value, establishes a framework for measuring fair value under US&#xA0;GAAP and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Level 1 - Quoted prices in active markets for identical assets or liabilities.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and certain accrued liabilities and our notes payable. The carrying amounts of our cash and cash equivalents (which are composed primarily of deposit and overnight sweep accounts), accounts receivable, accounts payable and certain accrued liabilities approximate fair value due to the short maturity of these instruments. The carrying value of our notes payable approximates fair value due to the market rate of the stated interest rate.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company&#x2019;s assets that are measured at fair value on a recurring basis relate to the Company&#x2019;s money market accounts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company&#x2019;s money market funds are included in cash and cash equivalents in the accompanying balance sheets, and are considered a Level 1 investment as they are valued at quoted market prices in active markets.</p> </div> 2015-06-30 <div> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> The Company follows the guidance in ASC Topic 718, &#x201C;<i>Compensation &#x2013; Stock Compensation</i>&#x201D;<i>,</i> (&#x201C;ASC 718&#x201D;).</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Note 7 - Stock-Based Compensation</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company follows the guidance in ASC Topic 718, &#x201C;<i>Compensation &#x2013; Stock Compensation</i>&#x201D;<i>,</i> (&#x201C;ASC 718&#x201D;).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company granted 130,000 and 317,000 options in the three and six months ended June&#xA0;30, 2015. Options granted under the Company&#x2019;s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="40%"></td> <td valign="bottom" width="3%"></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"> <b>Three&#xA0;Months&#xA0;Ended</b><br /> <b>June&#xA0;30,</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"><b>Six Months Ended</b><br /> <b>June&#xA0;30,</b></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2014</b></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Average risk-free interest rate</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">0.98%</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">0.85%</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">0.92%</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">0.82%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Expected dividend yield</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">None</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">None</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">None</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">None</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Expected life</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">3.5&#xA0;years</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">3.5&#xA0;years</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">3.5&#xA0;years</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">3.5&#xA0;years</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Expected volatility</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">60.5%&#xA0;to&#xA0;73.8%</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">64.9%&#xA0;to&#xA0;66.5%</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">60.5%&#xA0;to&#xA0;73.8%</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">64.2%&#xA0;to&#xA0;66.5%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Weighted average exercise price</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$3.37</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$6.72</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$6.97</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$7.83</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Weighted average fair value</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$1.74</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$3.17</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$3.33</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$3.67</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 0pt"> The amounts included in the consolidated statement of operations relating to stock based compensation expense are as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;Months&#xA0;Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Six&#xA0;Months&#xA0;Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cost of revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Engineering and product development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">60</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">34</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">111</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">83</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Marketing and sales</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">203</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">333</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">140</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> General and administrative</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">353</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">175</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">612</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">376</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">620</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">281</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,064</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">606</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> As of June&#xA0;30, 2015 unrecognized compensation cost (in thousands) related to unexercisable options and unvested restricted stock and the weighted average remaining period is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Remaining expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,698</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Weighted average term</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.31&#xA0;years</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company&#x2019;s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Period Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 80.7pt"> Aggregate intrinsic value</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Stock options</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">485</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,187</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Restricted stock</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,469</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,092</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Recent Accounting Pronouncements</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 60px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In May 2014, the FASB issued ASU 2014-09 &#x201C;Revenue from Contracts with Customers&#x201D; (ASU 2014-09), which amends ASC 605 &#x201C;Revenue Recognition&#x201D; and creates a new Topic 606 &#x201C;Revenue from Contracts with Customers.&#x201D; This update provides guidance on how an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Upon initial application, the provisions of this update are required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this update recognized at the date of initial application. This update also expands the disclosure requirements surrounding revenue recorded from contracts with customers. This update is effective for fiscal years, and interim periods within those years, beginning after December&#xA0;15, 2016. In April 2015 the FASB voted to defer effective date of this standard with respect to years, beginning after December&#xA0;15, 2017. We are currently evaluating the effect of this update on our financial statements and have not yet determined the method of initial application we will use.</p> </div> <div> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> Future minimum lease payments as of June&#xA0;30, 2015 under operating leases are as follows: (in thousands)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="88%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom" nowrap="nowrap"> <p style="border-bottom:1.00pt solid #000000; width:36.60pt; font-size:8pt; font-family:Times New Roman"> Fiscal Year</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Operating<br /> Leases</td> <td valign="bottom">&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">255</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">499</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">255</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,009</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> ICAD 15642000 -1.90 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> Options granted under the Company&#x2019;s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="40%"></td> <td valign="bottom" width="3%"></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"> <b>Three&#xA0;Months&#xA0;Ended</b><br /> <b>June&#xA0;30,</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"><b>Six Months Ended</b><br /> <b>June&#xA0;30,</b></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2014</b></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Average risk-free interest rate</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">0.98%</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">0.85%</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">0.92%</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">0.82%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Expected dividend yield</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">None</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">None</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">None</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">None</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Expected life</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">3.5&#xA0;years</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">3.5&#xA0;years</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">3.5&#xA0;years</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">3.5&#xA0;years</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Expected volatility</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">60.5%&#xA0;to&#xA0;73.8%</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">64.9%&#xA0;to&#xA0;66.5%</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">60.5%&#xA0;to&#xA0;73.8%</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">64.2%&#xA0;to&#xA0;66.5%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Weighted average exercise price</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$3.37</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$6.72</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$6.97</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$7.83</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Weighted average fair value</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$1.74</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$3.17</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$3.33</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">$3.67</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Note 2 - Loss per Common Share</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company&#x2019;s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> A summary of the Company&#x2019;s calculation of net loss per share is as follows (in thousands except per share amounts):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;Months&#xA0;Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Six&#xA0;Months&#xA0;Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Net loss</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><b>$</b></td> <td valign="bottom" align="right"><b>(27,786</b></td> <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><b>$</b></td> <td valign="bottom" align="right"><b>(997</b></td> <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><b>$</b></td> <td valign="bottom" align="right"><b>(29,643</b></td> <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><b>$</b></td> <td valign="bottom" align="right"><b>(1,187</b></td> <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Basic and diluted shares used in the calculation of net loss per share</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,679</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,074</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,642</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,759</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net loss per share - basic and diluted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.77</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.07</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.90</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.09</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The shares of the Company&#x2019;s common stock, issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Period Ended</b><br /> <b>June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Stock Options</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,618,043</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,477,871</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Restricted Stock</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">453,392</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">326,318</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Stock options and restricted stock</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,071,435</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,804,189</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> P1Y3M22D <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company recorded an income tax benefit of $107,000 and $28,000, in the three and six months ended June&#xA0;30, 2015 as compared to a provision of $25,000 and $78,000 in the three and six months ended June&#xA0;30, 2014, respectively. The income tax net benefit as of June&#xA0;30, 2015 primarily relates a state tax provision and a benefit from the reversal of a deferred tax liability relating to tax amortizable goodwill. Due to the Company&#x2019;s goodwill impairment the tax basis in amortizable goodwill is greater than book basis which results in a deferred tax asset that is subject to a valuation allowance. At June&#xA0;30, 2015, the Company had no material unrecognized tax benefits and no adjustments to liabilities or tax expense were required under ASC 740, &#x201C;Income Taxes&#x201D;. The Company does not expect that the unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any interest or penalties related to uncertain tax positions at June&#xA0;30, 2015. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company&#x2019;s three preceding tax years remain subject to examination by federal and state taxing authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not under examination by any federal or state jurisdiction for any tax years.</p> </div> 2 693000 799000 -29643000 14000 24363000 11250000 471000 36000 -65000 17309000 -27385000 993000 93000 17240000 -2286000 1700000 -1691000 -123000 -1723000 -29671000 7054000 -28000 1064000 7123000 -1962000 6995000 323000 328000 -14012000 44625000 577000 -2535000 -11700000 4528000 4360000 331000 0 13400000 162000 -1802000 327000 1142000 4543000 56000 254000 1621000 -347000 1362000 29866000 1116000 896000 188000 116000 13981000 27443000 -22719000 13000 92000 84000 250000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The following amounts compose interest expense included in our consolidated statement of operations for the three and six months ended June&#xA0;30, 2015 and 2014: (in thousands)</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center"> Three&#xA0;months&#xA0;ended&#xA0;June&#xA0;30,</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash interest expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">216</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Non-cash amortization of debt discount</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">313</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Amortization of debt costs</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Amortization of settlement obligations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">47</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">54</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Interest expense capital lease</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">23</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Total interest expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">70</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">614</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="8"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center"> Six&#xA0;months&#xA0;ended&#xA0;June&#xA0;30</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash interest expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">162</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">794</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Non-cash amortization of debt discount</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">254</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">448</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Amortization of debt costs</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">76</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Amortization of settlement obligations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">92</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">106</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Interest expense capital lease</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">56</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Total interest expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">577</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,431</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Note 14 - Recent Accounting Pronouncements</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> In May 2014, the FASB issued ASU 2014-09 &#x201C;Revenue from Contracts with Customers&#x201D; (ASU 2014-09), which amends ASC 605 &#x201C;Revenue Recognition&#x201D; and creates a new Topic 606 &#x201C;Revenue from Contracts with Customers.&#x201D; This update provides guidance on how an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Upon initial application, the provisions of this update are required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this update recognized at the date of initial application. This update also expands the disclosure requirements surrounding revenue recorded from contracts with customers. This update is effective for fiscal years, and interim periods within those years, beginning after December&#xA0;15, 2016. In April 2015 the FASB voted to defer effective date of this standard with respect to years, beginning after December&#xA0;15, 2017. We are currently evaluating the effect of this update on our financial statements and have not yet determined the method of initial application we will use.</p> </div> Facilities are leased under operating leases expiring at various dates through September, 2017. P3Y <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 18pt"> <b>Litigation</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company&#x2019;s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Period Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 80.7pt"> Aggregate intrinsic value</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Stock options</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">485</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,187</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Restricted stock</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,469</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,092</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> </div> 4666000 317000 333000 111000 612000 8000 36000 56000 14620000 9203000 116000 13981000 -26512000 13446000 6154000 9743000 8037000 3793000 7663000 800000 453392 1618043 0.738 0.605 0 P3Y6M 0.0092 0 6.97 3.33 The 600,000 restricted shares are subject to the following provisions; 25% was locked up until the date that was two trading days after the Company announced its fourth quarter 2014 earnings, which occurred on March 2, 2015; 30% of the shares shall be locked up for a period of 24 months from the date of the agreement; and 30% of the shares shall be locked up for a period of 36 months from the date of the agreement. <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The following is a summary of the allocation of the total purchase price based on the estimated fair values of the assets acquired and liabilities assumed as of the date of the acquisition and the amortizable lives of the intangible assets:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amount</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Estimated&#xA0;Amortizable&#xA0;Life</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="2"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,457</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Property and equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,625</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="center"> 3&#xA0;&#x2013;&#xA0;7&#xA0;Years</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Identifiable intangible assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,050</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="center"> 5&#xA0;&#x2013;&#xA0;10&#xA0;Years</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,270</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Current liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(4,382</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Long-term liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,164</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Purchase price</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,856</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The unaudited proforma operating results for the Company for the three and six months ended June&#xA0;30, 2014, assuming the Radion/DermEbx Acquisition occurred as of January&#xA0;1, 2014 are as follows (in thousands except per share amounts):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>June&#xA0;30, 2014</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Three&#xA0;months</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Six&#xA0;months</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,815</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,408</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Income from operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">566</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">685</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net (loss) income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(264</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net (loss) income per share-basic</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.02</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Net (loss) income per share-diluted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.02</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Basic</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,959</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,959</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Diluted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,959</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,667</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> </div> 2500000 6154000 2 The 600,000 restricted shares are subject to the following provisions; 25% of the shares were locked up until the date that is two trading days after the Company announces its fourth quarter 2014 earnings, which occurred on March 2, 2015; 30% of the shares shall be locked up for a period of 24 months from the date of the agreement; and 30% of the shares shall be locked up for a period of 36 months from the date of the agreement. <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The following is a summary of the preliminary allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amount</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Estimated&#xA0;Amortizable&#xA0;Life</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Developed Technology</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">900</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center"> 8&#xA0;years&#xA0;9&#xA0;months</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Goodwill</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">800</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Purchase price</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,700</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> </tr> </table> </div> 1700000 800000 703000 6800000 -1700000 -0.07 -0.07 14074000 14074000 14074000 -0.07 -997000 12000 9667000 4373000 -166000 6830000 -806000 -903000 -972000 5294000 25000 281000 -699000 2837000 2872000 168000 6996000 614000 2004000 1104000 200000 216000 343000 1865000 3000 313000 1390000 255000 1757000 28000 54000 1923000 69000 34000 175000 3000 25000 28000 4835000 2870000 -140000 1100000 300000 800000 4832000 3960000 1897000 0.665 0.649 P3Y6M 0.0085 0 6.72 3.17 -0.02 -0.02 -264000 11815000 566000 13959000 13959000 -1.77 -1.77 15679000 15679000 15679000 -1.77 -27786000 5000 11143000 8047000 -27828000 7878000 -65000 -27893000 3096000 -107000 620000 3265000 3165000 165000 35706000 70000 2272000 2082000 132000 503000 2330000 23000 680000 496000 27443000 -25436000 47000 2392000 130000 203000 60000 353000 4000 18000 28000 6188000 3788000 13400000 13981000 -27469000 4955000 4090000 2033000 0.738 0.605 P3Y6M 0.0098 0 3.37 1.74 0000749660 us-gaap:EmployeeStockOptionMember 2015-04-01 2015-06-30 0000749660 us-gaap:EmployeeStockOptionMemberus-gaap:MinimumMember 2015-04-01 2015-06-30 0000749660 us-gaap:EmployeeStockOptionMemberus-gaap:MaximumMember 2015-04-01 2015-06-30 0000749660 icad:DetectionMember 2015-04-01 2015-06-30 0000749660 icad:TherapyMember 2015-04-01 2015-06-30 0000749660 icad:ZeissMember 2015-04-01 2015-06-30 0000749660 icad:HologicMember 2015-04-01 2015-06-30 0000749660 us-gaap:OperatingExpenseMember 2015-04-01 2015-06-30 0000749660 icad:BlackScholesOptionPricingModelMember 2015-04-01 2015-06-30 0000749660 2015-04-01 2015-06-30 0000749660 icad:DermEbxAndRadionMember 2014-04-01 2014-06-30 0000749660 us-gaap:EmployeeStockOptionMember 2014-04-01 2014-06-30 0000749660 us-gaap:EmployeeStockOptionMemberus-gaap:MinimumMember 2014-04-01 2014-06-30 0000749660 us-gaap:EmployeeStockOptionMemberus-gaap:MaximumMember 2014-04-01 2014-06-30 0000749660 icad:DetectionMember 2014-04-01 2014-06-30 0000749660 icad:PriorToAcquisitionMembericad:TherapyMember 2014-04-01 2014-06-30 0000749660 icad:TherapyMember 2014-04-01 2014-06-30 0000749660 icad:ZeissMember 2014-04-01 2014-06-30 0000749660 icad:HologicMember 2014-04-01 2014-06-30 0000749660 us-gaap:OperatingExpenseMember 2014-04-01 2014-06-30 0000749660 2014-04-01 2014-06-30 0000749660 2015-01-01 2015-03-31 0000749660 icad:CadxMedicalSystemsIncMember 2007-07-01 2007-07-31 0000749660 icad:CadxMedicalSystemsIncMember 2010-02-01 2010-02-28 0000749660 icad:VucompMvuBreastDensitySoftwareMember 2015-01-01 2015-06-30 0000749660 icad:RadionIncMember 2015-01-01 2015-06-30 0000749660 icad:DermEbxAndRadionMember 2015-01-01 2015-06-30 0000749660 icad:DermEbxMember 2015-01-01 2015-06-30 0000749660 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 0000749660 us-gaap:IntersegmentEliminationMember 2015-01-01 2015-06-30 0000749660 us-gaap:EmployeeStockOptionMemberus-gaap:MinimumMember 2015-01-01 2015-06-30 0000749660 us-gaap:EmployeeStockOptionMemberus-gaap:MaximumMember 2015-01-01 2015-06-30 0000749660 us-gaap:StockOptionMember 2015-01-01 2015-06-30 0000749660 us-gaap:RestrictedStockMember 2015-01-01 2015-06-30 0000749660 icad:VucompMvuBreastDensitySoftwareMembericad:DetectionMember 2015-01-01 2015-06-30 0000749660 icad:DetectionMember 2015-01-01 2015-06-30 0000749660 icad:DermEbxAndRadionMembericad:TherapyMember 2015-01-01 2015-06-30 0000749660 icad:TherapyMember 2015-01-01 2015-06-30 0000749660 icad:ZeissMember 2015-01-01 2015-06-30 0000749660 icad:HologicMember 2015-01-01 2015-06-30 0000749660 us-gaap:OperatingExpenseMember 2015-01-01 2015-06-30 0000749660 icad:BlackScholesOptionPricingModelMember 2015-01-01 2015-06-30 0000749660 2015-01-01 2015-06-30 0000749660 icad:DermEbxAndRadionMember 2014-01-01 2014-06-30 0000749660 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-06-30 0000749660 us-gaap:EmployeeStockOptionMemberus-gaap:MinimumMember 2014-01-01 2014-06-30 0000749660 us-gaap:EmployeeStockOptionMemberus-gaap:MaximumMember 2014-01-01 2014-06-30 0000749660 us-gaap:StockOptionMember 2014-01-01 2014-06-30 0000749660 us-gaap:RestrictedStockMember 2014-01-01 2014-06-30 0000749660 icad:DetectionMember 2014-01-01 2014-06-30 0000749660 icad:PriorToAcquisitionMembericad:TherapyMember 2014-01-01 2014-06-30 0000749660 icad:TherapyMember 2014-01-01 2014-06-30 0000749660 icad:ZeissMember 2014-01-01 2014-06-30 0000749660 icad:HologicMember 2014-01-01 2014-06-30 0000749660 us-gaap:OperatingExpenseMember 2014-01-01 2014-06-30 0000749660 2014-01-01 2014-06-30 0000749660 icad:FacilityAgreementMember 2015-03-31 2015-03-31 0000749660 icad:RadionIncMember 2014-07-15 2014-07-15 0000749660 icad:DermEbxMember 2014-07-15 2014-07-15 0000749660 us-gaap:RestrictedStockMembericad:RadionIncMemberus-gaap:CommonStockMember 2014-07-15 2014-07-15 0000749660 us-gaap:RestrictedStockMembericad:DermEbxMemberus-gaap:CommonStockMember 2014-07-15 2014-07-15 0000749660 icad:RadionIncMemberus-gaap:MinimumMember 2014-07-15 2014-07-15 0000749660 icad:RadionIncMemberus-gaap:MaximumMember 2014-07-15 2014-07-15 0000749660 icad:VucompMvuBreastDensitySoftwareMember 2015-04-29 2015-04-29 0000749660 us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000749660 icad:DetectionMember 2014-12-31 0000749660 icad:TherapyMember 2014-12-31 0000749660 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000749660 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000749660 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000749660 2014-12-31 0000749660 2013-12-31 0000749660 icad:VucompMvuBreastDensitySoftwareMember 2015-06-30 0000749660 icad:DermEbxAndRadionMember 2015-06-30 0000749660 us-gaap:FairValueMeasurementsNonrecurringMember 2015-06-30 0000749660 us-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0000749660 us-gaap:RestrictedStockMember 2015-06-30 0000749660 us-gaap:MinimumMember 2015-06-30 0000749660 icad:DetectionMember 2015-06-30 0000749660 icad:TherapyMember 2015-06-30 0000749660 icad:LongLivedAndIntangibleAssetsMemberus-gaap:FairValueMeasurementsNonrecurringMember 2015-06-30 0000749660 us-gaap:GoodwillMemberus-gaap:FairValueMeasurementsNonrecurringMember 2015-06-30 0000749660 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0000749660 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0000749660 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0000749660 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember 2015-06-30 0000749660 icad:LongLivedAndIntangibleAssetsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember 2015-06-30 0000749660 us-gaap:GoodwillMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember 2015-06-30 0000749660 2015-06-30 0000749660 icad:FacilityAgreementMember 2015-03-31 0000749660 us-gaap:RestrictedStockMember 2014-06-30 0000749660 2014-06-30 0000749660 2013-08-31 0000749660 icad:RadionIncMember 2014-07-15 0000749660 us-gaap:RestrictedStockMembericad:DermEbxMember 2014-07-15 0000749660 icad:VucompMvuBreastDensitySoftwareMember 2015-04-29 0000749660 2015-08-04 shares iso4217:USD iso4217:USD shares pure icad:Segment icad:LeaseContracts EX-101.SCH 8 icad-20150630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation and Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Loss per Common Share link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Business Combinations link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Inventory link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Long Term Debt link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Lease Commitments link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Long-lived assets link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Goodwill link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Segment Reporting link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Loss per Common Share (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Business Combinations (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Inventory (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Long Term Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Lease Commitments (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Goodwill (Tables) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Segment Reporting (Tables) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Loss per Common Share - Calculation of Net Loss per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Loss per Common Share - Exercise of Stock Options and Vesting of Restricted Stock (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Business Combinations - Acquisition of VuComp M-Vu Breast Density Product - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Business Combinations - Preliminary Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and liabilities Assumed (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Business Combinations - Acquisition of DermEbx and Radion - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Acquisition of DermEbx and Radion - Summary of Unaudited Proforma Operating Results, Acquisition (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Inventory - Components of Inventory (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Long Term Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Long Term Debt - Interest Expense Included in Consolidated Income Statement (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Lease Commitments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Lease Commitments - Future Minimum Lease Payments under Operating Leases (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Lease Commitments - Future Minimum Lease Payments under Non-cancelable Capital Leases (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Stock-Based Compensation - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Stock-Based Compensation - Schedule of Consolidated Statement of Operations Relating to Stock Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Stock-Based Compensation - Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Stock-Based Compensation - Aggregate Intrinsic Value (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 151 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 152 - Disclosure - Fair Value Measurements - Fair Values of Long-Lived Assets and Goodwill Measured Using Level 3 Inputs (Detail) link:calculationLink link:presentationLink link:definitionLink 153 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 154 - Disclosure - Long-lived Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 155 - Disclosure - Goodwill - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 156 - Disclosure - Goodwill - Roll Forward of Goodwill Activity by Reportable Segment (Detail) link:calculationLink link:presentationLink link:definitionLink 157 - Disclosure - Segment Reporting - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 158 - Disclosure - Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 icad-20150630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 icad-20150630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 icad-20150630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 12 icad-20150630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 13 g89197ex3a_pg002.jpg GRAPHIC begin 644 g89197ex3a_pg002.jpg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g89197ex3a_pg004a.jpg GRAPHIC begin 644 g89197ex3a_pg004a.jpg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g89197ex3a_pg004b.jpg GRAPHIC begin 644 g89197ex3a_pg004b.jpg M_]C_X 02D9)1@ ! @ 9 !D #_[ 11'5C:WD 0 $ 9 _^X #D%D M;V)E &3 ?_; (0 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M P,# P,# P,#_\ $0@ ) "1 P$1 (1 0,1 ?_$ 'D (" P$! M '" D%!@H$ P$! ! 8" @$# @,% PT M @,$!08' 0@ $0DA$A,4%S$5%D$B(S,885,E47&10M*3XS24-296"A$! M /_: P# 0 "$0,1 #\ [^. 9SC&,YSGK&/7.<^F M,8Q^.0BQP+O?'Q5M\TUIW1,!V?G A8(1(B#% M*H[( !$,?Q$%"%T'&H MXX&MCRVGIEQ"=22I0JRO:+&0]9[[QP'KP#@' . < X!P*&_-YY(:[U;KV'ZL MM]L%0*Z=I5(XHJ<&!JDZJ\ M#R/ 2L\"MCQE*M:FO;2K [!UOL-J4OA;:XU+XX-;]FZQ=H'&I(G(0DN4HNTV M5KQG1.9[/VVX*5B]4(\8%3<$0@)Q9&+.,!U]$Y*3$!(_$9!0/<67C&1 R//M M"# <"ZQ^]GT[SZX_;P,@'OK'???6.^^N^^O7OKO'?^;TX&K.7@Q1B_LQZX].!B)"_M489W.0/C@D:6-B;EKR^.JY00E0M+,V) MS%CFZKU"@0"TZ% C)&:8//I@(>!"W4#=V-;,5! +;E#:AJ1/<\ZG$:I".R1W M3E.UGQR-.SJ4PRN-IE'PJG F41YMPYE%E S@"8T.-[624T74#Y8MSA$NVDV6E2RY]B'Y6J X.!4G??DRP0$"_!8?\ :UC(T[4 MC)#T67\ Q8Q^]P+#S"BS@^PP(1A]>PBQ@6,XR'(!8S@6,XR$8!9#G&?QQG.. M!J\-@<*KMJ-8H'%8_#F0YP7.IC/&FE"RM@G-S4#5N*_Z)O)((^J7*#,C-'[> MQ9_'@;9P$!!=DJNLNW+6IN$O9S_*:2$RIK'4-R3ZF/,KR_EF&(XN)\*,&G'* M4808$J1X_B$!%CW]9], _P#@' . 9G,'M1 MCW!0,C&C,6*Q%$XS@:I8?@O!1! .S#SQ@+!C(A8QP*J_&=KS+[$^ZWD'VTAC M6;?VXLB:9O!8=)V)&N,H77"-@R*A*Z;4SDG4G(9@1'32W9Z.S\2C#DJ"4+_E M\9R$,O\ Z++Y0NM54-J%KJW-EK^1.:[&538.N=9,2=ID$RA2VN7Y?DP5MM!-CK-)#-HU5ZYL)2OE1U$L!?XZ2>/LKDQL[H](6]UE:TYOCJ! M2:$M4Z+DS>JU!Y*)$:>,/]V6+/[.!5#Y*;(D5JR.M_'36#[ACD.P M[.XS'9.QBSDZ8NFM.XJ<$FTY%DXY:3\,CL09P(^UAP PI,!0I5G8P43ZA'O1 M6RZDW:W*N"^*\9&!+J9XY(2S:J:N.2E$8SI5,HNQ^ MV5=(]06W7FV9+5-AA=IZBLF%GN;"H;4V#(=.V)"G2S)=AW>0-2DA"F--*>"Q MI,8%DOO 3QG>UFNU50**6=;-OP2IX/.$36MBC[9LC:X,4]X=T!3FF2HTTB4H M%AB\M$> 9Q/Q^\G \>_&.^ X8K+HQ.6)LE,-?FF4QAZ1$.+-(V!P2.S(ZHE. M,B*4-[DA./3*B\AQWV$6<8[X$>=QMKZTTVU_LV^+)?6AO;8#&5#J@:5SN@;E M4CD"C/T<;CR/"DXLSYGIZ-))P+K..A9SZ]9QP*/_ !,[-C3.L6ULU[J5YO24 M3:6R:^=_=KD00L%+5U85LFJI;^AXW,E>!F6Q.(^I4%,HTJ+(BFXHC..^O3@= M.8>[B?<-$O8'3$9>36"2Y1O2$\MD?"@EY4M;J/Y!X;%R@CSCH6> M F]E]D8+J_7A,\F9V5BYYD3'#8-"D*Q&3);$FDF<$[TL6 E@,^7(!!& M:>;+>3KR#QE##/'IN ON:(RQ6A:'6]]8=9 :\4C!A#8TX' N9[ W1('>4KUJ M=8=[U;/$VC\X0DA 4(TLP6.PQ6KOB W5\7>Z+!M!#(#(_)O-K>+_?* M/^0O6+R%2YH:]_)]'HE9:F;5V^6FEK6IZ9M5Q4IBZL-J2)2E$I1ML @\;/5D MF&?Q'-:X"RH'T(ST#3-P]#_,[O5Y+]:DENS2'PO1.F'Z#[%*4<$"U+Z_:I3% M9$#.:Y-;GQ25)[(LD]"5[\*W).6RI@F9,*$$P >PL,@.KFWVA.QNU,IU"URI M"Z:AVVL.+V0G$[V(HJ^7U)(V>"((HXM\]L1BP;:;T#VQ4U453(5#'2NOT7DI):20$M65Z$>!%'.ZW&!%DC,**#[3.\!#J<:$;G[&;_ &RSI<0X1$-'['/K5I$]V- '!AYAH_(M%:_J/6&SZ2FU=Z MC0K7]FBD/ICQX6DW*).KG3(ZH6EUB=Q7G89\4>FEA?(^6 M0X8;GU)*+["8VKND'E+I;3M!II%[7UAUNB595S*(+7 MED5+%)#);#E;B>0_%,4F< 2 P#-"G!6Y+"%RA2 MP5%9SG&.\XX&GZ3^'R[6 M35=CIC?.=1&7@AZQ\?&2MJB<)RGB,_LYQ+.&MN[86985-DZM.;R1\-./4I,' M$MZ9,;C"?VCQCH/IKMX2[[TFKYGD^F>Z08+MJ^-S@QWC8MQUH]7?5%GQT4B. M=HG%VR"R&6MSY"6VMB%!Z9J.;W$(S2C,"4!'CTX%E&M>@#;5\^'L#L':LUVU MVF4(0HT]O6:2VH8]7J10G %P8:*J=K*(B%21TT[(@YRG"I=5980Y4JS<]\"P MKZ;']T;_ +_'^UP*H-3?Z*?O1Y1OK_H?Z@ONW&/Z_P#[T_EGY+^EOM>D^QOT MOZA_\<^P'V;_ .U_)_ ^H_,OJOXWR\"R.I?L]^B&S[$_;3[;^OY-]I?TO^B/ MY1/?Y9^CO\!_D?'_ "O]3V_LZX#+X!P#@' . < X!P#@' . < X!P#@' .!_ "_]D! end GRAPHIC 16 g89197ex3a_pg006a.jpg GRAPHIC begin 644 g89197ex3a_pg006a.jpg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g89197ex3a_pg006b.jpg GRAPHIC begin 644 g89197ex3a_pg006b.jpg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end GRAPHIC 18 g89197ex3a_pg007a.jpg GRAPHIC begin 644 g89197ex3a_pg007a.jpg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end GRAPHIC 19 g89197ex3a_pg007b.jpg GRAPHIC begin 644 g89197ex3a_pg007b.jpg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end GRAPHIC 20 g89197ex3a_pg011a.jpg GRAPHIC begin 644 g89197ex3a_pg011a.jpg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end GRAPHIC 21 g89197ex3a_pg011b.jpg GRAPHIC begin 644 g89197ex3a_pg011b.jpg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end GRAPHIC 22 g89197ex3a_pg015.jpg GRAPHIC begin 644 g89197ex3a_pg015.jpg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end GRAPHIC 23 g89197ex3a_pg023.jpg GRAPHIC begin 644 g89197ex3a_pg023.jpg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end GRAPHIC 24 g89197ex3a_pg042.jpg GRAPHIC begin 644 g89197ex3a_pg042.jpg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htm IDEA: XBRL DOCUMENT v3.2.0.727
Long Term Debt - Interest Expense Included in Consolidated Income Statement (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Interest Expense, Debt [Abstract]        
Cash interest expense   $ 216 $ 162 $ 794
Non-cash amortization of debt discount   313 254 448
Amortization of debt costs   28 13 76
Amortization of settlement obligations $ 47 54 92 106
Interest expense capital lease 23 3 56 7
Total interest expense $ 70 $ 614 $ 577 $ 1,431

XML 26 R54.htm IDEA: XBRL DOCUMENT v3.2.0.727
Goodwill - Additional Information (Detail)
3 Months Ended 6 Months Ended
Apr. 29, 2015
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Segment
Dec. 31, 2014
USD ($)
Goodwill [Line Items]        
Number of reporting segments | Segment     2  
Impairment loss     $ 13,981,000  
Percentage of discount derived from capital asset pricing model     17.00%  
Fair value of goodwill   $ 5,700,000 $ 5,700,000  
Business acquisition paid in cash     1,700,000  
Goodwill   14,198,000 14,198,000 $ 27,263,000
VuComp M-Vu Breast Density Product [Member]        
Goodwill [Line Items]        
Business acquisition paid in cash $ 1,700,000   1,700,000  
Goodwill $ 800,000 $ 800,000 $ 800,000  
Detection [Member]        
Goodwill [Line Items]        
Percentage of fair value of each reporting unit   315.00% 315.00%  
Goodwill   $ 8,463,000 $ 8,463,000 7,663,000
Cancer Therapy [Member]        
Goodwill [Line Items]        
Percentage of fair value of each reporting unit   255.00% 255.00%  
Impairment loss   $ 13,981,000 $ 13,981,000  
Goodwill   $ 5,735,000 $ 5,735,000 $ 19,600,000
XML 27 R48.htm IDEA: XBRL DOCUMENT v3.2.0.727
Commitments and Contingencies - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 28, 2010
Jul. 31, 2007
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Loss Contingencies [Line Items]            
Minimum annual royalty payment         $ 250,000  
Minimum royalty obligations     $ 442,000   442,000  
Litigation and settlement obligation, Total     500,000   500,000  
Royalty obligation non-current     395,000   395,000  
Purchase obligations to suppliers for future product deliverables     2,200,000   2,200,000  
CADx Medical Systems Inc. [Member]            
Loss Contingencies [Line Items]            
Tax re-assessment received   $ 6,800,000        
Reduced tax re-assessment received $ 703,000          
Hologic [Member]            
Loss Contingencies [Line Items]            
Interest expense royalty obligation     18,000 $ 25,000 36,000 $ 50,000
Zeiss [Member]            
Loss Contingencies [Line Items]            
Interest expense royalty obligation     $ 28,000 $ 28,000 $ 56,000 $ 56,000
EXCEL 28 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`.=U!D>O(PE:_@$``-HB```3````6T-O;G1E;G1?5'EP97-= M+GAM;,W:S4[C,!`'\%>IU6 MW17L4NE_:9J./3/))+]3S^^?`J79SO5#6E9=SN$;8ZGIR)E4^T!#B:Q\=":7 MT[AFP30;LR8F%HLSUO@ATY#G>C8%]I^\'N/L8PJF$,FT MJ2/*KJ]3?NHI':N_C[Q4OJ*5>>CSNPH_W[LZ4C^M29T-SZ6N=R5+*K\MJQ)- M;ZIPN/%OG5DW#BT,Z]]VC.?_>"T'-W'K^JMH'NU!@>W)QC0>:V?L<&Q4CSYN M?GB_^E\9'>5'!<>,*7HC.1 MVN\YEOD>?S=^77"Z/L:Y3M__-/0IF-AT."$2[^I#@/0A0?I0('UHD#[.0/KX M#-+'%Y`^OH+TP1QW8OG*\M"_V/Z'D4X$G1 MH>)%]2-F`Q+M*;V"^GH`A3&^.R6:E((C-Z."N[_8_`)02P,$%`````@`YW4& M1WNH42T$`@``N"(``!H```!X;"]??3,L1DS;''6!=#9$ M)-+G=_4HLO/0Y7KU(QV;FN'T]-F?Z.^S`TF]=FGX+6]3*,EW.JQX>/LQ?/VW4U/F^E6OQLQGTJZ^IW M/[[F-J62P_DB-],"T^.W(7UG^7ZW.VS24[_Y=4I=^:(B_%N@"O-!.A^DE""; M#S)*D,\'.24HS@=%2M!R/FA)";J=#[JE!-W-!]U1@N[G@^XI05(#&6M.$L*: MH[4`KH7CM0"PA2.V`+*%8[8`M(6CM@"VA>.V`+B%([<`NH5CMP"\A:.W`KV5 MH[<"O97TKHU>MCEZ*]!;.7HKT%LY>BO06SEZ*]!;.7HKT%LY>BO06SEZ*]!; M.7H;T-LX>AO0VSAZ&]#;2'LE:+.$H[CO0 MVSEZ.]#;.7H[T-LY>D>@=^3H'8'>D:-W!'I'CMX1Z!TY>D>@=R2=5:+#2H[> M$>@=.7I'H'?DZ!TO],YM,Z;M2QD/W3Y?N^:_X;#H`N]I_X-"9\^4GE\!U!+`P04````"`#G=09'=YC&OUT#```C#@`` M$````&1O8U!R;W!S+V%P<"YX;6R]5UUOVC`4_2L63]L##:/M*B$:J06Z(;4J M`MH]&^<"5AT[LQU*]^MW[4`6(`'2A_4%QS[G?AY_M"M-JS/2*@%M.1BRCH4T M'9R\;2RM33I!8-@28FHN$")Q=:YT3"U^ZD6@YG/.H*]8&H.T0;O5^A[`VH*, M(&HFN=%&V'5>[I)$<$8M5S)\XDPKH^:6#-8,1#?8!W@&6IX`2S6W'V$KPQ2G M/&;"J(`>^@KG5!C(4/\F/::GXH3*CR#[>N3RS;PD4]6G%HJLW87,^I)JB-#I MCO5\TF-^?F">PG%[2RH7$!6QAXO;6KR"-B[3;^V+%O[E)=C.9[:!1EPN1I1K M$W97MK,"9I7>M&EE/]NE2#'7=/,ZQ?A,@\RH`3>\;:RHYE3:!C'\#WZV&YG; M;-:/16*L#G\I_6:6`-9T@WS2#XO8XIA?A=-0O9;$X3*B`RD13F2H/2&S>ER*%E/RH\R@69@HY)'V:V M'`+85C*>$"IDUQKX$3%CS7VLDYCFZ1'!4L%K<49K$$S7IYP MN1J:J-S?*3?EAU45!],3/*['\7XNRP_230R^6EB]/BIK,%O[PHWQ&CPAU:87 MBI*^YTCW*^?H%H.*(N^5"G=YG<<92@O87O=P2ZK\'&A^Q]79G(?4HIC)$Z^Z M3(YQKMKU-E@68EW.9$5U^2Q?!8+7?]R(LU:APRZ<1=,78Y3 M0TV.7SEY'1ZH6I77H'!#^@3.T6A^:![Z<,^^4YRQPI\'I=^ICMQ&=4MG'KNG M8ROC3-(XIGA"H*^#-WKQL;WWM`YV_R4,_P)02P,$%`````@`YW4&1Y=8900_ M`0``:0,``!$```!D;V-0UR8PX>;9!M$Q0H+8@.9A%"M,3*ZLUQQCZ-?$<;'E:R#CHI@1#<@E1TX. MP-SUQ*PJI6#"`T?K.[P4/=[M?)U@4A"H08/!0.B(DJQZ-EMC&U.205^5T7'- M`RZL5"L%\J8=RGZG8F<$K\-1#K)OG_[^Z2%E2-95[H/JJYJF&3635!<'IN1U M\?"4SB97)B`W`J(J*(:M@WGVU?EE4S^BDU=5?0)02P,$%`````@`YW4& M1YE&UL[5I;<]HX%'[O MK]!X9_9M"\8V@;:T$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J; M/`0LZ?O.14?GZ#AY\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL M:$#05%%:;U\@M.4?,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP M&U@@?\YOI^1.6HCA5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C. M=GSVQ.V?C,K:=#1M&N#C\7@XMLO2BW`A(5M>5`TR``6'!VULS2`Y9>*?IUE!K9';O=05SP6.XY MB1'^QL4$UFG2&98T1G*=D`4.`#?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB! M]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95 MO-RCEU@5`9<8WS2J-2S%UGB5P/&MG#P=$Q+-E`L&08:7)"82J3E^34@3_BNE MVOZKR2.FJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PU MDSY@R.S-D77.UI$.$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;] MN'Z&U3-L+([W1]072N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E M>G@*-Y;&O%"N@GL!_]':-\*K^(+`.7\N?<^E[[GT/:'2MSAD6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^ M+,_Y/%_GM,T+,T.WF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1 M^^?!4;"C[SR6'<>(\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L M%.!D8"V@!X.O40+R4E5@,5O&`RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9 M;2)2.<)IF!-GJ\K>9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F M2J+S&5.^YRM)Q%4XOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M M#`DL6XA9$N)-7>W5YYNTB42%(JP#`4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG! M/3-R0]A4)?.NVB8+A=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH`1JV*^NJ]/^26<.[1[ M\8$@F_S6VZ3VW>`,?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY M@%CS#*%F.-^'19H:,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\ MW/[O#;#"Q([A[8N_`5!+`P04````"`#G=09'!`0:Y3D"``#G"```#0```'AL M+W-T>6QEAJ&T8A,-C*H/G0;T6V94>@ M%T^6,Z>_?B?)L>-`2)=U9?FBTZ.[YYX[*V?'C=ER^K"FU*!.<-DD>&U,_3D( MFGQ-!6EFJJ823DJE!3&PU570U)J2HK%!@@?S,%P$@C")TUBV8BE,@W+52I/@ M^0`A'W^G"IK@I\OW/UME;M\AOUY\N+@(GZYN#_%+=W"%D>?X6B0X6ESCX.6D ML_`X+YP=4"\L==#7D,:EDM-2+)#&S3/:$`[^D77/%5<:&>@5:'"()()ZCSO" M6::9!4LB&-]Z>&X!U][>3S"IM,OM,QSFF85C)EUE"0[[W\O392.[6VQYC/-I M>0"D<4V,H5HN88-Z>[6MH3BI)/4BG=\)[TJ3;32_W@MP"^3-E"ZH'C)'>`>E M,:>E@0#-JK5=C:JM=&6,$F`4C%1*$FXI=Q&]`;0YY?S!7N;'JT>6JI^=XH^ M.D*?QF3'BM9*LV?PM_<@!X!JC#94&Y;O([\TJ5>T,_T%#KKRF,)S2_Z7FEZ_ M:Z,:N(%OW9ZSDSOHOA49U4LW%_]VO.D/`*S;&OGO]6 MVN(OI07]B-N;HY,I.J`H:QDW3.XT$/O>N[>Z^63"C1,4.(MN')[NU)`,OCHF M68"LH"5IN?G!-LJXPP2/]C/F>#P.]5JU,OSA-LK2M:7S MK8QTZE=CMUSJ6IVZNFN5C>-\,CD:>V5DU,Z&M=Z$[)$67D,+&Z]D$]9*Q=9L M8:W4-OOT,1POM5$WR@<""[G9_"U;-3":,#/<5$ULZRD4W>O!E_X;G/2 M:9-.JDF5C1/L::K?O:A=H[:PZ[4._SY>R$2CEK(S\9J"?;KO+)OF99X?;1GI M9S=:W0<$IB^$K*.^4]=R,E"_T@ND-X_H9BC+H>_##*Q55Z M$K/L:$+`.QWT0AL=?\RR_MBH-)/Q+U/IT_]R)&R?G*='+*1MQ)F-1!$7=OOP M*#4I!OKQ1=/?V!]K.O`7S72;*@1]=K91-JA&T%%P1C>4E4:<2"-MK02`<@#E M;P45`"H`5+P:-(_T05,&4`F@\JV@"D`5@*I=T(D,.@BW%-^]"I3T/L5]YN=Z M936`C@!TM`OZZD(0&^4IH+8EQ'PMO8+A[V#X.R:.+FBK"$'#%]INJQJ&OX?A M[W>'7]@["M[Y'S#D`PSYP`5L5^):^5:[%%V; M,K)]<:ZYU\;@&!1LRA@V5ZM^5;E2&^=3NG`PZC5E_+I2=1K[9UV[KL\UU8NS M=%SW&4,4:C=EO#M8=$Y&I._$:+M5'A=R2AE3EC)5M^+&FP5#)N M/EL7D?BE)GJ/U"%%I=,%8?C*K`%WZ! M:A>,VH\3Z9\;/<=3JK:SQ4/_"*]D,X@*U2X8M5^*?=17B;.]V43MKR`*U2X8 MM7^I?)I9T_0Q2I.Z/T2AZ`4C^@[JPE)+3*TZZ;`91H6V%UR3L+.8#`+#A@UM M+U_3-1#JO(NT'(A+/>BT2K2]Y&P_A"IS1*'M)6/[WG5N.T]$H>TE8_L!U+=- M'*`&W2UC^P'4G/9TB$+;R[=Q5X&V5XSM^U']%42A[15C.W:8.^N" MP[17:'O%V`Y-9Y^<_>5T58_OSJW@WHK1/113:7C&V`^J*-M3BW/E[Z9NT MC*9+B!KLYCC;=][Q>R>(ME><[0QJWK6MI-6>(D,4VEZ]>]SIOVSN&[6D=U>3 M_OH(_6UJ>L&G_T/H8[O?*:O4-J?S2]?0O=,?&9E8=L:D7N";_>IDO]W?DI_^ M`?GT/U!+`P04````"`#G=09'KU%H7$T"``#S!P``&````'AL+W=OV5%3F^"5`U^91Z_U35B M__:8T&[K`[\/O%774JA`4.3!X#M7-6YX11N/X3G^>M'ZH:,,$GH5(@^;CC`R9$99+DOS;I@ZF,XW&?_5FW*\L_(HX/ ME/RISJ*4U8:^=\87="/BC78OV/:0J(0G2KC^]4XW+FC=6WRO1A_F637ZV9E_ MXLC:W`9H#7`P@-6D(;*&Z&'0KRXPE>F^?B"!BIS1SN,M4JL--E+.5!*9V>,Z MFVR)Z^!.1>]%F`=WE<8JX$BQ-PHP*`*9VPF`OLL.M1U^#S@8130/B'I`-.X@ MTO9XWA[W]GALC[4]^5S?6+$WBG0>D#@!B;9G$P"C6,T#4B<@U?;U!,`H0#A/ MR)R$S/C!9T2B)8U!&`D,03(/63DA*P/Y\J6DXSZL9,&GLG8BUL8?3[PJ*UG0 M!0B=#!V6&=()2*_)%E"`FV)WY6IB2:PFB]=INF#I`723S/8$4]^7U<`EE,A- M,;L8@BF*U<`%%/=>!V8KP^C[MW:P&I!D,$SBKRL4C,[8&K.KOGNX=Z*W1I@C M=H@.]]L.ZC/Z(2_R%EWQ+\2N5<.](Q7RI-?'\H52@641X9,LJ90W\#`A^"+4 M,)-C9NXD,Q&T[:_8X9XO_@-02P,$%`````@`YW4&1^ZILYW:`P``T!(``!@` M``!X;"]W;W)KM%>LQMG@PHX!]A-^^]K\)"3KW%]K^&DS%C M\KMMNN%^WLVG?OG:/NV&MUE_Y0.Y]Y4ASFH;5+.6):V M5=UM=MOYWK=^M[7/8U-WYEN?#,]M6_5_]J:QE_L-;)8;W^NGTSC=2'?;]!IW MJ%O3#;7MDMX<[S3*)?[#VUW3QY7"_89,&TYC'<6JB M[ZT_FD>KI/_4`VFM,W/^C">G%JV20[F6#TW MXW=[^6QP#&IJ\-$VP_R;/#X/HVV7D$W25K_]L>[FX\7_DS,,"P=P#.#7`)!D M@,``\4]`ZI7-X_I8C=5NV]M+,IRKZ6G#G'D;+WR\?BU1STCG M!^$1R#G+UZG24X)SSM[6(H-:I-?R3R_J5HM'M,[D.E1ZJ,@D?UN)"BI17DE! M*/&(<`,FE&`['.3;2K*@DLQWPP@E'I&D$,\H&?%L=%"']CJ`T*%QTC1DA!)/ M29E!1,[F02TYIAJA)<=4R@C!98X3IR)67Q%44F`2$$H\4E#YZA$0$>D*+*AC MONV$$+WLD9&9IK0@!5JQB)P%",OQKB84)<%B/=TE! MY.4>&05*$H^S1*P06D>L);B:[BO3!C1+'=%"V"K!>YR@O!(9R!GYP-%U04&$ MFK!=`IHAY9?(2$YE18F44BHF^\*6"6B(A&>6R+BYB>@F[(B`3D99(C+`%>5# M2+D5%S/HL"?"8F:4&L^X?"`>5(E4`3$;.81]$;RE42MICPPH0>5-B9@K*VY4 MKQ=)87_DZ'V4/R*346Y>(@0JJF(+NR/WEB8I=T0F(Z<&(5W$:`D[(^>X*5!: MD,DIGT8(6$S6\'`MRKTM2DWUXQF5L8C=DH?-DTL<$%'T(@.:%<4Z5B(F'!5A MGSQLGQRM,2:_KY;W^BT`Z[N8N0^[&4(95SKB%4E5MZ-T6O(EV.Q M5C:^?CL6JV5C>O/MX5P]F:]5_U1W0_)@Q]&V\S>'H[6C<- M.8[3J7;GO?_@XB]&>UZ^'UT_8NW^`E!+`P04````"`#G=09'-8B:='8"```_ M"0``&````'AL+W=O&Y^9TEKHAJ3;)%'=H.M:+ MAO?1P([;^`&N:X@U8HA?#;N)63G2\B^_[BD__O4@?/RF/V;&:[2?Z&"U;S]W1SD6=F".#JP([VV\IG?OC,WADPG MW/-6F/]H?Q62=V-(''7TW3Z;WCQO]@TI79@_`+D`-`7`-!B`70#^%)!8,S.N M1RIIM1GX+1(7JE<;KA4^Z"0JU@DS4FQ#-4.*F:9%DTRKTEF35!@1BP"05H&J-I1*<'%?9?< MZY);%_RQEV+N8A&P`G`9JCW0H@GQFA!KD@;6A[A9,;_`$OFY19_"ZU-8GRS@ M8Y&0R6=BT:'T.I36(0^L3OF5U?%`BR80>%5,LW(A@?EP#`)W5VB)7+:"?BN[ MN^6!#W;G&)B5(,?!3WLB"4:0D"]8(;^5W3/S,F2%QKX0R-+`K-83F:4Y3O,O M6/DW8FBW4!)8EYUC8)$5.+!3UG[.&B6SH^Y"3^PG'4Y-+Z(7+M6I:8ZX(^>2 MJ3Q@I;*>U6UFJK3L*'61J/)@SW=;D?PR7E>F.U/U#U!+`P04````"`#G=09' MQ[AR"%P%``#R&P``&````'AL+W=OR<24QBUQCC!3*>_?<+J&4#(]K:GOC8-]V%U6:]NL;M#D5^J@_E:5'E[\_+%_J4//,Z/QRY3V_+?D/369A6R^EI??<]`0=0G?RF/=_[]X^ZR; MLG`ART61_;2?AU/_>;%_T03"_`$,`M@UX-J./X!#`+\%"#1`0(`(;2&"@&C2 MPLIJ[T9%W6=K!ZWN+[YT5W]L%%VO?G1Y M`&$#9`L(FT<2B]R2K-KVO9U@2U\+K`]'&H@MH3C2A[M)TE^2S':3NV[RX5AQ M&R_NQPL7+X;QPL9'XRZJ'CG9D;`()T;.0[&%(F;$/)1`8R1"H-1")B(!8Q)Y M-46VF4EWHZ$FBV@BU#P46TCPZ2T>0HF%J&K'9YY*H3VI`VZ4](J25A32WZU% M**4"Z7!L*2,EDBJQ$!-<(JE2:%!3K>[+4M[Z55:6OA^OO<.BO?4[&A:+2$V0 M0;$,Y0:!$H`DH\B86(A%BMR79+R2S/WRM0@CFB&:#)0#$8@F`S4N$>$I-$>5 MN:^)$J^H_G*K"IDD6V"&,_]750!QK,83@-J9@`Q0"I0,63TI]@PIF3(7?.;)K6N.9@]\QG\MDFM2VGD+FR!86RZ31F/#E`$G:9`B8@A M(YT"Q;64`;('A%*_H""H:TY\`)8U!`>5!HCP&2%#,\1T78B2=U5'OB"3GH^[VJ6D-C9XR.22*C/[1 M^:CDEMS,4^D@=T"%<[\/K$K+K5X(5&D5O%6?IX:^XS^>O7ZNNJ%=2]$)M>W]"FFGNL)?4KM MRZA;^LWZG'WD?V;5Q^%4+U[+IBF+_IW)>UDV>=MC\MCV?Y]GN^N/8_[>=%]5 M=P?L*RG[HRG/[@W;]37?YE]02P,$%`````@`YW4&1S`*)ON7!```D!<``!@` M``!X;"]W;W)K*O3L9\R:6F)_#GP=]'')];=KOW5IM>IV)U,5W9?F8NKA/X>FK8I^>&V/J^[2FF(_5:K*%81A MO*J*<[W8K*>RK^UFW;SUY;DV7]N@>ZNJHOUO:\KF^KQ0"U?P[7P\]6/!:K-> MS?7VY\K4W;FI@]8O4^!B(-W&BVI)D5JR$ZVP0LN.HP58?/&\BM(L''+:!K`6\[ M@=0)>!Q`NP#Z-H"F`'AO,IDTM>V&U2PAB[4@RTFF5)H\=A.QW8G(C7X<(&:[ M$U.`Z-YG=-L=TF`,GXMR*TIT^MA)PCI)R$DL.+&:-!,TN=5H])CAE#62DI%$ M,$*:-!6,6`UXS&W&^LC(A]#&UFEB+1BQHOAF9#]UHD+6RE0\MI,)7DB$@((7 M$D7@L6*5XLT09%0HF;&B3%JR+I#7P`#O!)R!99"6OC;2+%4FY@,?,H^,`'B>`65K2IPK*X(LC:6T`!SWE,X\#/'< M`\K^E+0/D@A$VH/+$1%]IHO/_L"!+_0(P>=_0.`#:0,CT1+%`2:1]MC9@4CT!X!&GO(-$2(I0( MZ611Z+'.,607%E*^!QZ#ASS:D-`&TIHA$:2@/%8-\M!"2J]`@BB)4!+E)(+, MYWC)(PL)62"=#)PH2GS&ET<1$HI`0A&)EJET/'"BVY/]YV[X/`V)1"CEY"1: MQF*R,:M\QH:'&KH3JP0U$@T;`D12PNQT6OE\X,B3#8EL*)&-1(.C6Y8PCJP. MHE1Y[!W(PPT);BC!#1W<="AEX#FZ!#%+?-80#T$D"*($01(A`(A#Y/+--/68 M-,UGBIHH*.%VZT0I2`?UG&2HT\ACA/3,U#LL:^5N8CQ"\+#4!$N48$DBG4B' M%!YPN@+M@U[S5O;V$ MG$OG2^87&"]*?RK?JJ?<7A5_A-FL+\71_%6TQW/=!:]-WS?5=&=Z:)K>#+;" M+\.(G4RQGU]*<^C'QV1X;NV%L7WIFXN[_YXOX3?_`U!+`P04````"`#G=09' M=I/!M:,!``"Q`P``&````'AL+W=O<$SPSEG MSOB2#VC>;`O@R+N2VAYHZURW9\R6+2AN[[`#[?_4:!1W/C4-LYT!7D62DBQ- MDA],<:%ID-_M3%A`1\"I@L*N8!.]GQ+>0_*T.-`D60$+I@@+WRP4>0,H@Y!O_ MGS2_6@;B.I[5?\=IO?LSM_"`\I^H7.O-)I144/->NA<<_L`TPBX(EBAM_)*R MMP[53*%$\?=Q%3JNP_AG=S_1KA/2B9`NA/LD&A\;19N/W/$B-S@0V_%P=IN] MAYL@XI6)C6K>H8W%8ZA>BLWV5\XN06C"I"O,:<(L".;5K[9(Z35Z&NGI;?IV MIF_7#K=C]RRY+9#-`ME:(+L^XAISFC#9]R'9:D\5F"9>'4M*[+4;MW2I+K?S MF,8S^8(7><<;>.*F$=J2,SI_LO$8:D0'OGURMZ.D]>]G2234+H0_?6S&*S4F M#KOY@2ROM/@$4$L#!!0````(`.=U!D=2%2D'H`$``+$#```8````>&PO=V]R M:W-H965T&ULA5/;;MP@$/T5Q`<$+W;::N6UM)NJ:A\J17EH MGUE[;*,`XP)>IW]?P)=8U4IY,3/C<\X<&"@GM*^N!_#D32OC3K3W?C@RYNH> MM'`/.(`)?UJT6OB0VHZYP8)H$DDKQK/L$]-"&EJ5J?9LJQ)'KZ2!9TOVC@@C+#9Y`J2@4&O]9--];1N(^7M6_I=T&]U?AX`G5;]GX M/IC-*&F@%:/R+SA]AV4+CU&P1N72E]2C\ZA7"B5:O,VK-&F=YC]YMM#N$_A" MX!OA2R*PN5&R^55X4946)^(&$6=W.`:XC2)!F;BD%ARZ5#S'ZJTZ%+QDMRBT M8/@.>9K).[PJ!]'!3V$[:1RYH@^336-H$3V$ M]MG#(R5]>#];HJ#U,?P<8CM?J3GQ.*P/9'NEU3]02P,$%`````@`YW4&1]3& M.C.B`0``L0,``!@```!X;"]W;W)K:>=*0[NA1>1-NY4&!EP59>+11H*U`3 M`\V1GG:'U'_&W7KW%V[A">6;J%WGS2:4U-#P0;H7''_!O(5]$*Q0VO@EU6`= MJH5"B>(?TRIT7,?I3Y;-M-N$=":D*^$QB<:G1M'F#^YX61@UYF-WNX.$F MB'AE8J.:=VAC\12JUW*7[PMV#4(S)MU@SC-F13"O?K-%2F_1TTA/OZ=G"SW; M.LQFA_??"^2+0+X5R&]O<8LY+YB'_YJPS9DJ,&V\.I94.&@W'>E:76_G*8TS M^8*71<];^,--*[0E%W1^LG$,#:(#WSZYVU/2^?>S)A(:%\(''YOI2DV)PWYY M(.LK+3\!4$L#!!0````(`.=U!D<-Y-B;HP$``+$#```8````>&PO=V]R:W-H M965T&ULA5/;;MP@$/T5Q`<$V^MMTY77TFZJJGV(%.4A?6;M ML8T"C`MXG?Q]`%]B52OEQ M80_:_VG0*.Y\:EIF>P.\CB0E698DWYCB0M.RB+4G4Q8X."DT/!EB!Z6X>3^# MQ/%(4[H4GD7;N5!@9<%67BT4:"M0$P/-D9[2PSD/B`AX$3#:34R"]POB:TC^ MU$>:!`L@H7)!@?OE"@\@91#RC?_-FI\M`W$;+^J_XFZ]^PNW\(#RKZA=Y\TF ME-30\$&Z9QQ_P[R%?1"L4-KX)=5@':J%0HGB;],J=%S'Z<\NFVFW"=E,R%;" M?1*-3XVBS9_<\;(P.!+;\S"[].#A)HAX96*CFG=H8_$4JM'4LJ'+2;CG2MKK?S%(?(/N%ET?,6'KEIA;;D@LY/-HZA073@ MVR=W>THZ_W[61$+C0OC=QV:Z4E/BL%\>R/I*RP]02P,$%`````@`YW4&1VO_ MRIZA`0``L0,``!D```!X;"]W;W)K&ULC5/;;N,@ M$/T5Q`<4AR3M*G(L)5VMM@\K57W8?2;VV$8%Q@LX[O[]`K[4JB*U+V9F?,Z9 M`P/Y@/;5M0">O&EEW)&VWG<'QES9@A;N#CLPX4^-5@L?4MLPUUD052)IQ7B6 MW3,MI*%%GFK/MLBQ]TH:>+;$]5H+^^\,"H8O5:;/99SJY1:,+P%>8\818$"^HW6W!ZB\X3G7].W\[T M[=KA=G+XA?Z[66"W%MC=WN(:9 MO,.+O!,-_!*VD<:1"_HPV32&&M%#:)_=[2EIP_M9$@6UC^%#B.UXI<;$8S<_ MD.65%O\!4$L#!!0````(`.=U!D?_M@`@H0$``+$#```9````>&PO=V]R:W-H M965TQNZO(L91T5;4/E:H^[#X3 M>VRC`N,"CKM_OX`OM5:1^F)FQN><.3!0C&C>;0?@R*>2VAYIYUQ_8,Q6'2AN M[[`'[?\T:!1W/C4ML[T!7D>2DBQ-DGNFN-"T+&+MU90%#DX*#:^&V$$I;OZ> M0>)XI#NZ%-Y$V[E08&7!5EXM%&@K4!,#S9&>=H=S%A`1\%O`:#:Z/-`D60$+E@@+WRQ4>0,H@Y!M_S)I?+0-Q&R_JCW&WWOV%6WA`^4?4KO-F M$TIJ:/@@W1N.3S!O(0^"%4H;OZ0:K$.U4"A1_'-:A8[K./W)TYEVFY#.A'0E M_$RB\:E1M/F+.UX6!D=B>QYFMSMXN`DB7IG8J.8=VE@\A>JUW.7[@EV#T(Q) M-YCSC%D1S*O?;)'26_0TTM/OZ?N%OM\ZW,\.L^\%LD4@VPIDM[>XQ9P73/Y? M$[8Y4P6FC5?'D@H'[:8C7:OK[3S%(;(O>%GTO(47;EJA+;F@\Y.-8V@0'?CV MR5U.2>??SYI(:%P(?_C83%=J2ASVRP-97VGY#U!+`P04````"`#G=09'$:TF MAZ(!``"Q`P``&0```'AL+W=O1I"1+D^2> M*2XT+?)8>S%%CKV30L.+(;97BIM_9Y`X'.F&SH57T;0N%%B1LX57"07:"M3$ M0'VDI\WAG`5$!+P)&.PJ)L'[!?$C)+^K(TV"!9!0NJ#`_7*%1Y`R"/G&?R?- MKY:!N(YG]:>X6^_^PBT\HGP7E6N]V822"FK>2_>*PS-,6]@%P1*EC5]2]M:A MFBF4*/XYKD+'=1C_[+.)=IN03H1T(3PDT?C8*-K\Q1TOXAISGC$/WYJPU9DJ,$V\.I:4V&LW'NE276[G*8TS M^8(7><<;^,--([0E%W1^LG$,-:(#WSZYVU'2^O>S)!)J%\*]C\UXI<;$83<_ MD.65%O\!4$L#!!0````(`.=U!D?L@$*SH@$``+$#```9````>&PO=V]R:W-H M965T<.3"0#VC>;`O@R+N2VAYHZURW9\R6+2AN M[[`#[?_4:!1W/C4-LYT!7D62DBQ-DGNFN-"TR&/MQ10Y]DX*#2^&V%XI;CY. M('$XT`V="Z^B:5THL")G"Z\2"K05J(F!^D"/F_TI"X@(^"M@L*N8!.]GQ+>0 M_*D.-`D60$+I@@+WRP4>0O=G;N$1Y3]1N=:; M32BIH.:]=*\X_(9I"[L@6**T\4O*WCI4,X42Q=_'5>BX#N.?73K1KA/2B9`N MA!])-#XVBC:?N.-%;G`@MN-A=IN]AYL@XI6)C6K>H8W%8ZA>BLWN9\XN06C" MI"O,:<(L".;5K[9(Z35Z&NGI;?IVIF_7#K>3P^RV0#8+9&N![/H6UYC3A+E/ MOC5AJS-58)IX=2PIL==N/-*ENMS.8QPB^X(7><<;>.:F$=J2,SH_V3B&&M&! M;Y_<[2AI_?M9$@FU"^&#C\UXI<;$83<_D.65%I]02P,$%`````@`YW4&1R/9 M72>@`0``L0,``!D```!X;"]W;W)K&ULC5/;;MP@ M$/T5Q`<$WY)6*Z^EW415^U`IRD/[S-IC&P48!_`Z_?L"OL2*5FI?S,SXG#,' M!LH)S:OM`1QY5U+;(^V=&PZ,V;H'Q>T=#J#]GQ:-XLZGIF-V,,";2%*294GR MP!07FE9EK#V;JL312:'AV1`[*L7-GS-(G(XTI6OA172]"P56E6SC-4*!M@(U M,=`>Z2D]G(N`B(!?`B:[BTGP?D%\#D[+%NX#X(U2AN_I!ZM M0[52*%'\?5Z%CNLT_\F+A7:;D"V$;"-\3:+QN5&T^<0=KTJ#$[$##[-+#QYN M@HA7)C:J>8JW2A[1DUR"T8+(=YKQ@-@3SZC=;9/06/8OT[-_T?*7G M>X?YXO`_!(I5H-@+%+>WN,><5TS^J0G;G:D"T\6K8TF-HW;SD6[5[7:>LCB3 M#WA5#KR#G]QT0EMR0>TIZ_WZV1$+K0OC%QV:^4G/B<%@? MR/9*J[]02P,$%`````@`YW4&1W>LC"FB`0``L0,``!D```!X;"]W;W)K&ULA5/;;MP@$/T5Q`<$K^W=5BNOI=U44?I0*Z*=<_V1,5MUH+A] MP!ZT_].@4=SYU+3,]@9X'4E*LC1)#DQQH6E9Q-J+*0L%%_BKOU[J_; M4%)#PP?I7G%\AGD+^R!8H;3Q2ZK!.E0+A1+%WZ=5Z+B.TY\LFVGW">E,2%?" M]R0:GQI%FS^XXV5A<"2VYV%VNZ.'FR#BE8F-:MZAC<5SJ-[*W2$OV"T(S9AT M@[G,F!7!O/K=%BF]1T\C/?V:GBWT;.LPFQWNOQ;(%X%\*Y#?W^(62#K*RW_`U!+`P04````"`#G=09'8X5Q MFJ$!``"Q`P``&0```'AL+W=OVJZH*& M8D3S;CL`1SZ4U/9`.^?Z/6.VZD!Q>X,]:/^G0:.X\ZEIF>T-\#J2E&19DMPQ MQ86F91%KSZ8L<'!2:'@VQ`Y*="@94%6WFU4*"M0$T, M-`=Z3/>G/"`BX%7`:#[/W,(3RC=1N\Z;32BIH>&#="\X_H)Y"[=!L$)IXY=4@W6H M%@HEBG],J]!Q':<_>3K3KA.RF9"MA(PTT0 M\HV>17KV/7VWT'=; MA[O9X&ULA5/;;J,P$/T5RQ]0$R#;*B)(2:O5[L-*51]VGQT8 MP*KMH;8)W;^O;2Y%5:2^X)GAG#-G?"E&-*^V`W#D74EMC[1SKC\P9JL.%+=W MV(/V?QHTBCN?FI;9W@"O(TE)EB;)#Z:XT+0L8NW9E`4.3@H-SX;802EN_I]! MXGBD.[H47D3;N5!@9<%67BT4:"M0$P/-D9YVAW,>$!'P5\!H-S$)WB^(KR'Y M71]I$BR`A,H%!>Z7*SR"E$'(-WZ;-3];!N(V7M1_QFF]^PNW\(CRGZA=Y\TF ME-30\$&Z%QQ_P3S"/@A6*&W\DFJP#M5"H43Q]VD5.J[C]&>?S;3;A'0FI"OA M(8G&IT;1YA-WO"P,CL3V/)S=[N#A)HAX96*CFG=H8_$4JM=\[O%U M1K;9406FC1?'D@H'[:8-7:OKW3RE\40^X671\Q;^<-,*;`@-H@/? M/KG;4]+YU[,F$AH7PGL?F^E"38G#?GD>ZQLM/P!02P,$%`````@`YW4&1UEE M7(ZA`0``L0,``!D```!X;"]W;W)K&ULA5/;;MP@ M$/T5Q`<$+^LT[$0GP6\+H-C&)WB^(KS'Y61]I%BV`@LI'!1&6*SR"4E$H-'Z; M-3]:1N(V7M2?TFZ#^XMP\(CJCZQ]%\QFE-30B$'Y%QQ_P+R%^RA8H7+I2ZK! M>=0+A1(MWJ=5FK2.TQ_^;:;=)O"9P%?"URP9GQHEF]^%%V5A<22N%W%VNT.` MVR@2E(E+:L&A2\53K%[+W0,OV#4*S1B^P9QGS(I@0?UF"TYOT7FB\\_I^X6^ MWSKZ5M?;>>)I M)A_PLNA%"[^$;:5QY((^3#:-H4'T$-IG=_>4=.']K(F"QL?P(<1VNE)3XK%? M'LCZ2LM_4$L#!!0````(`.=U!D>L@DX_H0$``+$#```9````>&PO=V]R:W-H M965TW#2E4?=I^) M/;91@7$!Q]V_+^!+K56DOIB9\3EG#@SD`YIWVP(X\JFDMD?:.M<=&+-E"XK; M.^Q`^S\U&L6=3TW#;&>`5Y&D)$N3Y)XI+C0M\EA[-46.O9-"PZLAME>*FW]G MD#@&\#8@(^"-@L*N8!.\7Q/>0 MO%1'F@0+(*%T08'[Y0J/(&40\HT_)LWOEH&XCF?UI[A;[_["+3RB_"LJUWJS M"245U+R7[@V'9YBVL`N")4H;OZ3LK4,U4RA1_'-0O5:;/:[G%V#T(1) M5YCSA%D0S*O?;)'26_0TTM.?Z=E,S]8.L\GA_<\"VUE@NQ;8WM[B&G.>,?O_ MFK#5F2HP3;PZEI38:S<>Z5)=;NTY96,R`.T#K[]@L(CKLAVIL"Q^]\OT/U M0#4P_BX:C"7XI*03NZ"1LM^&H3@UF"+QQ'K@Y1F>31$D8 M1U$64M1V05V9V"NO*W:3I.WP*P?B1BGB?PZ8L&$7P,`%WMIK(W4@K*MPRCNW M%'>B91W@^+(+]G![@(F6&,6O%@]B-@>Z^"-C[WKQX[P+(ET#)O@DM052PQT_ M8T*TDR)_6-,OIDZ$(C*%CR!3Y@N2J*XX M&X#HD7YY<*OD7)LH9R",FZI0F.!>1^\US(LJO&LCJXEGFH/53(I0N7L1<>!+ MCTUZO)Z^<>F;>86;D9XFZP:),TCF!HG=8OGO%N>:@]44T3HD]4)2:P`7($[S MP%^1>2&9W4FZ`+&:8K,.R;V0W!HD"Q"G2=(T^3JD]$)*:U`L M0)RF7(?`R$LQ86511@N82?1`%T'HY]@V+.,ECA,]\/IA[.>,_0JSI0_`B[.8&PO=V]R:W-H965T)NS9R+"6= MJO9B4M6+[9K8QS8J<#S`8`?:?ZG1*.[\T33,=@9X%4E*LC1);IGB0M,BC[474^38.RDT MO!AB>Z6X^74"B<.!;NA<>!5-ZT*!%3E;>)50H*U`30S4!WK<[$]90$3`=P&# M7>U)R'Y&?`N'Y^I`DQ`!))0N*'"_7.`!I`Q"WOCGI/EA&8CK_:S^&+OUZ<_< MP@/*'Z)RK0^;4%)!S7OI7G%X@JF%F+!$:>,O*7OK4,T42A1_'U>AXSJ,7[*[ MB7:=D$Z$="'<)3'X:!1C?N6.%[G!@=B.A]EM]AYN@HA7)C:J^80V%H^A>BDV M]_<"NUE@MQ;8 MC?Y)\F>+:\QIQOQ'D]E5DVP22/]A,F/^[H2M!J?`-/%^6E)BK]TXMZ6Z/(%C M&@?_`2_RCC?PC9M&:$O.Z/SUB;.N$1UX^^0FHZ3UCW0Y2*A=V'[Q>S/>V_'@ ML)M?X?)74/P&4$L#!!0````(`.=U!D=OBI2RP0$``+P$```9````>&PO=V]R M:W-H965T MM->,'I44Q`*.W;*./N#:F/1"B\QH$ MU3>RA<;^*:42U-BEJHAN%=#"DP0G41#LB:"LP5GJ:T\J2V5G.&O@22'="4'5 MGS-PV1]QB*?",ZMJXPHD2\G,*YB`1C/9(`7E$9_"PSEQ"`]X8=#KQ1RY[!JX4'R5U:8 MVH8-,"J@I!TWS[+_">,68B>82Z[]%^6=-E),%(P$_1A&UOBQ'_[S6;4/OBR56O613L4G)U0B,F M6F#.`R:<$<2JKUI$>(T>#1;;]-N)OELFO!T3QML"NU6!W2BP_WN+2\QYPB3; M)O&J23P*W&T+[%<%]O^164AJP]L%-C%%MGY)YP:$T M;IK8N1INU[`PLIW>BOG!RCX!4$L#!!0````(`.=U!D?J0^@SHP$``+$#```9 M````>&PO=V]R:W-H965TU#I2@/[;,7!K#B"['-DOY]?0%"JY7R@F>&;4#@$/O4BA[ MQ(-SXX$0VPP@F;W3(RC_I]-&,N=3TQ,[&F!M)$E!:)9](9)QA>LJUIY-7>G) M":[@V2`[2;8=1"QR;A7O3\'981[H-@HX6-7]1,UFFY4C"2[#VM7,5U M3G\*NM!N$^A"H!OA(8N-)Z/8YA-SK*Z,GI$=63B[_.#A)HAX962CFN_0QN(I M5*\US6E%KD%HP=`=YIPP^88@7OVF!<6WZ#19?$XO5GJQ[[!([N7#YP+E*E#N M!8\XHI_S,ANSV58/IX=2QJ]*1&PO=V]R:W-H965T&,"*[2&V6=*_ MKVTNH=5*[0N>&#;$#DIQ\^L,$LE2>!%M MYT*!E05;>;50H*U`30PT1WI*#^=]0$3`#P&CW<0D]'Y!?`W)M_I(D]`"2*A< M4.!^N<(C2!F$O/';K/EA&8C;>%'_$J?UW5^XA4>4/T7M.M]L0DD-#1^D>\'Q M*\PCY$&P0FGCEU2#=:@6"B6*OT^KT'$=IS_YYYEVFY#-A&PE?$IBXY-1;/.) M.UX6!D=B>Q[.+CUXN`DB7IG8J.8[M+%X"M5KF:5YP:Y!:,9D&\QYPJ0K@GGU MFQ89O47/)HM_TW<+?;?M<#>YY__AOU\$]EN!_3SB_9\C;C'G!?/PEPG;[*D" MT\:K8TF%@W;3EJ[5]7:>LG@F'_"RZ'D+W[EIA;;D@LZ?;#R&!M&!MT_N&ULA53;;ML@&'X5Q`,4 MF\19%SF6DD[3=C&IZD5W3>S?-BH'#W#F(;8SP*I(DH+0)-D1R;C"11YK MCZ;(=>\$5_!HD.VE9.;_"80>#CC%<^&)-ZT+!5+D9.%57(*R7"MDH#[@8[H_ M90$1`<\O@%TQ9BPE(+&Y^H[*W3I?N/=P$$:^,;%3S M"6TL'D/U4M#T/B>7(#1AZ`IS&C'I@B!>_:H%Q=?H=+2X3=_,],TZX69TS[:W M!;:SP'8ML)VV^/WC%M>8TX2AR6V3[*I)-@FD7YC,F,^?@JP:)\$T\7Q:5.I> MN;%O2W6Y`D<:&_\.+_*.-?"'F88KB\[:^>,3>UUK[<#;)W<91JV_I,M"0.W" M])N?F_'&ULC53;CILP$/T5RQ^P)B2$;420 MDJVJ]J'2:A_:9P>&B];&U#9A^_?U!;/L"B5]P9[QN@FT="3.2!Q%>\)IV^$\<[EGF6=B MT*SMX%DB-7!.Y=\S,#$>\0:'Q$M;-]HF2)Z1F5>V'#K5B@Y)J([XM#F<4XMP M@%\MC&JQ1[;VBQ"O-OA1'G%D2P`&A;8*U"Q7>`+&K)`Q_C-IOEM:XG(?U+^Y M;DWU%ZK@2;#?;:D;4VR$40D5'9A^$>-WF%I(K&`AF')?5`Q*"QXH&''ZYM>V M<^OH3QZCB;9.B"="_(E`O)$K\RO5-,^D&)'JJ?UWFX.!2RMBE)%R:J9"Y9(G MF[WF<;S-R-4*39AX@3E[S&9&$*.^:A'C-7KL+>[3MX&^75:X]>Y)>E]@%P1V M2X'=U.+N8XM+S#E@DOLFR:I),@GL;Y@$S']TLE\UV4\"CS=,`N;+?9-TU23U M`MOHADG`?)X)LAA!#K)V-TVA0@R=]A,X9^?+?(K="+_#\ZRG-?RDLFX[A2Y" MFXO@IK820H.QCQX2C!KSW,P!@TK;;6KVTM]`'VC1A_=D?M3R?U!+`P04```` M"`#G=09'M4[%]+$!```6!```&0```'AL+W=O3*IZL5T[\`-6?6"V"=W;SP>@M(K: MW6#[]W>R?IMB5/K%=``6O0HNS1%WUO8'0DS5@:#F3O4@W4ZCM*#6+75+3*^! MUH$D.$F39$<$91*71:@]Z;)0@^5,PI-&9A""ZK]GX&H\X@V>"\^L[:POD+(@ M"Z]F`J1A2B(-S1&?-H=S[A$!\(O!:%9SY+-?E'KQB\?ZB!,?`3A4UBM0-USA M'CCW0L[XSZ3Y9NF)Z_FL_B.U8CA`2 M5HJ;\$758*P2,P4C05_CR&08Q[BSWT^TVX1T(J0+X5L2@D>C$/,[M;0LM!J1 MZ:GOW>;@X-J+.&5D@II+:$+QY*O7,LW2@ER]T(1)5YASQ&P6!''J-RU2?(N> M1HNOZ=E,S]8)L^B^^P^![2RP70MLIR-F[X^XQIQGS/9KD_RF23X)Y)^8S)C= M!Q.R:IP`W8;[:5"E!FECWY;J\@1.:6C\&[PL>MK"3ZI;)@VZ*.NN3^AUHY0% M9Y_&PO=V]R:W-H965T8:=DT+#DR&V4XJ;?R>0V!_HBDZ%9U$W+A18GK&95PH%V@K4 MQ$!UH,?5_K0)B`AX$=#;14Q"[V?$MY#\*0\T"2V`A,(%!>Z7"SR`E$'(&[^/ MFE^6@;B,)_7'.*WO_LPM/*!\%:5K?+,))254O)/N&?O?,(ZP#8(%2AN_I.BL M0S51*%'\8UB%CFL__-G>CK3KA'0DI#/A+HF-#T:QS5_<\3PSV!/;\G!VJ[V' MFR#BE8F-:KY#&XO'4+WDZ7J7L4L0&C'I`G,:,*L9P;SZ58N47J.G@\7/]/5$ M7R\[7`_NN^1G@&ULA5/+;J0P$/P5RQ\0`T,>&C%(,UFM-H>5 MHAQVSQYHP(KM9FTS9/\^MGF$1"/E@KN;JNIJ/XH1S:OM`!QY4U+;`^V, MV:H#Q>T-]J#]GP:-XLZGIF6V-\#K2%*294ERQQ07FI9%K#V;LL#!2:'AV1`[ M*,7-_Q-('`\TI4OA1;2="P56%FSEU4*!M@(U,=`TZ;S:AI(:&#]*]X/@+YA%N@V"%TL8OJ0;K4"T42A1_FU:AXSI.?QZ2F7:= MD,V$[`N!38VBS1_<\;(P.!+;\W!VZ=[#31#QRL1&->_0QN(Q5"]EEB<%NP2A M&9-M,*<)DZX(YM6OMLCH-7HVM?B>OEOHNZW#W=3]?O>]0+X(Y%N!?!XQ_3SB M%G-:,%]=LLV>*C!MO#J65#AH-VWI6EUOYS&+9_(!+XN>M_";FU9H2\[H_,G& M8V@0'?CVRQF:[4E#CLEP>ROM+R'5!+`P04````"`#G M=09'$<)X)2\"``"]!@``&0```'AL+W=OG)FG&*IAOSBBX83 M?#(B6OEA$"0^Q67MY9FIO?$\8U=9E35YXT!<*<7\]X94K%UYT.L*[^6ED+K@ MYYG?ZTXE);4H60TX.:^\-5SN$TT8X$=)6C&X!SK[@;$//?AV6GF!CD`J9*'"!AXXD3.^5O*= MM:_$M1!KPR.KA/D%QZN0C'82#U#\::]E;:ZM?;((G&Q<$#I!V`M"."M`3H"^ M*HB<(+H+%K."V`GBAQE\V[M9N1V6.,\X:X%HL'Z=X%+A7)LH9R",FUHT88IK M7;WE880R_Z:-'!,.F(UETG`:V5D$]H2O`HRF"+VQ&4*7(IJ>8MLQ\4R,CDFF MF?V_/I-A41<6#9<,.8/T_P919Q`-#2)GL/@[96J8VJZ(92!2FSN8QK;.*@AF ML9W%$(*SV-YAZ?,0FVPN'FTNMB_+\TQO%HD#--^;Q5`TC^TL!F$TOU1[RR5I M]*7FDM'F$O?//707#_,XYF$*?[`Y*>$7_426T/@[M]GC7X0KYC?BEK`0Y,JB/%[/\S8Y*HL,&3BEZH;TD_J,A9 MZMM4+X,]7NU`LJ;[6/1?K/P/4$L#!!0````(`.=U!D?=]<%C30(``#0'```9 M````>&PO=V]R:W-H965TWCOS;R)-4XZ0M]9@3&W/NJJ M86N[X+Q=.0X[%+A&;$%:W(@O)T)KQ,66GAW64HR.BE17C@=`Y-2H;.PT4;$7 MFB;DPJNRP2_48I>Z1O3O%E>D6]NNW0=>RW/!9B^CUB."/56WGDA2@6V-81G]"EXJ^D^X&-A5`*'DC%U-,Z7!@G M=4^QK1I]Z'?9J'>GORR!H4T3/$/P!L*09YK@&X)_(P0/"8$A!%_-$!I">)?! MT=Y5YW+$49I0TEFL1?(XN2L!IU)$*%M,J8FF,17"+/5 M&.C-0W(-<0>$(PJ8K,*SIS)XNHKY!)E&0/]!#4]%=O^)S);I]V7ZXV;YVF7P M!8&@%PC&`H$6`'Y$/!<7A)[G-_DT:=$9_T+T7#;,VA,N)ID:.R=" M.!8%@X7H>"&NL&%3X1.72RC_"CW5]8:3MK^CAHLR_0=02P,$%`````@`YW4& M1SWY2,$=`@``<@8``!D```!X;"]W;W)K&ULC57; MCILP$/T5BP]8,.:6B"`EJ:KVH=)J']IG)W$"6AM3VPG;OZ]O$+JB(2_8'LXY MRY>)`L$.6^"+5SO860@%O&S(;V<[($Q?^#\W1R^GS9!9#P02H[*2&"] MW,B>4&J4=.;?7O2>TQ"G^T']JRU7VS]@2?:<_FI.JM9NHP")6*LX$2`(8_W-JT=NW=G2+RM'E"[`GQ2!CSS!.0)Z`[(;&5 M.F>VKB]8X:H4O`>RP^9IP[6&"R.BE8&T:KHD:8-;$[U5<8K*\&:$/":>8'8. M`T=$J-5G4\3!'#UV*?Z?8.\0.5K.@(8,:%H$\D4DRP+)()!,!1(OD/YK,K68 MUI7A,5$.$_0`MWM`2CTORO,B?>(V*64.%-Y0O"ZQF6[)ZOB4PFK5@PTM-\:`D16@5/VB*QZ$X M0[#X9"FM%&:_T#&`^4G)79YGHOW$AT!\6[8<*/OYGJ+U!+ M`P04````"`#G=09'[AX"5LT!```(!0``&0```'AL+W=O`<=XK_6)J`(O>I&C-#M?6=EM"S*D&R-+(7*3D^N<>A.IW.,)3 MX;DYU]872)&3F5,H\(@.\-]&8Q1][[4:D7O_A:[C#U M%D#`R7H%[H8K'$`(+^0:OXZ:OUMZXG(^J7\.:9W[(S=P4.)'4]K:F:48E5#Q MB[#/JO\"8X3$"YZ4,.&.3A=CE9PH&$G^-HQ-&\9^>')/1]HZ@8T$-A-8^D]" M/!+BF1!M0M+!6J$1PQ:8_83Y]#'F,&)F!'$.5FVPR4:\M,$&>DIO"\23P&8I$(\"T7N/6<"T M@\TD MF6EL=W8?=J;3A]UGFI#$J4I62-/]^P4!ZZ28LB]1\-QS[KWA("[.O'\5!\9D M]-XVG5C&!RF/=TDB-@?64G'+CZQ33W:\;ZE4PWZ?B&//Z'8(:IL$`4"2EM9= MO%H,G^0>B)9+9(Q;ENWK!,U M[Z*>[9;Q/;Q[1$1#!L2OFIW%Y#[2R;]P_JH'/[;+&.@<6,,V4E-0=7EC%6L: MS:24_UC2#TT=.+UW[-^&_ZZT\J&Q!'&W9CIX:^S[ZM M$,D6R9LFLA@TP:PM!I?SF,KQX'G,@\7,(QZ=T@A)5"'>:I"K)IU6@VP6X&N" MU!%D4X)T($@OJL@'2&>J,!"8P;*81ST:%,H12;_.)?/FDAD*$-`-[.T&#N\& M\69`+`&9+W1M,"4($,F](KFWY7BJ82#%1./SW_(9,YM'XE=*J7+A@BED[3,#*@<"K,DQKBB*``GH7#X3AJPF>_:3]ONY$ M],*E.CX.9[T=YY(I$G"K\CBH#X=QT+"=U+>Y3M`[UR268VH`>8'$ MLV^_@!H/3AIHYR(<_/5)4O\(EA=;_JQ.QM3>KSPKJJ?%J:[/C[Y?O9Y,GE0/ M]FR*YI>C+?.D;B[+-[\ZER8Y=$9YYO,@4'Z>I,5BM>SN?2]72_M>9VEAOI=> M]9[G2?G?VF3V\K1@B_[&C_3M5+VWR+];^;"_^/#PM@C8'DYG7NG61-(`=S3-ZS^H>]_&&@AK!U^&JSJOOOO;Y7 MMMD\:S5W7>FFFINIO?VKL? M*QZSI?_1.@*&#Y@U,"H<9S;`C!-;1T1B'-G-.MG/.WD&)[^3]9O!0$>$]R,B MAB/"H=I@WH'H' M`C8.[2C0,P*-IANBZ8:PU/CXN&P<(P*MAN/RA=LZ+N1:3G([QT5!.,WM':?# M0)#F0Z$%*BCPT^H,AP4Z)@YD]"6A(;=UG!21F.1V"A92,V23X!X"JUB2*HS0 M"B,WG-%$@0YAC,GIS+<.U$I-C\3.<5P*->UP#Y%C%D>D$F.TQ!@F44ZDY!@F M=,Q(D30:24,D@E*Q`)6J[C91JQA#DV!L?DJ!42R.IZ<40!F+<'I.`612\6!Z M4H'4+*8I)>-XF1R?UAOQ`>C+O'Z5E3%R/"W\4<'@61$K@@N)KP%YQQK`A9F- M*//MW(:@7',3YCBFB(\VAFLI(XCI%B`QFY/C0FI*N/@Q7/UNGDNLES\DI9L' M#H"<47/"U8J!7*F8X$+C"TC3%Q`/T"QXKT,36YYU#XF8DRKFN&#Q?L?Z:1J& MT.X*$8:%XXK!>\70XW'6/:0I]>`2P$$"-!M?P&N`-&VM<'R[R$$I-)^JJ(<$ M(0XN)QSD1$]H[1H@1ET,N$IP4`E-V>U'Z/+GT1W+'V]"#DVHU=04.H@JBQS? M,W!H5AW-NQ#XID'`\*1NAW@,@/`H'WH>"$?N\A3>AW,?+6)@C]WD.4 M?A=X%PI)Z'>`B/TN\#X4(:'?KQ"AWP7>A*)O0DUP@3>AN*,)!=Z$(IY]&UX# M0WN)%7@'"MWO.0BO[7@'RCLZ4.(=*!E!<@!"&]`??"PZ)V_FKZ1\2XO*>[%U M;?/N(]'1VMHT?H*'QNO))(?K16:.=7L:->>E^\KG+FI[[C]:7K^&PO=V]R:W-H965T>V-%3D^"-!U^8PX_M2UB?[:8T&'C^NXX M\=X<:Z$F0)&#BZ]J6MSQAG8.PX>-^^JORTPIM.!G@P<^Z3N*?4?IAQI\KS:N MIQ`PP7NA$I!LSKC$A*@@N?!OF_EO266<]L?TK[I:2;]#')>4_&HJ44M8SW4J M?$`G(M[I\`W;$B(5N*>$ZU]G?^*"MJ/%=5KT:=JFT^U@GJ2>MZ0VVU]+.5,A,MGA.DV6Q/7DJYH]%X'GY^"L M@JP&3C3;40/O:\K_-4`RS(+`$228@D`=`&/O<4`P!H33@,`2!->4B=9TIA*C M\?W4C^ZK2J.",/32QS#A+$QH8<+K9:(IC-%$<7Q?4QI-G$:/0:)9D,B"+-2[ M-9H7&(<+?XH->F)_XUF0V(+<5)M.08SFQ5O=OFI7)$;UQ'N2S((D%B19`$F> M`DF>!4EG05)MS]*%G3$2/\BB;(%C3G67)9MER0S+PBK;["D6JPKC.+EA`9/C MJ4='_`.Q8]-Q9T>%/.GTL72@5&"9XJWD1U#+"^@R(/@@5#>1?6;.9#,0M!]O MF,LU5_P%4$L#!!0````(`.=U!D>](&W]Y0$``$X%```9````>&PO=V]R:W-H M965T/Y?T@KG_U;DW8.`(U;AA,P:'@53[@F.9Z4%GR01X.3-MUWOVM&_V<1! MMBS`08"O`I2N"I(@2&X$T"=S=3T13P3CYF*D\DZ6? MY\@6CY-X!92N'XYDDP7CE&PO=V]R:W-H M965T8.Y]56;.-FW/>K#R/'7-< M(?9$&ER+)V="*\3%D%X\UE",3DI4E9X/0.Q5J*C==*WF7FFZ)E=>%C5^I0Z[ M5A6B?[>X).W&A6XW\59<&:%:1V*#YOW&>XRJ!"%/&KP"T; MW#LR_(&0=SGX<=JX0&;`)3YR:8'$Y0/O<%E*)U'YCS']JBF%P_O./5/MBO@' MQ/".E+^+$\]%6N`Z)WQ&UY*_D?8[-CU$TO!(2J9^G>.5<5)U$M>IT*>^%K6Z MMOI)M#0RN\`W`K\7P'A2$!A!\"4()P6A$81S!9$11',%L1'$_PD\O5AJJ?>( MHW1-2>NP!LD-"%<"I])$.#M,N8E59FKR66#B;7K(3@.[2R0#N,-SN(&7?!/1"]%S9P#X>)85V?PF1".A0EX$O_` M7'P!](,2G[F\3<0]U>]$/>"DZ5[Q_7=&^@]02P,$%`````@`YW4&1Z@6>`J$ M`@``"`D``!D```!X;"]W;W)K&ULC9;!DJ(P$(9? MA>(!!@B!J(54J;"U>]BJJ3GLGJ-&I0:(2^(X^_:;I",R+D8O0L+7?__="$UV MYMV[.#`FO<^F;L7^T\<6H:VOU=LIJ?YW[D7S;>JOU!ZHT@SX(^ M;ELUK!45;[V.[>;^(IJ54TT8X%?%SF)P[FGO:\[?]>+'=NZ'V@*KV49J!:H. M'VS%ZEH+J<1_K.8UI0X\8#8!L37 M`.P,P#8`/YLAL0')388`:C>=*ZBD>=;QLR>.5/^=HIG".RVBE#UAU%33A-E< MZ-V//$8H"SZTD&70@%D"0QQ(`4C4$X$R,.H"^6,9D`EW)%@!06*'AX9`I@H1?>9$A@RQ8_- M)J-F$VLV^9HD&9JU3!3?9PI@4(+O,R4P&$\>FTU'S:;6;.HP"PR:.+P"XBJG M!(2DCYV24:?$.B7W[]T2&$P/Y!22-',]X`4Q"'/^!$I@( MQ[=OU6#PGF]8MS<35G@;?FHEO+GZW7Z(+Y">$S?[RVBVBD;V"S7T849?Y?/L M2/?L)^WV52N\-9=J.IE1LN-<,N4W?%&]/:C/DGY1LYW4IT0W'28U+"0_7KX[ M^H^?_!]02P,$%`````@`YW4&1Y08;VAK`P``.!```!D```!X;"]W;W)K&ULE9C=$!@B1^A#V.9V([27O1F4PNVFMB MRS830"[(A-`_G;WK,#';!877K\W1\:$]UD657/O'X4XS8.@ MV1Y9F35W_,0J^UV4FY&5]")I3S;)=%U06`4$H"*?^/\O;WXOKOW4:N!%6PKVA29/'RP-2N*-I.L_%LG_:K9 M!@[/3?:GKETI_RUKV)H7O_*=.$JUR/=V;)^="_'*+]^8[J%3N.5%T_WUMN=& M\-*$^%Z9?:IC7G7'B_HDCG08'$!T`.D#"'8&A#H@G!H0Z8"H#TB1,R#6`?'4 M"HD.2*8&4!U`;P("M;O=O=ED(ELN:G[QFE/6/K%X+O&Z32(S>TV73=Z6IEM\ M:%<_EF&(%L%'FT@S9,"L%$.)'=DH!/=$(`6`*H@/52!=.(DB>XFU86*'#**[ MP7;F<4*>)Y/'T?*S8<+QID/3=#C<^E`GB,831"9!-$P0Z00WG=".J=3.*@8G M,4+(CJT-ECJQC:Y(W-BCP>@0LS87@\W%NKGDNLZ0V1B&CA=)P"*)3I#:FWE6 M3(1FDYJA8!VJZ\P<=>C4KU`*EDA5B>CFOL3#AT$Q43IREZ=A3PK#2/[$3=F9 M&2A[IF5CAVS%4!K]HV>(;4#,*@PKZ]$0IL`N73UO%M`N*H1%:4,=.+L]1>^H5Y:, MC:5.\&0,^Q;6IA0YC&O50]3A;@!D%P/[&U;F15`Z(06%MX3^QY;`UH2--Z6N MYU)!9$(5V$FPL1*'R:XT1!*$1IY)&+2_U\!V0K2=Q*ZOI(9(/+46[!+$N(3K M)T!#F`(;<"T*!NVB8*<@QBEG'N5_NA]X&T0\_-^@K/UQA8W^#YHQJ2OM(O%Z?LP'YD]2&O&N^-"SEJ=7/1 MGG/!I&1T)[?T*,?X_J)@>]&>4GE>J\%670A^,G-Z_\^"Y5]02P,$%`````@` MYW4&1]Z^E:V^`0``;`0``!D```!X;"]W;W)K&UL MC51=;YLP%/TK%C^@-@Z0-2)(I=6T/4RJ^K`].^$2K-J8VD[H_OW\`8Q.4;,7 M?._EW'/.-3;EJ/2KZ0`L>I>B-_NDLW;886R.'4AF[M0`O7O3*BV9=:D^83-H M8$UHD@)30@HL&>^3J@RU9UV5ZFP%[^%9(W.6DNG?-0@U[I,TF0LO_-197\!5 MB9>^ADOH#5<]TM#NDX=T5Q<>$0`_.8QF%2/O_:#4JT^^-_N$>`L@X&@]`W/+ M!1Y!"$_DA-\FSK^2OG$=S^Q?P[3._8$9>%3B%V]LY\R2!#70LK.P+VK\!M,( MN2<\*F'"$QW/QBHYMR1(LO>X\CZL8WSSA4QMUQOHU$"7!AJ-1Z%@\XE95I5: MC<@,S'^[=.?@VI,X9F0"FW-H0O'!5R_5)D]+?/%$$X:N,'7$T"Q;,-CQ7Q6A ML\AF+4(G$7J;8#,3Y(&@CP2;Z("D^4>;VQ6HGD!Y?ELENZJ2S2K%1Y4UJ(Z@ M[/[^MDI^526?5;:?J.3_/TLQJV3K+2_BEA/ZR89%3$K(O[/@U4D:V`E^,'WB MO4$'9=VA#">H5&ULC95=;YLP&(7_BL7]:IN/0"*"U*2JMHM)52^V:R>8@&HPLYW0_?OY MBY16C.0FME_.>YYC')E\X.)-UI0J\-ZR3FZ#6JE^`Z$\UK0E\H'WM--/*BY: MHO12G*#L!26E;6H9#!%:P98T75#DMO8BBIR?%6LZ^B*`/+.TKFY9VLN$=$+3:!H]XL\?(2*SB5T,'.9D#$_[`^9M9_"BW M`3(9**-'92R('BYT3QDS3IK\QYM^,$WC=#ZZ/]OMZO@'(NF>L]]-J6J=%@6@ MI!4Y,_7*A^_4[R$QAD?.I/T%Q[-4O!U;`M"2=S/K* M5_Z5QPL,I\%K=,>YI+.4U%.2!8K3?,.KZ#8EFZ5DGK)T+$Z#TWN.93U+67O* MTJFL_5["!-_&8#3+L64#RA;^RUX49PNBO1=A%*(O:>#DKNC)B?XDXM1T$ARX MTM>.O2,JSA75+NA![[#6GX/K@M%*F6FJY\)=D&ZA>#_>]]>/3O$/4$L#!!0` M```(`.=U!D>`?-NLI@$``/<#```9````>&PO=V]R:W-H965TE2I9$@*[1[@82X@&NWF306/@3;;>#MUZ>4 ML-LNN8CM\3^?_\G$U:CTJ^D!+'H77)I-UEL[K#$VNQX$-5=J`.EV.J4%M6ZI M]]@,&F@;D@3'!2'76%`FL[H*L4==5^I@.9/PJ)$Y"$'UQQUP-6ZR/)L"3VS? M6Q_`=85/>2T3(`U3$FGH-MEMOFX67A$$SPQ&,YLC[WVKU*M?_&XW&?$6@,/. M>@)UPQ$:X-R#W,%OB?EYI$^0"<%;'SW6Y?*FPD4$Z"<`\H$R+\'+,XZ6"3`7V4N@T;& M3Q$U>4G</"JF&Z9J>[7O\!4$L#!!0````(`.=U!D>7I2MCO`(``'`+ M```9````>&PO=V]R:W-H965T*;UL?)_LSZB#Q,,7U(]/CGCH(!V7P\DGEP'!`T_J6C\,@I7? MP:9WBYS''H\HDX'AY125J M6Z8T[OQ'BK[OR1+G]TK]&[<[EO\,"2IQ^[LYT/-8;>`Z!W2$UY8^X=MW)#TD M3'"/6\)_G?V54-RI%-?IX)NX-CV_WL23+)!I^H10)H13`DB-"9%,B&P38ID0 MVR8D,B&Y2_"%=WYR%:2PR`=\<\@%LO\3V(SXP$1&98=PM?'0"`\^L.AK$:VB MW']E0I()9\Q.,&FXC%0"`1/ACP5HJPA=W0XA3S=L4`HB-919?2E2?Q)9+#-2 M94;SPXKD85GXC)5`/!>(I4#\L<@YLU-,LLR4BEDM,Y5BTF6F5DSVM:%$:RB1 M`FN#(F)\XSIN,0Q">6(\84C?4&WGC"YW'\G18M.E)VF[*C%P.A M6%!\4?/M-&07_P!02P,$%`````@`YW4&1^Z"H$7L`@``N`L``!D```!X;"]W M;W)K&ULC9;;;J,P$(9?!?$`!=N<$A&D!ECM7JQ4 M]6+WVDV;`,XW_\P_&)CT2KM7=B*$.Q]-W;*->^+\ MO/8\MCN1!K,'>B9M_\^!=@WF_65W]-BY(W@O@YK:@[X?>0VN6C=+Y=I3EZ7T MPNNJ)4^=PRY-@[M_6U+3Z\8%[K#P7!U/7"QX6>J-'/"EYL_T^I-H#Z$0W-&:R5]G=V&< M-D.(ZS3X0QVK5AZOZI_$UV'F`*@#X!@PYC$'(!V`/@,":T"@`X*E&4(=$,XR M>,J[[%R!.<[2CEX==L9B/X%UCW="I%=VF%3KF\;DXJ-8?<]0`E/O70AI!DZ8 MK6)B"U(H!(R$UQ=@K`*ZI@Q0AEL2Y(J(D:6&NR+E-Y&;9:*A3#1M%M+-6B`0 M#`+!5""0`LG,12R15K5"(1#.VSV%<@WY?G`;*A04A#"Y#96!MA1%]SV%1D^A M\C2K))QZ4@@"47@;RA4$D[GQ*50H*%JM+$JE@L(@"NY[BHR>(N7)DF2K$(B0 M;_&D()#8C!>1OD\!LGA2$`K#!9YBHZ=8U>(G%E.*B:#-4ZSO$[!8&G)%EEU1 MZF3^@IV7&!TE>N\N:,G*^#ROEC_/P#>6()>%A&VK:,C2BWS0L?14(Y;;5VHD M7F`'F.T`XPOJJQN@[YO-COZL6"P7F@'`LI'*[P7=M@3-EN#]]Y-FH&_QG6LH M6MD\*08AVZ.L(1#X"TPALRED?$%]^9!H!H66KTVN(1!;E`H-1<#R22J'=/'\ M6JP_MN#H.G8]0C#6S]2U8Y\"P7H@A58Y!G_)9>L9' M\AMWQZIES@OE_3`E)Y\#I9ST]?H/?8-/_1@]7M3DP,5I+#JO!DMUP>EYF)/' M83W[#U!+`P04````"`#G=09'9R3*YIH!``"?`P``&0```'AL+W=OE=1V3UOGNAUC]M2"XO8..]!^ MI4&CN/.E.3/;&>!U)"G)\BQ;,<6%IE49>T^F*O'BI-#P9(B]*,7-OP-([/=T M0Z'*SR"E$'(&_]-FI^6@3B?C^H_XVY]^B.W\(CR5=2N]6$S2FIH M^$6Z9^Q_0=K"?1`\H;3Q2TX7ZU"-%$H4?Q]&H>/8#RN;+-%N$_)$R"="'D^" M#48QY@_N>%4:[(GM>+B[Q<[#31#QRL1&-9_0QN9#Z%ZKY695LFL02IA\ACDD M3)9/&.;U;YKDH\ER;I(GD_7W`LM1H)@++)/`YFO*=<3H(>6`*5;;S?$V6;_F;#9X7?\#'^X.0MMR1&=O\=XZ`VB`Z^1W=U3TOK7,A42 M&A>F:S\WPP\T%`Z[\3E,;[+Z`%!+`P04````"`#G=09'V+D%'<I#^^R$(:#:F+6=T/W[^@9%%4W[@F>&F.T ME_N@56K882R/+3`B;_@`O7[3<,&(TJDX83D((+4E,8KC,,PQ(UT?E(6M/8JR MX&=%NQX>!9)GQHCX?P^4C_L@"J;"4W=JE2G@LL`SK^X8]++C/1+0[(.[:%?E M!F$!SQV,MDZ(/2&>"5%ZE9!X0O*)@)TSV]<#4:0L!!^1'(CYV-%.PX41 MT(&Y=YCX:T3E$)MDAF!M8-5%/+E(EBYB MYR*/OA=()H%T*9#X-CZ9W%A,[]IPF'2;?8VIO$ZTW7SO)%UUDKIA93\0R%9G MD?U\%OFJ@]S/(KDR"X>)TOSVRC`<*`X74W56\.*D#>0$?XDX=;U$!Z[TH;4G MK.%<@18);[(`M?HNF1,*C3+A1L?"_5XN47R8+HOYQBK?`5!+`P04````"`#G M=09'$1)9BN4"``!,#```&0```'AL+W=O>4N4QU[JI>>?>4>9?&'M5#S_W M"]=7'FA!=T)19/+R1M>T*!235/X+I#=-E=B];]BWNEQI_R7C=,V*/_E>G*1; MWW7V])!="O',KC\HU!`IPATKN/YV=ASR42V3&MV M=?@Y4RL6S26\5B22V>&:3;X6KH/W*OJV#&9AZKTI(L#@#F;58*)^S,9@".Z' M;`T$M0A/FK0ZQ:[-!087<;_$NL&0`:<&,V#TP2!(,%#+*,GC%Y+>ML#$97/63'"NNU0ZQV"-C!`W9(L[^&[5AAO782JYT$ M[`0#=@P&X['VV'&]AF960S,P%(X3(-^Z471XXDY!R&H"(7`1]:_A-8#B9&*] M"-NU,&C%_5HK`!$_F"85V*4"D"(3*$)[<\-O--=^/J#F@$@&UAR`4/)ER77[ M\@`P/+)3`!;$@VR/`)MX^B'[>8.:`VE8Z,":HK,2_DVOL)$?[]J&@ M!Z%NB;ROS;!K'@0[-[-[^P_$\C]02P,$%`````@`YW4&1[*@E.\!`@``Z08` M`!D```!X;"]W;W)K&ULE57=;J0@&'T5XP,4P9_Y MB6/2NFEV+S9I>K%[S8PXFH)88,;NVR\@SIJ&6>V-P.&,/BSQ.A?#B$,)P*K^VY4:8`BAS<>%7+2"=;W@6"U(?P M$>Y+B`S$(GZU9)"S>6#,'SE_,XL?U2&,C`="R4D9":R'*RD)I49)?_G=B?[[ MIB'.YY/ZLVU7VS]B24I.?[>5:K3;*`PJ4N,+5:]\^$Y<#ZD1/'$J[3,X7:3B M;**$`<,?X]AV=AS&-]O(T?P$Y`CH1H#)?PFQ(\2?"&!T9OOZAA4NNT#.!5P6B">!9"X0.X%/)C<6TXUMC!@8I]GV/JH<42A+XVC93.(UDS@S M\;)`ZHTC71]'YG60^>-(YW%D]^*8H\KL*W%LO&8VSDRR++#UQK%='\?.ZV"W M(H[=JCAV7XD#1EXWMFSLK-@N$'H3@7!])!#Y7:`56\:!EO:,@_EB`;-#J<=G M\A.+<]O)X,B5/M_L851SKHB6B1YTU(V^=VX+2FIEIAL]%^-)/"X4[Z>+Y7:[ M%7\!4$L#!!0````(`.=U!D&PO=V]R:W-H965T M!4GE*-6K[@`,>N=,Z%W4&3-L,=:'#CC5=W(` M8=^T4G%J;*J.6`\*:.-)G.&$D'O,:2^BJO2U9U65\F18+^!9(7WBG*K?C\#D MN(OB:"Z\],?.N`*N2GSA-3T'H7LID()V%SW$VSIW"`_XV<.H%S%RWO=2OKKD M>[.+B+,`#`[&*5"[G*$&QIR0;?PV:?YMZ8C+>%;_ZJ>U[O=40RW9K[XQG35+ M(M1`2T_,O,CQ&TPC>(<'R;1_HL-)&\EG2H0X?0]K+_PZAC<%F6CKA&0B)!=" M_#$AG0CI%0$'9WZN)VIH52HY(CU0][/CK84K)V*5D?9J=B3MBP^N>JZR^+[$ M9R#;#Q$ MA$$")-ED67H;5:^A;GK)5KUD0:+(_FV3+]L$3)Q^*>+/V^2K;?+IFQ4?3)-/ M;3)"KMK@Q7X9Z!%^4'7LA49[:>S6\_NDE=*`52%WUGIG;X1+PJ`U+MS86(5# M$A(CA_G(7^Z=Z@]02P,$%`````@`YW4&1TH1^:(5`@``V`<``!D```!X;"]W M;W)K&ULE57;;ILP&'X5Q`,4;"!`1)":3M5V,:GJ MQ7;M!!-0#::V$[JWGT\P)EF*&4:.;!A+!.-Y%`^K'L*YT[8W5%;T*TH_X MC07\.@R(_3EB0N=#",*E\-Y?.J$*45U%:U_3#WCD/1T#AMM#^`SV1U`HB$;\ MZO',-_-`F3]1^J$6/YI#&"L/F."S4!1(#C?\@@E13%+YTY+^TU2-V_G"_JKC M2OLGQ/$+);_[1G32;1P[1E8AW.G_'-D.F",^48H\'`-%TQD>1WBL!%)-F*0","X_L$R4*0;@D2ZQ+^ M[S+7F-&X-)BB3#Q44J=*:FV"^P29,V?FGW/G=+!SY\RV.0TF`65V7R5WJN36 M)KQ/4#AS%OXY2Z>#TB.GP61YXI$3Q$X9759&$P\*X(P*@']6`-TNH$=:"_+[ M?(%[EP"[3:#'1@6I.V[Z0-S,[2+SB9L]\!4#]V8!=K=`'XK<'3=_(&[A=E%X MG$T6Y/B8H\VA/:$+_HG8I1]Y<*)"GO_ZL&XI%5BRQ$_R%7;RFET7!+="37,Y M9^;B,0M!I^4>72_S^B]02P,$%`````@`YW4&1QLMI7@[`@``2`<``!D```!X M;"]W;W)K&ULC55;DYHP%/XK#._=0+A9!YE1L=,^ M=&9G']KGJ%&8)80F4;;_OKF!:`'WQ9##=\N1.4E;RMYY@;%P/DA5\Y5;"-$L M`>"'`A/$7VB#:_GF1!E!0F[9&?"&8734)%(!Z'DQ(*BLW2S5M5>6I?0BJK+& MK\SA%T(0^[O!%6U7KN]VA;?R7`A5`%D*>MZQ)+CF):T=AD\K=^TO=PN%T(!? M)6[YX-E1V?>4OJO-C^/*]50$7.`I(+E>\Q56EA*3Q'ZMYLU3$X7.G_DV? M5J;?(XZWM/I='D4APWJN<\0G=*G$&VV_8WN$2`D>:,7UKW.X<$%)1W$=@C[, M6M9Z;I]Q0F`)P8T0SA)"2P@_ZQ!90O3@`,S9=>=R)%"6 M,MHZO$'J<_*7$LZ4B%1VN%:33>.ZN%;5:Q;".`57)60Q<(#9&$P"IR&Y@?@] M`L@`HRF@.^8`-7W&8&L023"3X:G([C^1R9A!%S,8-BLPIXRCYP)A)Q`.!4+; M[>0^9*(QM>F%P7C3B/P1,1DB&@T1V1"+>XMH:!%]UB(>M8BMQ==IBTW\])R/ MB,D0R6B(Q(0('BR&F-Q@8!(_-UF,FBRLB3_SCQK,%]]+/&_FO%N#@]$L*K=J M<#$+VQE8Y@%V\]^I5897SGK)/7B,DP!?!+5]YM1#=TO?Y MH48$\A?:H59^.5)&H)!;5OF\8PB6FD2P'P7!S">P:;TBU[%W5N3T)'#3HG<& M^(D0R/YN$*;]R@N](?#15+50`;_(_9%7-@2UO*$M8.BX\M;AY\@+E`6%T$$H"RM<9;1'&2DEF_F-%+SD5<;H>U%]UN=+^ M'G*TI?AW4XI:N@T\4*(C/&'Q0?LW9&M(E>"!8JZ?X'#B@I*!X@$"O\R[:?6[ M-U^RS-+(C8643ZV$,\>(BGG8AM)^+'`LD@D$P%$BN07)O,-*8UA1I,-)^%MT'; M9T`[FRU*GR@X=?I-C4(XO\Z23JT83!@G0?`XS<)GYOPQV?,_9NYT M,'?_F&FA&X.)9_-)H?^WPX6Z:6;A-+.P9M([9A:V9=^]7)T2!^BFE3!P>M%A MQQ&X.K(6Y#H#_F3B$,0J/;HY.-!3*\S`&:/C];".],2ZP(N\@Q7Z"5G5M!SL MJ9!S3P^I(Z4"20?!BVQ.+2^P<8/14:AE)M?,C'2S$;0;;JCQFBS^`5!+`P04 M````"`#G=09'JPA_,.0"``#&#```&0```'AL+W=OK%[G6I4ID`LB=I]^TU( ML%@3H#="XN^<\S\YR0%F%]:\\0.EPONHRIK/_8,0Q\<@X)L#K0A_8$=:RW]V MK*F(D,-F'_!C0\FV-:K*``$0!Q4I:G\Q:^>>F\6,G419U/2Y\?BIJDCS;TE+ M=IG[T.\F7HK]0:B)8#$+KG;;HJ(U+UCM-70W]Y_@XQJU2$O\*>B%]^X])?Z5 ML3O9XZTTN&F\GG]3L>8'#>!:2:01B[F57' M#,1::R8,T94)9"[6A%"74-A/"!FQZ;B#L'.`^PY"XR"[51FU3*TSTZ7Z^2X-]+54]ROH`-VB MD%T4LE;U5I-FTI'MG$_D5G;.K=S>NJ#I73BG90/%3/>\C]=`=6,0B,/SMS`]T]/.\KZB+=LNR-#,'Q;6:8 M*`FC$5$3P;4!81;;^D;0>Q\\DCW]39I]47/OE0GY:MF^!^X8$U1Z`@\RNX/\ MJ+@.2KH3ZC91:>O7;#T0[-A]-5P_71;_`5!+`P04````"`#G=09'F76OAQ4# M```7#P``&0```'AL+W=OR9VI],>.I/)H3T36[:9`'*1'*?_O@()!R+0LF+3!]55 M`&&8!'51-OYBUH\]M8L9/\JJ;-A3ZXEC71?MOR6K^&GN$W\8>"YW>]D-!(M9 M<([;E#5K1,D;KV7;N?]('E:4=I`>\;MD)S&Z]SKQ+YR_=@\_-W,_[#2PBJUE MEZ)0ES>V8E7595+,?TW2#\XN<'P_9/_>EZODOQ2"K7CUI]S(O5(;^MZ&;8MC M)9_YZ0-?7LNFO)_U/%IHP/`!,`)P#R'0` M-0'T4T"@E?5U?2MDL9BU_.2)0]&];?*@X&V71&7V1)]-E23ZP<=N]&T11>DL M>.L2&0R,,$N-H2'8,:NOF$!I0(7`((2.A8`60K/K">B0(!HGH*:2[%)EVF,: M78G!I#E-[:@5AK**B5`QD1&37]+$8S$:(H:QBX],I@OFJI6@]+$9<$BN*]([K`R&I`;$80H$80.+]F`LBB9^N0PE%T. M;F48K.S@,+`T[!LZ-N`M&ZB#PPS(Z:,&W,F@30J92[4Q7FU\0[6XM2!Q^*@- MB-`H>(TL[A183#J5,LW(*>>#[A/8?#I1-=?&M"GMH_H M07'V[2;N:&IQ].6&4X/BE,83@C"470[N:#HXVF&2*>YH>LL>W+()MSCZQN4W7? MZG.;?I#\,!Q#SV?AQ7]02P,$%`````@`YW4&1RX;I:HN`@``S`8``!D```!X M;"]W;W)K&ULC57;CILP$/T5Q`>LN<-&!"FWJGVH MM-J']MDA3D!K8VH[8?OW]0W"II#D);:'<\Z<&<@X[RC[X!5"PODDN.%+MQ*B M70#`RPH1R%]HBQKYY$@9@4(>V0GPEB%XT"2"0>!Y"2"P;MPBU[$W5N3T+'#= MH#?F\#,AD/U=(TR[I>N[?>"]/E5"!4"1@X%WJ`EJ>$T;AZ'CTEWYBUVF$!KP MJT8='^T=Y7U/Z8_9NN M5KK?0XXV%/^N#Z*29CW7.:`C/&/Q3KOOR)80*\&28JY_G?+,!24]Q74(_#1K MW>BU,T_BP-*F"8$E!`,A\.\20DL(GR5$EA!="=E=0FP)\4T&8&K7G=M"`8N< MT<[A+52?D[^0<*9$I++#M9IL&M?!E8I>BBA.!.Y4AT/0@BN93;'I,?,=&CTGF,;O_=6;-AKW9<-RRT+8L>RP0]0+1 M6"`R`N'K5Y>QQC2F$H,)'J>()U/$UN--BG248FTPON]'H>=Y\\"-`;XF27H7 MMXUM9\/DON#.9L[\[(OB;(W)9(V)J3%Y0B"=?)'I\R\RFW20/>[RUF!N/8+1 M?Y4@=M)3DCLE/3?"?'=#=!C$*SVO;N)K?['Q)^);.;C-;+C*%WD+3^@G9*>Z MX"CEA]#@X4BJ0-.N]R&HK>;4,!XR.0FU3U08S;&PO=V]R:W-H965TP;4`H1 M_?<+J&6#5W242PS*TTWW"U*WM+B6U:_ZJ%3C_2[R<_T\.S;-9>[[]?:HBJS^ M5E[4N?W/OJR*K&EOJX-?7RJ5[7JC(O'PVGA/^W3;\-^R6KV6^<_3KCFVT08S;Z?VV7O>_"BO?RC,(>H<;LN\[O]Z MV_>Z*0MC,O.*[+?^/9W[WZO^3Q*@F=T`T`!N!K?GV`TX&O"[04@:A&@0NAI$ M:!"YAA2C0?SP!%^+U4N]SIILN:C*JU=?LNX#9/,6KSHGK6>O[KVU*M?]X$LW M^K$,8[;P/SI'R,"`66E&P#2RT%JHR$(>4RX2O&!"4O$YVE%5ETBU,5!V-BJ2XP.PG&;1<'S0%.KT M_,&)1:&J0W^X5'O;\OW7 M[*#^RJK#Z5Q[;V73E$5_*+(ORT:U`0??VA=\5-GN=I.K?=-=BO:ZTH=4^J8I M+^;,[7;PM_P/4$L#!!0````(`.=U!D=56!2YM%X``$9T`0`4````>&POS"2= M3!H9T54IO5`#%&8:#J@B5`$:+:46<8?J38AT;>H`?8@^2IRDW_0G_:H`2,]L MJ0473HGW^_2O/B=/A;Y7X[9L_)8'/[Q=^-9_W?_ M]/LZ_Z??'_[I>;DZ[K+BH--BK5\4A_SPJ%\5/&9>%OI:U_=IE=6___[P3[__ M'M_A]Z;Z35D<[FMX9YVMF[_^\['HZ5$_T3FWR9UZMTJ_]KEE;Z)7P9'7/S29FW]=E_'3:_^5"E MZ[RXTS>/N]MRV_SUU;/E\^9WC"\'@TZIGJ9;[-*/X/W[LHJFF>Y6F7P M._RZYB>[%ESN=@!;-X=R]6NB;PC@]=OCH3X`5L`!1NLO86=%#:/"I[K/-=73Y[J)SHO](?[\EC#>/$=9RL`E@'AP[CKJ-*Z MAC%_B'Y.ZWM"W15^R/YRS#^E6W@^F@1!(=/I:H4DH-95MLK@T=MMEN@B.^AR MH]/MMGR@]0.VZ75YO#ULCEOW"CSR9#B0"0.?W,NPIH8P47BX/BH>P1 MA]Q.5X!4QRW=V3H#DKG*F;C@%L?)=-;8Y#B93P==VWQ+:VY?QZL"`.@NAU.6 M!UJ7D.[*ZI#_NUO"H)^,%\-P#8-Q,AO-NQ;Q_?8B=&? MI?L<%\*[NSX_-A^(.X:S+_!&3RT!J%Q^0$S@@P;:=0#BEA4K>%A?X81Z_K3Y M%A'%^W*[SJKZOQ`R'1XC.`%LEL.KF88^T;W^`%9?::!'Q^P'G1X/]V65_SL\ M,DCZ_3[^)Z+%C[HHBTSG=0V@U&M;->#%!>,.^]'`/*8>3))%?YJ,&H@-7\]& MPV0PFQF\^E&7CNK3[S#H9#QKOC89PVCC:14\>1E?O'J7(B[>9X<!S/HF_@$ET<8>S:&<1X^R3`C4.?2Y]@U'J-)9V+B-\[.P: M6A^_9`'R:-DMPH58E71H.1T`;2&1I**W>Q0QX7I\D<]AI87GY`Q\CRY6J2+D M?L\LJX4NE^OC*N;]-UGU*0=T(,0^[O?;%G;!9*"#JSX#$H1[KSHF7OHR#<[B MHT0'BPZ'C$2O9\,K"N3]FV M)!QNOO(FK7[-#N:%&N3JZ(Q^SHH,-1W"\?4N+TAK.N2?XN6+A,8B#O+R+3RU M9I37^0[X1-6V"#Z;,MI@\[G7>#J;JMR99P$.I!7\EPD7#S"YS]%HPX-P,_1UY^-P MQ(SA$9S]E-;Y*A(M\^WQ$*/TG[+\[IYH_">X,CC?XKB[A9'A8(5\')'TH/0` M2SO2_9^9_B*"14KC2V")E^NH],H&7@E@#%%C!=#>KCR8TXJEHS\?:Y%##R6R MVA(X.;"_PAPO?(N?2:<%1/V4`SW4MX_ZBLX#+O[I92M8GN"=ST\0I)_2-2$$ M3UZW/$%2\?5MBNO!RX$S9UK7`?'+AHY'HZ_SFL0-(9"W+-EUJT[(W[+#82M" MT.TVOSN!Z+282]#]JM<79+8-:PT&53N-248+37+IHJVK,#US8(_U(@/8-9.6RN M/@O7HE\0INP!M0N4&@_9ZKXHM^7=HSN!TV^VBK+Q*=GKPAO\XQ%$K;U^<_W' MH_X)A:B#?HXD,]8&[.F8`VG=W)GSV+"](4'RV%7@76@A.8[EY'V'_TT=P=7>ONS\%NV\''F+BJ:(57ZXP_/25N98R2 M)^R1SUJ>28!A@Y16X*2PB3W9NB][,4.`[WKE!B5<(IIP3DAT@:DUH_I`?[E7J#F7/6``"NKYCB7S[B,]G^P._BVSG8Y%;48@6N=P! MM*Q26M#'&_WS^ MN^!@0*/>`A]4Z3;@*@F]FC-AA,D*A$-$:.1>A(#>LZH`OEC7*6BN2-Q2%LCW M_@4+FW5+V)>.?.-QRUFC*0FTRLPZZA)Z#X8Z;ID,.56B^>J&;P[^JS)1(_// M>H?ZJR`AHB0<1#"!,L:I!&?99TA8LNUCXCP8&Y)*90>MDZE+)[.6L$3YD_7T M!??!95 MD(S)-8K&A#\W+YXQ[C0IAVH]L1HN8`L+0&A+1<,I_GPL5K1YV@))BHQB[6/@ M]__5NMET5QA/??9V@]1VGW)9RP'O3__M?_\2\6P#;D MCU2/Z(]DB'H.V$8ZF?'/P3-;^-XN$38.HZDW:;6ZUX,1@QX?@T&D\[BB6L$7 MH`I!Q2!\3M"P!HJ%@&P0TDQ"8+M+$9!)GB71(]R7-OO":VEN#)`?R0EBV_&` MS)%7UE-B6H*36Y7`-`B6/WB(4_'W_Y[5QG*#Y'C'ZR41#E>`UA-BT&*0(F"* M?JW9+%4'=JF>-DO(:S?;6CV`I@Z"#II1@!@BI)Q"W2XS,4;D0V M3`%34)IC4JZRST!T@?QNLHR1>)-_AE-#$W&&GA:`.K+*DFU@BZ2;U9M'=_@L M\#E=!=<(>[S%SSV$,6MHLEXE?\G*+%D?]RBTWK,([F2R0WZ0%51Y_2O.2PHR M<<@]:C5K!8"/9[@"%E$"1^OIF[93M)>#^R1^L\XJEE5O,R5K8@)!-V+'8%!` MRL1'4\)SK-0!P]K1]K?Y)E-"+V@^8"UW`.NXE=XY8(F`(`=H7N=W*/\F@/G; MG:C9&'/`?`)NDY90I?M'"U&\6[-LH)9-FN@\!IXX=8/FX;1:U_JG$OZGD):] M7-[\1')(ZW//RC5)3H0(^/CRADB?_KA'UJ]_*7N`3_W%-1`#%&S>`'JB:'+] MG,^8H,1`]-)!8XWR$(_W40K]R4 MF\,#WN.+;==,XV"FQ7QR/>U/:'CSLGOGF9+?F>";K1A:8Z[1<#6\-GM'>:T< M!K";A*XA@@21%*(]VHL^T6"240LQ42(1`*ZR/0^%5>K8X[="O`UR"Y MZ/L//V!1Y?`D/`&(?[O%I?@P0! MY,Q_*]@W7?F'=_(>P@>\"R_?DG%7"("AAN$N\[(Y4UXX=?B, M=)Q$&V_+>)0@3"-"PPIACBT;*7*F3CP#Z#Y''$V!2%+=67:7'OR1F!4#`"(3 M9?>?7`TN%1>(7ZK@N!$2R^.!%PUOP`%8DED[P-O``LJJ5BQV\/V%P,,+K7]D M$R'0[K`C! MA'I=PBF@%$8<-P4N?',V@#YJ(!&'B-4(,\3;0+;PUD8"#@LGX".G^%Z+[-?;`K MZ^`AD&$0J&Z1Z($B0$Y#E%L!`%3EI-VU<<&+KN.)OQH%DRVS)+<0EB=K)GKF MLASI0N8'!"#[A':?#@H!]Q&02!*SQ4U#4SM)UMT<3$&V**#'RK-6ZH9LF@1_ M$9'8E_7AVL"A:CU2F`B)A)@)6*^&Q6Y94S6T/:1>J`Y8'KQFV"^(`FAN-*B)_DRD\A+5KXV M,IG1T'V9'%$+;A0X&,$[BU09$0`YFXF=-&+Y;;9*@1!J3WS(G&\?%2R*_[A.MQAAQF[K M2%]B:.E,$AR2TZQ?ZI'ZA//4& M%&7"=YJ2F9:`*=-Y<_*6["B?N/CW2G(BXQ&,8\_U7:CYH_+CD:3&P0"\HWV* M050$)$^C243\]=4GWP`"QQ-J8@9L&EPD>I]XG7G8(T;`P&"MZT[U'>FV)?N. M)Z+ZCP8VHWX=RCL6$"P1R9$V4GSA"MV&,.LFXS6;&WWS_I5WH[$B[]WA]7!R M/1OTE'>3@8!'Z(56@CJ[,X85'O=@B*(R]YWR=E"0J2@$#PA@B1Z+!*@UB+^9 M)R`&QH;PC"ZC%B+]>S<<`@0A:JM^[&B'B@',8UYM%^T11C8+>W8?MR'^S%OV MAK8GYJ.WM0:A#3%A9!M,W`J,!$)Z`)K>#/<) M;,V?/\.K?SC>6C8/Q,"M4K6LTIGG*!0DG#^VV:E;G]]]AA8.H ML`68/60@$I/=&M"F]>;M2*#AHR0G"G?S.!_N?V(Y1A:> MZL$P]/88@FPHQZ'*T@.?I[DHFB+$"#N#DAE"Q"4R><(N:#_MLAY/+!2$R7+:8BMFVX6RR M$IGWR"%%.']I=&Q#!>01`FMV><'+;`-*T1I@8CR%KZA&S*?Q6CJ=JY0_+)$U M5@,RS:"K(L5\(WZ.90$630RR>ZH@7$59%-E6GB8YDE"(3?9M*$37D*XE[)KQ MFI\V*U-F(G=WY*[+V5!J28!.-P>!;GN.#'I)ES1KA84F*W3^/3.4HC"EBE>% M6M0MB+.HG%(X(%.`X^$QL1&Q!J@3I!QB%*&YD+1@Q![]@?=>(6?=`=8P(8,U M[EDK!Q*V@N-`5RB*I4D05I[$`>MY<8T#.Y;16#PJRH6^00<[*?3LU#V$LL(V MK>M\DS<#XN'CIQP&=[R7T-[,Y'.B1DPP&7`;D<4J7'N->&8T!A1C0/#GF)C& M6&Q%1BK2XI>K6QS*L+]T#XO\3!@&BW\R&H\HVX02M*:S,:6?!)YM.+8Z/`G8 M`0`?DF8DXS:WB>F:>8Z%X9Y^DZ&[;ZN?9W0:+SYC`!(&NUI7IS*VM,9!H=G; M7ZQ^,A@-W6)'(T["(;SJ\$VVG<&DL3T\_R=#2;KAD6<+^N.$TU,&5HW##9ST MZH8%MKHA?R)&&0IKPQ0.#Z41\`"?GK%_Z#F(KROKI+%_64>'/"8"(CTDGYTC MV[YEY4>?YH%D8S@)`/`.`WB!*FT?D:SC#(AH%%IDZ"$/VA!)56/(B(0]L@V! M9`I:O1DN.2_Z=$LR"6N71I31GB@3BR]Z#W0.83;*SGIMPI%-"BU&)4>Q]VF% MM+'&[&5^XESTTE!?Z]:A?7`@60NYZ,I%#MO(:#8C8-2TL1(#ET3.8A^5Z(>' MLT'8P#>"H$(_1[,I3BLO1FLSK;]SJTJ7CW0DNELH0'S M^[,Q_34>@J"7S"8+%7\, MP+2(XB51DD&S(US/+8BJK1&OK0]UTQ.LG?%#O4]7V3_^CD*PJD_9[YC(C$"N M_A^Z=3QU<="SL?*HMX5>[JM\JP%GA%6"^(M!O\8Y%OH4EI3X\TXD9+6TFA/I M`#QA*%$Y:9I_)>C%):G&DHPDA<3IR2"9"7^6R-R>_@B04`4K4H'RUO#UX%&0 MV@E?WO),:YD)8Q_)\7-DO8+#R65^T?,TI3W=9O3P'1=C:'7&O2L!5UZ7Y:]Z M:;CJFQ1P$]X!1J??"0_25\LW[X!!>X^_>4]=2F M2($)_$8%T5MLCT)CR+*\92[*"1:*!B<;9F=T!VNVBG`O3#@V3V%D9O MV).L3.H<6A/8'"N=\!J*G#?,\,OTV&3>9%VY*Z^5P'LJ@0/=D#8`JZVXWQB'`.YV&3#IM6='1'/^*F6!W&GD$E=G$YLHU)7\DP\9 M!@23-]IZ-L@@UO:&'(,+^N7S9F^R@Q.7"Y*CK8^\KZPYH4DHCN&"`]HN!D1*=.I1G!G$GFY(85!*' M#3`TKLJ[4;)YN9AF,XBYFVCR7I,7/P>>]>+V,VWO/>A*@+?`>__Y"'"*3#>V M1&24O4&!^B7IBEVL%[`1W81$JGADR6%`!8R_(`4,!Z?L*G:-RH(2LCQ0B@,: MS>AQ;Z9(*PP4!5`F M,CJ09?18`1#^Y0@0)H8XE8G";20P&V4,>^9(]2'+J#^"*O"===O0IE`]8WG- M+98S3<1(!4\/QQ'U]^BKLH+DCW0]T13Z_!1J-#TUA>^R\(*4`K>]\X^PN6@G M3L[!Y#N*=5]PN1@S8GR[`'T?;_1/:0$@\DMOV2->G=6K"F2&]([E9!*>[K,M M$4_YS=\*P[XM1O$CSHRR,ZP@@A3?!).1C0\N[I`"*60)( M^SK;%=:BV$RLN7VTU/1H=0+S#5$7%5.7GFK2H1-Z38,H&;*JOI8FV0$BDF3H M\RF*9.5B]?4422;Z01%!&B:C^3`@2.)X,BSNR4!^AZLI-QN^;,X\(&L4*J*F MR).E9;@"DS#JID2TZ*9%9Z@<@].7D#+=2LH4DK(0FTGH/TW961-,,91-?FBFZ@%KN"K:2Y<%=3^K[E#* M,_>G0KE-+WU%^1T<5V4.1A;1(N"QE':#9(M\T"Y;$"72&+>5OR1#U4Q82=/% M$,9<^-%CH8NHWP-.!9<@1_HAS+"Q,3UD%&F^.6I[T[CQ;,0HP9!B;:[$2H>] M@7W/BTR7<["1XH8&M/B-=,MJ!KUIRVI48Q]M;_9[DQ/[4.$^M-O'\+)]U/EG MU>U?['EFCT;6BF.17GP(HK0X:)S;F7/2D%1C&'DB=85 M%M>I74&29JCNM^DO,*BHTJ^@O-:M(KBW;5:RZ>*EA146&%?UE MAA75,*PLC5$E;U9JTVR?CXTKJLVXHI%LDTT"):0-QJP;P'"L]F"35M1I@\DY M(XDZ:R318B0)92QG7BLP2L@K`HCWQ=%&E]E4E&=3D;W+P]%!7F)M"2OAZB=Z ME(PG,]5>CP_D@.EPHMC$/Z,*P[5ZM<:PZDW.&4;194Z3_J2O)O3*H"_O6,O- M-!G.^JJE:*J^&J,0J)^JUVV%0/75,!E,Q_!S;/<9)//)])3AIYNSV$-VQA?? MJ-/,A8X"(=&DHSI-.OJL24=UFG1TTZ03<:,EFSJ/M3@,N6#%,(H?P5PC@#R+VL3 M`>I*0F"5.DS@]PH`-9/!&[4-OB0(!?%0*-D)T9UGNC5VY#=5F(!],X,-PF(S[<_6*CZ]1JDY/IE,]G4_(]7N%'M"G MYJ"OAH@]>C1L^DA)O] M=IQ,IS/=69I*/W=E9L[$.HR)X-@W"91LX!)=71Y4TB;!.BAH6M[6)49K)^I8 M<#XA43CXI8;'KG>@O%%0+8_"P1^D[B%#D30"FV"J!%R,GYC_],L%`-`]V&BS MFNS7T_X<_K^83-2?RNI7B>:B#)+A<*0G8_422R-BK#S24W0RCQ<#^'?8GRAW M9DC21\,APDHRC(M<(GG5'Y"\/F^I8H;??<&I,YD/AT0[,FN1KBA"2)+(/H!5 M$(_;K:AK(#W=P5DH<5?YP2&^326K-CGJ4R_3%>?=+)VWE4O&8#4`[Z#%C3S0 M5QC3MB-2(.$[])I$]J(9^B$'=K^CO'1'"HDY8X9&N>%=8&9[-#DE]JK;1U.E M5@0DV7'B+1P4F4\XY'-RJ>J7&++XZE6B7_?>]1+5^1R53F*W'G8$,"_0?/8E M=8.9S/#[37XX"D'`"?AA=C\0Z3W4V7;#:R6!!)V[F?%?^XEGI+N2>Y(B.\;E)C`,Q'^62+TEHEM(1!TMZ0Y@*A_0=_ZF$HY)P2GIB M"`M3#BO#K2-^US-I"%PO`8$$]_J6(8[44";1>9_!WC&SC)R*N_RX MH_RN$[B@*-B'A&?,TR1A!$O1L3?XR6#0&WJ:E(<3>U.PS"#,^IAYB-)QTDT% M;THV-<4N9EN!_E@(?GKU$C$_TLXI;"Q.:A%!8RN5$$E6;JV=B+`6:9LSNU,3 M1RT00"$(>`6A'BOE7AI@08MR,K_1`XD5U)G;E50K#$0N#$4,ZD_5?JULC\V> M"LMLKT(C191^""6$IR'GS[IBBZA:6[3T)^KO?_V_D,P/INH75$7)DW.J1":] M,!J,5&LA38JDID>&\^B)]I*9>CQ#OM2L5-NHO`?,:Z2X#&2\"3WKPS]3C*#J M$-G.'X0&4,:1%N,+#T(/)V,]'L?;=`32\]A\40E)WIN8.83/6L^R`F MLQF)`>/1H&.CUJ)5&V_[D6$S]TOKH4.8*T:>(@AL^FV,Z)!^HR:]&9I"BZX! MC`6CB8#M-Y#;)0?'23S67(J$"L9S24&L[KMB'F*,#XJ_!-1FT=W&27FU'&UF MBS/)8!4X82<;0>L47UE+DC5^:8,1S/&B.&DMM"@X4QE7"\(445FA-F MNTSKSH@/MP):YWT!%R\Q>E]VVQS!LTY1I!8(//I96FWU?\MR(-88(7_(5GKY M,]DK_H`Q&/F*W/;ZJLXR+5TM>OHT@"MO>79I#>4RQ`A*,*]757[+@0PTT30. MD*:'O=8;7]:5XW*!=LH";7,ZY6JCT[IK`Z2Y&`KH6Q//5#8>QL/*N70#FL,J M3-M0:P9802*;`T)8-.MI*4@D.%)G9J@5ER."DRZR!ZII3@0(\U8+=RL=ZT"A M!]C^A-@^)QH,Y^<2#=J+`RJOJ8TY2"M,$VO4#>RVBC0R^\6DR0DDDC3D%AY5W^49S"VR M'X.0(]S.T/,_.%[S:!`$#UK.G.BQ7Z>"'&_!<3-52!OQEG:1"C$CHNC6`/DH M[@DGC$M&$HF\:(I#JMU2!=27V=U@YL*-D5@U#HL1M5M`/H<7C/WDT??F#\]# M?0%&"(@;?)C-QHP/@``CP8CY0MT<;]EV'J[*8UZ#9-$?JM=HT+#-$8#=%]JYZN.P`"5A`:Y7$1J!WU2]$@ZW1*BZ8]PH7.Z95/Z"#ZS9$M1C2KV26Y9COLT.#YC"@`^R58"QUD3% M&6\IH;PMT-N&]KY_M$$"@O!KE(20J[+N1),*=KU5Y5>V#@C;WH3;MW"5F MC[3,.$:&O@[-25B;F8?.K/;LG(KJR7PR8>[4PBQ,;*=#S49<)9D!.IC/;?D) MED+'EG)95+_V^)/1G-(:E4%VCC!8,W`QA7@R6DQ-U(LU3#R9F>\(LR)1B'LF M_,3%'+V>"7&W#+]"M_\DB`HLD3WCU-D;8_J%K]Z9+7Q-*LA,7^NNY06,T9C+ M`Q9%-5T,BYH-YE3W,5PXRF8T@0J^3H+![S##EFS,+J%R-&"IQ.36B"7!"B?J M=+YFS^;UF,&M:A74:I,B];";@HO4;=-"S%D2SL\N6N-W^&F;PF'=K(`89%@3 M8)UM/:7!LV)X3E[;#BFS7&QS5 MB?7(Y?N]Q?P[^'<^P7\70_H\_$Z],+5S*6$0R\H_DOGP%Z0-X3_N68J:'P&3 MY;#ODY_<6Y]*]-03\D[[/5@'T(#9J`?+FHY["_IS.L7OXU^'[E<5=9&Q"6OB M9QSU1J">3WNS(?Z[@,^SWGP4O^>U]D&>/<8W@4'B^R/\=SH+`A2:'L9+[$\J MR/HGF.ONH=(4?;\ZS;%9N``X+OH:X#_T6LS4!;VAX`[T:*P'@X&&HVOI#*6Q M$^ITH4=P5H-Q7W5WAM*C"3PRF^CI8*A'LRG(X],A6I*&\P%94?I37-ZT/U7+ M5C7!"^`)CHURP*^(]AMAR%=A810&#'8.>4AYI+8-B00R&.T+?'$,I,J@H(S,( M`(_R=4\DV#X-,R75LG/>9NJDF1TEN0EYL0;SF9\TR>L8)&,`D&'27PPCQ^%) M*T"KOC\'EG7R+?6RQ(H2A<9.6,^V:;Y#=4FDG?X,TQ76.3$!&L"GZQ&]UD M:\)36)KBFIY6R>DN`]\?D@SZ,KNMR*<.L-#GD.;W2Z0R>?8@8>>PJX.4JZPP MC$"^C@_B4#;]"K/^B`/4.7F87;C&:(94BIPV5"#]@U><+&QDD%/L+<8R;CGL MQ0EUWNPJO4NQGDEXMUQTDCTL\*G[5*ZXK380QGV&(>@)5H+8KA\P^92KGF5^_#K= MAJG!`'@GCUA#BEF*[?/$FI\?PK<"@;Y(*3;*QKRE7D%;`@"JLY/]JC<85@T* MW#K%DA5BTQ#CE2E!A03WIO:MK\S<4^45QQ:\R["JC=%' M6.E0YMY,="\\9^VW9+68]$WD//L[Q92""@>N0[GH:'%[!N/KQOBF$AB\P@M3 M;7#!QV'./-W6-G&8X=TU69+UY[;V(U4,`&CCJMQX>L!NX5ED.?<\QVDTDN81GM81^7$C*@>'#'*M3HWP M/!L&`V7<[0[KG%\M"&4F*T>1B?VQT^;GQG%@9>\PA"]U.7SI=OA2%\`7;/C) M:#&)($M=#ED`$1YD3:R%XD+(TAYDV7&4&^=2"&UI1'0:OK@-JN_(.0$)3%^; M1NBAO7^ZA;S:*5?&/2S2+%6!JCJX,*ELX1>N[*G7CGXV5I1R46VJ+\ZN(@U< MA%.P5H`-5`*(LK!0&$4[;DX6`XQ`$3,EV;A1HEJ5P,%M.Q!3%B'LW41M@4RH M:BUA<1SQP0*)/YM7`PQ6"RXVY;64%4FS7E<_2YOAUC) ME*B]<6R1;8 MQ]E;&WCU@*=)#P%ION0)]:CZ;[E&1O8)/R*BP]=\?2+=H;+%;]8X#MGCX6=E MSOI6]D&BONPX,'=*#D2ZRZ20%[69X+)ZX;6M+CP$#'N)0VSITEU8O^T*@="9 MKZA`B)1KHA2K[19C#B@H\D`]$=SJ3-&_8!\9)S9000VN;0O$C+*%]+Y$<8FJ MVU)38:'&5?`357S%RZ%G0'JVU?)92TCK$OL./4JT/M4B(IL=VAC'P--"-0\P MDFZ)(P<0+JT7/W61!)$Q]B4:>_Y(ZNP;ZH2>M7JGO<>>>_W0SOBB%Z";=DS0 M:4WUJN.'+C\I@$D#JFA`=AFXI:F___5_Z==HN*$6B/]Z+"5[17IN4$T3TW:# M@2.GM(`5IZ10%'Y0-Z7G#8EUR5X5^R,^1%=/;A:93MFF&.4M&I=9#G"= M`\]":D(1Y.8O@7NXJ+_00J7;#%LV/O$3"*A(%&\F[G MJ8ZP#77A3>(M4G&D,I72Y,7`^P=>;5&:Y4BE&FED(7L+RKH]Q.DUP`LHRC"+U/ZXR-O173Q^O2*],Z!-0@` MQZIU?2X?RM8_H`]^.U33&]/OHIQH^Z6?;VRT3"/7!1D_Z/PZ5M)E3]YB06R5 M5M6C'Z8HQ0LI`:MM3?J*^1Z7,J:01C^IC(*BJ$\E"5C4WH5TXAKT\KU=^E-O M%Z>VIEJV%B3E>,*2?P-K6ZY;`:^K#BZ2UD:S>#?1.`H>@@]"!6?F3U>WSV<@ MN?(;*AW2@R_CXF^]V#[*Z&4Q6J!HC>S,FPIU4^5ZBG+U899`S1+\44&*S1YE M41:DF7UDP%1%(&&KV[AVD;"N+?G4ZOLLL\:.*E-^2PA+W[F? M-+,!XB*/-+MXK&#_0B1E&TTN8$AF,_26TR=JX0^Q<]EK>:[B`EMG[D`W[@"# M[T^0&]=>K*=>MI**FAUO/^@K4$EP>4^;J02F=Z4RYV:8F2&_%,.@EES#ZXU_ MI1:QGNCA-)F,^B9VUT3PTI<2&;HTF7FG'OW"383]8W_3!@:C9#*=-U;%7S8W M<.K15V3P?N/=L"?JT`W_4A;NDJD)LS)!<:9FF3/_D>Z\90.YBSDP^6>4J:-. M@5/A3T80162I]G-4@YSO8`C3&H`19XTV,!.%Q,EVV3HT+WMVUR?#66_L;`PV M-Z_1SI@2\%1+=K3-L>-8O)$WF/>4.Q\;D\$)O8WTP0$-(ZF$(DJ;=9D*'=.40M05$NJ;>9>'MF850\U-X^.]@-S+.0 M],54X4L0"@.BO3;4C%ZOO247;4G1(=:,DL%B8OYOTVGQ1WI@DLQ&$_ZW@83! M*/-D@02%_]_2AAXS^Z@1>_=O7Q!+.^B3G.]&[4@8*?QD4`[%DIS3_LP9G=AP ME*@OLQ9-$)Z(,4K+A]2I2&(>=U/,YF=C5@D^O0VAI5HVI=IBD)ST9H+8 M4_;[%EA%15+_#GA)&P[O%,J/\BLD^8%L##A"NG9"`51=L8NE*ZJ1> M102;O]G3R[8F[%ZKH36K.6(#";S_'M29=MC*ZQ5/U-,33]`.`F\82RD%]U29 MA*]9$X.:28RM#__8=2(P1=N^B-QKFO>+9]N]0#I8LQ'N;%Y18)J3>U21?8:Q M'K+M)Y-:U)@V;_3!$QW+Y'Y4RGI%P]`'HPL09):U-*-,#VVYW]8ZD:.7YF.1 M<]UCEMW%7>RA"7O#6!IL^1HF-=;0FL=@BSG:&_X,ND6-MDBVT'UH!&4Q'F-W M@XP]A3`L1Q.QI=Z#+I5]3FW*&4B49IU$!`Q.$A$_'D"Q814\Z.^H_%YJOI.) M4HY=5#H:K4CEN0;9^`%;(C/$2A[EUKKI;_P./K2$8+NF2XWTHD<"1]YZV!]: MHKUJHUC!"S/@?-`^[JVKTKH\8*&JL5!N_F)Y,HY"XT9^%00J#L!O'"0!@APF MA9LT-\+Q[-@N)_VL>/"VQ.6`R3,K_KQ`JXGY@VAO@&]P(.G%VF&V@LS9!]S5'??*,1.CKZ3E)O M^TQB%BB*>9O_FI%9"6@P^;!-^*TO!7L!N_JN*@$T\II"C?F]0ZN.;@U3_$I/ MR>ZN!_UK$$BH^RWLN6NUV-IQ!6B$Q$P%_9Y1HN:.E52[."%'/$UT55;^E$^1 MRQAC,KM!1;9"`4SA,_+ZQ5%,=JA9@ M0&)O=WP]'#1"-Z5!JYB44VP(1T*`'`E,OKI'4S:1N+#),)N[S'T&%^#0-2WD MSJZ"0\'>QN*HL=L16]4!CH/2\:AG_7V?";T1*\HT"+(,TP3=< MV8\M8QJ7!)^$J2X"3"QCN_\N+0HRNAK;P)DY;+%FSJ\F6S%YP+C3A^_IN6PY M[*(Q5\GCX>9MH?'5EHU@'!1/?I>4_2OXF$67-,+M<.%!C=C"+D3Z^`*L>*%. M2%7AONZP_4%9R3X(/(\[KR4")_5ZVR.9@4J3N#Z_UL7"O:VHM;B$UYK**D%( M$=6B10/>RA9=[[H2%5Y[HU6/8S1EY16]8O9(IT6S`EU>7$TS`XS8\)<2CHA*=%U#O)Z&&R:BEQ+:/Y9 M^+FE`ZB82E2K%:@.CYZ:ZLR&3!I5R!V\4Y0ZTA5_)/HB# MA6*OPVVVJS?92GME(0G_=.%W.P[9L:XWQXD:8J7?*3C#Z'VN8OHS'@V2>K:( M^,Z,U@68LI2!'[E9:C_R%.`:G5,X]XM4>6Y,KK*)18\(#[CSNQPJ4UCS*&KY M[.SQ3`J!ZZ6=&3CV=SV8$0L[1[E#AD;AM`1NE:@37@`UD39WK7A3&VI[)J%I MM^PX>@R(_E7;`I``9.N:*:TM%P8KJ(%7PH@M)?ZE5B.NC>KGY;71`9Y2%%M! MJKP34PB+=QCU)UR(]1G1D!O/8?RCM<^Q+S.D4=$)FNK[>@3M:\:$1"F":QB_5):6_FQE4VHD?*$ M8=]MO*AV`OB#9,W]X MNGT#?7-27JL,&@B4K9%P,1?US:94TJQN"6'R;:/&C'3^-FV='$/5\2)P`3J@ MI<8+XR%R6F6>E8M>Q'Z%S`$]8VB-3E1;()G$-$LD_GQ<6Z(\4-*I MU(3"^K::C+*\;/D6%@#\YO04!73J&FP&0VC3[>D_W><44MH:.)W9U=<=RY<@ MC2Q1ZQS$)5.8T#[%DI3(84026DLO4A6^@VD!;I7Q@%59N.`Q;]WI]=2-)_P5 MF*S`A1K60+HJ"C5`("EWH.H!$RY050>$J8Y[$_CEA_!R.S61"Q.IA;/1K85F MT9AIM`P@`[9(Q):-,=1&QJ5&FD$S(M!&0`M+V(HJ@>QZBT+S6GO:A<@P'LT$ M+4&)D(ESP@9$8@VJBGH-R3PH,5=1DV72!&$1ZR$TH?I>%`$77T*DV__L.S%> M.5NX6+&_P.:,L276/'Z![C[IF]ZP;MI:7ZM@111&&&KP]%ZDQ"M"-F[)0=_Z!=`8?ODD>$DI'5\J&[4_8 M(5WT`U+OJ`(7R?^9+6P;1;C]&`WOX0JKMJ1V8JIUA#DBE+,2<>=2^H/R8!3? MM[7MJ.()VXB-:A";^"U0P;'UL=&3XP145L:YNG(-XW(Q5%:YJ)D$#9DV!@J, M_N+WM241Q)*7H9I%'@TTY8M@U8QF>':?9QM71@,]Z.QO>9/^FE74M^79V^=O M*.5(R@+Q*R\^9RONO?=V`WLUS[YXZWJ)^DU*Q3WI8$/(-)Y:+.&*D3/ZI3^6 M:H1ZTD"!=$G#R?.11#D:3+ZS&?+NOIJN8ZR>-IE\9[$L/-51"NT'P[,3%2$0A3NSP\*:YM ML?/T4Y=<@%@H)NH@?,Z01"`9_YYU[![0U-8Y)O;MB*/-2/"+.4.[ZV@[F/TCPE;M-=A51CH$\;>(A02=NPHKR`R9710^Y'.=R%)Y-M)6 MGITB7+QRFR&D5I@>BZEIADTPQGJA!(0]B1/H:7M. M?O?E<1,1C;5+4`0@!Y(M1$R;1/LN3^\LC&BQ<,$851Q3$&I3DB-52VRM:NWJ M1S4):A?XZIRO_(L-O54,+PQZ7M^` ME=2^F*K26\R`$&;OMP:,^#]594AEO*ZN)"BW7I?,RU4ZG;&CR:J\G&6"6F?-,0I#VQFXXJ,VF6I+HO$V MI[1W#BAU"808\06+O\LE0.:N*A\.]S9-:24!.I\PYR]T]9&2XFO&MKBA:,$A M/)##/C":>=2$9E(>B[PG:V==RL`1%]HJ:ZX* M0+GRV8.5W;TQC!_/%6`(-8"EWXLCY=YU)LH,TW*8AQK=K:PSVY!%LEGMGAD' M`R$AMBD/9M\QT:LHM):&=84>F2^AF("`R.6=6+A/MX]4!&J/A0JHHC^=A^+. M&&0+D.`KD#M=EDNLL-FC)E4+#A"%0!0KL/I>7'/XH@8(EP8I&>K-#Q1Z'KE$94(Y9*:8@W=OJD-[*]F3<^FCR\AH'PS\:JX^R&>1FIH$X_$1*X"X8@D MS3@^?=0(F3*V<=?+66$OY__W_^EJ[XX(%I32)-0P.=JTM-O,6=]-N^,&HWY7 M@FBP11/8\LT[75/U'H^JIZ[SB#GV+MM&F)#?XO,+:KF0=Z]=]$*VX)CC M6;(8S8(GO=9$)K3]:CA-YL.Y?NJ'Z'MVEEDRG8XPJV0\GM)+YQM=X[#39#`9 M\[_J)\F62@]QMH\9?X$]D_5PE@RGHV`*7\47AP#9YTNW"`L>J_3_\*^%_2C#.=]KO,H+\>%R]!4;,W$+]Z>,\NZ?J!?;Y95 MY)T0LVQ4+B:4F84O^';IQ$,*G$H0@VELW!9>\GQL\F>Z_I1R7VJL+.0\YXCA MI"&@7<:4NW&*Q(=&%$]C6(5-8Z62D#RY_/Q9JBYX0S7/A?4F%IX?K9I/3`U3 MFF&]=$$8F2^M%JE^`?8$HTQ$KDT\PPSS.%Z'Z5%+"<_PN+IE MYZZ)4D\P4A@'6V/)^15O+0DJZ?-`W&+>66@I6,9/R,DI$XT<>T;Q>/'3JP_/ MN2::,7';MFNOO*1,VR"ML05N#$6%2OW:@DG<_B!41?R]&$LL@8VME<'[-_.: M(^4\9[H(FU)P-+EK\`KYRTPLMGG9NS+EKHS"+7_US65K<=_46(4LG+=YE9WG M(9>82!8+,J<"Z^=[;35.OXFK_7FY?*?H#PL+-D_@=$7"KRUYV=ROS^ZP$N-B M,J'_ST?8?F21S,8C^G^_3T4^"CZ84RE$LQK_S)LKZB_ZE"6VF'*>5Q^+E@(/&PW'=D6C9`8K&B;S M&2X%*VY.@'GV6\>GE^P'N"E MR7PQPU4L1MA]PQL&"OALE_?'$5!1-&N5$0SK"6IJ/JZ[^YM4P&2VXS=W5(%D, M1_P1.]GQW%>C9#I#3AWURKB:T9ZF`^S$=X7M7G"CV.\%GOZ9NCT4#>D:)#.L M.,PBRV+!X@3"DFA+LOL)!C[`L"!DO);N2]0=)6R_Q#+%HC_B>6>T=OZ;7XOQ MZ@G=R7PANUS,9.?#!6^23V'0AR-NB@;O69-?KFS3V'=5R:W)6XND?,"LI9^P MY?=9>6.LK_6YX5'X>).:FN3((4GTP(;P@/[+FX_TRS6L'.NL>SY=]2 M8B9>[::BMN9-5#*B$,YOL@>1!+"*K6- M5>BN5?1P(+)-'??H4E)6$W3-'@I]C]W""^Q`@5*\5!QR^5[&ATW1>+`"R>A# MM\V&*Y3#J+N\%OV!V(*5E(`4^[VR55H8>RLI+56V0?-<+28)"6LS%0:=D9G7 MIMB`)>D(_.66N6OV6?P1;.Q!8TVTF)[ZN*?2;#EYY#SE.A';I%\/Y^".31*Z M17_DR>EMM,5D!R"!-J63["RL<^>4(Q%67=)>E_$J>M?:4$Q8_B=7>FFC9-UB M_'MD=X!;8YAPCJ.89L'RHO(VW/.A@KVN<+;(`?E-%T/EFS@4?%-A"#%'QC!8 MN-JD"(FK$!+MW?.$2B;$P&3;Y8A+I5$'"4KF2DR2,YS83M2D6E(6E9=1EL`U MW.4%5^';'"B(0Q0RC*LU-2OU$JYBR[G7%K,_E6*!H412;S&NP7).V8/%&M5= MVK"&Q?:&R^=1"V"/B=L$C M4?(W`;8+IW%YT)$&9S04DAZC7WT-SE/;S!(DC(#12)%A74KQ/09^=2HU6Q_3 MFC"4JM9+1A.<5T7EQKCB[>>U@:>7$]&)$YY(V$&UP_=U4C7>5N!XTLD]!X'Y4,8./;4!Z)QA]3K*L44E'^ M4$#-@/.R>^>9DM^EG8VY1Q-' M*==H(J;PVNP=Y773^]R2=3,'?0%FXHY6,(DY9?R!YT2\,F$<.C,5B[T#2*P- M";5)48W7HB=KOWYG4+`L-YY#C+G*ME3)EVLD$:OBP`H_?#>A9#:O_!E94Z*` M&!E+PDQ80J$G*;!3#*`>TZ8!O#5Z5EI0B)]J>&I=5M?6$E)2UGN3VGDEVO`$ M_WCS]@5'.5_E,`8PM&I]S05*_;>"?=.5?W@G[R%\P+OP\BWI0IYO,-XEOOG3 MBQMI>H23FV@2RDED>Q9ZO9&.$^OWMHQ'69=469.;D&W9JI*;THB41T\^P>VC MXJ@,D^!(68%V).L5(*?[QJ/M5(L(%DA>]>"X31=@6C2\`0?@!4=;P!,+FE>Y MO`D\4HSP1VY+`;2<.LG8HEMX:!R4M-^F*[&6N:@Z&TGT(^H`7*J4?4P8,H8> M8L5);V30-W[K8Y'_Y,L]Y1/3PR M7&(4PJ'*;[E:K.N.V9KAW?#^=+W+"@=,Z&QP4GN5Z])3:"27?">;;3N3)OYL M&IG2:`&3#\-8'&Y0S()^B6:NMP6S)?IN3P!5YF+UQOM1]GO7<9N-R`ZW`?31 M;+QQ<@>&%X#8OGE4]BMZR5,9:4=A.8Q&Y*@4.##QC2(?2>20+>!ZZ[(*2`[7 MQ9$D<*).A#U^X?\]I?6Z@$.;)^QI7@*/8BI7*RQ=?'C`HG3L2#,IAO)@0D'/ MMQ(W+[(&'`Y79I;74<]%5S`IH:]X``9>(]2D6UO"SUO#:I7M":U\W90*^V'> M7.Z#75D'#[G:RUX",\BM*85G66G7UM%)BT:9%W3?'W(I[NP6PO)DP]/A2!1+FD\E#`E"(J[$#A,9)Y+,_K= M-TW>D3(6GXGNMA,9F4GD)2M?&YG,-A'Q9')$+0Y+%JJZD9#)U%,^K&*Q;VT0 M^M$(B7`NCWOTFFT?35'[>H]S-3I8MIVI1LU!6>Q#$K;GGH8]I$T`;&E-M(&` M!,^7=329@+NK*+-0?X8DGM/(<7GMGT6J;!]2CBKXR]/!A0G9J M`H.DKI.[G!$A*N4MVE$]<_'LE.='T_G'G^B[4_%'Y\4A2XV``WH\V M$LID(#N-1JQN@?KD&T`P1C?0Q`S8-+A(]+X8B_EACQA)XG>G^HYTVY)]QQ.E M,+55OP[E'0L(EH@8^R[WOO!N-%7GO#J^'D^O9H*>\FPQ# M#IJN=-=;QA!%9>X[Y>V@(%-1`67JS4J9`^Q1]5NO^\:&\(PNHQ8B_7LW'`($ M(6JK?NQHAXH!S&->;1?M$4:Z9]_NXS;$GWG+WM#VQ'STMM8@ZOAHQ*5X'&/QH[D43>_S2':!A.W`IL]CWH`FMX:!>((Z#@:XP_'6\OF@1BX5:J653KS M',4.A//'-CMUZ_.[K[#9*?^^VB_'NW`0%;:U1%=0%4)`F]:;=UVC,%E@?Q"% MNWF31NA(6$%N#F&E-UE2NXV4+?K&AI4MJ- M41<+3X;II<9GB`?A;++B;7Z4-AA4.TET;$,%Y!$":_$:YCNV`<&6(_^#:1HJ M;.;,SU&/43^(Z2`1SK7O$K`V!NZ&!"PQQ4KV_%S0)E5(@ZY9AP>"MX+CP/9,*,0V8[&B^(J\N,:!'8-I+)XK+-T` M06`'G'/D>Y+%%O.#*(\G&!\[\&"Q4,>IB4B8F7R^M6J`')I[_<@/I+WAVJE" MK]$O@DC?QEAL`DE,! M)5Z!Y&5K%>9O%92_55#^5D'Y6P7E;Q64OU50SKY54/Y60?E;!>5O%92S;Q64 MOU50_E9!^?Y;!>5O%93_WL%,EB9I\-YIS\'\Q#I00H=SKX.HEV#"!ZU[H*]TO@ M]*+*'!S?R,62J)T8:28*)8F,N/*!!5=OD M`P-;0-6W&`A\QU+4ADK5F`I$2%&W$G\'=WW(*G\V+\!OCR&&!)QL(3-";H,Q M6H.11S.83-J$<6?_]W:(,C]/:2*!T[L4O4V:@Z6<%&B@DI+ZMQSRRL4&);;5 MNH2,JF6,5:0O*B<(6(61C9KV0$03H=9M?S`1RV)?]LDB(`Z%MJ%K!S]279I' MN3X^3++C\IMU1L671>\T9WTK^R"N(SOV#]2ODM>TRB;AM:TN/`0LO1"5GI:4 M%"<5FAAT5P],]#LVF&RWV/:9,@<.NE%QUZS.WXA83A#[;SH1Y/@*8\(YT0U+05"?JOZ9;81VJJ MEA4U"ZK`5"F;*2)I7D/@-UZ1%5R"*P@?T:SVM\+>HSYI"@WZ'FD4'SK5.U9G MET':N>D#>ZW_E5MF-WME2^2^V"-)PUJ90F%;Q%*Y\X.XBS@MJFJ$I/_`JZ56HM(7 M6^HDL7@G1=1\@4+BN'PU:NFI1SD9@=B\_;?Z5`MS%:0,!7%?@19/>O$C;T4, MH/7I%?DEC+B22-OZ7`4VTXI>-UO1)[;%O9?5&FMK8JU5US,(. M\%2VY5A1'VC[5J.ZMZD/*D5SR/+5MB9]Y?K)DZ^^9N"57%-*<2`EG$P!E"%" M(1+U0P9JEUGZ4V\7I[:F6K86U"GMJ*.VMA%_"AA8A=4>,0##QFU+G+'<1%NA M"/0R8J@@DC*:YXCK/C[PN+JM5WV>9J87$ M!1%=5+FE[WD!LM9!J@?C6-SX74K%POZ%2/JF?8\+&)(9<;PV55U_ZX_]K3_V MM_[8W_IC?^N/_:T_]JG^V$'_*AWWKXJ?_]899N5YXW^Q?`,SL`O=E\80D(OZ-JCRVI M,:MP-,3:K1FMQM'4B4I\)K[?/FRD^-]0HN\7LP*N5#:;2Q&VQ6+F*I6-1[92 MV7Q&-51K*06YSK='*G>)RPDMM2>VJGCUP$:GLP56]>O/QO37>$A5\28+MRZW MV6N"ZG!>7%1O)DOM]_KR:=!;].UW+;757GS.*@K4A86Q5?:MUTSDC]("@`+K M,5=]Q;P%GFN3.&7O;;?-`$:5+!.*=&5;CY0-`"KFEL&MQTIO&9_<,BJW#'[. M]E>`,41DMR);X^#-4<6P9C(Y%?N%Q.CFF2=OF7`<`3$14('`VGR6@PER'\_O:$HQ*C`WCL0 M:/(=6[B708KE.U/-X1U%*OUD+!`OK$?)F=[8EL8*XM*X7QKN?_P=*^^W@:27 MU47R?DB0]MX:HS10=:"ZFHTN/8&]I,,'9E!`N?C.L/RV\>'YPCPF,OV@EBP> MN*-8>H^\QDI'SVW!^P^NYNNBWU=SD4$61H6RS!4+0K\+MT&5+?O]YI'%-:X[ M[_?\Z<:)M>&)JHM/-+3#I1XZ83(<3Q16O9_J_XMVI5WZL3-Q,9IKT)WTUH5<&?7G' M7O,T&<[Z=A'^P5R-D]%\2,4Y30.,X.=A,IB.X><82(".3*:12.+N^6-!8C"< M!NR2J@-[_1K?L]:9:*]>>6,L_7FW_:'>IZOL'W]'T>K5I^QW!%M'._+>C!R[ M/QK=,FV(W!>DR2#,&,\[@_SW!@N",NNF5)J8%E(0(N$(;*/$"@-VOUQ:"58C MLHLL]\890X+:OG,JT3X<)N/^7(G62RS/.<#T9#K5T_F$A`>NGFMKZ0[QIH&I MM/QF%WC-\@5+#5RH%3[T3[[B"2+A2RPC8=GYR4+^IY[+P^;;,54JCD5<%,TQ MT+!3)C5)4W0I]ODV6K4*'LW-HPDKC!MGXR`@*F_K$B-G$G4LV,AF/`PU/':] M*S]QIC"/0FG:;.='S)#:"*ZW06B.DC_]#@$`>0_6V%`3=9[VL5;R8C)1?RJK M7R7IC**PAL.1GHS52ZPZC`4`?J;4$^#[BP'\.^Q/E#LXI$&C(1:5'B;#P;@M MQA[X"-"#YUCEM^N8;0'B%V*,\6N7/P.`*[?YFFBBP..-"=8ZS36,[5WLZ88'N*4JP'83T_$'HP10!<+887W@0>C@9Z_$X MWJ8["&P5,9M>>@X@10_ZTW,',9GJ6?=!8)5MQ,OQ:-`:,D-*="[VGBY$>LEA M.&\`=7?''0?+Z'?IHUB)R*CI^&=[+(V,L9,Q>.U[,T:;Y9LM19ZMB<8E@N7I M,$W@?\E94BADN#4IZ1`R!+J$.4]ZO%C@AQE]@^?3[T6R;9O/J"S,OB;;@J M!X;P_*(_5*^1A%OXNAI,L6@Z01VS(I#+851ZRD;<-#L,)P,1XZA&F/WI MB1[/XP8MJ!1>LWX5A$!U@:?13W_&]&EK91?AZK_4HI@"C4XK<,G?/VCU:AD4:QI76IA$9Z9:8GA1'?<">UZ@Z,&WE$0 MF1;S[^#?^03_70SI\_`[]<)D@:QS*I=I>KG^@J6EPG_[".0ZEGHQXL:SKN+>C/Z12_CW\=NE_5GZA$`$I"LF5KY!'M M8M3#GA+3WFR(_R[@\ZPW'\7O>:95[+@UQC&]Y[=C(&_!&A%^VD0:(\CX\LI!DHS/R2N!TY#AG55BO^.+940- MNO75YLYF@0P@("@L8J\/I''J!6B>12:%$PM7U9R+V6%+D.E"C[!7Q[AO6F:P2SSHFJ%'$WAD-@%)8ZA'P-A!YABBY#&<#XCK M]J>XO&D_TD4_^@Z\X+IHA^^=5^UC(0!(#,8WR]M=`V5^S^MO+%& M;)*BX_*V7K)68*5S2SD1Z*,;@3X*X^:Z8]I<&>R>W]UOYY\8B0$@Z/7[?_!7.^"" M%`W;;WC*0$D6$_-_:P)6IM!>,GT#?Z8><^^D;Z#Y MW=E07MGN?Q2L0,+*7X=>WT;K6 M2Y=,^\KKQ'H%H)3FVV@J(,L]2Y8_WCS75T]./C.^X!DS3@QN><'N MNALUGJ\KZ(PM@4FC,_+%D-7_WB61M,?%7>NS$7#V+C`?B$\*8.%[$Q@%Z\3P M7*SH:[_X8"AR`D_Z?[>=[6\)->/'HS:8%T6777I`7QU-YA\<;RN2$OW@JQN4 MGEF;?!%$?:$D`5%A..0.U\A%7[&V:37:$RT6Z[ M'FP/SKK6[1+;J:BLL]3"06ATTONJIX&4$;YWKM!?TJDSM2_XX3<@7=K,FB@B MT<;7-*.CFD^:@*=!WS@FAV.]3A]CU.DXUO__0]3:"<0IM/_GX[9G*OQ%[ONV M6+`H#B^(Z8E`DX.\0-SM!,HPJBD.\VL+;HH""$[&-77-Z!U@:W'`9B!3Q#K$ M$V=V!A3_@OVV[RC1EP/FB`&S^?6D_>LWZ>>O6.6L?3#`A=;O+Z0L+?%_OX&2 M!%5C3:'MDP^9XJD1_(0EBN+0=&K*:"3F[IO%*JF@-,G6VN*\O%NX<%3?G,L< MVW0P_ZN'D.Q.U*.]R92U@-.@>W4NO M)A<3V6DT^UQV'0\HP110>12B3&R^0@7VB( MSY8K9G?%,)\*7.[&.T2[R_$.:WPU$2W$,WSB2S!MW89I#43[39C61(+?BFG1 M'+\)T[H1K7FMI^#LM[Q[*8Q>PCE_2Z"TSU\#-1W^/A&F?T[S/"UMDOFM@T/' M0:%MH<=M"F80,GSV@688\I>\T*&ONGC8:]T1,OSEDGD0LMO\L1&S&[G#@MC= M,U&YOT$"`[+0,SZ$2)>CP5_9:A`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`S^5L[OV&C1QI=7X7M\# MVT"3^^'B-_Z`/O:\VRT;&2OBNVF^\M^RO.Z.'>G*_[C6_Y&9'CZ&N$>38,K$ M>ZG5VGR25+0Z^OW0]`BX*3^!L\I,R%CW,9F(^TM_!T7SRR8X<0]?K%A<=F3^ M/73ZCBJ8=9Q,4$FZ#G*#AZ9<EWJFV_TY,2Q[.H^+?7;"B^NO;V5-0`+"XCWHY!%M"^V.0>1"9V0)<#XXLL M)RZK2**"Z^ZPX##4PQ8K68-R\LD$H!H;(Q\B*NDX-M4AB$3.69NYX&40Z6XR MH6)7@LD>Z(QU"A8;QL\W&G]@/E5DF&B/3!E.6K_VKO0KD\)^.[MLR_0Z]8S+ M\>K0XQ:-/VPFGM2!_R73^$[RYG`+K`C`I4F:.49)C'@!4<%GP[J;MO7_V:9 M:E]ANFKF=G4]$*1;7?)0US-="5*7/A\A[V]*98I&.Y5_U*KKMR<9N4>_K^O# M/_U_4$L!`A0#%`````@`YW4&1Z\C"5K^`0``VB(``!,``````````````(`! M`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"%`,4````"`#G=09'2'4%[L4` M```K`@``"P``````````````@`$O`@``7W)E;',O+G)E;'-02P$"%`,4```` M"`#G=09'>ZA1+00"``"X(@``&@``````````````@`$=`P``>&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4````"`#G=09'=YC&OUT#```C#@`` M$```````````````@`%9!0``9&]C4')O<',O87!P+GAM;%!+`0(4`Q0````( M`.=U!D>76&4$/P$``&D#```1``````````````"``>0(``!D;V-097)PC$`8``)PG```3```````````` M``"``5(*``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`A0#%`````@`YW4&1P0$ M&N4Y`@``YP@```T``````````````(`!DQ```'AL+W-T>6QE&PO M=V]R:V)O;VLN>&UL4$L!`A0#%`````@`YW4&1Z]1:%Q-`@``\P<``!@````` M`````````(`![!<``'AL+W=O&PO=V]R:W-H965T&UL4$L! M`A0#%`````@`YW4&1\>X<@A&PO=V]R:W-H965T&UL4$L!`A0#%`````@`YW4&1U(5 M*0>@`0``L0,``!@``````````````(`!8RT``'AL+W=O38FZ,!``"Q`P``&```````````````@`$1,0``>&PO=V]R:W-H965T M&UL4$L!`A0#%`````@`YW4&1VO_RIZA`0``L0,``!D````` M`````````(`!ZC(``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`YW4&1^R`0K.B`0``L0,``!D``````````````(`!&PO=V]R:W-H965T&UL4$L!`A0#%`````@` MYW4&1V.%<9JA`0``L0,``!D``````````````(`!_#T``'AL+W=OLJG*,!``"O`P``&0`` M````````````@`'4/P``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`YW4&1ZR"3C^A`0`` ML0,``!D``````````````(`!AD,``'AL+W=O M10``>&PO=V]R:W-H965T&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`YW4&1RH"IS"R`0``%@0``!D``````````````(`!7D\``'AL M+W=O&PO=V]R:W-H965TU3L7TL0$``!8$```9``````````````"` M`4I3``!X;"]W;W)K&UL4$L!`A0#%`````@`YW4& M1QS8,62E`0``L0,``!D``````````````(`!,E4``'AL+W=O&PO=V]R:W-H965T=8``!X;"]W;W)K M&UL4$L!`A0#%`````@`YW4&1]WUP6--`@``-`<` M`!D``````````````(`!35L``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`YW4&1Y,7V*3>`@``J@P``!D````````````` M`(`!*6(``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`YW4&1[T@;?WE`0``3@4``!D``````````````(`!QVL``'AL+W=O M&PO=V]R:W-H965TH%G@*A`(```@)```9``````````````"``6UP M``!X;"]W;W)K&UL4$L!`A0#%`````@`YW4&1Y08 M;VAK`P``.!```!D``````````````(`!*',``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`YW4&1X!\VZRF`0``]P,``!D` M`````````````(`!!GL``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`YW4&1V&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`YW4&1[*@E.\!`@``Z08``!D``````````````(`!Y(D``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`YW4&1QLMI7@[ M`@``2`<``!D``````````````(`!7Y```'AL+W=O&PO=V]R:W-H965TK"'\PY`(``,8,```9``````````````"``3B5``!X;"]W;W)K&UL4$L!`A0#%`````@`YW4&1YEUKX<5`P``%P\``!D````` M`````````(`!4Y@``'AL+W=O&PO=V]R M:W-H965T``!X;"]W;W)K&UL M4$L!`A0#%`````@`YW4&1U58%+FT7@``1G0!`!0``````````````(`!=:(` K`'AL+W-H87)E9%-T&UL4$L%!@````!"`$(``!(``%L!`0`````` ` end XML 29 R55.htm IDEA: XBRL DOCUMENT v3.2.0.727
Goodwill - Roll Forward of Goodwill Activity by Reportable Segment (Detail) - Jun. 30, 2015 - USD ($)
$ in Thousands
Total
Total
Goodwill [Line Items]    
Accumulated Goodwill $ 47,937 $ 47,937
Accumulated impairment (26,828) (26,828)
Goodwill Balance   27,263
Acquisition measurement period adjustments   116
Impairment   (13,981)
Goodwill Balance 14,198 14,198
DermEbx and Radion [Member]    
Goodwill [Line Items]    
Acquisition cost   6,154
VuComp M-Vu Breast Density Product [Member]    
Goodwill [Line Items]    
Acquisition cost   800
Goodwill Balance 800 800
Detection [Member]    
Goodwill [Line Items]    
Fair value allocation   7,663
Goodwill Balance   7,663
Goodwill Balance 8,463 8,463
Detection [Member] | VuComp M-Vu Breast Density Product [Member]    
Goodwill [Line Items]    
Acquisition cost   800
Cancer Therapy [Member]    
Goodwill [Line Items]    
Fair value allocation   13,446
Goodwill Balance   19,600
Acquisition measurement period adjustments   116
Impairment (13,981) (13,981)
Goodwill Balance $ 5,735 5,735
Cancer Therapy [Member] | DermEbx and Radion [Member]    
Goodwill [Line Items]    
Acquisition cost   $ 6,154
XML 30 R46.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stock-Based Compensation - Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period (Detail) - Jun. 30, 2015 - USD ($)
$ in Thousands
Total
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]  
Remaining expense $ 4,698
Weighted average term 1 year 3 months 22 days
XML 31 R33.htm IDEA: XBRL DOCUMENT v3.2.0.727
Business Combinations - Acquisition of VuComp M-Vu Breast Density Product - Additional Information (Detail) - USD ($)
6 Months Ended
Apr. 29, 2015
Jun. 30, 2015
Business Acquisition [Line Items]    
Business acquisition paid in cash   $ 1,700,000
VuComp M-Vu Breast Density Product [Member]    
Business Acquisition [Line Items]    
Business acquisition paid in cash $ 1,700,000 $ 1,700,000
Estimated amortizable life 8 years 10 months 24 days  
XML 32 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 33 R57.htm IDEA: XBRL DOCUMENT v3.2.0.727
Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2015
Mar. 31, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Segment revenues:          
Total revenue $ 11,143   $ 9,667 $ 24,363 $ 18,187
Segment gross profit:          
Segment gross profit 7,878   6,830 17,240 12,764
Segment operating income (loss):          
Segment operating income (25,436)   1,757 (22,719) 3,045
General, administrative, depreciation and amortization expense (2,392)   (1,923) (4,666) (3,671)
Interest expense (70)   (614) (577) (1,431)
Gain on fair value of warrant     699   1,835
Other income 5   12 14 16
Loss on debt extinguishment   $ (1,700) (903) (1,723) (903)
Loss before income tax (27,893)   (972) (29,671) (1,109)
Detection [Member]          
Segment revenues:          
Total revenue 4,955   4,832 9,743 9,007
Segment gross profit:          
Segment gross profit 4,090   3,960 8,037 7,324
Segment operating income (loss):          
Segment operating income 2,033   1,897 3,793 3,413
Cancer Therapy [Member]          
Segment revenues:          
Total revenue 6,188   4,835 14,620 9,180
Segment gross profit:          
Segment gross profit 3,788   2,870 9,203 5,440
Segment operating income (loss):          
Segment operating income $ (27,469)   $ (140) $ (26,512) $ (368)
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.2.0.727
Lease Commitments (Tables)
6 Months Ended
Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]  
Future Minimum Lease Payments under Operating Leases

Future minimum lease payments as of June 30, 2015 under operating leases are as follows: (in thousands)

 

Fiscal Year

   Operating
Leases
 

2015

   $ 255   

2016

     499   

2017

     255   
  

 

 

 
   $ 1,009   
  

 

 

 
Future Minimum Lease Payments under Non-cancelable Capital Leases

Future minimum lease payments under all outstanding capital leases are as follows: (in thousands)

 

Fiscal Year    Capital
Leases
 

2015

   $ 774   

2016

     1,039   

2017

     89   
  

 

 

 

Subtotal minimum lease obligation

     1,902   

Less interest

     (163
  

 

 

 

Total, net

     1,739   

Less current portion

     (1,251
  

 

 

 

Long term portion

   $ 488   
  

 

 

 
XML 35 R50.htm IDEA: XBRL DOCUMENT v3.2.0.727
Fair Value Measurements - Additional Information (Detail) - Jun. 30, 2015 - USD ($)
$ in Thousands
Total
Total
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
Goodwill and long-lived asset impairment $ 27,443 $ 27,443
Impairment loss   13,981
Impairment charges on long lived assets   $ 13,400
XML 36 R42.htm IDEA: XBRL DOCUMENT v3.2.0.727
Lease Commitments - Future Minimum Lease Payments under Non-cancelable Capital Leases (Detail) - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
Leases [Abstract]    
2015 $ 774  
2016 1,039  
2017 89  
Subtotal minimum lease obligation 1,902  
Less interest (163)  
Total, net 1,739  
Less current portion (1,251)  
Long term portion $ 488 $ 1,020
XML 37 R37.htm IDEA: XBRL DOCUMENT v3.2.0.727
Inventory - Components of Inventory (Detail) - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
Inventory Disclosure [Abstract]    
Raw materials $ 1,608 $ 955
Work in process 223 54
Finished Goods 1,491 1,205
Inventory $ 3,322 $ 2,214
XML 38 R52.htm IDEA: XBRL DOCUMENT v3.2.0.727
Income Taxes - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Income Tax Disclosure [Abstract]        
Unrecognized tax benefits $ 0   $ 0  
Adjustment to liabilities or tax expense     0  
Interest or penalties related to uncertain tax positions 0   $ 0  
Company preceding tax years     3 years  
Income tax provision $ (107,000) $ 25,000 $ (28,000) $ 78,000
XML 39 R47.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stock-Based Compensation - Aggregate Intrinsic Value (Detail) - USD ($)
$ in Thousands
Jun. 30, 2015
Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Aggregate intrinsic value, Stock option $ 485 $ 3,187
Restricted Stock [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Aggregate intrinsic value, Restricted stock $ 1,469 $ 2,092
XML 40 R9.htm IDEA: XBRL DOCUMENT v3.2.0.727
Inventory
6 Months Ended
Jun. 30, 2015
Inventory Disclosure [Abstract]  
Inventory

Note 4 – Inventory

The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows:

 

     as of June 30,
2015
     as of December 31,
2014
 

Raw materials

   $ 1,608       $ 955   

Work in process

     223         54   

Finished Goods

     1,491         1,205   
  

 

 

    

 

 

 

Inventory

   $ 3,322       $ 2,214   
  

 

 

    

 

 

 
XML 41 R43.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stock-Based Compensation - Additional Information (Detail) - Jun. 30, 2015 - shares
Total
Total
Black Scholes Model [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of option Granted 130,000 317,000
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.2.0.727
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2015
Segment Reporting [Abstract]  
Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss

Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands):

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 
     2015      2014      2015      2014  

Segment revenues:

           

Detection

   $ 4,955       $ 4,832       $ 9,743       $ 9,007   

Therapy

     6,188         4,835         14,620         9,180   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Revenue

   $ 11,143       $ 9,667       $ 24,363       $ 18,187   
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment gross profit:

           

Detection

   $ 4,090       $ 3,960       $ 8,037       $ 7,324   

Therapy

     3,788         2,870         9,203         5,440   
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment gross profit

   $ 7,878       $ 6,830       $ 17,240       $ 12,764   
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment operating income (loss):

           

Detection

     2,033         1,897         3,793         3,413   

Therapy

     (27,469      (140      (26,512      (368
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment operating income

   $ (25,436    $ 1,757       $ (22,719    $ 3,045   
  

 

 

    

 

 

    

 

 

    

 

 

 

General, administrative, depreciation and amortization expense

   $ (2,392    $ (1,923    $ (4,666    $ (3,671

Interest expense

     (70      (614      (577      (1,431

Gain on fair value of warrant

     —           699         —           1,835   

Other income

     5         12         14         16   

Loss on debt extinguishment

     —           (903      (1,723      (903
  

 

 

    

 

 

    

 

 

    

 

 

 

Loss before income tax

   $ (27,893    $ (972    $ (29,671    $ (1,109
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.2.0.727
Goodwill (Tables)
6 Months Ended
Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Roll Forward of Goodwill Activity by Reportable Segment

A roll forward of goodwill activity by reporting unit is as follows:

 

     Detection      Therapy      Total  

Accumulated Goodwill

   $ —         $ —         $ 47,937   

Accumulated impairment

     —           —           (26,828

Fair value allocation

     7,663         13,446         —     

Acquisition of DermEbx and Radion

     —           6,154         6,154   
  

 

 

    

 

 

    

 

 

 

Balance at December 31, 2014

     7,663         19,600         27,263   

Acquisition measurement period adjustments

     —           116         116   

Acquisition of VuComp

     800         —           800   

Impairment

     —           (13,981      (13,981
  

 

 

    

 

 

    

 

 

 

Balance at June 30, 2015

   $ 8,463       $ 5,735       $ 14,198   
  

 

 

    

 

 

    

 

 

 
XML 44 R56.htm IDEA: XBRL DOCUMENT v3.2.0.727
Segment Reporting - Additional Information (Detail)
3 Months Ended 6 Months Ended
Jun. 30, 2015
USD ($)
Jun. 30, 2014
USD ($)
Jun. 30, 2015
USD ($)
Segment
Jun. 30, 2014
USD ($)
Schedule Of Geographical Information [Line Items]        
Number of reporting segments | Segment     2  
Total export sales $ 11,143,000 $ 9,667,000 $ 24,363,000 $ 18,187,000
Intersegment Eliminations [Member]        
Schedule Of Geographical Information [Line Items]        
Total export sales     $ 0  
XML 45 R44.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stock-Based Compensation - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) - Employee Stock Options [Member] - $ / shares
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Average risk-free interest rate 0.98% 0.85% 0.92% 0.82%
Expected dividend yield 0.00% 0.00% 0.00% 0.00%
Expected life 3 years 6 months 3 years 6 months 3 years 6 months 3 years 6 months
Weighted average exercise price $ 3.37 $ 6.72 $ 6.97 $ 7.83
Weighted average fair value $ 1.74 $ 3.17 $ 3.33 $ 3.67
Minimum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected volatility 60.50% 64.90% 60.50% 64.20%
Maximum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected volatility 73.80% 66.50% 73.80% 66.50%
XML 46 R30.htm IDEA: XBRL DOCUMENT v3.2.0.727
Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)
3 Months Ended 6 Months Ended
Jun. 30, 2015
USD ($)
Jun. 30, 2014
USD ($)
Jun. 30, 2015
USD ($)
Segment
Jun. 30, 2014
USD ($)
Basis Of Presentation And Significant Accounting Policies [Abstract]        
Medical Device Excise tax included in the cost of revenue $ 132,000 $ 200,000 $ 331,000 $ 379,000
Amortization and depreciation $ 503,000 $ 343,000 $ 1,142,000 $ 674,000
Business segment | Segment     2  
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.2.0.727
Loss per Common Share - Calculation of Net Loss per Share (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Earnings Per Share [Abstract]        
Net loss $ (27,786) $ (997) $ (29,643) $ (1,187)
Basic and diluted shares used in the calculation of net loss per share 15,679 14,074 15,642 12,759
Net loss per share - basic and diluted $ (1.77) $ (0.07) $ (1.90) $ (0.09)
XML 48 R8.htm IDEA: XBRL DOCUMENT v3.2.0.727
Business Combinations
6 Months Ended
Jun. 30, 2015
Business Combinations [Abstract]  
Business Combinations

Note 3 – Business Combinations

Acquisition of VuComp M-Vu Breast Density Product

On April 29, 2015, pursuant to the terms of the Asset Purchase Agreement with VuComp, the Company purchased VuComp’s M-Vu Breast Density product for $1,700,000 in cash. Under the terms of the agreement, the Company acquired the breast density intellectual property product, which will be integrated with the Company’s PowerLook Advanced Mammography Platform (AMP). PowerLook AMP is a modular solution designed to provide advanced tools for breast disease detection and analysis, including CAD for tomosynthesis. The Company considered the acquisition to be an acquisition of a business as the Company acquired the Breast Density product and certain customer liabilities which were considered to be an integrated set of activities at acquisition. Accordingly the assets were valued in accordance with ASC Topic 805, “Business Combinations” (“ASC 805”).

The amount allocated to the acquired assets, was estimated primarily through the use of discounted cash flow valuation techniques. Appraisal assumptions utilized under this method include a forecast of estimated future net cash flows, as well as discounting the future net cash flows to their present value. The acquired technology is being amortized over the estimated useful life of approximately eight years and nine months from the closing of the transaction. The following is a summary of the preliminary allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life:

 

     Amount      Estimated Amortizable Life

Developed Technology

     900       8 years 9 months

Goodwill

     800      
  

 

 

    

Purchase price

   $ 1,700      
  

 

 

    

The assets obtained in the acquisition of VuComp’s M-Vu Breast Density product and the anticipated future revenues are included in the Detection segment and, accordingly, the goodwill resulting from the purchase price allocation is included in goodwill of the Detection segment.

Acquisition of DermEbx and Radion

On July 15, 2014, the Company entered into two Asset Purchase Agreements, one with Radion, Inc. (“Radion”) the other with DermEbx, a series of Radion Capital Partners LLC (“DermEbx”) (the “Radion/DermEbx Acquisition”). Pursuant to the Asset Purchase Agreement with DermEbx, the Company purchased substantially all of the assets of DermEbx, including all of DermEbx’s intellectual property and customer contracts. The Company paid the following consideration to DermEbx: (i) $1,600,000 in cash and (ii) 600,000 restricted shares of the Company’s common stock, $0.01 par value per share. The 600,000 restricted shares are subject to the following provisions; 25% was locked up until the date that was two trading days after the Company announced its fourth quarter 2014 earnings, which occurred on March 2, 2015; 30% of the shares shall be locked up for a period of 24 months from the date of the agreement; and 30% of the shares shall be locked up for a period of 36 months from the date of the agreement. In addition the Company delivered the remaining 15%, or 90,000, of the restricted shares to US Bank, N.A., as escrow agent, to be held in escrow for a period of 18 months pursuant to the terms of an escrow agreement. The 90,000 escrow shares will act as the source of payment for the indemnification of the Company by DermEbx under the DermEbx Asset Purchase Agreement.

Pursuant to the terms of the Asset Purchase Agreement with Radion, the Company purchased substantially all of the assets of Radion, including all of Radion’s intellectual property and customer contracts. The Company paid the following consideration to Radion: (i) $2,382,000 in cash which included $182,000 payoff of an existing note payable and (ii) the issuance to Radion of 600,000 restricted shares of the Company’s common stock. The 600,000 restricted shares are subject to the following provisions; 25% of the shares were locked up until the date that is two trading days after the Company announces its fourth quarter 2014 earnings, which occurred on March 2, 2015; 30% of the shares shall be locked up for a period of 24 months from the date of the agreement; and 30% of the shares shall be locked up for a period of 36 months from the date of the agreement. In addition the Company delivered the remaining 15% or 90,000 of the restricted shares to US Bank, N.A., as escrow agent, to be held in escrow for a period of 18 months pursuant to the terms of an escrow agreement. The 90,000 escrow shares will act as the source of payment for the indemnification of the Company by Radion under the Radion Asset Purchase Agreement.

The Company did not achieve significant synergies from the Radion/DermEbx Acquisition. Prior to the Radion DermEbx Acquisition, the Sellers represented one of the Company’s significant customers in the Therapy segment. The Company recognized approximately $0.8 million of Therapy product revenue and approximately $0.3 million of Therapy service revenue, for a total of $1.1 million related to Sellers, in the quarter ended June 30, 2014 and approximately $1.6 million of Therapy product revenue and approximately $0.5 million of Therapy service revenue, for a total of $2.1 million related to Sellers, in the six months ended June 30, 2014.

The amounts allocated to purchased and developed software, customer relationships, trade names, employee non-compete agreements and backlog were estimated primarily through the use of discounted cash flow valuation techniques. Appraisal assumptions utilized under these methods include a forecast of estimated future net cash flows, as well as discounting the future net cash flows to their present value. Acquired intangible assets are being amortized over the estimated useful lives as set forth in the following table. The following is a summary of the allocation of the total purchase price based on the estimated fair values of the assets acquired and liabilities assumed as of the date of the acquisition and the amortizable lives of the intangible assets:

 

     Amount      Estimated Amortizable Life

Current assets

   $ 3,457      

Property and equipment

     2,625       3 – 7 Years

Identifiable intangible assets

     6,050       5 – 10 Years

Goodwill

     6,270      

Current liabilities

     (4,382   

Long-term liabilities

     (2,164   
  

 

 

    

Purchase price

   $ 11,856      
  

 

 

    

The assets obtained in the Radion/DermEbx Acquisition and the resulting revenues are included in the Therapy segment and, accordingly, the goodwill resulting from the purchase price allocation is included in goodwill of the Therapy segment. As discussed in Note 12, the Company recorded a goodwill impairment charge related to the Therapy segment of $14.0 million in the quarter ended June 30, 2015.

 

The goodwill is deductible for income tax purposes.

The unaudited proforma operating results for the Company for the three and six months ended June 30, 2014, assuming the Radion/DermEbx Acquisition occurred as of January 1, 2014 are as follows (in thousands except per share amounts):

 

     June 30, 2014  
     Three months      Six months  

Revenue

   $ 11,815       $ 22,408   

Income from operations

     566         685   

Net (loss) income

     (264      32   

Net (loss) income per share-basic

   $ (0.02    $ 0.00   

Net (loss) income per share-diluted

   $ (0.02    $ 0.00   

Basic

     13,959         13,959   

Diluted

     13,959         14,667   

XML 49 R32.htm IDEA: XBRL DOCUMENT v3.2.0.727
Loss per Common Share - Exercise of Stock Options and Vesting of Restricted Stock (Detail) - shares
6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Stock options and restricted stock 2,071,435 1,804,189
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Stock options and restricted stock 1,618,043 1,477,871
Restricted Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Stock options and restricted stock 453,392 326,318
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.2.0.727
Lease Commitments - Additional Information (Detail)
3 Months Ended 6 Months Ended
Jun. 30, 2015
USD ($)
Jun. 30, 2014
USD ($)
Jun. 30, 2015
USD ($)
LeaseContracts
Jun. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
Aug. 31, 2013
USD ($)
Schedule Of Leases [Line Items]            
Rent expense under operating leases $ 165,000 $ 168,000 $ 328,000 $ 327,000    
Operating leases expiring description     Facilities are leased under operating leases expiring at various dates through September, 2017.      
Capital lease           $ 409,000
Capital lease bargain purchase option amount           $ 1
Outstanding liability on equipment leases 488,000   $ 488,000   $ 1,020,000  
Annual lease payments, remainder of 2015 774,000   774,000      
Annual lease payments in 2016 1,039,000   1,039,000      
Annual lease payments in 2017 89,000   89,000      
Total lease payments $ 1,739,000   $ 1,739,000      
Minimum [Member]            
Schedule Of Leases [Line Items]            
Employee stock ownership percentage 5.00%   5.00%      
DermEbx and Radion [Member]            
Schedule Of Leases [Line Items]            
Number of equipment lease obligation | LeaseContracts     2      
Assumed capital leases $ 2,600,000   $ 2,600,000      
Liability recorded on capital leases     2,500,000      
Outstanding liability on equipment leases 1,700,000   1,700,000      
Annual lease payments, remainder of 2015 383,000   383,000      
Annual lease payments in 2016 396,000   396,000      
Annual lease payments in 2017 76,000   76,000      
Total lease payments $ 855,000   $ 855,000      
XML 51 R53.htm IDEA: XBRL DOCUMENT v3.2.0.727
Long-lived Assets - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2015
Dec. 31, 2014
Property, Plant and Equipment [Line Items]      
Carrying value of asset group $ 2,861 $ 2,861 $ 4,255
Impairment charges on long lived assets   13,400  
Cancer Therapy [Member]      
Property, Plant and Equipment [Line Items]      
Carrying value of asset group 36,800 36,800  
Undiscounted cash flows over carrying value of assets 2,800 $ 2,800  
Impairment charges on long lived assets $ 13,400    
XML 52 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 18,208 $ 32,220
Trade accounts receivable, net of allowance for doubtful accounts of $228 in 2015 and $203 in 2014 7,764 9,642
Inventory, net 3,322 2,214
Prepaid expenses and other current assets 422 540
Total current assets 29,716 44,616
Property and equipment, net of accumulated depreciation of $4,678 in 2015 and $4,861 in 2014 2,861 4,255
Other assets 94 132
Intangible assets, net of accumulated amortization of $10,492 in 2015 and $14,738 in 2014 4,674 17,504
Goodwill 14,198 27,263
Total assets 51,543 93,770
Current liabilities:    
Accounts payable 1,804 2,151
Accrued and other expenses 4,235 5,554
Interest payable   180
Notes and lease payable - current portion 1,251 5,044
Deferred revenue 8,049 9,120
Total current liabilities 15,339 22,049
Deferred revenue, long-term portion 633 1,525
Other long-term liabilities 639 795
Capital lease - long-term portion 488 1,020
Notes payable - long-term portion   5,602
Total liabilities $ 17,099 $ 30,991
Commitments and Contingencies (Note 8)    
Stockholders' equity:    
Preferred stock, $ .01 par value: authorized 1,000,000 shares; none issued.    
Common stock, $ .01 par value: authorized 20,000,000 shares; issued 15,906,378 in 2015 and 15,732,177 in 2014; outstanding 15,720,547 in 2015 and 15,546,346 in 2014 $ 159 $ 157
Additional paid-in capital 210,406 209,100
Accumulated deficit (174,706) (145,063)
Treasury stock at cost, 185,831 shares in 2015 and 2014 (1,415) (1,415)
Total stockholders' equity 34,444 62,779
Total liabilities and stockholders' equity $ 51,543 $ 93,770
XML 53 R45.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stock-Based Compensation - Schedule of Consolidated Statement of Operations Relating to Stock Based Compensation Expense (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Engineering and product development $ 2,272 $ 2,004 $ 4,528 $ 3,866
Marketing and sales 3,165 2,872 6,995 5,464
General and administrative 2,330 1,865 4,543 3,554
Stock-based compensation expense 620 281 1,064 606
Operating Expense [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Cost of revenue 4 3 8 7
Engineering and product development 60 34 111 83
Marketing and sales 203 69 333 140
General and administrative $ 353 $ 175 $ 612 $ 376
XML 54 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727
Basis of Presentation and Significant Accounting Policies
6 Months Ended
Jun. 30, 2015
Accounting Policies [Abstract]  
Basis of Presentation and Significant Accounting Policies

Note 1 - Basis of Presentation and Significant Accounting Policies

The accompanying condensed consolidated financial statements of iCAD, Inc. and subsidiaries (“iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, these unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at June 30, 2015, the results of operations of the Company for the three and six month period ended June 30, 2015 and 2014, respectively, and cash flows of the Company for the three and six month period ended June 30, 2015 and 2014, respectively. Although the Company believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (“SEC”). The accompanying financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10–K for the fiscal year ended December 31, 2014 filed with the SEC on March 13, 2015. The results for the three and six month period ended June 30, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2015, or any future period.

Revenue Recognition

The Company recognizes revenue primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement.

The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Update No. 2009-13, “Multiple-Deliverable Revenue Arrangements” (“ASU 2009-13”) and ASC Update No. 2009-14, “Certain Arrangements That Contain Software Elements” (“ASU 2009-14”) and ASC 985-605, “Software” (“ASC 985-605”). Revenue for the sale of certain CAD products is recognized in accordance with ASC 840 “Leases” (“ASC 840”). For multiple element arrangements, revenue is allocated to all deliverables based on their relative selling prices. In such circumstances, a hierarchy is used to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value (“VSOE”), (ii) third-party evidence of selling price (“TPE”), and (iii) best estimate of the selling price (“BESP”). VSOE generally exists only when the deliverable is sold separately and is the price actually charged for that deliverable. The process for determining BESP for deliverables without VSOE or TPE considers multiple factors including relative selling prices; competitive prices in the marketplace, and management judgment; however, these may vary depending upon the unique facts and circumstances related to each deliverable.

The Company uses customer purchase orders that are subject to the Company’s terms and conditions or, in the case of an Original Equipment Manufacturer (“OEM”) are governed by distribution agreements. In accordance with the Company’s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references.

If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer’s post-delivery acceptance provisions, if any, and the installation process.

The Company has determined that iCAD’s digital, and film based sales generally follow the guidance of FASB ASC Topic 605 “Revenue Recognition” (“ASC 605”) as the software has been considered essential to the functionality of the product per the guidance of ASU 2009-14. Typically, the responsibility for the installation process lies with the OEM partner. On occasion, when iCAD is responsible for product installation, the installation element is considered a separate unit of accounting because the delivered product has stand-alone value to the customer. In these instances, the Company allocates revenue to the deliverables based on the framework established within ASU 2009-13. Therefore, the installation and training revenue is recognized as the services are performed according to the BESP of the element. Revenue from the digital and film based equipment, when there is installation, is recognized based on the relative selling price allocation of the BESP, when delivered.

Revenue from certain CAD products is recognized in accordance with ASC 985-605. Sales of this product include training, and the Company has established VSOE for this element. Product revenue is determined based on the residual value in the arrangement, and is recognized when delivered. Revenue for training is deferred and recognized when the training has been completed.

The Company recognizes post contract customer support revenue together with the initial licensing fee for certain MRI products in accordance with ASC 985-605-25-71.

Sales of the Company’s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13. Product revenue is generally recognized when the product has been delivered and service and source revenue is typically recognized over the life of the service and source agreement. The Company includes the following in service and supplies revenue: the sale of physics and management services, the lease of electronic brachytherapy equipment, development fees, supplies and the right to use the Company’s AxxentHub software. Physics and management services revenue and development fees are considered to be delivered as the services are performed or over the estimated life of the agreement. The Company typically bills items monthly over the life of the agreement except for development fees, which are generally billed in advance or over a 12 month period and the fee for treatment supplies which is generally billed in advance.

The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20, “Services”. The Company provides for estimated warranty costs on original product warranties at the time of sale.

Cost of Revenue

Cost of revenue consists of the costs of products purchased for resale, costs relating to service including personnel costs for physicists, management services and radiation therapists, costs of service contracts to maintain equipment after the warranty period, product installation, training, customer support, certain warranty repair costs, inbound freight and duty, cost of supplies, manufacturing, warehousing, material movement, inspection, scrap, rework, amortization, depreciation and in-house product warranty repairs.

In September 2014, the Company reclassified depreciation previously included in product and service cost of revenue to amortization and depreciation as a separate component of cost of revenue. For the three and six months ended June 30, 2014, approximately $343,000 and $674,000, respectively was reclassified to conform to current period classification. Medical Device Excise tax included in the cost of revenue is approximately $132,000 and $331,000, for the three and six months ended June 30, 2015, respectively and $200,000 and $379,000 for the three and six months ended June 30, 2014, respectively.

Segments

The Company reports the results of two segments, Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of our advanced image analysis and workflow products. The Therapy segment consists of our radiation therapy (“Axxent”) products, physics and management services, development fees, supplies, and the right to use the AxxentHub software platform.

XML 55 R35.htm IDEA: XBRL DOCUMENT v3.2.0.727
Business Combinations - Acquisition of DermEbx and Radion - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Jul. 15, 2014
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
Business Acquisition [Line Items]            
Business acquisition paid in cash       $ 1,700,000    
Common stock, par value   $ 0.01   $ 0.01   $ 0.01
Revenue from products   $ 3,096,000 $ 5,294,000 $ 7,054,000 $ 9,503,000  
Revenue from services   8,047,000 4,373,000 17,309,000 8,684,000  
Total revenue   11,143,000 9,667,000 24,363,000 18,187,000  
Impairment loss       13,981,000    
Cancer Therapy [Member]            
Business Acquisition [Line Items]            
Total revenue   6,188,000 4,835,000 14,620,000 9,180,000  
Impairment loss   $ 13,981,000   $ 13,981,000    
Prior to Radion DermEbx Acquisition [Member] | Cancer Therapy [Member]            
Business Acquisition [Line Items]            
Revenue from products     800,000   1,600,000  
Revenue from services     300,000   500,000  
Total revenue     $ 1,100,000   $ 2,100,000  
Radion Inc [Member]            
Business Acquisition [Line Items]            
Business acquisition paid in cash $ 2,382,000          
Restricted shares provisions description       The 600,000 restricted shares are subject to the following provisions; 25% of the shares were locked up until the date that is two trading days after the Company announces its fourth quarter 2014 earnings, which occurred on March 2, 2015; 30% of the shares shall be locked up for a period of 24 months from the date of the agreement; and 30% of the shares shall be locked up for a period of 36 months from the date of the agreement.    
Percentage of restricted shares held in escrow 15.00%          
Restricted shares held in escrow 90,000          
Restricted shares held in escrow, period 18 months          
Repayment of note payable $ 182,000          
Radion Inc [Member] | Restricted Stock [Member] | Common Stock [Member]            
Business Acquisition [Line Items]            
Business acquisition restricted shares issued 600,000          
DermEbx [Member]            
Business Acquisition [Line Items]            
Business acquisition paid in cash $ 1,600,000          
Restricted shares provisions description       The 600,000 restricted shares are subject to the following provisions; 25% was locked up until the date that was two trading days after the Company announced its fourth quarter 2014 earnings, which occurred on March 2, 2015; 30% of the shares shall be locked up for a period of 24 months from the date of the agreement; and 30% of the shares shall be locked up for a period of 36 months from the date of the agreement.    
Percentage of restricted shares held in escrow 15.00%          
Restricted shares held in escrow 90,000          
Restricted shares held in escrow, period 18 months          
DermEbx [Member] | Restricted Stock [Member]            
Business Acquisition [Line Items]            
Common stock, par value $ 0.01          
DermEbx [Member] | Restricted Stock [Member] | Common Stock [Member]            
Business Acquisition [Line Items]            
Business acquisition restricted shares issued 600,000          
XML 56 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727
Business Combinations (Tables)
6 Months Ended
Jun. 30, 2015
VuComp M-Vu Breast Density Product [Member]  
Preliminary Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and liabilities Assumed

The following is a summary of the preliminary allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life:

 

     Amount      Estimated Amortizable Life

Developed Technology

     900       8 years 9 months

Goodwill

     800      
  

 

 

    

Purchase price

   $ 1,700      
  

 

 

    
DermEbx and Radion [Member]  
Preliminary Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and liabilities Assumed

The following is a summary of the allocation of the total purchase price based on the estimated fair values of the assets acquired and liabilities assumed as of the date of the acquisition and the amortizable lives of the intangible assets:

 

     Amount      Estimated Amortizable Life

Current assets

   $ 3,457      

Property and equipment

     2,625       3 – 7 Years

Identifiable intangible assets

     6,050       5 – 10 Years

Goodwill

     6,270      

Current liabilities

     (4,382   

Long-term liabilities

     (2,164   
  

 

 

    

Purchase price

   $ 11,856      
  

 

 

    
Summary of Unaudited Proforma Operating Results, Acquisition

The unaudited proforma operating results for the Company for the three and six months ended June 30, 2014, assuming the Radion/DermEbx Acquisition occurred as of January 1, 2014 are as follows (in thousands except per share amounts):

 

     June 30, 2014  
     Three months      Six months  

Revenue

   $ 11,815       $ 22,408   

Income from operations

     566         685   

Net (loss) income

     (264      32   

Net (loss) income per share-basic

   $ (0.02    $ 0.00   

Net (loss) income per share-diluted

   $ (0.02    $ 0.00   

Basic

     13,959         13,959   

Diluted

     13,959         14,667   
XML 57 R36.htm IDEA: XBRL DOCUMENT v3.2.0.727
Acquisition of DermEbx and Radion - Summary of Unaudited Proforma Operating Results, Acquisition (Detail) - Jun. 30, 2014 - DermEbx and Radion [Member] - USD ($)
$ / shares in Units, $ in Thousands
Total
Total
Business Acquisition [Line Items]    
Revenue $ 11,815 $ 22,408
Income from operations 566 685
Net (loss) income $ (264) $ 32
Net (loss) income per share-basic $ (0.02) $ 0.00
Net (loss) income per share-diluted $ (0.02) $ 0.00
Basic $ 13,959 $ 13,959
Diluted $ 13,959 $ 14,667
XML 58 R24.htm IDEA: XBRL DOCUMENT v3.2.0.727
Long Term Debt (Tables)
6 Months Ended
Jun. 30, 2015
Debt Disclosure [Abstract]  
Interest Expense Included in Consolidated Income Statement

The following amounts compose interest expense included in our consolidated statement of operations for the three and six months ended June 30, 2015 and 2014: (in thousands)

 

     Three months ended June 30,  
     2015      2014  

Cash interest expense

   $ —         $ 216   

Non-cash amortization of debt discount

     —           313   

Amortization of debt costs

     —           28   

Amortization of settlement obligations

     47         54   

Interest expense capital lease

     23         3   
  

 

 

    

 

 

 

Total interest expense

   $ 70       $ 614   
  

 

 

    

 

 

 
     Six months ended June 30  
     2015      2014  

Cash interest expense

   $ 162       $ 794   

Non-cash amortization of debt discount

     254         448   

Amortization of debt costs

     13         76   

Amortization of settlement obligations

     92         106   

Interest expense capital lease

     56         7   
  

 

 

    

 

 

 

Total interest expense

   $ 577       $ 1,431   
  

 

 

    

 

 

 
XML 59 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 60 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727
Loss per Common Share
6 Months Ended
Jun. 30, 2015
Earnings Per Share [Abstract]  
Loss per Common Share

Note 2 - Loss per Common Share

The Company’s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period.

A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts):

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 
     2015      2014      2015      2014  

Net loss

   $ (27,786    $ (997    $ (29,643    $ (1,187
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic and diluted shares used in the calculation of net loss per share

     15,679         14,074         15,642         12,759   

Net loss per share - basic and diluted

   $ (1.77    $ (0.07    $ (1.90    $ (0.09
  

 

 

    

 

 

    

 

 

    

 

 

 

The shares of the Company’s common stock, issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive is as follows:

 

     Period Ended
June 30,
 
     2015      2014  

Stock Options

     1,618,043         1,477,871   

Restricted Stock

     453,392         326,318   
  

 

 

    

 

 

 

Stock options and restricted stock

     2,071,435         1,804,189   
  

 

 

    

 

 

 
XML 61 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts on trade accounts receivable $ 228 $ 203
Property and equipment, accumulated depreciation and amortization 4,678 4,861
Intangible assets, accumulated amortization $ 10,492 $ 14,738
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 20,000,000 20,000,000
Common stock, shares issued 15,906,378 15,732,177
Common stock, shares outstanding 15,720,547 15,546,346
Treasury stock, shares 185,831 185,831
XML 62 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727
Goodwill
6 Months Ended
Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill

Note 12 - Goodwill

In accordance with FASB ASC Topic 350-20, “Intangibles - Goodwill and Other”, (“ASC 350-20”), the Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the Company is less than the carrying value of the Company.

Factors the Company considers important, which could trigger an impairment of such asset, include the following:

 

    significant underperformance relative to historical or projected future operating results;

 

    significant changes in the manner or use of the assets or the strategy for the Company’s overall business;

 

    significant negative industry or economic trends;

 

    significant decline in the Company’s stock price for a sustained period; and

 

    a decline in the Company’s market capitalization below net book value.

The Company’s Chief Operating Decision Maker (“CODM”) is the Chief Executive Officer (“CEO”). The two segments and reporting units are Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). Each segment generates revenue from the sale of medical equipment and related services and/or sale of supplies.

The Company performed the annual impairment assessment at October 1, 2014 and compared the fair value of each of reporting unit to its carrying value as of this date. Fair value of each reporting unit exceeded the carry value by approximately 315% for the Detection reporting unit and 255% for the Therapy reporting unit. The carrying values of the reporting units were determined based on an allocation of our assets and liabilities through specific allocation of certain assets and liabilities, to the reporting units and an apportionment of the remaining net assets based on the relative size of the reporting units’ revenues and operating expenses compared to the Company as a whole. The determination of reporting units also requires management judgment.

 

An impairment charge is recorded if such an assessment were to indicate that the fair value of a reporting unit was less than the carrying value. When the Company evaluates potential impairments outside of the annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. The Company utilizes either discounted cash flow models or other valuation models, such as comparative transactions and market multiples, to determine the fair value of the reporting unit. The Company makes assumptions about future cash flows, future operating plans, discount rates, comparable companies, market multiples, purchase price premiums and other factors in those models. Different assumptions and judgment determinations could yield different conclusions that would result in an impairment charge to income in the period that such change or determination was made.

As a result of external factors and general uncertainty related to reimbursement for non-melanoma skin cancer and in conjunction with the long-lived asset impairment testing, the Company performed an impairment assessment of the Therapy reporting unit. As a result the Company recorded a goodwill impairment charge of $14.0 million during the quarter ended June 30, 2015.

The implied fair value of the Therapy reporting unit was determined in the same manner as the manner in which the amount of goodwill recognized in a business combination is determined. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied amount of goodwill. The Company identified the intangible assets that were valued during this process, including technology, customer relationships, trade-names, and the Company’s workforce. The allocation process was performed only for purposes of testing goodwill for impairment.

The Company determined the fair value of the Therapy reporting unit based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. This approach was selected as it measures the income producing assets, primarily technology and customer relationships. This method estimates the fair value based upon the ability to generate future cash flows, which is particularly applicable when future profit margins and growth are expected to vary significantly from historical operating results.

The Company uses internal forecasts to estimate future cash flows and includes an estimate of long-term future growth rates based on the most recent views of the long-term forecast for the reporting unit. Accordingly, actual results can differ from those assumed in the forecasts. The discount rate of approximately 17% is derived from a capital asset pricing model and analyzing published rates for industries relevant to the reporting unit to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in the internally developed forecasts Other significant assumptions include terminal value margin rates, future capital expenditures, and changes in future working capital requirements. While there are inherent uncertainties related to the assumptions used and to the application of these assumptions to this analysis, the income approach provides a reasonable estimate of the fair value of the Therapy reporting unit.

The Step 2 test resulted in an approximate fair value of goodwill of $5.7 million which resulted in a goodwill impairment loss of $14.0 million.

As discussed in Note 3, the Company acquired VuComp’s M-Vu® Breast Density product for $1.7 million. The product will be integrated into the Company’s Powerlook AMP system, which is a component of the Detection reporting unit. The Company determined that the acquisition was a business combination and accordingly recorded goodwill of $0.8 million.

A roll forward of goodwill activity by reporting unit is as follows:

 

     Detection      Therapy      Total  

Accumulated Goodwill

   $ —         $ —         $ 47,937   

Accumulated impairment

     —           —           (26,828

Fair value allocation

     7,663         13,446         —     

Acquisition of DermEbx and Radion

     —           6,154         6,154   
  

 

 

    

 

 

    

 

 

 

Balance at December 31, 2014

     7,663         19,600         27,263   

Acquisition measurement period adjustments

     —           116         116   

Acquisition of VuComp

     800         —           800   

Impairment

     —           (13,981      (13,981
  

 

 

    

 

 

    

 

 

 

Balance at June 30, 2015

   $ 8,463       $ 5,735       $ 14,198   
  

 

 

    

 

 

    

 

 

 

XML 63 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2015
Aug. 04, 2015
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2015  
Document Fiscal Year Focus 2015  
Document Fiscal Period Focus Q2  
Trading Symbol ICAD  
Entity Registrant Name ICAD INC  
Entity Central Index Key 0000749660  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   15,720,547
XML 64 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727
Segment Reporting
6 Months Ended
Jun. 30, 2015
Segment Reporting [Abstract]  
Segment Reporting

Note 13 – Segment Reporting

In accordance with FASB Topic ASC 280, “Segments”, operating segments, are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker CODM in deciding how to allocate resources and assess performance.

The Company’s CODM is the CEO. Each segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments, Detection and Therapy.

 

The Detection segment consists of our advanced image analysis and workflow products, and the Therapy segment consists of our radiation therapy Axxent products, and related services. The primary factors used by our CODM to allocate resources are based on revenues, gross profit, operating income, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring items (“Adjusted EBITDA”) of each segment. Included in segment operating income are stock compensation, amortization of technology and depreciation expense. There are no intersegment revenues.

Our CODM does not use asset information by segment to allocate resources or make operating decisions.

Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands):

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 
     2015      2014      2015      2014  

Segment revenues:

           

Detection

   $ 4,955       $ 4,832       $ 9,743       $ 9,007   

Therapy

     6,188         4,835         14,620         9,180   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Revenue

   $ 11,143       $ 9,667       $ 24,363       $ 18,187   
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment gross profit:

           

Detection

   $ 4,090       $ 3,960       $ 8,037       $ 7,324   

Therapy

     3,788         2,870         9,203         5,440   
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment gross profit

   $ 7,878       $ 6,830       $ 17,240       $ 12,764   
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment operating income (loss):

           

Detection

     2,033         1,897         3,793         3,413   

Therapy

     (27,469      (140      (26,512      (368
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment operating income

   $ (25,436    $ 1,757       $ (22,719    $ 3,045   
  

 

 

    

 

 

    

 

 

    

 

 

 

General, administrative, depreciation and amortization expense

   $ (2,392    $ (1,923    $ (4,666    $ (3,671

Interest expense

     (70      (614      (577      (1,431

Gain on fair value of warrant

     —           699         —           1,835   

Other income

     5         12         14         16   

Loss on debt extinguishment

     —           (903      (1,723      (903
  

 

 

    

 

 

    

 

 

    

 

 

 

Loss before income tax

   $ (27,893    $ (972    $ (29,671    $ (1,109
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 65 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Revenue:        
Products $ 3,096 $ 5,294 $ 7,054 $ 9,503
Service and supplies 8,047 4,373 17,309 8,684
Total revenue 11,143 9,667 24,363 18,187
Cost of revenue:        
Products 680 1,390 1,621 2,570
Service and supplies 2,082 1,104 4,360 2,179
Amortization and depreciation 503 343 1,142 674
Total cost of revenue 3,265 2,837 7,123 5,423
Gross profit 7,878 6,830 17,240 12,764
Operating expenses:        
Engineering and product development 2,272 2,004 4,528 3,866
Marketing and sales 3,165 2,872 6,995 5,464
General and administrative 2,330 1,865 4,543 3,554
Amortization and depreciation 496 255 1,116 506
Goodwill and long-lived asset impairment 27,443   27,443  
Total operating expenses 35,706 6,996 44,625 13,390
Loss from operations (27,828) (166) (27,385) (626)
Loss from extinguishment of debt   (903) (1,723) (903)
Gain from change in fair value of warrant   699   1,835
Interest expense (70) (614) (577) (1,431)
Other income 5 12 14 16
Other expense, net (65) (806) (2,286) (483)
Loss before income tax (27,893) (972) (29,671) (1,109)
Tax benefit (expense) 107 (25) 28 (78)
Net loss and comprehensive loss $ (27,786) $ (997) $ (29,643) $ (1,187)
Net loss per share:        
Basic $ (1.77) $ (0.07) $ (1.90) $ (0.09)
Diluted $ (1.77) $ (0.07) $ (1.90) $ (0.09)
Weighted average number of shares used in computing loss per share:        
Basic 15,679 14,074 15,642 12,759
Diluted 15,679 14,074 15,642 12,759
XML 66 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stock-Based Compensation
6 Months Ended
Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation

Note 7 - Stock-Based Compensation

The Company follows the guidance in ASC Topic 718, “Compensation – Stock Compensation, (“ASC 718”).

The Company granted 130,000 and 317,000 options in the three and six months ended June 30, 2015. Options granted under the Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values:

 

     Three Months Ended
June 30,
   Six Months Ended
June 30,
     2015    2014    2015    2014

Average risk-free interest rate

   0.98%    0.85%    0.92%    0.82%

Expected dividend yield

   None    None    None    None

Expected life

   3.5 years    3.5 years    3.5 years    3.5 years

Expected volatility

   60.5% to 73.8%    64.9% to 66.5%    60.5% to 73.8%    64.2% to 66.5%

Weighted average exercise price

   $3.37    $6.72    $6.97    $7.83

Weighted average fair value

   $1.74    $3.17    $3.33    $3.67

 

The amounts included in the consolidated statement of operations relating to stock based compensation expense are as follows:

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 
     2015      2014      2015      2014  

Cost of revenue

   $ 4       $ 3       $ 8       $ 7   

Engineering and product development

     60         34         111         83   

Marketing and sales

     203         69         333         140   

General and administrative

     353         175         612         376   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 620       $ 281       $ 1,064       $ 606   
  

 

 

    

 

 

    

 

 

    

 

 

 

As of June 30, 2015 unrecognized compensation cost (in thousands) related to unexercisable options and unvested restricted stock and the weighted average remaining period is as follows:

 

Remaining expense

   $ 4,698   

Weighted average term

     1.31 years   

The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands):

 

     Period Ended
June 30,
 

Aggregate intrinsic value

   2015      2014  

Stock options

   $ 485       $ 3,187   

Restricted stock

     1,469         2,092   
XML 67 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727
Lease Commitments
6 Months Ended
Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]  
Lease Commitments

Note 6 – Lease Commitments

Operating leases

Facilities are leased under operating leases expiring at various dates through September, 2017. Certain of these leases contain renewal options. Rent expense under operating leases was $165,000 and $328,000 for the three and six month period ended June 30, 2015 and $168,000 and $327,000 for the three and six month period ended June 30, 2014, respectively.

Future minimum lease payments as of June 30, 2015 under operating leases are as follows: (in thousands)

 

Fiscal Year

   Operating
Leases
 

2015

   $ 255   

2016

     499   

2017

     255   
  

 

 

 
   $ 1,009   
  

 

 

 

Capital leases

The Company entered into a capital lease agreement for the purchase of certain equipment in August 2013 for approximately $409,000. Under the guidance of ASC Topic 840, “Leases” (“ASC 840”) the Company determined that the lease was a capital lease as it contained a bargain purchase option whereby the Company has the option to buy the equipment for $1 at the end of the lease term. Accordingly, the equipment has been capitalized and a liability has been recorded. The equipment cost of $409,000 is reflected as property and equipment in the balance sheet and is being depreciated over its useful life.

In connection with the Radion/DermEbx Acquisition, the Company assumed two separate equipment lease obligations with payments totaling approximately $2.6 million through May, 2017. The leases were determined to be capital leases and accordingly the equipment was capitalized and a liability of $2.5 million was recorded. As of June 30, 2015, the outstanding liability for the acquired equipment leases was approximately $1.7 million.

 

Future minimum lease payments under all outstanding capital leases are as follows: (in thousands)

 

Fiscal Year    Capital
Leases
 

2015

   $ 774   

2016

     1,039   

2017

     89   
  

 

 

 

Subtotal minimum lease obligation

     1,902   

Less interest

     (163
  

 

 

 

Total, net

     1,739   

Less current portion

     (1,251
  

 

 

 

Long term portion

   $ 488   
  

 

 

 

Kamal Gogineni is an employee of the Company’s and a beneficial owner of more than 5% of the Company’s common stock. Additionally, Mr. Gogineni is a significant shareholder of Radion Capital Partners (“RCP”). RCP was the lessor under a lease between RCP and DermEbx (the “DermEbx Lease”). In connection with the Company’s Radion/DermEbx acquisition that closed in July 2014, one of the assets and obligations that the Company acquired was the Lease. Pursuant to the Lease, the Company is obligated to pay a total of $855,000 as of June 30, 2015 and the liability is included in the minimum lease payments above, with annual payments of $383,000 for the remainder of 2015, $396,000 in 2016 and $76,000 in 2017.

XML 68 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727
Inventory (Tables)
6 Months Ended
Jun. 30, 2015
Inventory Disclosure [Abstract]  
Components of Inventory

The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows:

 

     as of June 30,
2015
     as of December 31,
2014
 

Raw materials

   $ 1,608       $ 955   

Work in process

     223         54   

Finished Goods

     1,491         1,205   
  

 

 

    

 

 

 

Inventory

   $ 3,322       $ 2,214   
  

 

 

    

 

 

 
XML 69 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727
Recent Accounting Pronouncements
6 Months Ended
Jun. 30, 2015
Text Block [Abstract]  
Recent Accounting Pronouncements

Note 14 - Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers” (ASU 2014-09), which amends ASC 605 “Revenue Recognition” and creates a new Topic 606 “Revenue from Contracts with Customers.” This update provides guidance on how an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Upon initial application, the provisions of this update are required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this update recognized at the date of initial application. This update also expands the disclosure requirements surrounding revenue recorded from contracts with customers. This update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. In April 2015 the FASB voted to defer effective date of this standard with respect to years, beginning after December 15, 2017. We are currently evaluating the effect of this update on our financial statements and have not yet determined the method of initial application we will use.

XML 70 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727
Income Taxes
6 Months Ended
Jun. 30, 2015
Income Tax Disclosure [Abstract]  
Income Taxes

Note 10 - Income Taxes

The Company recorded an income tax benefit of $107,000 and $28,000, in the three and six months ended June 30, 2015 as compared to a provision of $25,000 and $78,000 in the three and six months ended June 30, 2014, respectively. The income tax net benefit as of June 30, 2015 primarily relates a state tax provision and a benefit from the reversal of a deferred tax liability relating to tax amortizable goodwill. Due to the Company’s goodwill impairment the tax basis in amortizable goodwill is greater than book basis which results in a deferred tax asset that is subject to a valuation allowance. At June 30, 2015, the Company had no material unrecognized tax benefits and no adjustments to liabilities or tax expense were required under ASC 740, “Income Taxes”. The Company does not expect that the unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any interest or penalties related to uncertain tax positions at June 30, 2015. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company’s three preceding tax years remain subject to examination by federal and state taxing authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not under examination by any federal or state jurisdiction for any tax years.

XML 71 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727
Commitments and Contingencies
6 Months Ended
Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 8 - Commitments and Contingencies

Foreign Tax Claim

In July 2007, a dissolved former Canadian subsidiary of the Company, CADx Medical Systems Inc. (“CADx Medical”), received a tax re-assessment of approximately $6,800,000 from the Canada Revenue Agency (“CRA”) resulting from CRA’s audit of CADx Medical’s Canadian federal tax return for the year ended December 31, 2002. In February 2010 the CRA reviewed the matter and reduced the tax re-assessment to approximately $703,000, excluding interest and penalties. The Company believes that it is not liable for the re-assessment against CADx Medical and no accrual has been recorded for this matter as of June 30, 2015.

Settlement Obligations

In connection with the acquisition of Xoft in 2010, the Company recorded a royalty obligation pursuant to a settlement agreement entered into between Xoft and Hologic in August 2007. Xoft received a nonexclusive, irrevocable, perpetual, worldwide license, including the right to sublicense certain Hologic patents, and a non-compete covenant as well as an agreement not to seek further damages with respect to the alleged patent violations. In return, the Company has a remaining obligation to pay a minimum annual royalty payment to Hologic, of $250,000 payable through 2016. In addition to the minimum annual royalty payments, the litigation settlement agreement with Hologic also provided for payment of royalties based upon a specified percentage of future net sales on any products that utilize the licensed rights. The Company has a liability within accrued expenses and long-term settlement cost for future payment and for future minimum royalty obligations totaling $442,000. The Company recorded interest expense of approximately $18,000 and $36,000 in the three and six months ended June 30, 2015 and $25,000 and $50,000 in the three and six months June 30, 2014, respectively, related to this obligation.

In December, 2011, the Company agreed to a settlement related to litigation with Carl Zeiss Meditec AG. The Company is obligated to pay the remaining amount of $0.5 million in June 2017. As of June 30, 2015, the remaining liability recorded within accrued expenses and long-term settlement cost for future payment and for future minimum royalty obligations is $395,000. The Company recorded interest expense of approximately $28,000 and $56,000 in the three and six months ended June 30, 2015 and $28,000 and $56,000 in the three and six months ended June 30, 2014, respectively, related to this obligation.

Other Commitments

The Company is obligated to pay approximately $2.2 million for firm purchase obligations to suppliers for future product deliverables.

Litigation

The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

XML 72 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727
Fair Value Measurements
6 Months Ended
Jun. 30, 2015
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 9 - Fair Value Measurements

The Company follows the provisions of ASC Topic 820, “Fair Value Measurement and Disclosures”, (“ASC 820”). This topic defines fair value, establishes a framework for measuring fair value under US GAAP and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

 

    Level 1 - Quoted prices in active markets for identical assets or liabilities.

 

    Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

    Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value.

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and certain accrued liabilities and our notes payable. The carrying amounts of our cash and cash equivalents (which are composed primarily of deposit and overnight sweep accounts), accounts receivable, accounts payable and certain accrued liabilities approximate fair value due to the short maturity of these instruments. The carrying value of our notes payable approximates fair value due to the market rate of the stated interest rate.

The Company’s assets that are measured at fair value on a recurring basis relate to the Company’s money market accounts.

The Company’s money market funds are included in cash and cash equivalents in the accompanying balance sheets, and are considered a Level 1 investment as they are valued at quoted market prices in active markets.

The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy.

 

Fair value measurements using: (000’s) as of December 31, 2014

 
     Level 1      Level 2      Level 3      Total  

Assets

           

Money market accounts

   $ 26,530       $ —         $ —         $ 26,530   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Assets

   $ 26,530       $ —         $ —         $ 26,530   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

Fair value measurements using: (000’s) as of June 30, 2015

 
     Level 1      Level 2      Level 3      Total  

Assets

           

Money market accounts

   $ 13,568       $ —         $ —         $ 13,568   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Assets

   $ 13,568       $ —         $ —         $ 13,568   
  

 

 

    

 

 

    

 

 

    

 

 

 

Items Measured at Fair Value on a Nonrecurring Basis

Certain assets, including long-lived assets and goodwill, are measured at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be impaired. The Company recorded a $27.4 million impairment consisting of $14.0 million related to goodwill and $13.4 million related to long-lived assets as discussed in Note 11 and Note 12 and remeasured long-lived assets and goodwill of the Therapy reporting unit at fair value as of the impairment date as noted in the following table. The fair values of long-lived assets and goodwill were measured using Level 3 inputs.

 

Fair value measurements using: (000’s) as of June 30, 2015

 
     Level 1      Level 2      Level 3      Total  

Non-recurring assets

           

Long-lived and intangible assets

   $ —         $ —         $ 3,195       $ 3,195   

Goodwill

     —           —           5,735         5,735   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Assets

   $ —         $ —         $ 8,930       $ 8,930   
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 73 R16.htm IDEA: XBRL DOCUMENT v3.2.0.727
Long-lived assets
6 Months Ended
Jun. 30, 2015
Property, Plant and Equipment [Abstract]  
Long-lived assets

Note 11 – Long-lived assets

In accordance with FASB ASC Topic 360, “Property, Plant and Equipment”, (“ASC 360”), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group.

ASC 360-10-35 uses “events and circumstances” criteria to determine when, if at all, an asset (or asset group) is evaluated for recoverability. Thus, there is no set interval or frequency for recoverability evaluation. In accordance with ASC 360-10-35-21 the following factors are examples of events or changes in circumstances that indicate the carrying amount of an asset (asset group) may not be recoverable and thus is to be evaluated for recoverability.

 

    A significant decrease in the market price of a long-lived asset (asset group);

 

    A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition;

 

    A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator;

 

    An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group);

 

    A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group).

As a result of external factors and general uncertainty related to reimbursement for the treatment of non-melanoma skin cancer, the Company evaluated the long-lived assets of the Therapy segment and reviewed them for potential impairment. The Company determined the “Asset Group” to be the assets of the Therapy segment, which the Company considered to be the lowest level for which the identifiable cash flows were largely independent of the cash flows of other assets and liabilities.

In accordance with ASC 360-10-35-17, if the carrying amount of an asset or asset group (in use or under development) is evaluated and found not to be fully recoverable (the carrying amount exceeds the estimated gross, undiscounted cash flows from use and disposition), then an impairment loss must be recognized. The impairment loss is measured as the excess of the carrying amount over the assets (or asset group’s) fair value.

In connection with the preparation of the financial statements for the second quarter ended June 30, 2015, the Company completed its analysis pursuant to ASC 360-10-35-17 and determined that the carrying value of the Asset Group was approximately $36.8 million, which exceeded the undiscounted cash flows by approximately $2.8 million. Accordingly the Company completed the Step 2 analysis to determine the fair value of the asset group. The Company recorded long-lived asset impairment charges of approximately $13.4 million in the second quarter ended June 30, 2015 and as a result the long lived assets in the asset group are recorded at their current fair values.

 

A considerable amount of judgment and assumptions are required in performing the impairment tests, principally in determining the fair value of the asset group and the reporting unit. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair values and, therefore additional impairment charges could be required. Significant negative industry or economic trends, disruptions to the Company’s business, loss of significant customers, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of the assets may adversely impact the assumptions used in the fair value estimates and ultimately result in future impairment charges.

XML 74 R34.htm IDEA: XBRL DOCUMENT v3.2.0.727
Business Combinations - Preliminary Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and liabilities Assumed (Detail) - USD ($)
$ in Thousands
Apr. 29, 2015
Jul. 15, 2014
Jun. 30, 2015
Dec. 31, 2014
Business Acquisition [Line Items]        
Goodwill     $ 14,198 $ 27,263
VuComp M-Vu Breast Density Product [Member]        
Business Acquisition [Line Items]        
Developed Technology $ 900      
Goodwill 800   $ 800  
Purchase price $ 1,700      
Estimated amortizable life 8 years 10 months 24 days      
Radion Inc [Member]        
Business Acquisition [Line Items]        
Current assets   $ 3,457    
Property and equipment   2,625    
Identifiable intangible assets   6,050    
Goodwill   6,270    
Current liabilities   (4,382)    
Long-term liabilities   (2,164)    
Purchase price   $ 11,856    
Minimum [Member] | Radion Inc [Member]        
Business Acquisition [Line Items]        
Property and equipment, Estimated amortizable life   3 years    
Estimated amortizable life   5 years    
Maximum [Member] | Radion Inc [Member]        
Business Acquisition [Line Items]        
Property and equipment, Estimated amortizable life   7 years    
Estimated amortizable life   10 years    
XML 75 R51.htm IDEA: XBRL DOCUMENT v3.2.0.727
Fair Value Measurements - Fair Values of Long-Lived Assets and Goodwill Measured Using Level 3 Inputs (Detail) - Fair Value, Measurements, Nonrecurring [Member]
$ in Thousands
Jun. 30, 2015
USD ($)
Non-recurring assets  
Total Assets $ 8,930
Long Lived and Intangible Assets [Member]  
Non-recurring assets  
Total Assets 3,195
Goodwill [Member]  
Non-recurring assets  
Total Assets 5,735
Level 3 [Member]  
Non-recurring assets  
Total Assets 8,930
Level 3 [Member] | Long Lived and Intangible Assets [Member]  
Non-recurring assets  
Total Assets 3,195
Level 3 [Member] | Goodwill [Member]  
Non-recurring assets  
Total Assets $ 5,735
XML 76 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727
Loss per Common Share (Tables)
6 Months Ended
Jun. 30, 2015
Earnings Per Share [Abstract]  
Calculation of Net Loss per Share

A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts):

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 
     2015      2014      2015      2014  

Net loss

   $ (27,786    $ (997    $ (29,643    $ (1,187
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic and diluted shares used in the calculation of net loss per share

     15,679         14,074         15,642         12,759   

Net loss per share - basic and diluted

   $ (1.77    $ (0.07    $ (1.90    $ (0.09
  

 

 

    

 

 

    

 

 

    

 

 

 
Exercise of Stock Options and Vesting of Restricted Stock

The shares of the Company’s common stock, issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive is as follows:

 

     Period Ended
June 30,
 
     2015      2014  

Stock Options

     1,618,043         1,477,871   

Restricted Stock

     453,392         326,318   
  

 

 

    

 

 

 

Stock options and restricted stock

     2,071,435         1,804,189   
  

 

 

    

 

 

 
XML 77 R26.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values

Options granted under the Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values:

 

     Three Months Ended
June 30,
   Six Months Ended
June 30,
     2015    2014    2015    2014

Average risk-free interest rate

   0.98%    0.85%    0.92%    0.82%

Expected dividend yield

   None    None    None    None

Expected life

   3.5 years    3.5 years    3.5 years    3.5 years

Expected volatility

   60.5% to 73.8%    64.9% to 66.5%    60.5% to 73.8%    64.2% to 66.5%

Weighted average exercise price

   $3.37    $6.72    $6.97    $7.83

Weighted average fair value

   $1.74    $3.17    $3.33    $3.67
Schedule of Consolidated Statement of Operations Relating to Stock Based Compensation Expense

The amounts included in the consolidated statement of operations relating to stock based compensation expense are as follows:

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 
     2015      2014      2015      2014  

Cost of revenue

   $ 4       $ 3       $ 8       $ 7   

Engineering and product development

     60         34         111         83   

Marketing and sales

     203         69         333         140   

General and administrative

     353         175         612         376   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 620       $ 281       $ 1,064       $ 606   
  

 

 

    

 

 

    

 

 

    

 

 

 
Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period

As of June 30, 2015 unrecognized compensation cost (in thousands) related to unexercisable options and unvested restricted stock and the weighted average remaining period is as follows:

 

Remaining expense

   $ 4,698   

Weighted average term

     1.31 years   
Aggregate Intrinsic Value

The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands):

 

     Period Ended
June 30,
 

Aggregate intrinsic value

   2015      2014  

Stock options

   $ 485       $ 3,187   

Restricted stock

     1,469         2,092   
XML 78 R49.htm IDEA: XBRL DOCUMENT v3.2.0.727
Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
Assets    
Total Assets $ 13,568 $ 26,530
Money Market Accounts [Member]    
Assets    
Total Assets 13,568 26,530
Level 1 [Member]    
Assets    
Total Assets 13,568 26,530
Level 1 [Member] | Money Market Accounts [Member]    
Assets    
Total Assets $ 13,568 $ 26,530
XML 79 R41.htm IDEA: XBRL DOCUMENT v3.2.0.727
Lease Commitments - Future Minimum Lease Payments under Operating Leases (Detail)
$ in Thousands
Jun. 30, 2015
USD ($)
Leases [Abstract]  
2015 $ 255
2016 499
2017 255
Total $ 1,009
XML 80 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Cash flow from operating activities:    
Net loss $ (29,643) $ (1,187)
Adjustments to reconcile net loss to net cash provided by (used for) operating activities:    
Amortization 1,362 748
Depreciation 896 432
Bad debt provision 188 27
Stock-based compensation expense 1,064 606
Amortization of debt discount and debt costs 323 524
Interest on settlement obligations 92 106
Loss on extinguishment of debt 1,723 903
Gain from change in fair value of warrant   (1,835)
Goodwill and long-lived asset impairment 27,443  
Loss on disposal of assets 123  
Changes in operating assets and liabilities (net of the effect of the acquisition):    
Accounts receivable 1,691 (2,035)
Inventory (993) 22
Prepaid and other current assets 65 96
Accounts payable (347) 31
Accrued expenses (1,802) (576)
Deferred revenue (1,962) (198)
Total adjustments 29,866 (1,149)
Net cash provided by (used for) operating activities 223 (2,336)
Cash flow from investing activities:    
Additions to patents, technology and other (36) (44)
Additions to property and equipment (799) (465)
Acquisition of VuComp M-Vu Breast Density (1,700)  
Net cash used for investing activities (2,535) (509)
Cash flow from financing activities:    
Issuance of common stock for cash, net   28,214
Stock option exercises 327 293
Warrant exercise   1,575
Taxes paid related to restricted stock issuance (84) (101)
Principal payments of capital lease obligations (693) (65)
Principal repayment of debt financing, net (11,250) (4,100)
Net cash provided by (used for) financing activities (11,700) 25,816
Increase (decrease) in cash and equivalents (14,012) 22,971
Cash and equivalents, beginning of period 32,220 11,880
Cash and equivalents, end of period 18,208 34,851
Supplemental disclosure of cash flow information:    
Interest paid 471 1,068
Taxes paid $ 93 $ 80
XML 81 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727
Long Term Debt
6 Months Ended
Jun. 30, 2015
Debt Disclosure [Abstract]  
Long Term Debt

Note 5 – Long Term Debt

On March 31, 2015, the Company repaid in full the aggregate amount outstanding under the Deerfield Facility Agreement, dated as of December 29, 2011 (as amended, supplemented or otherwise modified to the date hereof, the “Facility Agreement”), by and among the Company, Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., and Deerfield Special Situations Fund, L.P. and, for itself and as assignee of the obligations held by Deerfield Special Situations Fund International Master Fund, L.P. The Facility Agreement and related documents were terminated as of March 31, 2015. The Facility Agreement was to mature on December 29, 2016 and was able to be repaid prior to the maturity date at the Company’s option without penalty or premium. On March 31, 2015, the Company used cash on hand to pay the $11.25 million outstanding principal amount due under the Facility Agreement and approximately $162,000 in accrued and unpaid interest on such principal amount.

The Company recorded a loss on the extinguishment of debt of approximately $1.7 million at the termination date in the quarter ended March 31, 2015.

The following amounts compose interest expense included in our consolidated statement of operations for the three and six months ended June 30, 2015 and 2014: (in thousands)

 

     Three months ended June 30,  
     2015      2014  

Cash interest expense

   $ —         $ 216   

Non-cash amortization of debt discount

     —           313   

Amortization of debt costs

     —           28   

Amortization of settlement obligations

     47         54   

Interest expense capital lease

     23         3   
  

 

 

    

 

 

 

Total interest expense

   $ 70       $ 614   
  

 

 

    

 

 

 
     Six months ended June 30  
     2015      2014  

Cash interest expense

   $ 162       $ 794   

Non-cash amortization of debt discount

     254         448   

Amortization of debt costs

     13         76   

Amortization of settlement obligations

     92         106   

Interest expense capital lease

     56         7   
  

 

 

    

 

 

 

Total interest expense

   $ 577       $ 1,431   
  

 

 

    

 

 

 

Cash interest expense represents the amount of interest paid in cash under the Facility Agreement which represents the interest of 5.75% on the Facility Agreement through March 31, 2015. Non-cash amortization is the amortization of the discount on the Facility Agreement. The amortization of debt costs relates to the costs incurred with the financing, which is primarily a facility fee and a finder’s fee that were capitalized and are being expensed using the effective interest method. The amortization of the settlement obligation represents the interest associated with the settlement agreements for both Carl Zeiss Meditec AG and Hologic, Inc (see Note 8). Interest expense capital lease represents interest related to the capital lease as described in Note 6.

XML 82 R27.htm IDEA: XBRL DOCUMENT v3.2.0.727
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2015
Fair Value Disclosures [Abstract]  
Assets and Liabilities which are Measured at Fair Value on a Recurring Basis

The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy.

 

Fair value measurements using: (000’s) as of December 31, 2014

 
     Level 1      Level 2      Level 3      Total  

Assets

           

Money market accounts

   $ 26,530       $ —         $ —         $ 26,530   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Assets

   $ 26,530       $ —         $ —         $ 26,530   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

Fair value measurements using: (000’s) as of June 30, 2015

 
     Level 1      Level 2      Level 3      Total  

Assets

           

Money market accounts

   $ 13,568       $ —         $ —         $ 13,568   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Assets

   $ 13,568       $ —         $ —         $ 13,568   
  

 

 

    

 

 

    

 

 

    

 

 

 
Fair Values of Long-Lived Assets and Goodwill Measured Using Level 3 Inputs

The fair values of long-lived assets and goodwill were measured using Level 3 inputs.

 

Fair value measurements using: (000’s) as of June 30, 2015

 
     Level 1      Level 2      Level 3      Total  

Non-recurring assets

           

Long-lived and intangible assets

   $ —         $ —         $ 3,195       $ 3,195   

Goodwill

     —           —           5,735         5,735   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Assets

   $ —         $ —         $ 8,930       $ 8,930   
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 83 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 97 243 1 false 28 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.icad.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.icad.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.icad.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.icad.com/taxonomy/role/StatementOfIncome Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.icad.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 107 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock Basis of Presentation and Significant Accounting Policies Notes 6 false false R7.htm 108 - Disclosure - Loss per Common Share Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Loss per Common Share Notes 7 false false R8.htm 109 - Disclosure - Business Combinations Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock Business Combinations Notes 8 false false R9.htm 110 - Disclosure - Inventory Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock Inventory Notes 9 false false R10.htm 111 - Disclosure - Long Term Debt Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock Long Term Debt Notes 10 false false R11.htm 112 - Disclosure - Lease Commitments Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock Lease Commitments Notes 11 false false R12.htm 113 - Disclosure - Stock-Based Compensation Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation Notes 12 false false R13.htm 114 - Disclosure - Commitments and Contingencies Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 13 false false R14.htm 115 - Disclosure - Fair Value Measurements Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements Notes 14 false false R15.htm 116 - Disclosure - Income Taxes Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 15 false false R16.htm 117 - Disclosure - Long-lived assets Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock Long-lived assets Notes 16 false false R17.htm 118 - Disclosure - Goodwill Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock Goodwill Notes 17 false false R18.htm 119 - Disclosure - Segment Reporting Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Segment Reporting Notes 18 false false R19.htm 120 - Disclosure - Recent Accounting Pronouncements Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsRecentAccountingPronouncementsDisclosureTextBlock Recent Accounting Pronouncements Notes 19 false false R20.htm 121 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.icad.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock 20 false false R21.htm 122 - Disclosure - Loss per Common Share (Tables) Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Loss per Common Share (Tables) Tables http://www.icad.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 21 false false R22.htm 123 - Disclosure - Business Combinations (Tables) Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables Business Combinations (Tables) Tables http://www.icad.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock 22 false false R23.htm 124 - Disclosure - Inventory (Tables) Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables Inventory (Tables) Tables http://www.icad.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock 23 false false R24.htm 125 - Disclosure - Long Term Debt (Tables) Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlockTables Long Term Debt (Tables) Tables http://www.icad.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock 24 false false R25.htm 126 - Disclosure - Lease Commitments (Tables) Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlockTables Lease Commitments (Tables) Tables http://www.icad.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock 25 false false R26.htm 127 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) Tables http://www.icad.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 26 false false R27.htm 128 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) Tables http://www.icad.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock 27 false false R28.htm 129 - Disclosure - Goodwill (Tables) Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables Goodwill (Tables) Tables http://www.icad.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock 28 false false R29.htm 130 - Disclosure - Segment Reporting (Tables) Sheet http://www.icad.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Segment Reporting (Tables) Tables http://www.icad.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock 29 false false R30.htm 131 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformation Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) Details 30 false false R31.htm 132 - Disclosure - Loss per Common Share - Calculation of Net Loss per Share (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureLossPerCommonShareCalculationOfNetLossPerShare Loss per Common Share - Calculation of Net Loss per Share (Detail) Details 31 false false R32.htm 133 - Disclosure - Loss per Common Share - Exercise of Stock Options and Vesting of Restricted Stock (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureLossPerCommonShareExerciseOfStockOptionsAndVestingOfRestrictedStock Loss per Common Share - Exercise of Stock Options and Vesting of Restricted Stock (Detail) Details 32 false false R33.htm 134 - Disclosure - Business Combinations - Acquisition of VuComp M-Vu Breast Density Product - Additional Information (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureBusinessCombinationsAcquisitionOfVuCompMVuBreastDensityProductAdditionalInformation Business Combinations - Acquisition of VuComp M-Vu Breast Density Product - Additional Information (Detail) Details 33 false false R34.htm 135 - Disclosure - Business Combinations - Preliminary Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and liabilities Assumed (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureBusinessCombinationsPreliminaryAllocationOfPurchasePriceBasedOnEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAssumed Business Combinations - Preliminary Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and liabilities Assumed (Detail) Details 34 false false R35.htm 136 - Disclosure - Business Combinations - Acquisition of DermEbx and Radion - Additional Information (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureBusinessCombinationsAcquisitionOfDermEbxAndRadionAdditionalInformation Business Combinations - Acquisition of DermEbx and Radion - Additional Information (Detail) Details 35 false false R36.htm 137 - Disclosure - Acquisition of DermEbx and Radion - Summary of Unaudited Proforma Operating Results, Acquisition (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureAcquisitionOfDermEbxAndRadionSummaryOfUnauditedProformaOperatingResultsAcquisition Acquisition of DermEbx and Radion - Summary of Unaudited Proforma Operating Results, Acquisition (Detail) Details 36 false false R37.htm 138 - Disclosure - Inventory - Components of Inventory (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureInventoryComponentsOfInventory Inventory - Components of Inventory (Detail) Details 37 false false R38.htm 139 - Disclosure - Long Term Debt - Additional Information (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureLongTermDebtAdditionalInformation Long Term Debt - Additional Information (Detail) Details 38 false false R39.htm 140 - Disclosure - Long Term Debt - Interest Expense Included in Consolidated Income Statement (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureLongTermDebtInterestExpenseIncludedInConsolidatedIncomeStatement Long Term Debt - Interest Expense Included in Consolidated Income Statement (Detail) Details 39 false false R40.htm 141 - Disclosure - Lease Commitments - Additional Information (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureLeaseCommitmentsAdditionalInformation Lease Commitments - Additional Information (Detail) Details 40 false false R41.htm 142 - Disclosure - Lease Commitments - Future Minimum Lease Payments under Operating Leases (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureLeaseCommitmentsFutureMinimumLeasePaymentsUnderOperatingLeases Lease Commitments - Future Minimum Lease Payments under Operating Leases (Detail) Details 41 false false R42.htm 143 - Disclosure - Lease Commitments - Future Minimum Lease Payments under Non-cancelable Capital Leases (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureLeaseCommitmentsFutureMinimumLeasePaymentsUnderNoncancelableCapitalLeases Lease Commitments - Future Minimum Lease Payments under Non-cancelable Capital Leases (Detail) Details 42 false false R43.htm 144 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) Details 43 false false R44.htm 145 - Disclosure - Stock-Based Compensation - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureStockBasedCompensationOptionsGrantedUnderCompanysStockIncentivePlansValuationAssumptionsAndFairValues Stock-Based Compensation - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) Details 44 false false R45.htm 146 - Disclosure - Stock-Based Compensation - Schedule of Consolidated Statement of Operations Relating to Stock Based Compensation Expense (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfConsolidatedStatementOfOperationsRelatingToStockBasedCompensationExpense Stock-Based Compensation - Schedule of Consolidated Statement of Operations Relating to Stock Based Compensation Expense (Detail) Details 45 false false R46.htm 147 - Disclosure - Stock-Based Compensation - Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureStockBasedCompensationUnrecognizedCompensationCostRelatedToUnexercisableOptionsAndUnvestedRestrictedStockAndWeightedAverageRemainingPeriod Stock-Based Compensation - Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period (Detail) Details 46 false false R47.htm 148 - Disclosure - Stock-Based Compensation - Aggregate Intrinsic Value (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureStockBasedCompensationAggregateIntrinsicValue Stock-Based Compensation - Aggregate Intrinsic Value (Detail) Details 47 false false R48.htm 149 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) Details 48 false false R49.htm 150 - Disclosure - Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesWhichAreMeasuredAtFairValueOnARecurringBasis Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Detail) Details 49 false false R50.htm 151 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation Fair Value Measurements - Additional Information (Detail) Details 50 false false R51.htm 152 - Disclosure - Fair Value Measurements - Fair Values of Long-Lived Assets and Goodwill Measured Using Level 3 Inputs (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfLongLivedAssetsAndGoodwillMeasuredUsingLevel3Inputs Fair Value Measurements - Fair Values of Long-Lived Assets and Goodwill Measured Using Level 3 Inputs (Detail) Details 51 false false R52.htm 153 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 52 false false R53.htm 154 - Disclosure - Long-lived Assets - Additional Information (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureLonglivedAssetsAdditionalInformation Long-lived Assets - Additional Information (Detail) Details 53 false false R54.htm 155 - Disclosure - Goodwill - Additional Information (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureGoodwillAdditionalInformation Goodwill - Additional Information (Detail) Details 54 false false R55.htm 156 - Disclosure - Goodwill - Roll Forward of Goodwill Activity by Reportable Segment (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureGoodwillRollForwardOfGoodwillActivityByReportableSegment Goodwill - Roll Forward of Goodwill Activity by Reportable Segment (Detail) Details 55 false false R56.htm 157 - Disclosure - Segment Reporting - Additional Information (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureSegmentReportingAdditionalInformation Segment Reporting - Additional Information (Detail) Details 56 false false R57.htm 158 - Disclosure - Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) Sheet http://www.icad.com/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentRevenuesGrossProfitSegmentOperatingIncomeOrLossAndReconciliationOfSegmentOperatingIncomeOrLossToGAAPLoss Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) Details 57 false false All Reports Book All Reports In ''Condensed Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements of Operations'', column(s) 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements of Cash Flows'', column(s) 1, 2, 3 are contained in other reports, so were removed by flow through suppression. icad-20150630.xml icad-20150630_cal.xml icad-20150630_def.xml icad-20150630_lab.xml icad-20150630_pre.xml icad-20150630.xsd true true ZIP 84 0001193125-15-280728-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-15-280728-xbrl.zip M4$L#!!0````(`-)U!D<)KE?\'^<``![?"0`1`!P`:6-A9"TR,#$U,#8S,"YX M;6Q55`D``XNKPU6+J\-5=7@+``$$)0X```0Y`0``U%U;<]M(=GY/5?X#HX=4 M4I66T/=NU]A;N&Y<95N*[)GLY$4%DY"$6@K0`J`N^^MS&B`E`@0E\`;"\S"V M"8#L[_2Y]SD'O_WEZ6XZ>HBR/$Z3CR?XU#H91368["?!S')Z.\ M")-).$V3Z./)SNR@I_FOT,\RCR2A-1G]S+K^,R"D>C6Z+XO[#V=GCX^-IEDT67W,Z M3N_.1@@M?N*/:G4?1B-Q2L@I6[ITF90]1)/3^9<^_UA9D/2E8Q7VT):BVMI7B^C_+6Q917 M6E9C5C`IZ@N:X^9GU<7:K7'KK:*Z-5[7,0:&+K+G]F?F M%\UCM/'8+,M`;-<]-[_:0M7H:7S;_I"YTD*G)(S'>?L3Y:463''R$.5%^S/5 MM19$>3Q>0[AXW/(;270#XCY9R^;Z+$NGT=G\MI>G9G?M3TR*[,QPRAG<$67Q M^.4!T`CO/Y,FJ/'6!I3/+Z[ MGQJ!*S\+L[%!U$UIE$_<9M'UQQ,C-6@A,:=/^60+G=)=79U5L$"B/_A)$1?/ MH$'OTN1[D8[__OTVS*+\?%:4M@7LS6B<)D7T5%R:=4;I].K"QY@HBA#"'%OH M?RR0Q:OO/[PKZZI$H"QV!5(_2^+JF;S\QI/1)!K'=^$4V/3SM^!D%`-;Q),K M)2165%Y1JGS;D@0%6G/$A&4C;2F)'.KS0+J*N)A?D2M^\@ES22S.Y&]GW0!4 M8.<:[X,SR^,DRG-XXF>0(V,;Z.PY_3R,[SJ,CM\3]F M<19-[&3R!3Z.IW$11SE<`TZ:?$[@)VYBN#G?F$J,:/@K%HQJ83UA+27`7:+: M7/]?_?[=6R8=HBN4LQSI$@PF$A-?(T8\@C16+ORN"JBD(K#@IS!LR2=MF?]^ M.SLP+>H$_VN:3AYC,,V#IQ`^^:0:%%HL?B\\M/BR5OI]BXKA4XB`],G],-%[ MQ*A3?$F^+\+L//M>&(/Q1SB=11=15HK\AM1CE@2%4E*/2,Z?L*"$"?5*3:&X M(KB=FE?W47;53:]96!'&-$:>L`EBFAB]AC5R18"%]&S-!>@U<.,,<:U3"[]2 MM@/HP^DVM_1.BJ4+VQ.X(JC4%`B]%7LJRK4T[&D3\$@8MSG2GB611UU'4Y=C M%?A7V!"1G7QB5)&#J;E5LAQN"[ZER7CEY[ZDR+`=>9=*A]N@BRP%15`\7TS#I(`[?+CWWH35O\3&@+DC@O"#;6E]5=QY056WLO1R'W`(<&*RX.)PV:GHNA_&QJYO/B]LH^W$; M)EOZV,?9`_!SA,7[B$364&DO\!=D1VB5'<\#XNPNF7R.1W*T+\-4OS M3;4BM13%M7!^#2QK!94M'9=JI9&ON`V>KY1(NTHAY5F^+[3O$L]^48+,TC50 MZY9?@33IDK9;G#"[">/D8I:-;^'3\WO#2/:=2=`="G>;S]\=.=A@)7DI07:6@2!$QN0ZSZ^W7(3/YB/[,&O/U+SD?\49>,X+^7NYB8KLW0@75FUKBGP?.QQ,J,34N2*E0<6J;E"/1IZF2.:W\"7F#^,+/813^)W< M+MPPRY[CY*9OBF+-E+`50Q0L(F*N`QP*_TV`IX51?[Z_$S^;.V%^H'@VYU=9>7#UJM7G>[1F![9/9,XIVTP0'(YW2TH; MI]S29)5]CT2T^O:9<.KUZ^"A*`,YN(0OJ'(3%R`0<"&\V92-N46-N@5B4\RD M`F)SHM4R6]_/LN@]OPH M9?-`7.$K!F#!YP5[]@JV9=%K$V[597M6W*:9<<>&A8XR(S%6(RGYQO+?P;G+ MR<=A@8KEHX\NZS]T"G45\'8ITJX$H#LG2"^RZ#J"@'CR*S"V$=LF7[\-X'VP MGR%$&AQ0L'GO0*R6_8[D#A);>5ZIX4>D>D-HV_#5Z?!KBBS139'MAJI.B?-[ M4[T$"JV,C?)@5H`O\#5.XKO9W=S=R;T9^#`_'M,_HS#;W?YV]^QLH@%KX"+J M4X*8(@I<#DJ1QQV!;=NSN4VJ@S/"ZZG6C5&UIRT^W]V'92ID/)[=S::&E-5' MY@N^;![P[T(,[E.L";:1[:D`,>IRY/@05;@T<+2PG?(4D5H6+>DA@%BMB8QW M(6W%'O-,Z/!X`]0?TWH;WIA#JI/#GDQBX]R'TXLPGGQ.YGF%)9W3(PFZJDEI M#HDL"+EJ9'@?RE:<,#P6H*6IWXH'&O&U(Y M*RNO(UL^T2N3#J_9LO.?T_BFC(GS_H6\(VBL8(M)(X&R$:;UZ=VE>WL$KBBS MJ/8T8IP!:V/?0UIICK0FGJ80>_M7UE\'^7N2O1P"_`B?G"B) MKN,B_YR,T[L(/KB(0#64F?]DL@C8P6AD^W`#-TCW8N9X-N$VXIYBB'D"*,&Q M0$0+SV7K@`C7$$A&]MZ[L.P+!"XNZ.`9@" MM=XMV#@DMJ?3]-&TOP1IYJ6SG\7U;+H@Y64TCN*'0;,"!`&D$1%OA*A.C,NH M`$L13?PP2\"F+&M(D)]X'`^1`N`D(RR9;,2![V-II,X6!^8OCN7!L/(5K`'7 MKJ2>0()H8'_'G*IZ"B-@>^,.NDHQ^7((14@SP;NR]$88M'4];A^^7>GI6XUD MQMI:V>72G63R2X2NH+$XYHRN`]B*XTW3.VA?'1M?G;YE?->YZDLYFFW*&OI0 M-J1*S:\Y-FRKWX"K<5%:(1.M`R!01E$RWKLL/N7QAR2>?CPIP)?;>O/$2Z/7 M1M:U?_O8W6$HPX(W,@F;94J[Q]]#SBE86^84VA()-<-Z#]\4ER8(_CZ-RIJ3 MI!9>[:O^O0=I!\^"":F:;O9>T*ZU:H-U-8DY6^:4KC74K?)2/[L[@%K?C]Y3 M6^B]8V>-NJM`V#DIV88:L$/::#`)]>ZD$"TI]3WDT(_BD75'+4&3*=4%]%K? MK(O%'"1V-74/]9#$OK$3"SJ:^H(Q'LHPO26TX#JK3H5Q#V:`KV*DIG@SX5T">? M=%VIO8^BCMJ_NY^FSU'T/XG'47O(-#S]4M=RF/#;_D5:GR2_7W30OOJ7% MGU'QVGW2([$\XBBJ-4.VQTS]A)3(#FR-.'$L$CB6QP/^VC$A=)TU#D:!AH^X M37-='YE4VA:;MS6^+>I,@C#.2B_&`P:;IOELO^54[[GXQ/:5$HZ'+-OGB"G7 M1MIC`F&,+2)MB]L>?MEMWFR[?P-$4]G5CTJ^187_-)[.3(7HUK,9#K^;)8#7;-[:A9#=&F!*LZ;J1YP#Z=VJ-4P,-:,)7A1FN$Z_ MU86WF?/!JA&(\8B66+08]5;%L3`#V_2Z]E/Z:LH]3:]PJS5?ZG%=,0BF_"&_ MK2;G##!:,>ETIG&[,:NM?4_SH?K8K$JB='N=\II]^M\T^_MGDRT<1[VR8,=] M,AV&A+9O4VWI*\F_^S`NM6B2FTJ3I0!ML-J#FYH9TK#+[^+8-%NRJ,W[G!A? MU!0G+:X,,HG"3%JAS@"[8#Q\CW,?X8:IPB%6,ZW6N;^Y[."?D^PR?0ZGQ7,/ M5;GM!T?<\0;SO`]MB22+/`0@#09AX5MN7-D9KX>1X^=T.Q MA'B%'-_2Y,#Z;G641G>HIK9>\U>H;RR_S0_<6TK$='(S6<[1,W]*\V_)&7XR MH\"D%N7<%"&$^3>S^)8Z3RKL6M)%..`.8BKPD",#;O[I!K`VQI@P.J_L-^*R M63RY#O&1"*.E8D3U1Q@R]T;!%QHH87HB1.GI45.+2*UA$8)1PO"2Z%!)*%XF M#!9XS8C*=PA#"*.V1R$@=S$&9U%@9`LPCE@R[DL/VRY9&E%#N5##I$Q?E"C# MFP&1X6@,P8;&$$>S*FQ@5N5H5H3M8D7VG^DUM%!:`G8I*:';.9?*9IR:*MY` M,!LQ&D`$X=CFA,:<4X*P$.J].)=4-.=&=\_^[I;^V`+K]ND08M(A*PQ?SX:4 M3N?KJ)SSZQ<&.+]>W.D_C:/(G-GL(2A\@P#-B4%D];Q526(SGR*;*HF8KP72 MD@1(*F$SY@E;V$$UELF4:I]R/G>JM\*W1!]S0YZ?7_MY`6LKHLGOR03$PYR- M1&6X&4S3Q_S\(1$FV!EI0'E9*RF$&Q1H9E*%*R M0H#]24FE"D_QWJ1D4<]@3B[.'Y,HRV_C^QU&C+V0`OQ\5OJ0DN$W2-&67G&$ MM+D0P`6!!)MH>P%2O@?_=%SM"4^X`7%K(\864O`.F%]V3-XK6?L;DU<%)4S4 MRU>',R9O_\Y=3_X]&UB8TU\"@.V2`-CK,(:EB<)8"=Q!DE;SA9VT%)D?!JA& M'WJGT0Q[G5'>^H-]4:_%V[&HC;FA%W5MPS12(X^B4/,4G^+>BSY?GF'ILC-J?3UD[8RW&( MVO2L<_MNB5U+K'O67K3E=4X;]A+L')AM^NZJ5;S2$9:G?!<)Z7J($0C,@#M\ MY#''MP,-EAX"LP4W='O!UR%.L2DFW2;*;SNIN]K2Z@T7JKFI&T_JWGVL,5L! MO,?9DN388XT/C&XX8XT/#;0<:\R9H$P,8ZSQ*N`#SD@E@QMK?.C]'LQ8XT,# M/>98XT-CJU[#2D$HWII%WMM8XYY%=C]CC?<^J/5-*NRC3JYZ$0BQ-&[([Z:# M6A>#+[^E1;28-=M.VI>]Y!FL/T,P,5D&,SSV4&:P]@#8S6+G5 MF#N[PPS6O8W=[(.733]6XX2^Z]C-@T^4[&/ORQ,#2>N)[>%.E.R#).!Y<_"\ M6UOTCC-1L@_4IM4^=V#(0/VII9N-)KU-6.P#]<,++6FLO&2S^/,&.QC M/XUAYHW74/F'KU1ERBP;(P;M_LAPH7MN4]K4?]D2S#PXL7YO3<.4W M/+_MA4TW%/ZRFW34>!;36AJ@_1I&V>7=N$ MJ@/,;.H#GSG:D=PZXM"F'D2Q'-./FQA[&-K4AT8%!A6,-#V<_H]O.SO.`^@@^^IX'U`,F\Q8<)KK/`]K+])P>M(J)$XFUQL+O?WK.+H@Z M-<*47?[O=7A.#Z+&YU!W&YZS_T*Z/CR9 MDT^4D)7(8N,BNGUU1,PA]S(9@`:2.9Q:B&C"$+,U1HYD-O*%KPEUA4=->_%+ M\3L_[LR$]93IBQ+5NXR'0X:C,03;B2%V,V3]]4&7[<"F_$DW^S[:#=N^0=NOM9I;$O-:&3*F`&UX[/S2H\)8.?(];/L?@D!+/1\SU*%+"=9!V M/.+:'-L692^S"B[DGQV"VG5;?P`F/SQJL#T7V/IS)Y;O8;/+GO.]P:[$G0Y^ ML_>-VFPVWVFO%U)?*H&\+%Y=M(%79R7SXN7SS/Q99KUF=S]-2]AV5=D-PM1Z MY5\)(Q17I"04LX@JKPN^;/2[E3%;6!'&P/QYPB:(:6(C"&\T2Z]M7=*/,K4+MBPYVIK5SM2N:Y2`=:0TP)@:56$KPM.^!$8MB)!=N2?JB] M9].]1,=E+MW&='=CS/F+;[:QV]7,2R!;%IM9[Q6-_CN:@EKP\W&6/NX=>\?& M@L`#;X5B\$65`M=4!,@1P"W:HI1JY5#.Z3S_7L%^%\B:03*]8N\R,*4CFTQ.KE><-B.I5\U=7#DI@"&-J`/1$VM8-^G*3-I@@&KJ17L M7=141^1L@&IJG3?=#9'83$V9-IG724E?PV*6@;/BA<7F:0^Z2'!A)HWWQ8E6 M+2Z#Y1.%F8VP;;0M=5WD*`=#4&!A/W"Y'ZC7Z6/PO0)A@HA>KB5=M^+U"M@\ MLR\\[R:RV`Z8S;$A+HMGUZA?@V1=(5N\*>MMC7&7;37V133?D?4*H?$6P'F) M^Z+CTHNGLV*CR$'-A>R-6>UK&DI7)^?YRE/*O(X!$]]%C$D*PEB^TYDXA"O. M)7--0M+4[5NGUA+3KL%1!VOJ,,+\%D+^AW@239QG"'9!YYS#\D)3-6R/B_BA M*L4LRXAG\-G\XD;3J;K09"\#+,IB<$1,:FAYNW?#^3:#.&$>C^UD! M9E4Q5C0)LO3.#,Z;%27=SJ^;WVW?F3J@/5"HFR]"J2N)#=SB_C][U_^<.*[D M_Q77O+=;LU4XZZ_83FJORH#9EZO)))=D=V_O-P,B>,=@GFTFX?[ZZY9D6Q8F MF`0(6W7UYFT2L*7N5JO[TRVIY9CHOURU.*VDTM+$[*,C.SAK87C/W"\[[>SM M=AQ9'"Y_=X'(T[E@/+'4M;?BR1T<[8CP#W#8YX1@Q,(K:.W7P_N6!WH`PEPO MQLFPV/CNJN(P.OBNJ&HP5?DT52@##VX$E9\]VA/O3[@:IU M#5^U?!_'$3?OP82VAP`0G$$739K-T\G2B8)-ZJ4Z'F%,LN($XCX[F$_'&AZ` M<>51D^@^6)1[.A,$;%ERB9FC!+6G8PFW8FM26>7M8>R&F9$/49PCCW@<2RJN MLI,/>13'N#N=#`C[B;MIZ8;3XCQPX\;38+?G#@Y9JUY`'@BV1>[4BTI%?79RTF2`\'F6\MM, M$/?(-$%D4DYY:#0-DW02+<)T?9V3.3UI#&^F21Q3+6.X[2Q%YM!`3O,:[-E1 MA+`=G]#3:F<*3G0\3R\I5A/M6YP9MS`]LB"G]@*ZU1OX!N4(;(>%-SU[MMY5 M#:\[Z%MVSQ[Z`V`0K(8C1QN-Q#=GUS8/55VP.VK,`?@$G4 MNFI_H/>-H0>6T#89@UVM#KZ:B9>VNQ8[_/W)7ZLL9U;CCQ`O"3IQ)-%V0ELX MH5W)`;S*AEQ0*,O9K5NTAMS]75.I%E+J$D&X=R$Z3>"+O&,49R.UZ9:$D#=SH*TABD44\+K.1;A M8HQWR(&*9'3I@=TL>):A%+AFVY#*;;9D1RH/A3H!7]_CYJ/XZ$/=L'MC.-!M M8^"J7D_WP`D-'+RH+5#[QF!H:4'7<+4!2RJ;1CTYV4AZFS/#;#.2/#'.<9BQ M.+IA>$Z]4-@^7&W)AW!IG6SW5U>%7B#EI:4]ZV47NW;%;!!$GV-]V4@U&8+444 M[V.SE*3'50/BK;@QS4&6%L[=5Q3^=?]/P6H"-@FVMV-END.A1M<68W$[? M=)G)"5V;B[>5R]7<=K+2(K,LEW6[-+DPI*? MY9H/WN!C>.;686]D9&M>!5,18O5?J>CO:>=].SN'!W\=J\%XMV%(6EH@"\`H M,3XSF6.ELAP1R_=S7DC"2IRF?/7%#CY>M?E?\(07W]/P&UX=*NZ/.T>[C_GA MUZS^JPR]EI)!=U&D+>Y2,H]6\W/D7\>]*M(MY[OX>'7^GZ.:8R+"ELK-2F2W M723=_S3JZ?R8`Y-9CM!W\"'?Q%8DT8=)^F&6NVTD!3-7UMQM]&]C,WM,\$IR MB#II-==J>?`Q:7G2YAPE8[!-K%)%^D-R+9^%/`^7W];IX75VTI)9:RY3!QPWW`ITC<[2.JHQ5MW(@G#9^($]T:?"#=]2U7>K$ MG(EFL1S1#OH%)C?]-ET^.4?4@9?P=2OVME"^E;<'DN2-SQU[RIB5D38_6IH-_1]R\0FNEXI%5J;IRVS7PHR3# M3\P^S!)7OJ6N=7+\2!F'$XL`7$/&MRVJ'&A&`!I73$ M?;(.XWQ=^8OW\-OEM2L\R_#>LI2@6W8OP(UW7=\!>]]J;R2&;0=XR>/5`#O^>IEJXYJF<--178]JV!V?6U M@08$OR71L'#(X4?YR8 M5;S22#7YN;U6(Y_=[W"-LAM\%_L`B::G'NWBE_ M<.U_1_G[5K/=X*#4T[0]3E,?U':?A$6L\&\:.PZ''=UVGX15#_"UI9O[F^X/ MK9-$JV9KKEZ4*SY.W20ZM:EIHU?=`/9WCUHYZ6Q$ZMKN_A6>VY6B*D6*)M-R M'-?1CRK3YN,N/FZC>Z+9M=ZZ>H2?Q/>?PW12'1[)LM6\V.2P))B1^CV)H9DX MRM?W^]5TW)2X5.>_J,%M>L;^Q3D=R^H-+54#OP7Q9=]4>Q!QJ8;?,P>NI=L] MG^,U6I^SV[5W'0HZJ)3^CL-25N0_]K`8/-4!PV(9'STLH]T=CO;I$"LAZ>\8 M#4GZ;Y&OR8/.._//[HTDWZ.P>T1MOX^R;\.4D")/\$Y=;ZO;FP58VTM>0\W6 M-/=8JMTDDA/8FT&$2^&+R8E&H*D$=]L1P,KQ1[8KHC3V%'ZVK3^^N?!7>F+S M>L$.`DF%]HJ=AW=I]/;%KE>&X2VU\]H/#(8:%ZZYQ]@<3E@'FB)M^J5?8CGI M4H/^=B/5A1C@HNL<8!:]36`[+XN!X'28I/.P;1V#_@P)SO5:F1/+\&S&]%V%1C]L1,TS&M&&(J<-U&0%.0>I==E.\#MR1>W% MC9L4ZKO'6G/87C#O7ZH]I4CP.@7#TMS64FDL3?#:"\?2V[^)@/$(AFNW%N^Q MI"6D?)MMS'1#Y4]@4@\F93S`;7J\H/7^7+Y!.B3#Y[;M[I=9W_YU!S] MA$27@V1,[U@91MDXC!GV&\)G^SL!N]B7)F\_-&W3&@Z[:M"S`-(Z9J!ZMN,# MKO4UT_<"MV?>D)+PX]KTWA!#JAITR%M#'L8S,EG%Y';ZVR(EX^1I$?UO/3;"?4Q?$UK]``(=#(6R M1SQH\@B2ZL5O.?ZZ;0[XWL#RANY0U9VA!R+Q#!#)T%%[>M#3#*N8_/+IQK__]?JKVKM]?+R]N52T97ZE#&^_/JH/ MU_\37"IZ]<'0O[G^\N>E\AC-2:9\)<_*?3(/%U<*;^)+,'R\5-P?R@\>;^\N ME>XR_\3[]3,EF2K_N5J0'\/Y\NH?+[YV96H=!5D$E:C$"1*JE1S+6B5/X%7"(GYZ+BEA@:<"C\$W;!B4M-QH"ZUD]!`R?I_/ MB/+,8U(E9$$I/#L/(YP[RI+=RA5!8YDR3>(X>\>X*4QQE.)L7?S]$DG_WRJ>O^\$D)X^AI\D>-^U M?J!/4;;R2?V9[[SA49+GR;SL4]>WOW.8SW^N4YN^2;P@B">09P*2^$>_'P3# MX:=F]O)D^:E)8=XSSW0ROU(>@_]^5*^_#H*O\(D*'Q7=W)'TPO.#:ONE9?D_MF@'@!=<8JOY0=U5=AXC`,YWNH.?L MQ`OS,'V*%BHH^F47%9G_S0;D4A,^BLDTOT0X,`7ZU0S$==1O+[< M,JVN%TH(06LZH8=[GJ-\I@S]AY[B/_25QV0),:=I:ZH!X($/,K#=OZKDF"DJ MM%+(D?IZ6DF_>GIPU5$^BR]CTZQ1\:&?.A0DX#B'BS5"$+R)6WDJ6H9@2(G@ MNRBEE]<`7`GQWV(5QLH(PD:&0T8D?R:D^*)L)9HJF"G)V4/C*(4(!:]0PCH_ MT6(",5A.E"A'`#*'>%Z)HV\D7@-!(8*A19+CKSDE<`H4X.Q8$<18`LGX,L@C MHV_1+\9AFJ[!-4`332]<;!J/CE<(-?%U4B;[X/ZQ"1!&]JUTZ%7F"Y M/=_05=?1`I@#W:'J!H&FFK;3-X=!X'3[?7ZAKQ!`;*-[6\3[)QBP#XEW37KS MJ=T4\98T543[\.V$/A&'^]]1]TY2(5";PC`11FN-%/F0$\TFWC.C2Y,05+<. M'U#I?=\9>)JM!GW#5*U`#]2>8PY4JS>PP&;VNKZM?WA`I;M"U``=1_A[D5`6 MA$1G;E3"WS=%+`<,_AX%DU3ZSPQ^980O4YBT*7@$99HF0:&>$+B"/#26IE!9)>, MQRNLJ-O!@"];@=7^3L`PXT+_F/:`)KU:\80VR$L$]KNC3`EV"Y9Y&KT`!`-? M,"&(OZ(%C=FH58>`BXQS5C)IS6TM-%'$KVEUYP!0"KR.\/<+90B-<'*:@F.)YOQ&]26/-&AY%'.J4BC[!OV'>-"S`R@HK(,P5RC/""`IEYA M!6'QG*07RD.3/,N!0FYAOF700PF_+"4*4K\E%A;4-3?-4W>Q420WZ M[LTJSJ-E3-0!TQ2J\<4<%7=^B#W(W?\&C?+VZX2@R!#`;2?(JD/%/DGSD,I6 M[!L&&?`49@'A.^4AF>;/J+Y!O`]I5C-IGFNK7:IPW:`6^)=&&]FO.QUPA M3("B%07KR:<.M(F"2IFBT!G\($4Y+17V27"ZL*J-=L+ M'NXDA4#ZE2=VK!FL.W.A,*3P.[IDFMTEHC1QG#*LIY418`IZ1I^PH.E8?)+U M&H[S%;8'KX]G$'?RH:)QD=#6!37?2ZSKEV7TB6+DD0&D%C^L_!@;39P4R2IG MI,,[(*S2]V65=D^!B"3%D8\6O#KFAH9R_;QBJ6UPS/@=^PQG(A/HG![V7\;A MF+!Q``<5LNFB_+6:T)CC2IDESZ!]*0U,,P+/K$%ATC4E?DG8?=,4$*"4(#[Z M]XJ1V!1E"EET$HYG=0&548395PF"4B-K1HD(->HB).S`OW=IN#(%S1RKRZJO0D7*Y3K*@5: M:MI_&]Q(/@"(>D+XV![,RQI`60H MDP0DAID""OI"A:;!"H`<1JV<^DAI MJ"QH4H#9;#K_.S4#`*++&2DA:VP&0Y4`B>60EGK,5Z+0A`&`CO+G)`76<>&] M0,3%HQU$U\D(G3LI(R$0DD*%5#8`@PO\H_W/SF,.7S,VV(PK4#Z"%28O41;C M,5E2X\3"F*Q8RT/F8-#B2)P7259[#``UJOH(W<@4,$+&`,27?0U#M+=:6ZD?-\=!8%!2Y M[+X*]2I-HE=M,3^'9`CUGJ30K5/[JV[LEDF6J\4T81'%IIP[F)$$OCKEXF@$ M0@36V$(L=Y_GH5+B,&`07R*Y"?,#$8#?N@B*8(QE$2`<@U88KD15S`3KQ0`< M%<#3*F*6&+2VR$!C[YB#K@`20/,::&Y*Q^Q`^#*Z+^/H(@A!)D>81!:B;[1= MH*X0!Y:N;KI:4'L3"NF&,I&PY)&WR!6$+D7@^EL M]EM$%5$FRB2DR)0A1IH>ICZ\"G5'9!R"WQ'1)KQ5=,D2*SAA)VH8)Q`8L!SY M1I;D>L'Q%R6)!1GUE8(BHLG$:$'"N/7(!BQZ."=@_K]ACBG#1:DHFY$)%2F8 MCFJH3&J'4KK-KT$RS%Z"U6!F)FU*A;V>J"F3#O@^IYO"9*Y17/9"#%KD/_@T MXS3@/.,\D@(Y\?%';TMIJ@^SG*^K":@95I>1&3S%Z4-:.T5@40[S>9BNFLBV MQ.JO1^J8MJA2"A<*+4W`6&>8A4\?YEP+/>@(2$,TG:*FT5"'S7)HJ1SENWHF MDB43!),K#1+,15P`8U.'PVDA]N_P.*Z>D!`3LS!4]>Q&H6E%%"/T7?1^ZH[X&PAI"1"(%7+Q5Y(`]?.P)?1O3`!ZO.%VM7&=%QE[N'] MS3DH0):F62#X-#H)ZFGZBC'V.V-=:+R47=T>E^E[3-J78'ZSI2I]+PJM&@?F M?1C4HC-[46]%6GBX%#.];>8$FQ&%L'C-!$P`&QJ#2>&I`@0@KG]&9U:@295L* M><%8@V?=9`D_SR*:=Z(IDE*=L1_N^2;?&5+EY(>*;K"NB^V9E5,K+%Z>DC!G MDBW&CW93GS)E']@[Z^4\[)TH>NKL7EEE*HP['W0:)3/WP716<"XE?J*KCJP] MQ(H*QLFHUBH@*L(0%T5EC?Z![;ZA'D+:?5.L&XIAC&PR^=(D2\%6ZW_/[,JO M-=WKBTEA&.XRXU:8,?X0G8ULTPN\SC+<85.R&OB6K5HN-.$ZOJ;V/,'HCYAL*'^_]KP_#V_L;_'Q!X-';^P%]\OKKK_CVRY72O_UR>W^I MI$^CSUH'_O<34W.F\J``@%FN)%5G'T)KUX/;/Q[@R["4^[XT@@&BJ4? MIC:7R%K\0%4B8>58KB&OAPQ/J:\+XB,+`T*;\J'`*X_HH&#B(4NB%S1.CC3RES M+#O63^Z29Y)^29)OBL\0P$2Y">?S!%X'@*G<@;=$^*1\]F_N?KH0'[^YHZO6 M".2`B#A,<:V2K<.`?XN>%FQ5C3N\`F#@9TG,W!]CDBWB4)R*\?2XR-_`_\,8 M\&(FIH(Q24`!3C)/LO4"$U#11E@B8D24MS!7V8(V;F>J3V!D8U282`XC&P=F MBQ+P_#S'(F7<&@O7WO$A(@W;A_Z/O3=M;MM*%H:_ITK_`:^O7657`0I!<+4G MJ:(H*N-[[=@W4F:>Y_GB`H%#$3$(,%@D<7[]V]WG8.5BDA(7D">5F8@D<)8^ MW7UZ;X7"67.GAAA,1KNTQPPZ]K(E7U+H"MFF*!R6D1^'(L1H`K([+(UPX!), MIQR*D<;2)7<%MY(4;PLG%V&^V)2+`Q<]WY+CK<7Q$(5-7MVO$`N2XC!7"YV2I58K+PP6@<^/$])_J8*W^V:-Z%B67`FY01&O<11Y(@)R"[,?G)0\"L MZ12DX1`-F%GY'R7&8F+<.\39&H9DLVCLVP7#`IIC+2005#E3Z784HX]8\;#Z M:3)_2*Z\1X;!Z<*1FUJH22]>](X`AX.1@0PM_QS3$S=L1JFX']_U[RG699 MB)LHY_SDZF1.UP]1[8@G<&8Y'P4HLA/*2L^,YSF+;N2C53GU^7/#;\&.DH.X MZ:`?@:!##$V,86?Q*P46F&CW`DAHN!'`V##=;U?46]]2U*[M1`Q\D5S%E=M9 MFK>X`31S('DQ"*R;-=EN/2]KLM7>/&NRM>NDR1><>HT1??A;I+P]K;%^6T- M$D:=S=K+.&_VY2=@P"^5O[D*>7:;Q[N!U+4RTU/TPH'K[2Z]WRN7Z-FMU7:; MV/FR6UZ`O/!LIYRJFG[L9G]R^6@?Z'N,R)JD`58.03O50M"MK]=:,8MLW9%? M?O5E_!1W#(FOA0OF25PP"TYY4P3;]9P[OHU?"@DT:*SG/UX*&N'?^LV7= M"[*@2L9SA(S'`"9@^S$(IGOD/-M/>GRL9ZZXAK1_+K5_DGDSB_!/0N<6N=LV M<=*D]BTOI3R*)K8*QU"PV-(D33@IB7&!`7HB9 M41B!EM@&2U:[G'&/`@W2*>'MM+*&,-/-+>`$[>D[=HB7O+77+)@,AD^$%'^8 M=E(J0'IG-_+._G?LSC)>B6Y9+-Q9]&F2TDB(C8;[1W^%A9ET7_DCBN0IX`3NAC,-N%"+T7YXLYKR'#N$8\=/ZFTC>G%)S]E8?EA\JG M3YA\4)A$O%^%6S-Q9Z:15<7HN*GIV*58 MQL3#:0JO:[:@4E+P:UUM%3WG2?YM[B'Q!&>MHHRAPJN'KHR*M?S)!/DFECM4 ME=>URYJ.^1B)8X2R06@8OI]D(?.3+,RIS':;)1!]4.K--^2`A%!\4H_8F#5VE/5Y@%J+)XP>RM5/6=Q)G M",_7&W-N+[N0$IT&-WR@ M?*-B,&67#EM-QIP_=,+:/V^5*],#[/G]LG=)+DL66H'_"&O@$1SDOQ\SEP0& M\5M^0]P=J'>2#2V-73&];.A\$"H,P)>:_"R6Q^MZH6R3Y$E1U#'6B^%=*))< M)1)J;#;QTK(6Y0I9PUEZ)\9IU$KR#3&KO%K9V[(LR=E>EF7VOR)ACW"CVGEH7)U"`SJQX/@A2V$0$#\9CGG7_=Z24AU MDSMD\0T"@^`=4N2:%-6S^DIQZ$9)[A-D@*MOE'#9C9+=)RA0;7^CI*P>AMGV M1LG=)Q<_;7VC9/<)7MO;W2C9?2*(L7"C9!?*JOLDO4U@B&WO$WZ;7/RT]7TB MUHF4L\/[1%!7=IV(+^1M\A)FDA0G'9Z];UICAV%2J'//3P4S/V:@W]RC]I-@ M/+Q<5%KR*@NF.#H469D_KH7:#==+;O&:H,P,$8M%[*%<3+,<;YI?87*A)"EB MY2RV/ULPL"6AU^V$=[ M#3JKZ2ZM2A"0H3::[;,(`CJ!"->O>>-P6D1D[ZCVW'C7NMJJ-ZN$<^5U+`[1 M-N:&IT(`V;?M[,__N[C=T+GRSH\VUA0<.;P&LA>/-' M"*[7#H#AQXC/E4U%:*GU=J4P5\J@BV30G,VH5(P=(/$5JIBIUXL)%QAN%."89C9DUNGX(NFWE8^16;1;BA1J7-;2F)JT M'G8A,&AQ\$QSD^"9I]VA,K"&;9S@+1QUCT[PRI/Y3J(&[O*T1?T#,'@L:3>" MM.-/F!*93TAEL.2-FR95`;([8Z"Q9\:VPR.D?*R5:2I^TB9;<+(P;1N3\)8L ME#8:8X\P*OCN/*T33J?RN!L1PW2Q*J8SB]OF(3K_;7K`TGL(:6^FF'2 MN5%Y2TS*CT-86)C4+T_3I9(PM7 M@)._%C)56,USW<'\$!7DF:\59I6=RA_=@MHQ<\;`7.Y+C!\*M M\[1;$)RN@6ZUAT`TOJB294ZO5%#*,S9;KZN-6F>WFST//]A'KLF1T43H($G= M]BHYPIJMZAFEGQOIT-DQM9\KX_^=1N3Y?[KZ:#ZP-Q^"K@Q!'NNJ&V M6CO.^_M!@-`P4"S7#,-?7O6F4Y=I6`8-(TZ\>Z9Y[!$;`[]2?A8O)(/,]=== MKV%NL4M]>5^LQZ[1:74&S9ZNU:YU0VM<->M:UZCI M6JO1N&KT!U=7G9O^HAZ[9%V:ZR9XT[N]$NT$L?-?O5-;T%)P$>4;Z$U?/SMG[DA%_B8UW"4?OKX^T#[9VFHJU[_?W[[ MX\N?OU]KN5'KS:8J_O=N2Q^S0)@E_1@QLBJ+/Q!!2%@&)<#^FB.*\3*I=MT4 M(.-%::TP1/AIX(2\G!R,PKQ[\QZCN7*=,;.&E!C!P(O#8215@)5D8'!`#8=: ME#H>A4(D\5GF@^FX:6&^@-UCPU`78ZP>'/8(2QKR-I98QVI4V('-+"J,ITS, M[R#`][]5]9<(OJ!#)K70KC?U&ZW1A;]Z[7Y/ZW9U_;IA=&ZZ=>.;\:W^ZE=- MO^S6,@C\8#LEYF6-F1V[[,OHAFKI?'8\9Q)//F$[UZ^\;%QXXP>BZC)]'=XA M'NR`LUW=Z'7#:&C]Y@UPMF9;UWK7[;:F=[OM1J-^T[PRZC_L'CXQ@WO'TT!X M>4_"B?C,;Y_"5RX;1>^QA_T(UJ^%SG_8>R[/T.>1.7'%T-VWLU)/ND6<^NM MPWI+.Y[;\-IA+6O&?K0Z;_+!'B6O:AK2DORQ$IYEX"_)%.6B;U&N2,JGK*B? MLBRY:0OR!\UOP!B&$)2(69Q4O(8"NA"9' MG5W7+)E;PIP.M>$1Z\OS&9;I77FVU;RLU5!](B$#:WEZT7NX!?B76_`SY,I5 M,::UVXN]*>6<\ZU7^TSJ/;ZC;55/BU9KQF(E>G>G?'HDW:[@+KI*G M/+B/-NV,"V`D]2&2))E?RG_5Z)]%I_'\H&=1 M9_"'L"12LBM'J[K:7>+4.ED>;;PP4GQ"PP89*EE8O;I;;_66L>WYKW1J2BXM MN?1AN/0=LF@5ZTE7CAIUM7UN(O-.V+$E:AZ1^;B"U_);7:TW=_8T.1?!L,"7^6SG7-'9U_,BAT(GG0=V MR^"F(T_PX(F7WK@)_`FFM\<1*:1?1F5'(B^I_@+NT'GWY\??;^;]@4:_7>\U M6UH?)!NM48,INC>=CM:L&9+<< M@#9SWE_[5HP0OYM-V8OY/&^,IM&XN6EI@ZM&76NTC8'6;;9[VE6O5S-ZW4'G MJGG#?9XXZC]^+B\D6]X`=AO-^@S[^KD?@>4^_0^;O9QOUN@,>K5V7;OI=IM: MHU7K:=U:IZU=&8/F3;O?J??U)JP3C@%/H]WHMEHUOMJ%ZUKF@W[FD;V\3[K= M;O2[_>:5UKLQVEJCT>MKZ(W6!M]J)+"ZBBZN9NY$#F' M3NM298Q4@:*J('.)[Z26D;]L0"R^&]@>@QQ1=M?C`FXX'QCHWP M8[Y-'CW'V^.R@(\BJOJD98`LT[5B-VUT(P*YJ8,/QGKG2E0,F67&(:^PP9Q` M8:,1=EY\]&/75L;F`S[!/&H(GZ`,!:ID'O4YAKWVB:!?O5QH8FT_^EIQDG,G MO+0DQ/Z*,FS1.,4X7%&&G4^]50&`)0+L2^E[&PE=B_/=A7#S`E48OO)^E@.L M=4,+&*8_9W$`Z=-S-1N*K^PJ2N",3FMU:8+4Q_]B(#_^#>^_),B/6?V.`_!7 MBPZK4ZYNZ0+_,JUFUKFNMO2.6FLL=DJ</Z M'YG<2FA?.71O-`W5Z.XXX?KXMFW46ZJA'[[:R-':T?+%@;/+=$_5B)\]X8YE MCK.'WWF(,'E;1=E`43E&7U=K;;CBC(9]\"U)R18YE> MU+.2'N^4M0=3OKQ=OW7=Z+<;@Z9F=+I76N.ZT]>NKGLW6KUQ7>MUK_7&H+9/ MNS[A`EJ=\PA#9@M>V%[1J#`$&?7S@*,++@3KZ'_#![//U!R6MVIU_:LY%BG\Z3EWT)@P$%+.X]#]OE=]Z MO:^%15UB"C<.XD\=3WA0`/3F/0%'Y:Z2,%_1G()+G=U.'#TZ.QN4(DBJL\-[6;G$^5&2XNT+2K6CPPF-V*M:.%SP M1&1>NQVFG#+,HF;8]0*_M\QPK(RHZGK1YU:<5XRRT MCPL3#IGKL`?`*W+"X2]V6KT`(XU3#%F(`I20:K._8TS#CGQ*V*9!B+`D1A`38A*>2.T)J0G98V'JZ<7ZB2_<.'`C9 M&U(Y3P;G*]ZP\<9+7K%Z*6^8*DN(NLEP_)8/8D(:.^<G2V4X#'_N@)"0\]WO(@@?'$DP@C*=38([A95)*&H,%TOD0 MTQ['#,M2N(`Y<'DAETFZ;ZAXN&$,$A@@%7MP0%JQF"B[808!\@W148@]P44) M5^:(B59*(^<)4`PPQ688OPB4G=300/\^("!O=SG+XRKO1@1K8\X#;V&-'-(? MXM^72+[)SA,@J85E(U],VH901$%NR5)P68!;Z8TQ.V(E7$F3:>3CL*)!J\* M#B(?GJ-',+ID0D!PG1$.(K@VS0E"P3WP"^H$504$GD-+!QB1[=QCR)Y*W-Z= M8%E/V"U(JT*B`/PB4%`CJ@3/.=P3\-$U.E?/)[TZ,DT`94W/-@,[5*Y\^`^\ M5KC9L`904?9=^&[?MTG+$%)`88C>;?%R5/Z)1G\LP M*);GYH9#AINC#U<3RC>W_BAZ1/0=N)LLK;%X:=U.4VO5FL5E)%.L&KD/(XN7 M2Z))`K[D:DM0+Q'0$-%2K')"XCH))UPD@^$R.XU:886BP$-NX@58@6^5UH;\ M:R+.7&$<@'DN&JH)Z:"F%Z:%@6Q1)2CA*(@G(`@2X?"P-=`SB'DBEPZ9Z_(; MG/K-A:0ZA;$U5BPGL.()EF6!KT&"5\8.#`;BR@QGBT,^4<*NF>#*8CP^&F=N M_%E2`J\4OLWN,GR82A1]' M?.GP#@`KO?O"#+M'L`@_P)/GLCI'D"*&"OS\0`6]&%S,^!O_+A/L00+ZSJ*I M:UJ,GT.F]2M_Q395O/J`E;0`^P)5Z'@HYSZ`'DZ+GW*)-@WQQ&#LOV.^1'ZQ M%.@BWQ.1F=:X"(#CNW>!%,-44LEZ35+THQ#[D5^',=&6$&V6:4QX_@(F/D!- M*(X`5V'"LZ0P#?Z.A9CUV?1BA"MH!4$1^[\,/I?N@``[^P%8 M/5)<+ZBM910XPYB;]Q))A_.O,EM>%M^[?!AN-H%E*+8/$$/=B80^4R&W"P_H MA85[JA"JETB*)"2&B8B(XQ4D3:*JG`$FHVY\(E1N4.'[XG%YA+Z;$BGX#N\N M2N>)C"3YQ18Q[Z%H7IHQ-"!=M/Z,,A$8%@7_=4:S#&DY?XC@C@E'<";(J'!? M'*@V/^)B[U!>=8X6`4P();%$8!<%\1*!',T-">F3-4SQ8E08.<\F^E<+#`!` M%_&EF'RP,1R5#TM,CS3%XZQ1JP4"M!,]@@8_YH7\A$2+D*)V.4R1+:8 M1-D*+PO\*+L,3&J'Z[('-,\OX;:$'X6+AW110.1T^DS5RS`)G2$!O^=P&6DI MB;"LNJF%3T5F-_7#2$O(A&L4\W"&69'="8,G-PG"VET1R"^NS^-`J?PQH!*? M2G(VOP>*/@$$0:*,<2L"J&,P"IQ['#.3%@+551Y?(XU5+- M!"00S0M"\R)SS`\D_+)TG^K1B1*2V$/SVC?R+D!7T`/3JVXD+(YFSMR0&A*F M0O/.[PI4ET1QP8J;=S/8&4(A-;U/<3YAOD@TC45XH;C)];DE/YI\DW&Q/ERKFB@6Z3$?!^LJ@&R)KKY:4T>S1692N%1NB8'1UKG,(LB' M7ZX)'J@Y22//.O.81JH.IW(8*3WEKT5+)#ES1()$WS,)1%:T;"2J7+N\%(Y"@D3R>8YH@.\!ZCP0%EA@3\99.[_M,*$*# M*'IU,H-)Y-]S:35EM@Y>,UAW%N@!>"'L?<0X[!(,^_S'QQR&+3(KYG!*JS>U MMGX$EJ7.* M5,$6>UDZN/48?*K=YPB@2"_$5Q>:XS)VCW$>F[P%'9%?IR:[]%HGPKS\R-EYOL\T+)S"(5S&$4MHFRO.$K)\?`^;^%$ M&6$\"QTK+)M)DK/BEZ*HOC9"1F;!D7N.A3<*4-=XEIC=<]>2#5.Y/M?NT;6C M9JM(!&+2G[G7)!$B%KMCGYY@E'_&PU2``R::+9F,/7.+SIPL,%MY,?.>%]P* M>Y[G!8;('^/B,\MA`HB!+J!TQ$"/(P\N4=9"E$C'2MK2?_<`E5;%\4]'KQ4G\CKR\5!65%!/1K36L'L&E[A(*EMX M/_`N$G1#E)I()'[#O!I39IG"-$C8F'B!IY MU`N\SBW5RKBHD7#QG"P,4]CV/N>)IH>41.^2.]$7,D-#7M!TNUW-VS9]. M5D>:'I\LPWJ*:'*X!R_E[8HYB@2/2G&-LP]UN;Z9BLUE02P+@4H&(X!,T7=# M:T/SS1`43K314?UQSM'C:,873T@K6)/*[P)A2J;Y\+K`#@'T`2DD0,EN`OR/ MWU.PSBDW4<(-90%8>-P8*HX@T$RP=M)_Q"9L-@46X&1AI(ZGX="L3%;9%H[$ MP`,*]BV&5)*5E0?E146I&?L`.2.'V<5=3K%9"6PQ+_3159+L."_Z6"5"0.=C M#H#BKBY",42>F5@8T@8MQ(V+HW$O*+^;%D0_A:NBGF"[YA16_$0LDO;RVF@8 M*H:1XRBO6^T&?BB&*L)IAD70P(:`-E`&X!)#6OB.7Y[)DUQ[OE0^,PRKC1[] M7*>C/@]_N0:MW%H4;9+^,!]/(5X5:E_Y1?'U@CC.=,A44\Q??*"W9*(@<(P) MME6"B\F=H3R$\R*'Q1#@]%KDPY;43RZ$Y8>=N\=F)1,P:0O%?293J.LH.\LU M%S4Q!B;*2UYUF==2E"E&+`H7-&9[L?P0O573:X/>M79]!6IVHWXUT'K&8*`U;GJ#3J/5;=[4:UOE MASROY=F"[F9(HYQ>5W=@RW5!*S.2Y7W1MFIO=C&7OE)7-"4YR&V340X&N&+R M:;V)PRT!9FL7L%S6M2_3N8QF;4[GRH@E5#08)0$_<8HOR&OR3$6=#]SB@Y9" M@(I^C(@A([M/1L9[U9F@H$CBS[GFB',/6?3(ZW9YW&_)1W%&"@H+ M"V-11$0WR!'DT@$I#`T*W_&>C\8F7@_HJ4U3'K)(J7(^!KSLHC\*WQ*1'$$@ M0O<7O;#A!7^V*'K#XQP*L,X\X(`3<.>;W+V#QA:+\B$BN'3N*<@!!<<JWV9K.2>$ESN?6RC+':0?)F(ZO%AQ61\\/4:_7Z^@/IFR^A/&^82Q"E MWH2Y7IJIXY2;KGDL$BEZ/,W@+Y$CPW-0GC?/.%8$JHD5$FH/R94GHZ8 M>`E1N?,PJ!`5T3C,?"FD"2E)F#_%M=UGT3@+/5#H+>&!;TE;8$G%DHHE%>^" MBCUVS\.20(>)`90S3L$,I&-_`JI;%##/EO0GZ4_2WT[HSV86^JY_D"+/"Y?S MB$%>M"($8N6Q]-P=\@'-$I)*)95**GTA*C5+M+DLD8FGOBD6[W&2>%^'#)TM MV#5@Z/O?N?'NLA+T>?S6O+MEBD-_[+"1\B6U`5PSB])#E,_F=Q:4G6W]+]>E M9#>1G\F'&3PQBS=M^#("9KW@_<&7!8ZZO*=0Q#%12RA,;?0<7L0&V7S)A;A3 M!^+`M,:IWY"'D>5C/Y/0+`Q*$<%9$^%,SX6AT%9X#%8^T.5GN(ZRV,:TB,51 MV#\KA<,30R>\8-&\PP'39?EI M%5$3S6N(H(G/0;QA9N'Y6*'@4KG)CX:Z`HY7&@H#)YDMIJLZ?0X-#_`D)\/B)M+HL#(Q8AN87#;`12YI M`WU#A>0,](8+8H[<8"GDFFC"%I&9-9E#%93&GJ.67 M,E)!+GT<^R)G_2)+LTC!,+<[-\040F`R6/XKBP^`=Y.L\4TXR=/N.,GT:2NA MM86C[E%HK3R7W8F4W_/R?)176T@RE0(*L4M<>EZ>RQ)SH-"SU,&[Q(=KEKD5 M!K,5/+D865-@29?*OY-LAX2`&/Y`-_/4CT1V9+9N*IL41^BS3(VK_(Z8,!.# M3&C-R*+5E'CX)HF\1+AX*8>7,G%@A>3:+I244M)29'P)-&%2W@/F3[WJZ%1/ M??F""Q6#\$&*0<_! M_"1X$.=LN53U),Z()/*DR@5GK^5Z*?-.^.(1%K>`E0:Q1DH83WCE;F2/0ZRP M(1Q/68U%==X7-75-3%%.=JV0^*5FVT#`\3)]=!G,KS^M%\%-`%,X;">>)/D8 M'%PBEY]K*YA>SJ%VJ5P[(\JIC_+K)T`E:%)FU:'P@,\<8Z M[Z)&CW%7&X^N-!>1&J\%Z$]254J$<-(8O.8-KVTH"IGD;PVDI(EI;QHE7P5> MMQ.)LA<2-\(3(6'O"8#I`9-(T`//7622`)X+N22:Y>JID!3B3(9Q$'*>@A(7 M@$J;P",>[%4)OV.-2*Z(\,CLN8J1(F[/];U[#;-\;,X9\L@1\1Y]Q>#H3`@N MAUWD&+,@V#D)4!!N#@1B&?F$16+X9L:_YM$5AG^M-RYKR@1^Y^&=-L6WTUA_ MQV:`$?FK@GTELJZO_CA8&@,]^',,>?'Y$DDJS+5W22MH(DZ_8%EA.6^')V+BY M?$$/T,W&GN_Z][-<:@E7,>!.P,HY5.,Y`'ZM>7`<85:/8Z'!AJ*2_<`25:XR MG>GBI[0VPR.OG9OD`GHN]Q[#E0@X+#0[T>TS'^E78!Z2'C-J8!DCK@;)]D;:(=X MY%4P*&N6)Y8"T0D!61`0ET1XD#H51")J4+-"KA3SF2`ZMZ8LQ'4Q]P2D:"R3 M+?85S@N8'"!I9;.DHBJ(18DQ;C$LTM1/K$7B8%O:P"7[B0O:"!(R)4PGY7T# M?X1[I2[WB6AX'_B/T9A25--RPEA^"JN?Y]Q02?':?'15(KU>I-6))15M3D54 M]XV*W),0YL-%8X8\UR\M2SAW]L+VDJ:;HX*6JV%(0A429_*F.&5NU4VH3]Q( M$TQUPE*]2(,.RVK`YT81JTI-:_,FM5Y2485JRE-%IS0]!A!(Z`B))1FU#](U MBL74Q=XYKR\H0Z1#%\R">OL-OV\#%!Z1G'!H,W&S"&D2U2$D85)UA*W,=&?_ M(:4K3BJ#$%R$C5&$.?#T?%'T2MBQYJVA*="3G#&N^J)"C16%>"E;[_YR_L2+ MJIZ2U/?C*A_<2,".<-RT!@8R-G[EYV5RQQMSQ2OU#F?97:F((O)-A1"4H)H[ M2S)K>-XK!SU:C4E9S+N@\UIA&LS,-;"D$`IG*IG>FF(L/PPR#=H.?B=N_%QP MF'@6KWJJ"<;?H;V084)4#_SWV'&9J*R#["K=>P80IUCVD4,DOWJJ=TH"!S]1 MP2ESU742Q)PF9<@282=)EE+S=T1ZJZ3)WZA7F*'/BV0GZ'&1UG]>]Y*4G'1] M3GH;L:E2)QE/L!PAI'MYEE$"?4ZT1VVN>=E.E#EQJ19&6J@,4AE)$NP+RJ`\ MNK7M$,@$8ZS5CD"F1"NC5,/2$J;)?\7X5=FS_EG[5YSHUH,/RA627J1<8Y&@ M*"TZ3ES]M9X=<%HP%W]%(0K/=<@YXSV55<0__>5*R5NVR M(W%U0UQ5L*828M(CEGO-6[?1KOR`Z#:_1!DWN)'6[7]'D5Z>RV M`?0&TLS*9M`]RXHG,==H"_4']M7^>5%3XM?;O#C?'#F[_C$H[457N.U8$E+[ M:F*\'F3F(-%HJUVCO=O-OCRO.0QG,=;F+)E1X^"\Y7DCG#SI2)`]]]VMV,[; M>DOMU#O;;OO=?MG-L8@VJQE0+DH\<^OOE?^\!&:TU5;+.#=RT`VUT6A5:==G MP3?/17#)K.'^2+EFP60P?"*OWA^FO6\>VZWE;KNS[K\]-%\DF62?L>"D3/ M*MI+I>2DZ4K7*V43J<263U?(V,C*(>(?JR94=*IUN4J^>9I8=24)10O%8H'BZZLC:-L_%!4WVKIIL&4#8 M41O5,W-NN=>FVC::9[)7O:'JW:T#M,[6.6H`H[3]>.BR/7+G[2<]VDM.PO'0 M6SI*./Z@>OXK'GI#Y_@X=-2"U3R6Z5_]4WH$P\/1%O@H34 M'NP+QYMXNM[-NPL.(A-,3X]$),@.X]\\N@338Q)59"+IB:*]3"0]2OYX:H*( M3!@]^PM6)HP>C%54PB>:69;V%*WR[`DW1Q`)/PF__<&O^FJ'3`,]DWM2IH%* M34*F>TJ58D.N(=,]CY1?'*^M4J9U2IM=%4!6"2PY+>%"IF^>$W'(],V7VJVT M0!ZK!4C"3\)/6B#W8H&429E[EP!D4N:/S04R*7-C;KB_#+CGSWB<%YB$H(3@ M,OXPEX(YGTZY(B62YT[:S'D_\"(GFMTX+@OZ9L3N_6#V8OF2AM$9]&KMNG;3 M[3:U1JO6T[JU3EN[,@;-FW:_4^_KS6_ZM\:K7WN6Q6`%%&)-:_G'STL65\SZ MQ(C)?V'`),\2_IZ:ZMLT+-M3GM7Z"N.+:D5U_?N-==YP&[G=,04 M[9:FL3YB#W7AP,*>P=A-^%[YA.W@%4-QO&D@T-7$C_I'OOWZ6^U>,<]MVEK#_8IL^UQI^H-QI MJ78G](+GLO7-<>M0S\DURS7O@/0/0^BK(TD^Y;1_4/N=M"C8(8A>5J>0D#HB MEY2AZMUS<;_M8:^G*TNM9K%'4Q))ANI)D!U?O%\E@QPJL.E3"78XU?8`$HH2 MBA**IP3%4[$8K#8-DI55Z4GKP/%**!)2>]"8.VK7J%1JXW'O58JKQWVY22A* M*$HHGA(47ZSA#+T^%QN]1>!P,?+X:^!/61#-OKJF%_4\>_!W[$PQ1FE!IYH7 M"SGN->OU]G7W1NO4>SVM46M<:[U>O:49@\YUKU9KW!B#;K5"CO<:].J*4(S? M_8@INIZ3%8T/!5]CICYDL1H'#R`^^O#MCYYB6I8?V)3+]^A$8^6F=WNE]&[[ MH)=-'4LQ6C4U!_7^AX2*5(7H"+V\,%!*2]FCUQ]4Y6W^31P4ALL_\4Y5HC%3 ML!")ZA!'N`U]W/-NQ3,`9 MWAUIX@=,<9WOS)W!A*8'@(OPCXBFSP+8,1H1OH$!:%+E/O#C*0[@PKKXF_B" M90;!#`-9\B_E7SF2`/:CQS^!$AIP5*.IQ'#T!5Q;=L!Y%%*LP(&+Q#%AN,A7 M;`8?)G"7*(]CYJF()G#*INNJ,(PXHK>`2;G#>@<'#"\S/$Q*9T%,@QO%?V"! M.71<)YI=*G?C."1D!40"?/!\!=^G.PS>4_P`1A@%[.^8>=9LP0C)\([O72XB M.X`$C)#"0JOK'#6IHQ>BVLBT(C\`8,`"V!,`P.7I%@)&M`!^FX:PK"*\.*JG M-%%`87/BQT!.,)+II7C_M@">B3DC@AFR;%,8T`''$@%8$!X`^2'[$1"/@BA: M1W6_+9>^9%('C_?7:[4WFZ5Q=-YLXE)#XV?R9JZ/G,M&47Z8>JU>7W\@??,E ME.?M*2%\X8R`9($\;68%(/`R)&TDWXD9?&<1##4-'(MN('/NRBQ2\>8"NZ1. M29V2.M>A3M.&6PZ(D]^_@D;Q-GR*4%2%FQ".W&,!_O(X=JSQ#ZD5[]0A`V!? M8(8D/./3RP[<]-/Q+(1I7511;:KF)TE;DK8D[7V1MLON31>E?2&0<\K$2WF( MJ6ZH*%JN,^&"-HC=EA^[0..C$;.XNIDJC>8"/;?(!D!_\2PWMDE0]]+%F!8O MXAD(@3T,224>@@8-,O<]-C[S`\D5)%>07.'%N`*I[+RIH"B@:_EAA(:#'+MP M9\@+V).%7"`Q"PD%.W#N'<]TX1'V-`5>('1D86[*U^8-\&J'(XJM9*JEX@*\ M*L5[2>V2VE]:!D!_4JZ\/MJ\@?#A&D;J-,,Q"@"N_PATB?>]/QG"S6]S4YZI MC)TPPJH\0+ES+V:OD:$:39&@Q/M_L>1.1Z[`X$EAH+;9A)@!R!,A>:4<+\;A MTA&`#_B60S8WFAYY#J@,Z]@$+BO!-"I@Q@Y)\`ICEPRIJ/8%P.HSFRT6P&&@ M`,)WL6>Q(#(=+YK!*[Q%;>3#(`%S)L,8Q#N2Y<35H$0!,ZFM`PX,L-,F\(X' MFU?"[VCF1?MNH(I;)/&C9%98'&+>E2)N)M%Q70G9/W#8(W]W0NN8 M^JC&.K#XS/]R2:5_D@E3J[LM5E+P^Q#&_8885S#\J MPAO2`:Y$T$O&`WS:;, MLP7`N:4\>?2"JE7XZ`3(ES9R'6[@=MBQ%"XZ>H)9[`#)N3_T-KEN?NRI*+IR ME+=`$\3\`B`T0`_`3,`%GUR39%3)2(-C^PC&M+D[D-!H%*.$EG=SO%VT"!3Q MF!TF=IXP(H7/QE6$H8IS.Z&%3\)W.5P;!?Z$UH=X`X_`:9#,]PZ1',;R4,O+ M.3GI=IG$8>I[`4GS/\SFQ%=^CKQ8264M@`I!KRB+SL$2-IFGP+>I2BD`FA$L M56S)/*42T]?&=&!5GKC=TPMZ&K"I&:2J!+GZ0#OP+.2R802XQ(OGC.A`\.>0 MH;U/^3LV`^"U"O(H>TGE'+7$*=%7&%&Q-8=8ENG.0B"%*5PV,=HX`//+U,<1 M-,_5N:\&ZW+CC)Q7![ISLW\Q8OC`,HN/0+ M%Q[2(@C%]B(+3HXNK3'>*T1^I3WHQF4CV0+%*VQZR'1"9D[PX*>#JU$*E[T8 M.L\ET8><[$#A!PL[%R(OF;;2BGZ;T/G3[NA\^K25WMC"4?>H-U:>!^Y$T>ZE MTAJ/&TCO\;]B.Y4\$4'CR10Y8B@0]._8P9O,00(!-0IXX03Y3E2\^T`OBN#* MG08.<,\I&5@`Y1/*%B\4D'H!=8M@!IQUZ@>DK\6>`U+NO\>.RTKB]9"Y#H@5 M_()-]A`NV809^AYN&[F>[8Q&C-3*_'/<0"P,S'1GI^)$OK0F#"^DA("ABJB@ MNHXC%.3RE.7P48<9'"_AY=N<9=MC]W#_/*!-VP8)`]55X#AP4O[$L5#O\&P` M*_#D(!8+)9:9X[`%X2"U?JM<&@$8Y^WH%DSA3U@0JL3MDJ@8N'H86<9A(71P M$;M'59<;Q/#TDV$9B56)Z:QH=DL#7U!9<='59N=C880VG)-S)N8,Y1QN3L=Y M83_".I\_&?*\"?Z90Y_D?$C[AD,'[IOP=<&+X9U1',4!6W`R18[*_UT<\;I) MP.J2(KO9DSLHI]OOMSKM>JVAU1OUNM;HMII:]\;H:3?MMM$;])HWS5K[)&); M]<[N@UN[BJ90"44Z-^5SKH2B#&O=HBIQPJQY!%THI&[_P0F)M($?9$&NG7HI MR!5!Z^!@>"(PX-R9$-WGB(L.QBF8+!<&P,)8,%DA!!8%2Y)'<24V&R&WRW$; M%=D-7"!..,9+`%1(<\(>_>`[*:^!4/AXA&#*H;CN^^=M)JK\UNM]I44S;YP$ MR=K9^A5SZ,=1?HA\#<]+)5?<$];*5TG5FVDBA"1L*Z=S\LN,!R>1[O"874<6 M(_$4%U]4Y(%3DC4G"DPO'*&1);6MS)2W)CI6G(@/^BX+LD@O?HJS\$/RV0+# M-.^9'X`_8<($GEGYB@+H"ZG[?H^L,0 M`TY1C.*ELH49`R6=\K.Q-_NYXH#4E0 M+BGDF.`"%V'^'F4./6J#"FUA5`H%J26?5"6,\?(,E;^)ZB]^2N@>:3P$0<(U M@\44_D&\DF,4@C_D5X+N%,X_/N#[?-E"7EFP7.X:]W@&B>4'@0^'3?:/X2S_ MF!#"0,0R^4KC(8HRZ)D4IE_TWN!"6#`I:?R244E&)1G53AF5`8SJSWF=(Y'I MD>;#>(KF54[90(H1)W[/3VB;N`8J95Q'X*RB9.Q##;%@D*L&-1^_V:27\T$Z M%(!8S.A%*R^/K4`_YIQ=%$;(]$;,7\A4QU)H!KGP9QP_1&YB^*-#SFO9TOF\ MWH%^B8.%1QJ*L'(1W$+YM?@'>@H`V/B$2D&IY(X-A/^3B"'`0 MQZ68.YM17(4PC6",@X>5AY3PD;%INH%WZGH;3)91W&)Q@YEO-X^Q-OR/XS$B M]Q@8'["Y*`Z0OW'IA!+ZTE,I@23U50%`8(`"]/)3AHOG3%@JN5/2O':*+;!Y MXC(2)/XJR6ECLW*1*0H9,Q5MLR"<@DD56*%)`79)'XPA5BL148#)J2V<8`+0 MG&5)GPF*RH-[YL'EX0K*@V=SKZW@CN3[2S@D1;Z4.%$26F%9?'!^IKPQ=CAF M#.VCY!4.N&:3&D/-1'^#(1Z`#+E+@:SG,UH!(0SAC]"WB@F_.0M-HG])7-B@ M8V5:54&H+L*^%8V7DV`6\%FZW;+;:`79EXD>QD`)>+DPE8E21W*PLAEFM931 M9S?#K,MFF')JV0QS03-,O7/9V%DSS&M0129#%N0B/G6*^&RL"`-Y;HL!V1!S MFX:(L@_F>>]?-L3<"^>I:!.GU57O#U#O?J,C>^GGY)KEFG=`[(DCIR`3E"$->#RL?UXZ+(]WGC;3WJT@H.$XZ&W).%X MPG#<.C3^^,K[Z/4]U_>1P44RN$A._5)3R^"B!<%%M=IE?6?!18M+R=%99!Y] M&5@D`XL.L6T96"0#BV1@D0PL.J&`%[GF_:Q9!A;MC]*W-"KKAMIL==9Z]T@L MZ-+7("%U9@1T@EZ9DPI#D%"44)10/"4HGJN:6L7`(BG"GJY@)B%U(@0D1=CC MOO`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`U^L=0],TO:G7M/^MU6K-;[=WU]_TCOX-(Y!J+:/VK?9*<>Q?7CGV MMTZKK7>,]K>;;N^J8S2[FC[HU[7&3>-*ZS8'AM:I]9K-UJ!1ZU_UONGPXJ^X M$;&/\N$LBF-=+6^7).WY`/L\$E#``L4/-W/RE?&!_',*PD9!X!"DL^"&M2-N MMULIUP8Z;^:"U9.5?_&4S]BP.<,RT;BSJ>:[2F-$L^E06/(H=EW>0/S^/F#W M9H2QQ>8$R[HH?AR%D>G9//+99@$]>,U8,'*8:RLWIH4-J&=*#UZE8#65XI[M M%8U$ZUU:CZZ\-4.8A\&PMJJ$,6(TC@`O^X'BPT3!HQ-2H+-O.S"?G32GI\AJ M^)GY([ZI['CZ'^:7E/UZ_>&=>D$]KZD?^@0/,@<4-;>SKX'S@--#FD2 M_C@^K6(O<,6)0N:.^'JI_3?,P1A`%H;`I?M#8&+B_3$N!S:7K6W))/!N<9F? MS1`^YA>`4>GSH!1Q]!2.#X/8OA7S"$4,25=@B(GCB>/'PU^"B<7189QL_$=L M/^\K$S,"WH2)#4OQIT5KP>W9\B M0&`D[(8.R*],&8`'WH3!I@&;./'DF%%4W-&C[W6 M]A\-%!* MLTO$^85P84^F?LBRHV9/@-+T!:8>\<04/\8]8J8.RC1$OX"*$4M@Z4]9(+@' MLB0"V1CPCG`I=)Z`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`R MCNG@\)E2U*G$@2AK,,J>%)G0,`)9(%?F6#^.'6M<'C/+HL9LX^9EN_DF24M> M,$0T#OSX?KPTEWBI-=1)=U!0FJD>@C"0BFEAB/F)><[]0OLJ69=$5G\H=XIH=)KJJ`!ZQL&C@3,W#-%#G&-`P<)7_QYP0FVG:3L0L MI?<;;@A>_R=HG_>.I8*^9REO0]@^E1?IO+O\@09X\5-^D>D"MUMZH6<[!&I'OO\3K$OWDS3*-8S48< MI)*>)*'$,)4]#MY"\NB[NGZDXAI^8`-;9)Q/WO1NKT`;F#I`_;=]I=ZI8`[87B255T:`6>FA3:H3(/'G$''XO%*.19 M!ZX<"A;+O'OSG@I;#)&',F!/)K)/)W(8<2\8A'-SO$P"%J5\GA2:$8(HN8;, M!]-QJ80"KP9S'[O`]&;$I!X<]LBH"`UQI+'#1KD=V,QR0AQE8GZ'6[;_Y?HS M+@F_IKHG8_\1N:P/$CLP$*S$`7S.CP.+A:("3H@KA_%H00#N(VES>O0X>K>L MX@T_`W[S]0=?+I6!"4@@4$VY9QZ>'4/QX(%Y,=Y$H\"?\)O0=+$0$=R[MF,! MFK"_8V=:KA($0P4/CCC`G^&6Q+-H=/H#@O0W_;^&H>^QZ6WE:V4F;X#LJ M<98@5T(*HI$U,5A@28II/R`#`MEJ@IS5]$QW%CJA$/4>_>#[R/4?03+V[=@B MINW9A9[22P9&-FK:#N>VD7BV]_2$CQ8'*U-8TIZ;"^,S%,0C/PAY%2K@R+AJ M(O_@Y]QQ4`EF-L*'!G]8^2DRAOC4`21B#*BBL6)/,% MRR8UC%EC#\5[7EHNO\=$I+_DJ"6XF>=SR"1S)^"6%]IZ1/HE06;;9]1C'=&< M-T@KR"O#C-!R:$_XG2`^H"S*(POD%'D::Y[&;0F+RTQC*84)=H'W.3<48($W M#PT(N;"`U>_BN?[6ZWV%(>ACRG?H(6`Z)+.&HCA:6"H^]OXX3KB^I<:XDPMP MA<2P0>FT=3IGSY=1VP":.9"\&`36+>+6K3^OB%NKM7D1MU/N&'^>4\LFZFME MI5"].^4SY:(H`TI!<:D8]L]B!3LI<7>TX+AUGO8.#(FIU4_2>:$-ODB>SC%O M4)[@[C*MJM`Z=G6L9NI-*>L\[UOWBHY^2:Y9K78@5+4[6795X7'LEX M6J,*CY]*U\'5T8ZIC7SO[&[+L+^&VFU6KJWQUGOM&)5+1-ERKUVUW:AZW5#I]M4%')[@?1V]S9MG_A[9G))RU5[^PXZ_;X-HW\K7*\_-F)=@VU5:]< M_:QG)U0"?LM.IVM%?I]J7T0)10E%"<53@N*IJ,BKC84\(?`/;B&LBIJLZZI^ M1OI4JW4N:8_UAFJTSN5@]0Z(C8?7E*78**]J"44)10G%O8F-TM5T$L;:#=WP M^8!CZ8J7:S[/-4O^>*)VAI-SQ=>ZE7-D;+E70^VVSF6O';5FG(LYI:T:]:,L M\UT%Z>XT7?&&VCX_5WQ=[52OJ=/SG=+U6N5,J<_==%-M-*0G_JP-,!**$HH2 MBJ<$Q5/1D%?;"Q>9":NB++=!P*J<5+EMUTRULUX?N1/8J]Y6Z[N6IXYGLW6U MW3J\NBR%1WEA2RA**$HH2G]\-?Q-QV*QW=`?/U>NZRU6YWHG7?-RS>>Y9LDJ M3]3P<*RN^>?[=6K&V;DX=+73K9P#^P7RZ0^WI"H.GZ;Y_6V^K MC59W6Z1X5RT">*MO;WRLVE;K+;6I;UT/I6J[-5I;NPM6;E7:5X_;&B.A**$H MH7A*4#P5'7D]YWS99KAW`7)+W^;;>E-M&%MW/=^S>+%UT]QVLW*:\=8'6E?; M>E44@:WS$FJ-'9?0D@+C<5\O$HH2BA**IP1%Z662-EB:\C=JW>FJBFE/',\) M(Y2L'UBQ_QYONI7O92>:U55'\E:-;E7L>MON45>[]:T]%1798T-MM4Y<@7IK MJ*VVOI,]GHJ98#5+^Y@TOC\4DWJV87[[/,FJN2!:ZW69.86M-MM;FT6JME5= M;1A5X6`5$=-,QU-`[AJ93H!+BJFE^J,9!*:WWP2E'UAYMAAA'H'P53XDMJ': MU5(K15.M[M9FQD-L66+)0;!$WWV[@_.0(;]@=_E#N9>>BP7GU_"BKM]WMZQ-5 M3RUM5\9`>K3G*GWUAYUS<^204)10E%"L+A1/1>->'=Q).BR M/=XEVT]ZM%>RA..AMR3A>,)P+'+>GR,3YLA],0P4RS7#\)=7O>G499J#,3+6 MV/3NF>:Q1]?QV"OEYY3UVLX#_OV/G^-0NS?-Z7N1>O,'FV(0H'=_[826ZX=Q MP.[84W3E^M;W7V$JY1_)"S>F$_P+_=0?O6D]HW^KU_1FK674OM5>*;'G\+>F M,/$KQ6:6,S%=V%3]E>+8O[QR[&\=N+X[1OO;H%:[&1CU*^VZ>U/7&LU:1[NZ MN3:T^E6_46\/:O!%[9L.@_Y:N]3;V497K+NXP5MKS.S895]&`S/P`"3A5Q;< MCLV`79FA8_4\^]IQXXC9=W@4*92VWWQI@_V:7ALTKFI:XZ8.&VS7FUKOYD;7 M!OV.T6T;M<[-=9-O$$]4'&@9385\?O7E[N[+9[J;A72_5-PO"?HE$;_S)OV" M4+^57?8])8PG$S.88>!"-&9*WY],36^6&62['T+%,ETK=GF,*3SGL4AQJ1(K M`UD"@0LC.:%BALK(=UW_,53>.AX,Y\>AZ=FAPIXL-HVRQS%J%8XO*2@UW08( M=?PBOZN\"+.<@HD$U].AYH`JV$?_RZ=/O:^W\)(%NS6G(2"]Q5P,9;8`XWYY M5>.?IZ9M)Y\?'3L:__*J6W^3BGX60VI_I0S]P&8!/E40THK,3;S?:K]96Q)+ MWC&6O_)2W\NI]SKU&O)\YT?8O(:TOSOYH'@=)R3^7S7Z!U,.1>1Z70;R\$[CJ!9K;7FR'UO&4X'0G=&>U.:\/Q%H7%)".6S<;;DMY10*"K?)=P!#TPOYU@V>&$>M-M=6N5.;A MB^RZH=;:YY=A`V?=.+],JKK:;NX8P^7M<&;FH=_G_-:*I@S+E\C>;X.M`P8O M*U.[8MLMUBYKI[Y%_;);E;HRSSA%&=AZ;KJ7A*"$H(1@U2'X@P#6!2&IVP5@ M+HWBG$Q=?\;8+0L>'(LE`S$;XQ29%Y)>WW-A"/KKR^@/9OGWGO,?9L.\C@_/ MA5'X\G&>C=YUK=GI&UK-T`=:H]_4M=YUJZHUMK=OOUWL'C/'-WW]TX M#;K$/"XWMG,6$M\CS[U)%I0(_L/K^8^2DO[P.PP1,)>7]X]\>`J!.<2#@->S MDTB*^RD4Y)F&@\HPS\W"/-M-&>8IIY9!<#+,4X9YGCB&RR#`\H9EF.>I;UB& M>4H[_G/L^*C3H7H2L`?FQ95I=U`YU^6VK:G.9)];MVFMV#YWW#?NM&)2!MZ] MXS$6H*$$G8K3P+=C*U)LX%6N/]U[`MQ5A7M6V<7.&@89W?(>F/' M=_9I26VBWQ[OJ%=HN5PU4*IIL;^5VGSWA MYN@AX2?A)^%7%?@=1A/>QSEN:5)MU2MG4MMRI_5.Y>Q*6^Y45VNMRID-M\7? MFI3%SC8F6$)00E!"L.H0?$YD_\L&Y2^+_?_H/3`O\H-9/PX"^&M')9L[C;YQ MT^]UM9N.H6L-O3_0.IVKKE:K=P9M8]#I=^K]'X;R3\S@WO$T$#W?MU"0%9_Y M:;^OY;YRV2AZCY'Z(UB_%@)0WG/9ESZ/S(GCSMXOL9/>4;3^9.I[#`/Y_9'B M)#!2J;(!?&-BQ+WI60P&#!1_"`(]BY@*;\?>A#PV%!H/OX7PH#;Q']"#DXSC ML%"EX'U>%AJ/3#$Q^O_'D?RY_6#0?@XBM>QC!I"4!):C-%_IFC'W[=:;?)!] MB:C28/[DCY7P+A_.HH"V5#0ITGE2J+FS>02_KA\NF'WW M;HP5T8[)QC@N)ABO7]9J2>QDPMWS&QKBWV8N'-L?97\O#,/.A6D?71#I0:%U MS2PV&;(@!S%]`<1V'84Z9ZW8$./UY0K.,@=9_HI!$*+/"^](S?%L`/=[+?ER MB[OG#_,1KC`X,L=T]^_GWUHG;]46A^F5N]+NSMFQK[UVFXN]8"^VTV=R\"/# MYW_[P7?,@)P&OL7""D:N+&F:>\2(_=PM-Q>;UW:'X"?&PF\PK@&T*^4WW[>K MA_&ZVN@N-B:?,,[K:KUV2+[.,6SZE$>XH[6\"B$2=4Z2()\62)`O;+1YX2GW M*Y>?)PP/*\<8+\S44RM9561R0S7JBX.7CIB-;^O]5.OZOH46R;V/EO-(&![4 M;[':H<#=$#9SWHN?;YS0,MW_R\Q@X-G7SVJ167(Y&$9GT*NUZ]I-M]O4&JU: M3^O6.FWMRA@T;]KH<-"Q2Z3QZE<8N:X9^C]^7K6N;.4#+W*BV1_LGN*7O>AW M<[+W5>NO?OW8[UTK'W_O\V4O6E31Y_.)F2'["EACS5[>O].]:=4-7>]JS6ZW MIC5JC8[6Z];Z6JNL:!W^9?PO%@I/PC[_*]/Q6;12R8 M.!YHBM'8C.@W%R=0'LU0,6$\RYPZD>F*;^%+)Z+S,NDE4QD"+$PTKL38SA8> M\:=4'NIQS`(VG.&(%S^E\\$3-(=X*/*584S/*.SOV*&<27)FO=85L1KFV0`9 M&");&B[Y4NE9%K`CQ[MW9VII!)QER)B7+)[[MCP;1C$5US&'C@MHFCT6,!R* MV9?S+&N.QRQ"X"**PUXG3H0+"1=TZ7TQ9&^W].;536>@M6OP6J-5;VK=0;VG MU6N]1K-6T_5^K[L)LM>6(/L6R(U3D+7]=Q]8:2N'Q\8'A0"HY(!$<,Z,\PL] MCOLA2IPRQK^_\&IHWCW'.+[$^!B6>&-:B+P._(:^6UJ>K<3$3?S2JK%$F\/3 MDR.XW@/'C]&_B]7?D`H#/[X?*[=L&I$/145/2?M2Z;,`B5MT"0Y9,I@@^@LL M#^>Q1V`)G(C#2^4/)+JD'MR2M2`_>:VWFBK@-](AD/5KH][!CT3Q2,$15GGB M*8;.DS+!JD58P-GQ;60#L,\Y[YCPB/'A]!8?3HS=7G-L&&/)Z.0[4F&_X919 MF"+DSN99Q+X1((Z`G2B8N#2))X(C3LT9D1+R9SBWA1MI\I.!(>;.IE3"K]C2 M^=WR'1\X#@`][\<3!]#9(@Y@18_GE_E^UZ[X16&?2[2&%?[>#QP>[XW69:MT MYW36-GBCI*R@J+Q7Z\C+^;O3.X=NS\Q_G9/WI-]Z)0ZDL1$5,(W5I0MWPZ-M M[?UHG^O0:707Y]]++^;ZI]ZNW*D?EK*E&?B(39B[X,)'?,?IH(#MFP.>`BT8 M'#%Y,L">B.%%YMR,&N8,^HLT:;VS!W-//V_C/")CSUW.4DLZ!57RCWS%+)ME M[P/&4N,IFCL2?!^'$5ZR!KUF3J>!_^1@Y*<[4UXW M:ETTH%Q*8_61&JL)/;)Q+%$J-3DXQ>&M'$8NLR+*[<``2%`R83`T@Q5P`9!S))8W/',?3P^MK45"JE^V%%BY2S@DK*Z?S5EB;[U+4`7' M>`0\+.`YX!PKHG7(2Q=E"%7$)QP$CKJ$3`540B2I7S;31>'S&5;U0H["BXV( M'&I^'(41#$LVQ'38"&3@56A8+<*/FX%+\-$OV\E25F!1\48OX-33G*GQ M:0U3XR8^D)W;;;G1W'3=`FB+YXXX*@VUAS'4=JMNJ,4?RS;2PYA%*NWMDYEW:H]N.32DDOOEDO?(8NFDCR5HT9=;9^;R+P3=FSQ9`UEZ@>5O);? MZFJ]N76ZM>3+DB\?(V7ZV+^6VO0,[.RYC(VFRJC2Y5L3$#GVL_V-. M0!W]S<>^=YZC..B*5)@H$2D21A*/:N;&[WX0+LL+="9[;.18#F://'J8)S)2 M)GZ`Z1DP5//-RD$L?S+Q,0$EC'SK^Z72LVWRY)HN>M4_!Y<9)`MK5$(X50>F M->&2#K&$Y=AW12K$2'B(E20&Y*L91+"PL!B;\$?_:R$NX5*!;\B9R3W]8>CC M<,*-)S3U(8L>T6./CR(`$B?T6WPG/[KXX4*X0$HS+?%L+P+1Q4]EA[>9.;QY MT`3FHU$8B?+?L3L3&2Z^EQS?!3G"6<2/+._N3D,NDO"(Q,V;@H$6C_$B7^,@ MC!'8D9_]4/"WX[F(P;F7>VK"@-R%SMW/KSO-)L_F6972@HND$TB=T`ZJQY8; MV[3)"QZ*L2Q;9N@_P+H(I*;GQ3!W^ALZR8V.(=*5$M=VP":FPQ.<1L(?_MKH MMGB\A4>68_(*B_'LEYR-Z83_,MT8]8C M/U;/LS\)YY##PL_,Q$'L+]X?#,-V'._^R@R=<$<-Y^JU1J>'O>8ZS6Y?:^BM M*PU^JFGM9ENV4_Z@B"$^ M#6[NWBOHP!!?4`/"5L94T$G!O07H6.`V?'(&COQ@A=LQYS*$0=P,W,KCV+'& MY)28",ACJO0(C@C1,V:*[RDF)I_RLU"&>!@PQG"FN.R!N>2;$_G)N;?&#@O, MP!JO*L?W(["AHZ,`ATT<&]MTM?Z@E!T::%MUS6G(7JWK*>G6W\Q983/'2>$R M*3*#Q--2W]RW81S.M2&GWJL_)X?.G1_V:%^]E=1KH+?FB@0N]\A-MUE)2E<) MJ6=-[H4;XH/R[X_7=_]\K]3USF5CL4\0IR>'PDW&9@3/$BG:(=#B>^4MC%Q@ M?N^XD]4?*0N=%XO<%<^0]`]PECN6C(K.WJ5G."=F_R#%.#W/3W2/Z*4C.*R/ M;2][SM90/^?-&V>U>4I'>-D=K\%A?BS\O)HWR"]>U#([S',D7AWM,W>#_W.G M??S]>O`[?*/!5\DT7$]X+F/>'&4.]9Q(D>E MD6+O`!2]K:&QI3:-VEKO+JBV?0BKZJ)UK+?Y)9I`!HQ,^4:Y^457*"%US)`Z M<@):@U\>K7%>")MDY,HD36'KW859^44GW+%`+N$GX2?A=T#XG;IZ21KYH93, M([Y1I:`E(77A)K7:97UGH2:+RV$0P#._KPPS MR;TKPTQDF(D,,Y%A)C+,1(8_R#7+,).S"S/1#;796EQ0XTCMK])2+2%U9@1T M:C;]TW%32_A)^$GX51=^IZY>5C',1(JDIRMH24B="`%)D?18KS0)/PD_";_J MPF_C7M/G<1K&CA-@LKF15#Y5I MX&"["!>!YIH1HXXY$?Q!`Z5;P&&PBT\*PU'@3T13%""PD!JWP,\V&[&`8`!O MIWU9X&T:G>I*^?2;.<'&7/^A(+=[W[]5*YCEK2-6=+A)GE6<>!G)\"0 M&0Y$/%_D*A/3M;#XU+I14M`KHI..PFRCDTL*IB6:`<>B>A[[U$+ MCQS:\J8\'N&6_5<<\EXQN()\S2UL50/OL*5([N`17'@)970 M%OP`*W@`8O/CD-,8/U*X5&"3F-@*]2Y9@KC$67#/0E,T`R"F3;R@T,POZI:!P,/'&B*&6H,2Q(@7VZ#B`QWS"^#CP*CI05B"*>)FP$6$'L M$7>`XH&A">$AC@.C5S$/(>C/)'//$@)0P18L3O/W':HH0\^!:"& MU_D$\P+D@@*(RZ60HKS2]\/HR^C6!#3]"L*J-7MY::7;:=?;@\:-5FNV!UJC MUFMIO2NCH?6[K>MNI]?L=7LW!Z]F6!9?'/P;@4.]WCCN$:R=HY%;DM4%@C+@ MO.!"XDVB(FH;)3X`GMNQ!7]/X\`"Z@.<'1'/`^X'!Z^*)_,7;2BHC/=$PR\! M^T-L)^>*I_D(T_$L="R<504V[8&X3/>J>)V366#:CBDZR0&J3_G3R>I@D&0R M1+C`M/C5A/R(."]>05,:U1SQ"QBX/_`*TXMFN"K'MY'3B$W"BH&,7)PXB<'$8#V\MIH&)DXWVHW2'\H".74&+$` M&M@0T`90W(1?:&GG:,)^)7G2HKU=*I_A=D?!X)H1>`9/0*!DK9=AA MX\O\DD'?,>K9@@U#YPOFY+^5QE/:+3^=UZ"#YZ9I=^E#TC]Q^1SPZEJ*SAJ7 MYO*K<%G-X%MVC\3\!Z->P=[]1SHC.H6KF?CQY>_30;U_;=2ZNM;I=Z^UQJ!^ MK5W=U+I:N]NHW72:G9N;]E%5!Q:`2%`,&.M]@!(48!G(^,#]Q.^9@"4$8#A\ M%+745(5$^=VS0&'A1(P,^`?O(NG\UNM]A2'HXY"-L&UL3L)&A`^37H?*6R[, MQ2%,&+Y;T?I0E@G.FTB3%H@MF;LEIY8Y/Z]:B[(@[N@2^\POKP%>7F0GS3H4 M+NSY6/F,D(6PN(5K?-^0D'BY.#LG30&L.J8MV]WB=BRGLCMY=B]!^94.XDO] M;651^_T*5UOULX3DFN6:GY-!-A=^-B8[WR^O.LLGSQ[)>%>C"H^?5DK=-8NX M\73O;&W+D,N&NJQ9\^F%ES;4CK&XW=_I[;6KMAN+NS*?XEYKM?9N]UI]26TU MW[HC#]C^&W=N&.(^=_0M5>]4*N/B)3:-?*QR//NYF]8;:JM>J1JN+['K+N"W MK+MYI@'5$GX2?A)^U85?U53;=3)R\R%G%5!O=5W5ST@/:K5VK`<=S5[K#=5H MG:Y9\ ML.+V@9-S?=>ZE7,H;+E70^VVSF6O';5FG(L9I*T:];5"$:7K^]1ENM[UH^.I[-UM5VZ_!JKA0&Y64LX2?A M)^'WXL*@]/M4RJ*ZH?][K@K26RQZ]$ZZPN6:SW/-DB56W&!PK*[PY_M7:L;9 MN1ITM=.MG,/X!=R'W;,[:4-MZ#O>=/6%N]-TE[^MM]5&J[OMX;^K%J*_U;%7-=UV/6=XV::W M=X%P2U_BVWI3;1BMBH@+VSI,U7:S/W:XT=EWR2`N"Q M7B`2?A)^$G[5A9_T]IR9C?0WZL'HJHII3QS/"2.4E!_8@HYIA7Y@HL5I=21I MU>A6Q>ZV[1YUM5O?VF-0D3TVU%;KQ!6BMX;::NL[V6/5U/O5K.MCTGSX4,SH MV0;R[?,#J^8*:*W7A>04MMIL;VW.J-I6=;5A'#.G.F*Q"[OF8G-J[)4+RX@9 MMF(4/6CWRLA^8(798H1Y1,%7^9#8CFA72ZT4[;2Z6YL!#[%EB24'P1)]]^7S M3TLF_(+]T0_EYGGN:9]?HX3*M;AY]HYWG!IXA#O>6EW?)_\Z7DGQ$R9R@Z1H MLR%JNNC&CIUPC(YM*2>>/OF\[6Y?3Z=ZZF2[,@;,HSU7Z1L_5M^:A)^$GX1? M=>%7-4UY=7`DR95#-O(#EJ0Z1^;3WG7FK1VZ;;6S?5)813R!W?:I^ZSKW9TY M.X]GD[JJUW83]'EJPIX!O-OVXZ'+]G5;;#_C<5ZW$H(2@A*"NQ+Z?HY,F"/_ MA>T\X,=__!R'VKUI3M_?6F-FQR[[,A+I)W^P*0;.>? MTYNUEE'[5GNE./8OKQS[6P=NXH[1_E;O7W?;5ZV:UJ_5KK5&MZ-K'7V@:]=Z MNZW?7/5[]<;@FPXO_HH0$``0\`BC`!:)7^!B-1=7JYBT7/K]_],TY6D8N.K0 MMV>*IJ673_9B^;R%3'OUY>[NRV>ZSX04O*58W'F3?D$XU,HNR(^>8EJ6']BF M9S'ET8G&RDWO]DKIW?:5.W_J6(K1JJDY&V7_P]<`LXNBF:I\=4TOPDA)&&CP M=^Q,R42;/GK]057>YM_$06&X_!/O5"4:,Z7OP_%[,X(;_@L#NG/0!%Q2G!1- M%&>D8+M+^`%C-2TGL.))&.$^\'7'LQW+C$#2AR=#98)"O^M\9^X,)C0]D#LB M_".BZ8LQ"?`-#$"38E71>(H#N+`N_B:^8)E!,,/TJOQ+^5<8,,M_8($Y=%PGFETJ=^,X)%1`W2R$TU'P?0?C MW>`]Q0]@A%'`_HZ99\T6C)`,#YSFAO`2]_&*AFV%+M5U<:?TO MGS[UOM["2Q:U?CGJ6G;R>='QX[&O[S2:[4WKY0A MG#(+\/N"5E"\8L4;G3>;V+'1/I&\V7B3*CDN&T7Y8>JU>GW]@?3-EU">MZ>$ M\(4S`EP#O+*9%3`S1(,&X=W$#+ZS"(::!HY%C,F!E!WCK M=#P+85H7Q3G;018N<5+BY!HXZ;)[TT7!0-S='*60#0[C$&04D-@LUYGP.QEN M:,N/74#.T8A97.Y+I3=S@S""(7C')Z#@N)@MIF%Z)LH%D*(#)Q[ MQP-A>T8)(%8B!PJ%Q0(5+'0$/B(S!0TSMI*IEC)H>%5*`A)-+`\)?S_V;O:Y[21I/]]J_(_J%*Y MJJ0*L1)Z022W6R5CV,W5)LYC9R]WSY>40`/HB9!8"=GQ_O5/=\^,-.+%`6(; M<+C;K<4@S4M/=T_WKWNFOZ"'BZYMUA#*10(TE0.*32QC-$)AB7L(P8GG]]%P MC"ACUQ&[X>].:1RS%.W)"`9?`3L(!E2(4`DXA&(D-4")UO,W7,\:9D'N<@7) MK!M6`YKCUJN*0:'BC$#FB7JR'>!;/'<7LVL6T\C+]Q!K"G$2HXC455#?!*^4U9RE*53&A^N2DCP-&VTKY"% MH"T\+ZYBDZ09IT5>@CJPO?_-0L[:B\\1/#8%+[[(2)"(>G4#8(F6,$F5OU^6 M!J@@:"4.G3?Y*P7@/!@^`C%+A-XO5?=1H6+7<21Z&/7&6DT/^8BWUM1\DE,8$2'>*R9.WU[-V4QK5;.G M_:(">5>"XS65,*UX,'EXTYO+HP!]-JVG(*!.)ON\C\W@9E MT^2K@Z/1:AN5:%K500C]RAEH?&%AYL(8(C=3$F(K;?RU+D7X=UTJOFY@"C^: MD"J6N5]NA1R/+M7X_Q5AN:TC!8OI#$4V%Q0$-P05680K"!8@A@!1,.9UU0O<@[YFDD$>9K@M%$LPV@T8F01J\]Q-$&@$:2RR]U$X11L7FP2&4\]0T\# M6Z@9/:5,\%8'%1V;\/*5`H,D;$SWE:!!`1L,6MH@$K!2Z30:HE&7A$!64!I9 M(09*,JVH@-K>4$(E#;X9`8U5T&4(7:13EN4-$D<9;0'=R`A&@8'0PLW9&*UT M[H3BZLMF&>VJTEVMN[IE0`4MP1@!Q5"-L0A#7MGFIL$M;G,<>\%^83X"RE%7 MAO!%(>`*^\CU(<ODLHNQX,AX6: M1F2;YWX2=LGQ`2M_"'8@-#B$A8(QWG\8W+-LP[-\5^_T[(YN^UU'[YC=MF[` M"_US^*?;:Z\+@S^`@B)]9'KU;*X!?GX/;H/F:;JF$(J6M$8J6IU!&6_?M\U3 MCKX/6@"$0/L8?-6Z<1!-#VR@8)S]JP"A:!D&6/,!ZI(\C:\YV`2Z0.N"N1!& M8/'FQ0#VARC@[GY-VS:TKG_^57O'0H+VKVYS,-YR:'O8K"<%J(_5,P/(8QPR MOFMCJB[\J2L@Z[+YX#8\PVA@>@P9[&)`.-I`N\1(+F@!?TPAY/H8+OU:UT(? M4%P8&L)&U"=0;08%:'$P1?!?@YB\433[5F^M&`F?\QC^G!S8F)5SK8T`NQ\' M40)MUU@E(+\._4R8;:Q-`@P<@8=5FF:\->XUB=G2OK7:(MRCP[-2=UVQ^3SF M2,S%(([&Y.T*!_OUBC*XVZJLF?T#J M#>0QQ+:(GW.ZY2T"<_XZ'9)MA^;I#,01;X.[2;,XO`%K%YAVB)>-%R MN.:%WTGFYQ,PT,<39`X7QT*&&[=\Y=CK?2SVP/.!-(2_^.#0>%S!*9PLDOY! MG*>(*5]'4E7(`:>C6P<+.@=XX*V$-)N!O M@!&'EBK-`V@(78!VG0N-5\S!+OY;0(6<,T+.+GG=0R;2HT,:25,:1Q\E7-W! M2^)F+X'_H1.-#I$Z<8P9"01$#$_.$%_!&8NO)7F7Y0]]@GD0\VC\"]MNX!_#"*; MZB)>VRJ%B+@WRM#3`--H.,&,OKJZ!IMC-@,C.\MKK,YW(<)L$=XDI&Z?L:*5 M"_='J9`.>\4"6*:,HUO701:E1*0&FGY,O:[$.?@\'6\Z*/Q5&O$.A-4]V7(7YDI!NUYMQBWI"U`^&O< M\U5#H!)+PXFD<<$W'X(R)\$U0WLRH"SRN,R@ITP`URG$N M"2/2"#?'EN`' MF4XFZ3X0LR'\04AHWZ(@XW)`8P#0:#R\P).7]B`B4@ M23XPK"-R;#0LXB`3_?+T]SBFF!3!K_`4"X83!2.7(U1G(P.L.6;VDZ:EK1/9 M+5#B]`02E_E(M9\R0L)AH:JH)K#3H$QF+T'U6P'%X@\\VHN!-ANLO#J`A]#W M'[1FE"DL])%/QNQ]@=;9Q>AJ M`@/*+XHY'@-`^3@+>>>Y]@M MW6SUNKIMMRV]TW=\W3EOG;4S]=DRGO]J.JX-SK%146.K&=6)T0^B M[-^(I[_C$6LD*0>S'^ITEN/U/->QVKKC.+9NFUU+/^MVSW5HS>BZMMWW3>/; MI[-PW!H-7%-&?@QGM-1=BA]8R46T'+ST!9W5H%,TGBF.C",)V0@W/24(TT#1!\&/\@F:]-HH M`^UYDV9?**4C$VD0_$!.&;CA.N+/J\J<_ MS$>(4BK^SLL`/1O8(P(")-`>X><[2D"U[*QJ.>(( MA49YBQC[Q^Y%FK($T40K?.^`SNB$DQR!0BHMA`VA2?PBX"$VG"317QC7I"`; M3$\\KA![B9"4"#,-P/25&(D([:6#',]WX3X0);.";W.4Q)`L/5LD2T]S1XUT M59!A8D8^S*(!XPB+LO@3,)L#L*IO!>A#4T7'B=*Y2'IX@XU%LP9LY3,,&4L,@0=8]JB.LH&\0H9%&A]W4$Q>88B8_53::]/1[KDP%9GW)K6SBFW MU@&EW/Y!:86FIFO_4Z3H,9)6H"!X0(XZ,1'*K#@%2PF'%"P1^8W9Z6B-_$NX-K`_ M_D7L^NPGR;#(G#FH;G1'5K+F&_&*PN&"L=61D--!C/\&WT_%%<GE M"3\B.TPS<#K2C)"7P:WZF-CV8%,+^$B+`6X>Z+R()#G,(L6!(,)83STY2=A) MPM9)F`42]N>R>2*W?V161._`^>8L"3PTYUR;I)(IB=W1?N/F!.?Q9_5T*1$V M6TSF/?@S#`JV$]&AI/H]$9@KP1/K!?A?GR2T4!EP4:[:<`MY^91A?LNI+S(1 M\F^14#5W#R,"=%%D*PF6BVBT.#=0`D*8)PA3H8@IQ%D7#T1-I@2R*F)!XCUO<"]GH')PKRK-!JT:FO:Q,7(R&ISG?`X#[ MHYBRAT)&2?7"`\`$]X3"[3EX++-R`J\:FTU0#J,^Q?H$*SA>Y8<0_N5<@JPS M`:%%N`Y\TKE,FJ7^>H^I3J@9,HRIXI2WY7X$_YZ M&,RJ8!,+^5%\VRQWZ^I\0\TOQ^@[#[$5&;G](-U1+H)2DB8K.YBF";NM[CN0 M#'#@9%%'#=9&$G)44T@V9:U*Z>8`;EV*9-;Z<,@;YQ2+Z31./F&L3#S)N"E4 M^JN!-/B@B6M@(8[Z$,!Q2R.@Y:#5$09:_28)Q1>1!MOF";$;0X8<:0Q9]/H\ M'9)X?2"DNI>$YP'ES]P/HMBW',ON]UV]=V:W=+MM]?2.T_;U,]\W++_3\\Z< M_F=HX?FOV(ANN+IE_//GM>-:2MY%B)H`DTL>7.TB?/U0\*AY;I^USMV>[I^= M6;KM^3W]S/1+64#UG0<)3H8.:_)`A5_\TO)7AO*5VC[ MO$;6'\'X]3SZF[WFDD-_CP(P_F]?K[D"=AV2.2XB?J(,D[E*'!.FUZBLWCJ2 MJ1)9><)ZHUW-@;@B%B2?6(UGEHTUJM^7+ZR"4=0!SLV"#9NP0)UO*OSU8K2N M`0+HS]``^B"2I.Z?G^Q6K^WX3E?WV]VV;KO=OG[6\AV][;FMGMF&IUIGAY,% MW@;;FY9<)[(L+_MA1IN?#O?OFY)CK!\'"V]:1IEZ8YEM^IR*`R&+V3+D%&R4 M@M/4+D0;LA\.;=?BS?4M/L8E4>/=D>/S=8QHA"=5H4,#"EY M>#M,PC;^L?'5P`H8L>Z5'[2I#2YH]G:\,G[G8B0+;]S];OW252DBU5W[0TR[>?%5I8TUL)^=P1$*>=R M!>J8DT%[B-G_N$QY!\UQ?SM$EKE[R/;Q#?FI4?GX"]#=72A$9$5I691_T4=H M,]:0MV4'\`%O(%^Q3D:SX_UC+_UZSG[Z!_3*HK3DQ?)@2./:06A M=ANQ.-PWC[]/$W;J=B_=/G7M7G)\'(WVKLNMIE.U@4?!\],@#GP03U3_7]/! M84PAW;=,N$83[(RRE7E:?6Y;S;V8/J[=[*P9DNLV]V(5'2:56MM1Z:GO-?*< MA18(EX)]9=DPRD4R^;XE[875M-K[Z-=M;E;G[_[[[>QEONVFMZ)RX]/:299X MO0I%[)W/S6;;WH]\F7OA-Y#KC2J%WG^_[HKY[IR3>+17)WXL+VW/:[D]=)=K MFA`D1RE=Y:6F]0.NSW[B*5`4`TQ%2)$G/@[5V*^\B``S>()<1I5/@;_M`G]M MYU$"?]M^?^KZ4;O^<6-$98S.O3,LL&G44HG6W6^(\M@(=A5]/2ARG3C\>>MA M8W5'..'OBZ<>X81/*_S@6L1?PE^?>>D.K>J2:FWT,CS]U$`LSC]$] MR?@-NDO&_T,ZF>15;N.-TJ6+]-I&#K^6I#=9,/OE.?_O=X]U#_/&5M' MIZN_=\:F:?YH4UX5`3D\Q7:X9M@[.G8I%1U=1WUTJJUE')VU\MW:O/.CS=C: M+/;TE*9LV@^\9S\MJ^TW4;&4CJJ'>-L;%7F-KA_?N?QN9G=^/&9O.S_:E%US MHW25IS1EJ^WN7:492SCBJHD^`C$75:.`:RE"7F&U7P56NX+\VZJT!^UP>_8X MT>]$OQ/]CH5^^_&$'V,==X14W=;106H[SK3E'1VNM.-,S8;A'AULN"O_&B=; M;"O5:H%J#=-B$+/'4N:[]WB8N^&)@B<*GBCX4#;98=S+>T?57*U(L.S=.(G^ M7LPYIW)[+T55N[3(@R3,7ZEEY+#<.YURXG=S*Q=6%73W));&A/]DLGP5SVZ7 M911N%H^15.4">=DBJM3UP^:ZN][WY;I[]O:Y[J9Y`+G71QV[NRQY6)S8V$F# M[<'RM!MNYX$3;YY6:&/I%!S6$GCTU?YNB+]IF54;&Y_&OR\F.(CMCB[VSY%F<5VQKOUZIYLO1>"G>T66D M['K8HV%ZIP,"6WG>==/[^%RQAOWCI9"V&D;G@3.NON%Q+A?U^,[Z'/5B'\#, M/J]8!"[0ARQ-X..0ER=^V&+:7<\_-SI&5^_`%[K=,2S=[[J6WN^8;L]R>WVO MV]^INL>GW]]^[.E7'_PN"'&29M,@%F+Y\=)_?]6_N'R'WR<,'@4+A9Y\^_XW M</8`N5?=7&)=4%#4"_88,OT5Q'(NM8]OL+T\E-H]]5I476SR5#"TFKUE"K M+^*"G;2Q![\W*M94JDNMK2&L^Q"$?9MH[X);##W8#0H#]/VK,RW*C'#RX*>_<0KOH?03UDR)DVT27J#];ZQVLC\%BO686GR,G@C3^UJ M\Q0:"!F,;,Z+H+G0.$U#JG6*I2RI[-<\U89R:&5M<7ZU$2_N MEK%1S(;SO+S;""N.B6KA:55,6XP/WF=TXR2U/!!?Q_QVI++2.B]OGN9L>4!- M:.'/&30>X5)@#OEL!IJ2.N2<0T3*"7VC`GHE`455M`P+JF4\5#5@_'T*20%O MYCBTZ)IA.=A48P&,?99%T'W&L'PGR#FN`@<-9AG+&96$H=_K;].:$D6*:1%3 M:KO&1B/X'08%;8C1PY/8_RVO]5*-5(F]!7RY0E$04+R(ZU!-O*GR">RF>8I4 M1@21OUON7'+RI*,P]%9D&2PEX9"24;#O#.^K(C8=UMFTY`7>)30A.H7N^?QP MIKA^(^@4EH>P8UZ4CBY1CZ:"?KFH]LG#B+#4XLD!&T<)A4J"$3ROG8.FG0Y8 M5NWEID,Q2K>)6L.']8DI9$D-"<5QG8I89,B0Q:N1A65=Q2BO*L?C2#A,BRN( M[VT[F'93^R09#$L9`GUA;1G"'.(6KXG"`+6U!EY.U9*?SWZJ;@63=7ZN>4WD M6ZQ>S#"B$"6,ATNG#*@7KN4,[8;![&*L)[2B8N2RD;.M75*W:JZ&$Q86,1A( M_6(.[/8.QC0MII?P>A!+BZB?9A?\HK-D_`<#6RG_B+;7_9LZG;YINXYYKAN] M7ENWSSJ>[GMM6W?[-OS/=/M^NWL@A?$XN;0IIY<6(UFP:JC@@;L#]:!OH8E4 MTI2_G2_>";<065AOEBC#QQB"0@"C^K.:_\8QA6T"W!7HOX!JE<$%^>%.\BZN MQ1UU>=9%%+SM(PKM?<'Z&U+"^U8FWR;(,5\AR0=FTS`DOB@1QS><'J\MM^E6 MQ`,=0E:W)(]S/69GNO@ M&U4#(BD0D2%[/P+EE,Q?Z_++'51C";,?`0[9\-/+`LK^<;[9;>[W0#! MVZY__L^?ET921T9D6J@H+?B^0!3I8D3QHHLJ&?`LR*.AGX3G45S,*?%^Q]D4 M2<3?RK&'_+D6LF$T#>+\E^>ZM339?K_GV!ZTVW+,OFYWX)/?[L*,.Z9Y;EM> MO].R/EN?S>>_FHYKMZ#7:C5WFUF=.KT@0Y`M_\`R&4&+AO>\==9R/,=IVUV@1:O] M_%>P@CH*)5;.8AU`MA0I]&^"+*3L"U%Q_-\<.TP3ORK[_4!(6=\WG;[;MW77 MZONZ?7[>TSNNU]7[EG/F]OR>Z?5W"PH^4&KNVIKL6U1DAV;6UF3?M"([8JVK M:[*?*K*?*K(?2E.G+.!31?:-B5+.Y521_8'H_Y`IQ7L9\JDB^]ZI_-2SDD\5 MV4\5V<>GBNRGBNS_S]ZU];:-).OW`/D/1#`/,X#HY:5YV\$)0)'B3(!,$L3) M6V137[JZZNJN[JKN]5OO;< MK?N%D?W2B6TZ<:;V_\+(OJI+%T;V]:1T862_,+*O\=X+(_OY>9(+(_NR^75A M9-\J9[^+Q.7J[._N\YNR,=`UU[!$>]"71:8-5-$T!HIH#BS#8YKN*>R0^\(825!.MDPQ*M@M,.!.=+9P\.GY44`8SI6@-<@>`Z?WZ(:<>DLUE3B M%\B"XJK1XL67HY1;%&`V3/STB5\`:A'>R(]&=&$,KP7=+)$BM+2B8A3>H0ON M\XK0^5V]+I62.HWM-4ZY906O=Q/GA*FMU7 MX6.GQ'71\$N=KQVG]$\0\&6$]VY%NE;);;^/G_L^ZGS-6JQ05JQ.]WWK8M:7 M7UZFU(N76V8M_:H8/LF)498N_-7!M.O4Z(1VKV+2]B&91<:R>SM2+ M=)9+1Y[5+SRH<"[\1L=[XYYCI8L$+Q*\2/#H$KPL`,XZEV/?1I,?LO%@<#*D[DX-Y@PYHGO\I7QL95]YM+U(Y"E*ZD( MY1K.'"*,XL:F?"7$RPY*=]=>%PE>)'B1X*E+L*,4F+/SEBO.+%:.8?:(M(%. M_DVQ3#]\Z>V;^24+/,#9),@4D!0:3VW"APM,F<0Q@(5ZJ)51-)U5IE^RXU#N M32PY>SH,1OXTPU;@>V%9$E[X26P)5&!]&`0Q="+$[Z_K M\"\G"5_%.:N7<7'.Q) M;*U;6V>U']QCAM$S#7F_P,\K/U:AF;P^29I)IJD]==^V=R66!]4,MNC=^X9YCCE9("+5T^.,7O[N,:4 M6$\VCY_J/BEC?TY;K!<)[M;@KU$XHK6X0Z,&Q.0^2IZ"X)K3O,Z+3%29MC\E M,6X5!V,J.9%]2W(_JGZ.%-R?DOSO(/\ZXT_ENTI>DE;H>^6=%99PE;ZI6A83 M;9=Y(E,-0[0]VQ(UI2\I7E]R-0]9(N1W[[_(?ZM_*8I;D)9/@ MF_^X+YKQ@>6YGJWW1!'M M`/TQ-"2/Z` M8O:D`(L]644^>I^&$S\-(Q1:5#!@$WDM-32#@,U`!_V9#&<)'"0=3C,_PG?X MG*V79`#?CD)_2-7OWK[AK1/]0D*?^1-D8_X_2I`@1312W%X)+M%+X^EF(%-=+&Q>(Z_B6:+ZQM`BHQC!)_EM\B;-<@U"G4;D<"%FBY"?2>E\)=MXB\EZ142N5%?DF MXD288+^0#GL:5[BC*VK+H]>8=&O\SS3+.;4L]*"4UJ35.X"7(9,Q)P$N1X!"T=YSD M7P($50-538D@EQ-(%P*)P6P)^<\@>@B*6=!X=3BF-\^9T?&OLS+2"1Y1!M1^ M1(+@ZDP4TDB`G.8^O@AU.LG"8C70-D17#7MR$R*)R'`;J*XFO&>"*.?*B6;DT9^$,5?/X=.LVV1NRGE.]-C3_"Y)28F( MEAOSB43)#FT4J=?JO`2USU[R0JWQ)U-P0*6E((5;DN5^`0\6,\"D0-7R= MOV`QD%N(O-I\?#T2*/F:OA+!/=J\Z^"6BV%[_J6BJ2KATH=/WF(4)3N.QFQ7 M=+6!*3+/L41+LV51D25;-U@/!Y02GV^>9C$M]^`[UP M_/L0`BGB%?L\A!#;YWJS4\:I9SBW9(N9NFTR434U761.WQ1-^*]HRXIG*ZH% M;U8!M*J\>Z];JE2EW'H!I+HL2G*U;XD](J/^)46-SI^^1'Z;?_=>9C5@+;UO ML*?YX$@+'X`'S#L(304;Q52]/FJ-?K?;)S<8=G+FJ0`+?M2D5C.$/6\N,7ED M]<4/=\%CN'M,UKOWS)!KB*I]?L9RPJ-^?!N"V[$QN.^D[U!@V%1]M;ULXEC8 M)Z!0VPWXOQ_B+RF,>CAVB^7-@*\4P-#2#.ZN+&0=#*JN-89[$W3M-JD(2[-# MVZ9U*2MA$ANJ9+7:IDK_&[ZE;I4/[C/7!"@C)Z=B@"+4?ES(SA=B(,*0]3%2:1].8K7X8HQG^'+MA M5NZH?;[IFDP<0!G&4_A.X923..L'-PG&H3/K#HVF?I*.P]A/GS[DP20# M:X+R29,H(GM2[-EV468&7[692*CBZ[.0JMOZ"W5QK,%9J0W=7A=.70B4=H"/OT(4X$=['^K%\R:2Y\J:XIJBU9VO6&Q?*S.W@"_\%TP@/X*9``/V;3 MG!A='&95PRG-)+D^IU\"JV4_J!!7-W>#('QE3%=:-H/*KB_?M3Z&M?+ZFC-P M-$OT/'F`+$6>V+>MOFC*\*,EJ::M8QH4!E,SC*7[UDNU%Z(H'.(O>!AG'(S[ M3]_!/?/=(;IV;>,Y(,K<+XM+NZC/"BY,%$VMC^QV.->2VTF-8[B/6*4!@UIW',,T[)D)AKV0(:5AZ>(I@D_68ZMRA*81A<6 MV8R\N%I?8"_I>!U9&:X>?`FY[,#+FFM(4,\*Q&<0-/S8['PC/R+R,7P(QGQG MZL\@PL/!W_#,\\!$.9HF*K+"5$>2/,V5T;;#JE)E M#2NU%IJ5CAPWI@94/@2-6B7&[:*'!_V6%]9?Z\%98Y\YG0;CCY4SGQUT5K*) MSLJ4GEN#+J)II!?29!0$8]ITJS)4#HIR-)U,?2D6+E+J`=ZS0%JW6'!7P@WP MN&?(.3GC\='4?TVGA'+B?49!6C MDL;!KV=PK+1]'S$-51SO^(Z'4*MG!;MH_R!4U?15YF\EHE7;,V@WRRV,+VDP M":>3+@H`'+_2V!Q_%L=*"]!%/=?(R\FKIOFZ6=,O_E-G4Z:8$%)9<[W^#)*& M#L_.ID.DY"$P.X1O32"J`-9_8MP(ISM43?7/"?E]_%T@2S+=>FL[>FK#W9Q\`&<:;5C6PA<^VW#2;(6LKA$:,5MRQ*T[.C-UI"DI=E(,[)%AMH,J6 M(MNB[9IXF]?1Q/X`$#NJU[=TN^])BO5#DR3:5VDJZBH4R_'.5[4'/U"IV`/3 MU/NN*-D#360FWC]PF2["]),4PY8TFQ;C,MIRRY27`JUWGT,,1_ZXMEJ?224> M-Q;N!\6[YN8#VF>#%:'W"[!4P!>7D(Y]8G;=XRHR'=XS9&L.N1U!!>9B.$H9 MPBX&T[2C-(?7TO-6;-=!GD1(-\76Q`F!EZ6TX5R*HH)Y=JSV*[_XBI%( M6>B&-AP^8%7?>-3)&%L%+3;9'/K:8"H"^`L6U9/IQ([CJ1]]39[\*'\J#G4> M>F]8ZP]P1UBW#9BOCB*)MJ'A?V3-4=G`<2R)9[++^SC/];]JFNOK:)C:5%#Y M0^R`.F"!*!07G_!T41F__@T7)+NO$*&Y`ZLOVY+H6>!GF:O!L(+C$0=,8@,- M]%ORU*Y5B."EH.F^\Z2,Q29T?7AVC[R\.A\6HL6;P-GL;R#O\6?N77D:<9_"G[;>&N\*5P]SEA:NMXQ6N MWONK3[X4\LOJ4=-4A\DW;Y3/OOGO-`GGORZO1'VI/[V7IQ-C2\NUBF<^U94AYWV\%BE&S=DLU)D_>BU M&D^H!O6G)!9'.#/\ZD8OTJ+@!:-QD2XZ^C39KH57,5^VKFHM[[EJ_;D[&'O9 M#!KA/M%E^IS_]%&.7P_^A-Q.)ST&[[P*XI?,XB6S>,:9Q2TB(ED_.?[. M38-7&7RY&5VR0[7O'Y)*8>WTDY;)T$GK?7:-_9IDY;<_JT#W$>\[%G]M.[_EDEB[RNV3FSB4S MIQDG=Z1HTXVH'E/EB\E^K:FEBP1W:[;_115&I M`RM8I$F<(`2#(3!`%+BMA+BRA+BT:J^',S&QT!W>'5Y@_Q,)? M_E-!`8^WC#W[NB^$638-QH)]_9T^$26K1NQ=4A4@93LF2)"!Q!\1+7=^)SC3 M#&9,D-8XOX5?*XW]UBOHT7T0R3A#_G!!ES04PY*W?.7LW+@S46L1[S:/B'T= M*>9CP/XMN0]'T)+>TA)1S+?U]JK6^+>[$$F?<9I`8_>\S%(FW$YAYF#)@R06 M[I*?T`%J\E*BFQP'TK."53_TXNPE2W'Z!=B=4),"J[!N$-M.'')?Y\-%?P8\Q1=Q'.;`KZIZ`C%/EJ"4\88]_^[,,I;@R01` M&_"W%(:2V-9+1<%WIWB7G]1T5%?3F2[P5T(3Q4OA]1P?(L7QNX&7PO`0)WB/ M)@D%Q^&DD!]OD#2J0D_>@R&Y#>.8"AG

,*^$_I8*- M0*@@7QC;`+SWE).RTQ0H%:`VU@E580!Y45US&MI9"09.!'_G0\^1I_TIR`%1 MCO3Q,>*#-BEK(O/80+1L M`&`RU?)4775D1SEZ^1797!)^S673L?`**\0@[94?/Z&E]H5[/\W)QY7:'@6W M8*WO>3%GF`G<\HPB/YR@E8>G,IP?R;2P7V"W"@(X&/=IFG'G!`9K6+!+7@EV MA(5>;LD/0A-HX"*TL=,H)]<,[@\<$+C8B9_G&%[,WRB,_!@-WA#=.?0'RR-! M$]P%!6GN@R]YXNZ^A#6WNL,`'/H#S5WN/%.RS&!!Y\:YAA2\5?%:6*20+_1O MD4HP!T#8T5D0@^XNRL,)=]&P?IER&TLA%UEI'\&`?\/`9/P0H%Q*JQ^C>`HY MD*''"3,.>0HLK0IF7G3G2O@S^0E8P.@4@1WO10GZQ@?G!Z,(0GK`'R&(PC_S MP>1BI>")?S?#EBBU<$M^HI3[L$#S@.%&@;PJ6BK9$P@9A,E+`J%>?1!':PJ# M5QZ:6^(2/RD!'@BYB9*?9=4A&$?4V'`$L51:O)?8XLH(Z^(5@2[TH?I12D$J#!0]0U$0 MJ-.02@MA][%P;A+#K_"R#-4%/^">!Y<83)-Z`N"F=8V`U4G=?1`@WAL691]JW\>)I3/(IJBR8Z*TIZ98V2 M6?_>W*'LN&;6LV=QNU`RRU1>7C)+.U[)K+V_^G+&>OGQ]UD,5Q3W'=!Q=_QC M*ORKZ,'R.@R_"__YX'[[$]J2KHRYM;'; M[.5^$V9[.L$^TYW90?V=Z43W`;.#3X+VNS]M5WEJC\RQL=T\?NY'E*ZKX;![_$%*GCFJLUN>OC=#[X"J]]:'+'M.M4]/NK6]4 M]*1]'Z]]66I[^W5T95%>DFC5&+16$(P<@R1LW<+]RKOW3"^89+8!U^!M7R[D ME#9C,$'1?YH_4I07IR$H^.C^@`=S&`X>W_^1;D%[\$/6528QZU&V`*AJ5*29 M81>RYPJI,]MS+%DR1==4^R(S7$NT-=<6^R9S/=MT09[6#UF2."NX7&=HVH,@ M&I)NI9??2F"JQ1[A7_C?9NIG:LQ17>:(FB7K(AO8KFC+DBXZKNPHGJ5JDJ:B MT%2D55#5.DE=.Z8#$`4?&+Y,7$72ALS!>Z(E/+`,U'?O]0:G_(MX"CG;6WE@ MXS0P@ZVH\QS50+13+124#'/VC6WPZLPP`:]F,<7:A&=Y+8X),HTXRRM.YCE0 M!\5O(&V-M@E^=>`82E]SQ8'=MT0F2X9H,4\2`;;-7%6W)7>.7WLQ_ID]1"[J M0C,^!1OSB"!BTS)T1*PJ&VKX6G%%:=AE1@1^5=->A]*P9NC>OJ3)%CS:!\:H M$U=.@V)UCF+__&0[P;LN7YG2);ZR`R,W-Z(PVSV+UX$57):0V$O7Y`HCU%K$ M7J5H/!`,K:;L"%916UOL`XXX$9`R5ET:M6-J$)#B7,CHM,!6=&9-Q/`[A"BZ M!+_+IBZ;^Y.`CA)@&)!J&&X MJ1JK'=7>3=9!H"+MO6&I7;)76^!>UUX1;Y^AZVHGS!4'/#=7EF%8TA[-E8$" M,/B2:GUK9<=Y.`[Q7-A#:`MA@4QD7&\J3#=?O"^EJK#XL#587!HJ+#XD$]F035/4)%4S-!VF MA&FC$Y=_H`67P,@Q354MI2*=7>#OJ$A-[?_9N_+>MI$L_PGV.Q@!!N@!3*J2$DD=5$'2T6+,X.);5$D MWU&O7KWC]^SM0WVU6(IF+`5B\CRT`<&-\G3G&.)\X:?IY#$+*`:RH2/J_SD2 MC0Z#>/QZ+3+[^W`<`QDTX>=[4ZQX1$U3_LY0\5#]-$FB3?RW/4J(&Q(#^#XR M2.!APW6H:2#'Q;Y-H.DZN5_*71-P0;%]@$AK?2ZU42P$4P)5B`7ED3QPP?7@ MF&(YG`O*;"MC&61DMR&LGF="?G@*#0\@P+T69!FVS6P#AE:`0LX_GYF9C>:V MI*[W*?EUNYFEM]NP]&N4/,(]F%71KUTT".=1HR_X/]9518,:(;?!]7P=IS_" M)(JF@;X]5W/=U4OVX+S0P`L`B@Y"XRQ18%']6'1A#ON*)+`8)*XO`5BV`4US M8TOFIUNE*O\M:[*BOB.Z&!ZBX"5*[N(T^I+$N\_^7B.&@DW^QL]YWQ;]/;2' M8/CIV;I@=`O9'(Y932;6*\^5'XJFN)D&M4Y2%C_\7V#<5`)^(\-*``BS6?&2 MQ"^S5N<#]%K.C]86/^D@N,`R*_0#?BDT`HL?8(ACA89K,68P@+E$;!>;9@Z" M(/HD+`#.19%IL=%!OK3L;CE+LRY#T;PT+HTOG[=O_^,,F7\[^]E+ST2QC&C> M?#H3C:F#>4.T[`P25YR-?XY$2[MLG^CW7M.\8;?8^"-:RD0W:U_VJ=V/)LGX M^]E?DUXB+A25K&=1?G0Z/\M[OD9W6>.-:%BZ$@GT,Y1--/_'&09_FW;"Y73Q M?P8#T4PU?]U[V3DT[1CGER.23TS/NJN+G=WBY]X#W\V$OF2P`JN>L>PA\V=@ MJ]XS+F9MOS6TJF(S9K5/U[-.]X[-SBR%TULB-)W%7HK.\_3K&NQ+SH&DZS4 M/IW=4HKKK)?+*V]0&LQE)JX00A--2?EW2@HUCXA)KM'=RU*R[LNLD!>F[M*%FD* MIH9I_DAG;CCF?_P4WT>M:A9!)]HLXN7]]9EI;TNW"#XG9NL0$-]ZGP;W0[E3 M.WZ53H7`+9)%JZWKUD#G%FI5+]*JP=SE85%XX?;<+\>%1]'YCP)6)CT]6S@] M$4EO<\'M;9TB6^?`;-4$QWJ*;&Y29`@4:;(N>CNM\FBAAJ+VS1@]/;LX]1$+ M(8;6J=HOY!S;._OYU) M"YI(7_,]:_U\AR]Y?#V+KKELRTKIK\%E:"@]6"_^$7]J/K>)3(]2&P0&@@P8!/B6X9`P-`ATO1`0'(3` MTRVW.1GV)OU8Y"&?DI'DU1($T`SR\+LECG( M]RI\1@%B'SV-13H^R]GG&*(Z`3>V(\U)R?9I3GJ\-&?CC^[2HAN0&Y>;`/DJ MMSMN_IT0MD4$_"I,]/P=,AM]6!EHSH&;^*59^MM_U-J$SR:;%-ITQH*M2O#M M02Q"YP2T8LZ[+MJ;U#2$Z%LWY*)7[AT':)3)"-2NCT70L2VZ+OZK1[?6K//8J]WG>_AOB' M`JZ"ZO9;\_7Z[A_)8K=!]AI23ID/N3MG4ES?@\JY,RUU. MD_I^?KP414+M[_VVV[T_! M'*L(G9@01`+'H-P,&<2CR'!-SS:4`Y>F7T?Y+:8Q_RC==WCJMA,\%D.;U+6`;P>>85'/ M-PCR3,,QK<#PB1LX(8.AB=@L;"OGIQ;#U9M(:SI.KV!T":X_NB0/(O8G=T(A M7JXC`4^3IH)#7*VB^'F;,#VR!<4`(/Z#!+S')F4OD"(`Z$[S$&G(V>90;)@, MI0/O>1&,A9D`!Y3\H)5JJ MMS45\SIB*L.F>O$P%=.*HO3S,'@1W7=<,;[+D4;W?G2[Q8@#!C(5QX+VG=9R MX!`O,*EC$,^U#.*'KN%X@678ILO,T`Q]B^5]C,;"2MY(2)GNZFB4/!.^!;5R M09-U0[1K(U`'MF_;)D$&1-R0B:%3!@M-QS!]Y"+3-DU*O&^(KRA..+@`!:CP M%62LIU56N8CYO\>D.0P#D]C\*4A,L"",_^10SS$8@]`GV`X9PM_D:-,-)%>H M*9->@=2>INOR:[,LR>?).!WWAC+CM#4$U>=%]9N'7"VUF%)S>6RC(1L(JV$S]+:.M)ZI*-/Y>S3> M909A#?H.(V"QUS%6'JU8>NK,4OT&3JVYY+/N* MES_0!"9EE.%W'YEEE46V?N12X<.;*'F.[Z)4,6EUU]B[CP33U;-,"V]?TXD<2*7C6N9T&A9C)4+7$E&I-!^E_#.I MS/S(,_53;D:#PX8_#K,F;2'3RCSUU014%#>2-HE?<]5+?D1B1]!W#X>B=-ZN M6.C5%)0IE377_*IK+O;>H&DB%T.S(/2AB7S;8"YDW`#YU&`!"PP/^2$!@85L M(`R0G.-LERA<^N8K'.;\4RW=9>Z1\"6YPEV>OGAUX\CVRB/H)#%#%`06,!S3 MQ`;AMM5@..!4.93ZQ`\="FQ.E1C'"$EEQRB]=)FBZRB-1$6YB*1D16+"#FF\ MYOB.SQ=`?)L/D6';_"?F.1@"SV0^W_^RGI-*QF/)>Z]=:^(XD(V*%]8U+^U4 M[=747(2"7&BM6X0KJ5FY[XN]TH^>$OYZV9C.8?]87*@I=+Y2,<&KW(`-]%1. MO-S)37H#<4W_,1[&Z5A8Z6>-S_<0\W5L6V7??0,9:_7_DTCK1UDMQ!_#?I04 M>_0T7`/BJ%"P6]R.("?IS>B1KV+TGT&$\>-21?*#\L,V`C&6O7 MOH8Z+F+@F(%U*[Q,DB;VJ^X2EH?O\@K>:+%D[<)-]"!/<\<-&]<]FXHL'#7I MO/1B]>L7:%S4YBV+BI0M17E*FU.WXL57DG83C<<#V:A8Z(36D$R^X>3=S'6) M*)`\W9E*V](:93_"QEM7G;FX(4.%^JD=:6LX,"'*JPAF1(R!Y_]K,,HFB\J0 M..SN%*AHXH2HF'CIB>YZ8FS&]U3,`2QM_.[.:+:MYT'U=I`,J@YHB8:"[:LX MIM>CU]Y@_#JWDWN0:Q%JD&(C=@.91;.@_Q38"+D?\?-#U, M`L]C0%"+9R@>N7]-HZC?T3_8HIM&1T?4/N MOQE_6S&E4-8$$U#?!6]6=8L5_HP!N%,YM.\C8-IA8)@V$J@M+C1LAIF!`M>R M/.A1A]]FBD`$824\J+#DZ,C4PVR?VKHHZ8`9^B-S`"QV>&S.X1]:\QF@)J$- MGDQR1Y0;;704"@]'0";].1KPVPSB\>NU0,W9G8,,`^FA8XM?P>T` MHJ8I?V>HZ,,]39)H$R:9[5%"W)`8@-L"[JM[V'"Y^VH@Q\6^3:#I.OD&2-Y] M!!>696ZJ`CDHDUHH%8(I@2JD@O)#(Y<*8<>6RNWF!]YN\\"O4?((=Q=&A?F[ ML!?G'OP7_!_KJL+>1JAM4->OX_1'F$31],RUGZ;7U6RR!^.!T&L`[*;,S3*. M*#`V?OP<]Z-A7XT`%D_K]07`W:"-!7\'9,:6O$]7/>]S]HA_R0*]R^$7"758 M:5<*7J)$%#9\D8!W!Y?"+AU(]>4BBHH`UM!N_MA@D6Z]>W?LN7I2_@',G,^)98F))Z7HT_GS_M?=RF,;G M>HC#M>7'C[1.$!+'<*!/16R:&:[I`H/P(X6'4!#R3[,3+\F:_0HK[?@\U$:F M^S1K'DVB6">)+ND47?(VZ?1U#M%%>A#P[OKL%MU3R"KG]&J36)\S>R>\5/)$ ME&I#&YJUF5)*A=7Y0E-ZVP[^BEZC2G?E,9A5"*$M-S'W"PK?O$4]&).SFC*3 MS<-J6Q&Y`W-4N!`'8X^U,WMJX23LR`M3'5("S'!DX`4],H[,86BNA:.0;7?K M23XFCLPB*PZ'G`(S'!G3HN7J)7UQ9!KF!MB"&_K@R.S(E)K+8QL-48\CH]8Z MTGJFXH`X,FOI.XR`17T$HM2NP"4TCB2S#VGURC\DDDS995@)1&Y4;?YO$DE&@D)PH:M,R25EK-:D+):`2IHL+6YGK-JIUI+0)54;'\145:I3%>&:C*/O35`E7) MHN\0T"4ZH`1691\*ZY6_R]F&J%)15P-6Y7`P(PJTU.9:BBI63SW,B(KEB$0O M:852I3`CM8G<$68DBUU7*%0!,Z)">B)7:U*@$F=D'[)J=1O*.&VE-%\=S(@* MJ0F8$52!]E$&,Z*`0-%<`6RTQ'HV!C.RAQ6IA3B1@155JJLWPHPT![&A0(I4 MQ`ZTA-A0L48QUV%+8TTD:@( M/T`1?C`)MNHWC30%2*'`/''S3`KM,5H"4JB0NNA-Q@P=&I#BH!6?6T["*C%/ M]O4#PEX@(Y:%Z=HDW[*.%.*$'H/`-GP;NP:A/N.:Y3N&:PMELGW.SL(0K,J& MWP`?&HX5*,5!D+D*5/$1CP+]<1SJN#_KC.!S`(OZ`=W>2]X+^.`[) MW$PL`]!L'OJC0*XJZ(^L?7YK[`LUY#AT!1>2`4>M6DHC.-0RN01`^^@N?J!+A0X>`0H#)A!85!L'QMT07>I MJ(3"@#D4!C@Z0(D64!B%.>`'@<*`'11&#>8V`(4!IU`8K"ESTT(HC.T%L#L4 M!NR@,':60I,("])YPQ=X&X2%$X7".+:@1$?D!25'AL+(F2;)V(-I\F;\=OR5 MN`^0_R9."7WQE_LX2L[2N^^/_WZ_OW/GS\OTNCNXF'T_-Z[_!]N M3?A_*&&6)7SQV=?FMTHSU_SCAY?;9-"/?XU>G@;Q73R^BD1_U%D_YI^FG`__ M?#=EJ&3.U]>GR'F)TW),,+;SKN)9+7'P7'#,"5`?)[S/XZNY#;ML)EEH&!N'6_<-&']X6; M?WB?2VM/T:WW1-^V*&L_\5JLNO+3KN)A_#AY/$UE67Z8[)1EI;+T7DY064JQ M&RV5XV;,>2!WTQQ_(`_YI)GX9!3(C\;<`3V]?:$4-FZM]+Y^YQ[/T^N)R:Z4 MM]12=E^247]R-_ZZR0V3)-:GV\)R:%(LE?UI*,7-.+X?]Z"7J?QU=INDD2M+@KPE_ MQ;E?FZ$H#7IW/V[NOH\&49I]341BN&RO1OUH<$*2;5R2[>3.*K0O+?5^"218 MR2M/'H/;%]%9V>LWZYR3>N(C*L5W0N?N-R:Z+MZF:[Q-8V7IXFVZQ=MT5)8N MWM9^Z:T87::E--=[:/SH,4J^C@H?'FK!ZQ'WTUV']-293G:UQLQJ*;LCQFSU M%5@7LVV1R+J8;=NEJ%=D3P?N@"SNB3'4C3LF9TV]N"_^4JZO.?!S>OJ8#IY%:BN34/ MJ"'^MTENV64-R0W90JM%6Z'=R:WN>@,&0#76F[P,V8W(#=K5RM#I,98RT,I$ MPY\3OB$_73U/W"3JI6-??'O\>C.Z'__L)0UG2VM:S\;VEE72I`Q34[-E6$^: M6;*HV66HL^"Z?%^KY6?9IHU:&0W,Y7=J8CNA?,U;DQUFMI7)#C*BI^R\T3`= M#>*^#!%(_/ZR$&6_8G[;8!`_QL/>20JRR[CKF7'765NZE+MN*7<]M0784&@' M=\PTS;D[_!Y],18N?HYNHKM)PETS,?KE;C#I1_UL5LSCTV2<0YHNS%E[77Z# MLO1/V4W(-0`12].3E1(-N([2<1*+3GVI"Z>F!<7:FY,/>[6N'DA[E=)3A3KQ M;11?M9[K9")P+:L(TEZ%]%293G@KA=?5<[538EU!5YMDUE5TO0TQ=FVX;U&T M;:U':YH]72/N+O(C]>379+7EHOQ.*#WPUF37)09U30SJK"U=8E"WQ*">VM(E M!M4E!K76@"XQJ"@QJ*46=%F<-R"^KBN_+:D`[95(3Z7IA+=2>%T>IYT2Z_(X M;9)9E\=IO1CU"O;KP)Y"9[[0<9C;)<1L377>^)T`9,O/+5/3@,J*L/MV@3#%*[_VX[**A^DD1%D&T?^ST^.!ZO)`F/Q5O2/L<-(W&WJ"75HIQKD;#Z/6JE_R(QN%D MV-^4&NQ,[([*0Z@\ZA-^]F^?\LQ^_(W?LY?U8PBM%>Z8MFZ(2HD54[5Z2NP@J=A6"*.4;]13&*H2 M?D<20!<@UE4F78!8'XED01A&;8+LUKEJU2",E,ZGT?#A4_P<];D/?3GD_'N( M;P>1O%2C2/%;GT3P"*+-:KTC32_XU&O5_QH--<$>=WNRM-UT4N#OQ;*\\ M78:J4Z?FU*FS35V&ZFUIMOB7MLX[VUF=L#[J].;\MHI&=0?)HQG-3LM5:WEW MRNV4NJ5*K5/IA@*:.]B"+06"FZV9ZI*5M85!FEX=NB">J*09`UN_`C9@-[SH M.@B0;30P:R!4((UUK?5Z2J=]K?0::T+72GH`?R7K$&U.1#8@>FT7IM@N`-F& MYLDPS@A.!>!Q.J/F,3OD?,S^_.']]/?L%N);E>_'Z8@@2+_]<>,OW"3_[%?^ MV79W^L9?_%OES?KQ,^?1G'[QO=^Y7YS\_Q)+\A')F!C;(6I_86&!:S0?? M*8_=8&QA@S`34[.-/I+;L7J]`&@,1NB!!(D(-NAB%,S`!V5"J"01QO@`%:0Z M`Y-(46)R"69Z@(Q^H:C!82@D3P,9`%!+`P04````"`#2=09'Z&/-.)L6``#J M/P$`%0`<`&EC860M,C`Q-3`V,S!?8V%L+GAM;%54"0`#BZO#58NKPU5U>`L` M`00E#@``!#D!``#M75MOXSB6?A]@_H,G`RQV@,VMTM7;5>B:@7,K&*B4#2>I MZMV7AB+1-K=DRD-*2=R_?@^INR-*E"V99#HOW16+E_,=WLZ-A[_^ZWGI#QX1 M93@@GPY.CTX.!HBX@8?)_-/!_>WA\/9B-#KXUS__^I=?_W9X.)A.!YZCBCUTB:/W&!Y/#@\3+O[%A/VG[P]/?CD\^?GN]/W'][]\_.GT?XNE@]6:XODB M'/RG^P\H?/+^$&J<#:9'TZ,"QO\8W`:$0>GERB'KP=#W!U->BPVFB"'ZB+RC MI%$_@3L`CA+VZ:"`\/F!^D'9Z='S\P[^"?O\%<:^&B*9@-!P\=PO4*?#AA>KGQTD/RVH&CV MZ0"[CL"ZH,!;_=^.BJ1S]L0 M4R=,YN$Q+W5;OMR',-=['>':-"0P.=OQ)P##OXL)W&,,SC+Q6 M5"LVN4_Z)PY%[5C?HMUP@4)HQ>\>T0@VLB7:ENZD=N=473AL<>T'3VQ$/$R1 M&VY+X,N&=J;U$C/7#UA$T;G#,!O/)A1V.5A!?-R&Q+O%6)\'7_K!=M]]QVRY$O`V`11.`J6`;E=P-PMG';CV5<4)B7$ MMRV!M^RD5WA7SXBZF*'Q[#8,W!_C%:>!P3A\0XQS?CR#,S"DV`V1)TITAKE] MSUU._8AA@A@#>AY@[XJ[=O\=X7C[&L^^15PD(#+W+# M3E=!#Y3TS"A8L3Y>PE]T#;)2(FO`0HZHNP!980)CQAM8/I M-\>/$*SX(6,HC$%2Y,&(?\'.`_8!"*QPQN`\;W>:ZJ=VGS/S$M'EU<,S$#)U M/+YG[G,RJG7>(3MJ>[^-EDL8UO'LGC@1$`+2!@T$&>,55UI@%X$])/+#(H@M M6=,#(1VR:40>X0P-Z)KO%0&!?S,NW20_;@FYH=%.SR4ROP.>7J*'3C?7YG9[ M`C$B(0*Y)KQZ7L%^#9QT_(3ZPAERT[UP?\: M$)<;+GSGP0=Y=H5#Q]\G)VKZ[Y`I0A`5T@+?$V&-Q6I+A].\30^]`TN$\L\4 MM#'D"3XG5C(F*L!6`@.`']'$=PCC$E-,+1>+,GD^%Z8Z94G7M/7.3&[A\R(? M%)[B;EQ0]I/%#!^GR!>K^BZH;BK9WSOE9P_D]<[2>T*1&\P)_J/\^T7`0D$D M\NZ">X)B59/O#+F:>0^"#(,"&UHF?/F.N/479/U'`#P'TI<.[#ID#OHK#K95 M30P"T/]^.)]3-`?B01ZA&/155ZRQ;G=$21\=@BL*&P0Z%Z8H1+JV@[7NID.( MV?YW`TL.^G(W#/A`CZB/RS$5E%8:=38%=2 M.E6SN>ITYSQWNP,T-MNQENH7.-BQMMW8=(=0TJ'O$D-]FST0/PU\_SJ@3P[U MQK.L=Q<$5QRNS]=3M`IHR`_^6S3?P4JP=7=="@MQDW$?L$H[59N4VNX13&8" MS#X\(@)[UF?*/1\TF.$P^9+I[/&R'U/N&^&F1)`$X=3W<6*AKBM^%WP>#B?\ M7QWQ2QOYW?A>OP8A@E8S/W2FMK`MO(QWZ#D\]]OZNGHBP63^I#\8P*>,E+[Y M=>50KDIE[MFN)XN\?6W([OAYT-4@-_72^WQ_Z>+*=\7.5[Y:9V9@[G286W79 M-_[,9]7?2-=VH1-?IZ.JT%'?6(ONKJX'L;IM+8@Z';:Z'OI&5[!N];?Z&CK1 MB['3H53JJF^\><_<69#;9!.+-3=>,W&X"ZMMZJ;K>M!WI<)P+G4Z;;JA98_K M:-,2OI>]0Z73OGF063OSSCM?.?5]:$78Z:Q7Z:E_V2RQ[?8I>]9TT3>^"0U6 MB(9K[F4/80%=_3O"*_ZE/[RMNNP;?V9#)=Z(7T.98YA6L0&\/PZT[-0L'G2Z MQ+?JNF]^;!I7^YL(*CT9@+;3(5?OKV_D4\1#C`I620H`(N)NREQ=CWK[?A-. MN/D]$WYSL\01*(N(QT/OXU\Y#3O?P(N[/=[HMS]B%"_6"0*`!.!-J5MQ/2"@ MY6F1]"IN1\X<]B"N2$;L<.XXJV,^78Z1'[+TE\/X3NIICQ4"V MYI,3]BOXA4:H&-AP$5$J7'QQ][[S@/Q/!]NT<*P?82LP)M#-5Q5^Y-1\1:$: M]955M&#(W)T3!_-X[S@`-KEN%=_;JD;27%$+'G&"RVB./^JCJV%RE,KHH+(8 M_CQ^\/$\#MOD(=*UE#?7TX.&+;AF#O_CDOZCXPM=/;QP*%W#Z9?$%DH0J=35 M@BI?8;4`-HOIH/42S1",OY<$!=1/?TEA`^ANG/_R\CJH3U4;";'99QVT;>I: MA!)W`_R\[>VB@X,4Q0ZF"`OC<8;NFZT MC(0O&(1@[&(9$H6*.O`HG]>&G-!W5%Q763T48E03J M'/I/]D"O,!(5@5=9-3*8[7(B&C`:^"I*X>/#R&R4::4S>(]$2CLC"."&4D&\1?<0N8KL(I,W+4B#:% MTDNTHLC%:;:;X9)?:ODC286E`J*N`7WXT@E1BR$KI"-T=KUUZ/U? MQ,)X"_GN4)X16<;X^CI:PESA=&4\%1AB8W+US.\S19@M8LJX="V+?VVLIP4- M(H@Z_#KBT%MB@EG(LY\]HBQC"X_T_E$O0;Q*\XO$/'WC;)TVN=H%I22@,)LI@X( M6>+1FA$(!\(Z##5!7O!%*KU8W99&^_;7HSX.`IW)L[*RVL)/DU)28B0\?EE.:W4-LZ+JI+: M@GM?#GE=9&]%:3WAF`R!ZLZ#52YYZNI`A);5S^WZ.EJ",!T?L<0**-03>4!L M95'=-*N1:P*EJ>*D1G&QM!;*D9`A8*+>./0'*NQL,N+E%;1:S)J-)&4C\89) MPLJ@G&TPY\J_E5'`.PUSK5G!RCCA"D6PY.7>W$&M#+MK`%DW)221T*K6<$V` M]Z"6EJ*\JJ1)*Z/W]LRX&I7'RC"B2D6S'$O0(W^MC#U29%F%@43BE39\:VK4 M\DMW&)K-QU9&S;9B0H,G0!)&^YJFP0M+FR2&]C5AEMH[K(RJE5K'RL$8M882 M*Z\Q*0&OTZ&M#+!40MWH3;,RIE()NIH>:5-<92WL5OX_*X,I:^SII2E?5$2M MO&^J"+1B.D@B1@T_LR4F9)F-)+>,6WGOM"7:DJ5ZMTNG>D+R^.7A:S]X8B/B M8=B10RW)8S.Q_CJ@"I%*\O)ZDI.FU+"[('TF$)6TVKN`\QFVO4<,PW6^OF?( M&Y%LBT@>J)1G#^NT"RT\*@Q2%JM*YN)A#B[L8A;?-)'A5ZW>29Q.N;=;%(9^ MO%KRBP]503HJU;C66U&X_HZ?^:HS#]9I&!IHQB1C?N%\HBWAGIFHI5?4!ZVNDNC!O&!3TL6=LP'U48-XD.%TK8['U0;?8O.EB9& M39^-#(8N*$$4G2>/0",FK)H2PANK&8%E,T&@*I@7]8Q`(TUGJ0I+WH"FE+PN M0IZ(&!DQ%L'&'C]TVO#Z37,]W6@$%6-A"&57SXBZF"'9[=;F>KK1)(IY2I!T M$=55T83A$3/@Y75`+X/H(9Q%?JJ2R#'(J^BY8[!*%G&M`O^BF&Y:TT0KD@PK M"C":6M`2$Y\]MEQ\CED6#U]=N!-+B@B@XXD]DJ>@N?FU9WZ5C=%6QHOWS:+Z$\?*FR1]LTRVI5IY!Z7W M+4O9WVCEG96^V*?N_K0S/W[/LZY-L/:)37&[?3-.-<#;IKC77M=H^U!"BV)G M][%,:US8DJ#;/_D25?-W2B)WWWA7Y[63Q/N^,6TK)Z&=4;;ZEF]%LOHW1:)= M7(.=5_#VS[H7D1=6/H"Q33QEZN)+GVGYE3+]W&5CZCTAV3VGKN-U;51*!)DO2\\>Q% M/*6E^7TZB>K=D.,K\XK9=+&Z>ZYT:[_8[5'*/5[>YKYK/V"1"`;`<&A-*&+` MA'@XB7>+YP3/H#+L.[&)#Y!.`A^[_'&_[+&C$9D%-!ZUO3\)DT/@@P3Z;*)+ M\0B'B[R_\0P&,RDAOAE%:"JNCV=%30<&X%N\(8YG&_*J1NK3G17(?P!)*::4 M;[JI[^M;Q(-*;KY%Y]R8$%XB`E_6L'"\R`U-FS15:&`1^'@I,N0-?1$@*'!- M(NHN0/*=P#C$P3-C<@7#L^0:1>9U9JGS+SF(/.Y*+;R("8K&$@C6$$=9`97O M=+#"_X"=S(-E#TO=R02R6OJ3E^MJX_O[ZT]'%&H/:)IO0O;U\W-0AA._N M;N&0-(QA#VQMIN'U<'D?T[38F^V<[[H7ZSF5/>E>^%9\-W8??&RDP78N MM[W*MI^^+>)J,3RN_]7>V)N6;"?U1^O+4T^'@:"G3;QH,>A1FK;REH=E+%>Q MJ=IT8\0R]BM([E;>1=G#,%1QR"+/KF43M4I5M_,5$\L8KZ`1V'G_I6?1L_\= MVU:OT1X97[5'&Y['MX6!_Q)6X-7#,S!DZGA\!`VSZ=<2>\MG"EV/9_?$B8!N M(0H*JC-7WA2QR`^+F#6"26]WK+E3)2!Q;$GVHPX_0M;Y-7]F8!&O$'E&MC+%):3(%?52$:TT3IVG&R=$%#M^(VM+9;52_3V@/_C=FL!%TAQ6DL*:'RI[ M.37*UP\JA\7*8U`9Z\9@6IF>0QGLQEZVFPE&4U1!+AN;=B(7:=MX?FI$7#_R MN'QY`7)&X&./N]/CL)OL;8%VQYQ2*G9.BDCAL+%-U1;5G^Z>TY)FG)A0M,31 M4K+/-M=[2W!?=91M/(XF.KNY1_1(@9QR'O6*XTAKXZ34#?JNHQ!^O0'-8!DMQ)#XQ'::8#1)*!*>T7DJ?)5"MK4,"4*0M<<_L!C!MQ&"<(W+W%/P/V95<0NQ M4G[LGS_%K<=&LUB[0YV[G?E%<)\[`HL2EY;SO5TB;Y.2=I=8UU(N4:MK+*IZ MF:15$\9B;)1'VK9B)M)4)&AVVU.M#:,>LUR>L]LLEZ6;U?WE@NIXMK[2^>)##-1%A- M97)?_S//O(6\V%@+GQVR9G%V*5`H2(@?$;]MP/@U\1@ZCS[SSXUF>7$,DV`*=\BZH;BJU?^L0=0(6\D0*=2^UELMHN5^% M"/"21YL.O24/2@DY9Q]1O4.ZJ9:>EZD8[$8NSSIY"0SU`W&_IAY'?1TMKT\A MW^=>5N+=./0'XG.['D)-!>M?S])Q:M8#*!V3Y05NI?RDCK9A>5DI(:FCKUN6 M5KK&U:$WGA"[J9\&R1WWA&87-(J_\X6>9?*\)RC.GL0MMGGFI'N13([G!R\E M3H(OWP4_D#=\!#;.4:Q]\;Q6(A>R<<+7<#ZG")1QGC&18L*P*Z1$C7067?C$ MBU.LS1$Q,2=8)E3?@.X$?\=$Q_=[2O=YOB\P;*4T+><-PZSJF`RGB-]%`Y0B M39IQ>&Q@>C%!UL;30C`2Z86IE/WW3/BEX%@[&Y%5%.KD>1R++%((F\9ISDB_ MP$C#R,NNSAE*US3P_>N`/CG4*SQ]%2=R7)^OIV@5T)`?*[=HGH>AZSD;8@IB MDKC@8QA+-^G+KMEE'X14'F=CY3?N<)A\R=S0\3H;4YX>D5_72[)PXBP:4%[\ M+O@\'$Y$1E,-*E;#BW.5FE9]'2V&A^8'!ZM-#XWU.KEGD$J])9&W^#HNEX<+ MX:/52OI.3>F)A$_SS_+L_E7I;,\1K/_B(05C0!W0`40"RQ$H'(P'-4!-6+*^ M6#BQ;T8:.-]?CP;<)3#X1H=(@@*<"\I;G"SV35*ZD]56O=G&*:-?+JB:TIJ# MKGM?/%GH>AW'K+3%[)-Y6V_N$E./X;[D/;%6N@-*#$1O7-OJ'6&;HACVS$/I MB69EZJH],Z_5"^#;O'FX1T7Q:Q`BT-*2IW4'K@#*LY]'5GP^X&1 M_F`0G"N'`R,WMNUA-J'%]S&L4CJIG3-/$.B[ORN6<]>R7,0,;O MB,2XD:EQ$IN]`C*]+R?3R`E32Z=QTR'3B

?&E:<+/)+N0HW.A\07FF4"TB[N:AJ<#O7X\Y30]P?,(?_P]02P,$%``` M``@`TG4&1UEQ43X-(@``5$L"`!4`'`!I8V%D+3(P,34P-C,P7V1E9BYX;6Q5 M5`D``XNKPU6+J\-5=7@+``$$)0X```0Y`0``[5UM;^,XDOZ^P/X'7Q8X[`&7 M3J3\W?N3`<*V[[AX]OGDZ>%T^'`U M&IW\X^]__M//_W%Z.IA,!M<^QLCST'KP3QMYB%@!&CQ:*Q_[B_7@&DU=[`;0 MV.#.Q;\_6Q3]]X#]OS.`G_YY.;D;?'AW/AC,@V#YZ>SL]?7U'2'.IL5WMK\X M&YR>;GK['M/U:?#CNP\?WOV0^3+Q0^Q\&F1_NB+(BCIV@*)/@P_OSS^>OO_; MZ?L?'\\_?OKXMT\_G/\K6]I?KHD[FP>#O]K_!87??SR%&A>#R;O)NPR+_SEX M\#&%THNEA=>#H><-)JP6'4P01>0%.>^21KV$W0$(%-//)QD.5\_$>^>3V1ET MXX6UJF+:6!A.U>1-594]?RG MGWXZB[YF2P,=3I`6SY+U\2S^&)>F[B<:]7GGVY%,)=@9<$NPOTXWQ4[93Z?G M'TXOSM^MJ'/R=];AS\3WT`1-!Q'%GX+U$GT^H>YBZ:&3Y+(]J_^7:]\.%PB#8)P;'+C!>H2G/EE$5)\,6+M/DU&.?-9&--&"9-*> ML5)GPH;.#B5S`C5_>PA@9K(^QM-;%\-0NI9W[]-HN5QY%J7NU$5.):HEFSPF M_?<60=5$7Z'=8(X":,53S]$(M-X"U:4[J:VSX-";JTJ$O'TWL".A%6$!NW(78>W!F&D;,M'`QM&Q1V`)O*O>^Y MMHOHT'&B\;6\V@M6??<*17+G4WJ/"&P<"Q\_S&'N7EF>'7I11^/I-Q0D):)O M-1FOV$FC[-VL$+%=BL;3A\"W?Q\O&0T4QN$[HDSRXRGLF`%Q[0`Y40EE/%?O M6>74#ZF+$:5`SS/HKKAK^X_0C=77>/H]9,;#U^_A)=@G-+A&&+ZL[XGOA':@ M=!4T0$G#@H(5Z[D+^(NLP;)*;`U8R"&QYV`KW,.8L<6-G#&^@:$$HI!S:[GD MN^6%"%;\D%(4Q$P2Y,"(W[G6L^L!([#"*87]O-INJI_:8\[,:T06-\\K(&1B M.4QG'G,RRG6N4!S"WA_"Q0*&=3Q]PE8(A("U0?R(C/&2>3B@14"'A%Z09:*F M:!H@1*&81O@%]E"?K)FN\#'\FS+K)OFQ)LLEC2K=E_#L$61ZC9Z5*M?R=AMB M8H0#!'9-<+-:@KX&2=I>Z"!GA*]@18$QPYQ=)[8^4VM/`8^UNE4I`MBA$-OC MW8`UK=1IB=Q$NHH_WUCKZ\H0=1-*5'GVBBKBLV*D^]K_Y MV&8PAV<]>V#/+MW`\HXI"4'_"H42&:*1MMF/H$A0Z'`CI<)7WY%#"L&6_\%&)X!Z0L+M`Z>@?_J^G5= M$X,8:%X?SF8$S8!XL$>("_ZJ':TQM1J1TX="YK+&!H;.(R@*8=4X6.5N%+*8 MZK^OL%7"WS$5L<>;\W1_G;OV?$@VY9QAD%8=X^$$V2&!49A%F%Y-.31#2^/" M4C@3*G30-%M9!(1Y&'>PD3KI8'SQ?>?5];S-"#S1R`1]0=[%""_#0.D4.)04 MI6XVK95:#5#:K&(OUO%G'& MT[1W&PQ7-UA?KB=HZ9.`;?P/:'8`2E"[.Y7&0MQDW`>L4J5NDU3;#3*30H#I MAQ>$06=](2SR0?RI&R1?4I\]7O9CPF(C#$H$2Q!V?<]-$&I1\4?_RW!XS_ZE M2%[:R%<3>_WF!PA:3>/0J=M":T09']$JN/2JQKH:(L%D^6Q^,$!.*2E-R^O& M(LR52L.SJB<+OWUMG#VR_4#5()?UTOA\WP]Q;;6B\I4OUYD9/"L=YDI=-LU_ M&K-J;J2%7>CD3^FH2G34-*_9<)?J02QN6PM'2H=-U$/3W&70K>967TDG>GE4 M.I12737-[[9G%BS88K()8LW`:QIM[A%JNPG3J1[T0ZDP7$I*IXT:6HZXCG:1 M\*/H#IE.FY9!BG9N.U>^D[H"Q',RPRA!UV9B7^E35U\-'5N->S?+>-D2)Y'M5$HO+G M2[51F)PDU=;__D'1XY+2P+%.70Q4/)YI#IG53U1&9`*A8"/DJ(N.R?FD4`]' MVG-JT>=(A8;T=&99RS-F-ITA+Z";7T[CFQS.DQL#_I+\_-L01MYQO9!E9C^P M5+THI>]F%9]4N27^@N%389!(>S=<.%RPN;,AS+.>D??Y1&W;9^V3RN6ZN('A MBF5C-B$K88\ME"`L4#0"9=J0N+;-FR.;;]8"72=F9P6>,]4ZQ,MO'[1PLZ.0 MOR;F=2$+Q65U4+T]*G+@LHC\=`Z[BCO1(J?M-BP:D!8>QMV5C*J%=1&BN_?)W*,H8=/S!1'SN>3 M@+#339L??1R`>7_C1:[9YQ.Z2=S6,&WSJ,VQAT&1K;^=P^>:5G]=,>Z;);E9 MNK\];%G]T"E6.7;.EMT+/>P60H9%3#=C\BA<+.+-H^HVH`,W:N`B)`TVWX:- M#.G)W4%B!Z6\G@X+MH@J/J;`*VT(Y64^OK"*#AYNV6I#T7G'G>#V$T73T+MS MISSO2:JJ#I[2W#(_F=X;J2=GC3C\E%;3ZP<73!T*&GG[EYRG*]E,-5[WP]KL ME]^^AS93IR]Y=?K@3X-7BYVM+O!7Y>OILTZD]2_;>RL(0KNI(N>"EBCLK,$A M(2ESO4<9]5[L$5:;O?5[K'5<&&J[59E.J/-#L8Q M+@*2)0)0WU]' MI)?Y<#P19CMMNQQW$\7'P1R1Q[F%-\GD1Q!K.0W=D?(QIFFVM[9+[AOB)3BI M[J7UDO*QO:>?LJ>=CR''4AK:+F7N>:LC2)??=XNDFCFD=(357MI;#V6KX:G$ M7-"ZDW^U5NR>;&':4;Z,%BKCV[S%5.;*:`E9\'10Z=25J:D$S(^?H1AAFX_; M[Q;1DNX(JQ<)?/?M=VW4B5,P,R6,IU!32FL?%'N#0;'S']H$^Y?POJ=,MVQ^ M[&-_?>SO3<7^&H1_]8?4S197#D';"JM5JO9HPA*`%%O1Z5+?9HM.`@_?BO#' MSHBPB+O_Z0QW30>>MC+[VUN763F\MQ763V]=6'5Q_*T-KNL(F.$BS,VS\^ZD M84FA;UO&S3TWTW#^V;G^O%31F=(]Z"]W/"B+:VEW/.6\;5F&C#B%*3$]"[#% M+$<[4'T;$C[+.,J'2-Y6(F=F]FJ?G$9EL'YH609KC>?9==S:P1Z<>H1>1#?2 MY,H8DJ[9I\V:03FS^M@->?'[YG0$1B]RQH3]EZWT;R%3XN-I=!0V^2K/:)W& M#9'+G@5I>CIQTNK\MUR<8@7=T\WAAIPJU#NGJ'>:N7P]%Q72FCXT62\LE#-&XXY]_YA1^NR>X.7,`QI/=C6W-4.ZVRVCG_@5Y MS@C'PU\T,:3KJJ&4.1B),.*-F:_"N67?5/(86B93:#R-[D:'&25((.(65R.S MBG.K^?FTV\,]\5]I;D]N(UWU,JO) M;?,X1\1:KOGV:;Z`YMMSB[#N7#YJ(U-3>QA'\HY<'=)I2PRV>JXZWXO<)@:T M*F6O?FY^JW+W2MC<`76W3.I*MNL/(/0'$#3E?[W)R\=4A4"U9[4T(!NIH%R7 M#I=4P?>Z=$ZD(J+?I7,>$B!SE\YD\.-W73R;P8]D=/%413$>WL4C$5QLNHN' M%_9"!ET\?,"+T>L_;R"'157-O,GR+I_]H=U3DW-/CR&,MB!-55-[./:W,1=! M&)5#_D92Z7>@W*H)].UFOB12D@CCXFT(0UZS)G+YP63=6!@63KV4G5B4_KMA M)!AJ,!9:Y94OPX\H2@4_RL=IC+,DZPJ[._Q-Y8;3<&FWZ0J(`@ M6,6W;!6/,*@&Q#SU^-E$#"LZA$6=K&YFUB!8[NAJSC9`.H+I9+.G1J$(NV!@ M%1`+5%ST*DC$WS<4C*>/UBI]:]&BKBTOI^.2]<;&XIJ]>%GEL-^Q"5.2`%7, M1[1E0;];5HIF9HT&CDIS\0C6:L*0N4^;GF/RL[UY4DR3>6YBU!!4OKYIW"6` M>PV^-C55'CI-+>K2TZ>[)=]D`KX)X0ZYQ+.]@=4?F)3SX3N6@G;\O#LC`AA] MYIT)P4^I?>B-)-\=P:3K8JI>!4.M2PE[!KB?B2?8I71``Z2:^JJ=RS6LB#!T M+OFP,EJA/3&QG2D/&F)!(PRV"OB4:Q;]]'&<=YG^>**+K.S]QL9(&6$* M5FX4`^:',PH*ZO#I\V1L,A`F5H#B4P';['$I/H0-Z.>O+$C#*ZV?\J]6$#*] M<`TRE2(^5T$__:6'P+G%6TR[IKAJGAP1%%=44@F^>6O9['KU]7!&4.3;\P%. M7E$M5XK!H%%FI2`ZQF#-@ED+N_6<4<6R(+COX9;7T\'-1AG?6RXOOIT`H1PN>AB;9B.A)88!G\'NXYRU19,W4MJ`;%9@ M-:]-VP`V5F!N7PVW`4ZLP*#$SMX&J*_VTA1[=FU`X\IL\A2)XMJ>VC$W:<1) M8,'SA[@U>%(6N-G,RYL5RZM'(VQ[H<,>[+GR,?4]UV%3-48/T[QK?8@3LBAB MI[?<($[X-@5UZGZ><[OR@I4\&F@MW<#RHCDW?O;<63R[Q$)HL&,EN$"V;2>F MY=(B,YAI]R&QYZS'2#T-%RRJ5`075&Q!RZ,'^R2*+O;F%M=-^W;P94C/EC:( M\E'\,B(/`"FK91`GVT<>J_&2J:>;&WH;@H>(DK?0-C=378?H2IJQTB:,Y7&$ M'U_]_T46D5E-,JV8R>D$,8*O,3/P0&Q[*VQ6"2[DAI:(@J[[XKNAA+2[]JH M$S_$D"FA9%2WZ2NQGMU#C;(#RB_<""U%P4E!0:-RH0X]":#KJI1>MVC>) M36"HL1>)=5W$L1>JD]->Z8+CZ)8.!NKD!5-BG)D8 M3([;51S2JF"AR0&\BJR76>(F!^RJS^9CP.;:@W^-K?]"L%-[=OTQV,TBHOH/ MV"I;_.60D,F7_QXVNI4P19.O!6Y"#%F@W.3;@AOB/0N@Z[]`^`CZS8"K_TI3 M5LIAG8[<_%J-T0R24/5>5P,26W(K,/JX689/D1;>W/(7"\&8?)P2LIFY8&$; M>6S046\.Z4\R_X=)C%006/GZ9ZX-HSD5]]!'C\")E5/ M!YX>$S."45@AY]&/KLXE-+Y/=_<^\AV@7:JJB3P)4[HD*W>4+UW/?J;;0OVK M@N6N3#JT?2.?DN61O&/G_@1I98UT9/>DU=5 M]'W6'I/5/=KM4+E`5;-B,.+DED2`J]J&LKVJ0LH(TAXPJ'$_A:+=I\J,,<1] MXY[S4[?Y%-^+=K#(.QB?;%CV36R?52.AQOB*6::0$_FY[+.%US2J,,(,-79? M$'M^@K)'/F-QL6A)7'6(G5O+)='[GU3'Z97")\UW+)E\&1U66QZ5CT0GS./B ME]>246BMRC,*EF'8>\L&>X>I$L_H=I;IP]X3NG9?7`>Q5$3N M]4'-]ZM-FL_E7#U7X8H=7CT7B;&9#CLS&[_['C3#SF@?>S[N]-QZB4Y<^OLM M02A[O/\8\BSLMU72[+%%">?H5^3.YK!LAB^(6#,4?629E>F4.`KN6$Z%D9(^ MX%'`JN*LTU6[9"8S,6Y6B-@N10S-JSTS%5*@%2$N=*HKP2BUYJ]V(+`_Z+'' M#^^@AX%)_[(I8F'ZXR=!;7A9=,/M9U#"0H M*WQ!!+KJ@3!CTA>V)FKVPL_TJL_Q=/ORU`1YT:[^XJM%%+#,DNGV$&Z\7AD+W.MCFNI%RSL0",.L\V!5#IT% M+`D:L#GX@L2W6I75TO,&1.[JW+M$ZH+L!5$-@S@0`N;B.IW@0M-)A_3H5S*I MA8DFG,)ZWAFA"+;T.2S.:U#!GK]D(A6O9W$=O9DS:K2L7!:-RKZT2`UY7OQ` MY5>+_(XR$Y+'.K^".5&S2@&NHP.:#=D:Q>BFTL708:3S"(.R8PFW(=9T!*F4 M[#[:XU=F2$FDI]N`=1]!1*6.21M@ZV-,)L[K";\@"@7`'@F(:T=(*_0!7W:@^/C"+9AEL9Q-NQ]E M-B-H!IR.,+`!4\V.HP7]V34^^I$=;_'IH,*R_3DA(\\)U0G3QV>WM^_&T7$P M1^1Q;FW.DG*6US@,:&!A![2"ZK,O*D@R!YGI3Q_4#0]_CW8GV([2M!'_>_0X M8+J7\52_8C$>3(^1TF_+B80^7]YHL_UHB;K]=2)]HJ[Q*4T'[%EM0,<-RS%5 M8KRV`6\_5E(9QS6LBK=KP`:R#S%CASV2`(.+L,W>`FCL`M4KRUE]10[\VWM8 M4S:]1]CFWYLJ*E[?1*3(?C?S7T#D+K,.?V#_8+3^D#$*X:??;D`DP;K0D-O[ M;!0UE9-;.*/UB^_Y,U

=%\XJ\M+UAS7W"6J]/\Z-R!TO3B,2B` MLHI*J'FN$=9IS".LX0<4!+$I(A97>24M#V#Z[`63C!8J<_(%%8R@7X2=<0HK MF1/)>=4AQJ'E)6LAV>"*9H.HN$IZ]E9EX0.*_,(ZQO2>^$YH!V.2A%@$*'5A M48TTTVAM1Z10(1;!+]]JZC4E>*9/:_$TL*"@DM4V`4_8!B_*6DV012FBE*WD M";*1^U+\"&U)#354[:[G;SXN?K2\M+@2>BJ(IU&Y_`NYE/+MJ^SGX_M2/*LS M\\*9UXZJB9'8BOP8D>'!Q0G+C<'<\YPLSFN1"]&&C,T*G);#'_IS,)4R+(%@ M:,_-4ZRG1+9P&\[&5]N08?+#M]69RV$(5=^UU1!X M3*\G^0IF.OP=AR#CI\ES3Y+_.G?M^9!LRCG#(*TZQD,P[&'3!&UU:5%7S\,; M$\P3D;:;,&.>GR1/VGRDL M)[:UC?`R9.ZA#[N=YT:6R>4ZJG[E@?\HA)T;ZZZ77>WN-"'^:MC9,Z$;$=J= MU@BI&AY$8565/6B54'9V"X*._/*:J4__^8N+"#NZO;YC![?E6!%5ULQ7QF2Y M)>B/$#REHGR/*C6UZ],6OJ[R_O MRMSQVW@37)HTFNG.*J<^1%6U/)GG8[2.[\NX#;%3'(LO*:P/))#VX7*'1?AN M:QN"*4U[*[F'$CBS0WLHD1LX;\@;R0I%J1G?X1#]$89"8OUK#Q=*!R`:<`\+ MIZW(BM<.>QLH+:$OISW\8Z#`=EWW1$87)L2-1"&R4O1!_2Y0M`UK7X-R838C MI&5&J*[R])*`APJE)^=@F200N0G4I#Q:.D7*D+8R>>Q!)R;)0&Y6*!:!&1.A M@MU<#H25+HH]=*(-B9&U\*1"413!NU6S?HW)$.`?2C:%Q/1'.I[>^7AVQQ*/ MT\R&+[[OO+J>M]G\GRC,RVAL+N)QZG,8^AR&#L3A6RR[/@K?1^'[*'P?A=<7 MA;^H'(6_Z*/P;8[EFL/E-Y]=C5PWF%M06\O38ZF1+6!@IY":FUA2>Q\[(QQ8 M>.:RN\N2'9!WP%NB5A>CR^:>7#M&=%EZOF@/,QLB,-[BU@[F]&'X/@Q?-0QO M^OL29@66^TA\E;R%/@S?DC"\Z7%E`]:?44'4-LJC@Q'4XP8/BQSB5F7(JHP? M7K0H?AB_7/5HK817&6L@C#E]7B8HV-@]RSL`-4^"%8 M[LZ51>>WGO]*QR^(7%F$K&&"1^-=!%'4;4K+,^&+)4S=Z/Z8W0#L+\AS;GWR MQ'VU6*ZNICLQP;@*UNPV\H#=E/]'Z$8OH):%JR0J&L7/-\0+V`JKZ'UK$==3<+#J'[76YYD.^ M^0+'!J;D=4GQ`RMEL[W#0%(]T8F571NN8*S&]V'F1QL0[WKS0-(TT0YIUWC0 M2FX'S.D3L>YN@Z-9N$EN[US-[P+ZO48I\$!J2\T_.9\30@L>!=Z$D!2X7FK, MF(VHAS:L&AH/./LG0>(G!,OKZ3#*BJCBFV.\TDH,L6L4()LUR3?%=HL8D`1T MG6R3$UB)"/AS2)_? M0[!WEU]?PDN"+!I<,SL_6#_XT^#58G>G\DB1JJ?/OY*VBU.?2TX0)CU+(W#% M2@SIK!,F(2GM#C47C^2:"<7PXXXV[3#:*"48D=G2!FA1R.0AMD,;<$2I$>:9 M_]IQ0E4,"OU?_;B9XF%L;5Z\%)?E7HCV-%C5`VK`BRTU$/M"IZ1-`'T3/'-- M+NW)M0>'(_:P4.T/\#068='VI$Y;_T(NJNWLO@Y<6URE3410A7T9_D`PY0]L. M%Z'',H]JQ,U$]?5SUX<`^Y!-'[+I0S9="-GP3*^JKQBV@]N*`:IS7=!U'Z#J M`U2*8=(]^-?<=5TC+",T.%L?BBIW8SH3C-K'@SH7@>I0N$GL[WG,(Z$)M] M4H00$[=XBVG7]-+F"!Q!DKA_-YZ[<+'%#0W)U>D/5=1`+"T/T0EZ03A$_*LI M=DLI00@SU@/R9[#?S.'GK![C8>I5:Q^'VB(DO4I-O:\2B?5W=M/D:QWMAJN< MF7`XJVUY9:AL@\B=W1>K8^WPQQYX65.'I#:N[(+N(+QY@.C:GI6O@/6]+5,[ M^EGJL-?8P<1ZL!Y288##]!`N%A99CZ?IAV@^)/W2#Y,@:96JQ*?-/> MF#!$BD7Q*I@T5%G_TOPR']Q&4]8;RI[;XN?-_(0WB^V!^M0BQ^&:QN(Z6 MS`Y0(90-':)C?+-B0QNZ=!Y3=HV>>;9R>3TU.5<(PX3SA@[LU"Z[@3MP7]`U M6A)DQS,3INIPP2;]OZ,_;U9+T`R%!FK=IK2,RG:=\N2?*:''KV7KGTV`6]"] MH#IA!H0P"1(%`:KT$H'*S5[@";.$6*!,P>8BZTB_?@,5`S5!F7F12@';#%$> MQTWVJ`T9@,Z+IRROE`Y*Q\$<$9"0ZT9F.&\1WOZX>Q M6]"&85PF&K<^B[L-]+FPAMU=6R/$7GGW:U/*09-!>/-`J,."\+I0)F[Z:)6] MMSBCM,+<[B`<>[`<*^PDVG%\/7(HLAO:D/;8@"B$IF,;\B8/,XNW\1^!NZ,] M[?!X8JB-([;H>H4#9,3%I%J4Y*>`_1)(7W^"X#&%P47]VG"D2YT8)`(D^L]Y M'5='-(C\;T792L.-#]SDIE0VNM.&PPW501RY3(+S_@T%'7D#W_P`T4?_%I8C M!O/'2QFET1.C[!D01-E5C8EA].#.L#N%QG`PM*,[_=CA'-]S;1?:`2HN/=_^ M_*CN16MH;`_#X\7#[O0& MHC=D"+,K\H7Z2V1TWOMOKH_8P`4Z9C\X]U8ND>$KM<)`]!L(Y\D)1/6NV8K` MMY1H*AMPVD/D\FD=A3MJE0L3V@2>C/`+_,1AYSZS M;C+1Z1UMV!GAP,(S%P8^MMR[0[9ALWDW\&JRH"5H-4RZX(JB7#200+40V[L; M9+FL?SYC)#W#3@E__#]02P,$%`````@`TG4&1UY2I9%,8@``?WL%`!4`'`!I M8V%D+3(P,34P-C,P7VQA8BYX;6Q55`D``XNKPU6+J\-5=7@+``$$)0X```0Y M`0``Y%UM;^,XDOZ^P/X'7G9PZ`;LQ))EV/0D"4F MT8TL^B0YG=_O2P]\`R#T$7^ MAR/M>'0$H&\CQ_4?/QS]>C<\NSN_O#SZUR]__]O/_S$<@MM;<(%\'WH>?`6_ MV]"#@15!<&^](!\M7\&5M8!>"*Y<_X^%%<(!(/_O`.2#WS_>7@']6`/@*8I6 MIR:QKA\;S"^W:.T[IX#]ZCR`5H2? M!@[6YA3H(VTR',V&(_->FYQ.9J>&]M_LTVCU&KB/3Q%X9[_'#X\F0UQB#&Z/ M;X\9\_X3W"$_Q$\O5Y;_"LX\#]R24B&XA2$,GJ%SG`CU$G,!=J8??CAB+'Q9 M!-XQ"AY/<#7CD_3!H[__#<0/G[Z$;J[`CW'ZN';R^Y>K._L)+JVAZX>1Y=NY M@D1845%M/I^?T%_CIT/W-*12KI!-O22@(.`^0?XU3!\;DJ^&FCX<:\Y\N!1\MU3`!^*M?""X(24/_'A(VY+A]0P M)S5H)JGA'\G7-,Z.`'GRU]M+KD'SG*RXT$EO2M[C$(:--&5*)NIZY!\$5CF% MX4L$?0@%=BI MHOACA87)$R$`!<-!Z$3VL MO:P(?N0G79\!UZ=C>]J/_:2/QLD7A@HP+(OF(C!RG2L)DNOEVB-CSPNXPBWD MTID"_-F#Y`/I7)-PBH/;:1`Y9815"ERAWCL(HY,;>UF.]DD>^ M;M'XG6A34TM)8","4!D8US!PD4/_)0O.^YBE;YME M<:@6EG=CNGN M/J.`[1:Y;,<900YVO-2'/1BHRH#_BT8HTN8DU_.*D(JSP\RAP@%Q7A M5VRL%3Y=1G`9WB,\J,7_=NF8]M*WT1)>H1!_?XX?P8GDL^M`Y^/KKR'$*+]> MD<4#KO]X9D?N,YVNK7HCV'6U4C#:C2VBX!A/C&F:<68J#4"B%*!:#4"$P$8Q M,D,%8M7`.Z+<>_(ST0^D"H+%*WA'=,1=\7NP41-D>LI_[ZE4`^A;#4`\&FP< M3J;)/*P$^99\IBVS8GV])KY^0,%[@#;.MC8ZG:K!==V213%E=MBXDIEW;V.J M@;%_%7(8=6^]ZZ06\QWV;)\MNZ%(A)-L08KLV:,F?6]`]`-6IH0B+-8:\#B, MU8ZOI;!3^AX')ZH7R5N$ MV'-K-C,SQB$8C^>8[._UQ_7`!%U'1*Z#21UN.40?9 M:V)GT:Q@F1Z"S3X;D;>:W\?;LU=D382#9=&7*.%Q)S%C,>-\+@_ MH^N+-O)50&5;UO-[O!23U':Y?6#3F.8CM<)]':2[=S"*/$B2S>N%YS[2;P52 MW^)B`?M=4#GS3^]V-[:@Q3+,#:$Q]8*L8I#6#$@``J9N0@-I[60Q+*#U#T"L@:24JG_G4;*@ MR^(`6E$\A;[-A;EM4FOG(I6&ON/D#:^?A:+.#LQ>6.P3JL M\7`HJLP,8>S-1S.MG+B^$7FREC.IXB&]F8<.A)E$(-@B7U4VRP&RV)7K0[H: MJYM(SL0?#C]M=!:&FFE.C%:S*/"-*!$O]SQ,"FOHQ%*^:MN)!\)R.Q!MD=+R MS:0.?WVUEO`"+2V7N[6CJIATOLET$3^Z:5PQ&AL`(A5\B^4JQ0Q-S2U#O("Y M1$4P(VW%Y94*Y M;"WGCL'2`[MJ=UWAL[("O?8AE./YI#C@Y>\TV]\NFK* M[Y2LLNBJ#3?+2`,R-@[H)FEUR:*Z7ZWRC!3R^&$%SCVNI>RM9.Z9/DF!K;C& M^>:324(`I#P@`N2^[&MNABYL1F_Q7Q0PN5C?L;:5M94?K=`-KQ]N<`NEZQ;/ M?.?.??3=!_P`3E=%;RS86US?:S'WT%5X,\QD/IW$:S1I;63%(EL?P!4"ID:0 M5=G;W0A%3-&O?S2E_5.^[+,W)^E=.JF7Y9,M4,UF6>6^;I>1$S30^1Z^1!\] M_JF&>XGL,>/81T_Q(X1&LS'+)6@+)I8(3$BU@-8K*:OISU7Z7JZ2F2RU@20V MM]K;Y^VD8IYE_W%G/V$GA->K^-1AEVRM^8( M:J`S2U-$'20E'UF'K@_#D#G?*>0]+1EG=:;=QO/T+KJB8),Z MC]B*:5P<*3"W6!%L58B1NOU` ME]DFOXHW?!/AVQN/E MY'Q?Y((<:+C@ M>5(BMTJAI0K^[K^-_V)]Q`79.E9GT-BW8G^-?B*Q5IAEIJ-T$Z>:/45BSU^N MKVC4CI6]ALS'L@?\E7EFIJ:4E1AXUW5:JP+-PQ1 MZMQ4`[[=D[D:('_%3)=>B8\96R^7A.`QJ__J6VO')3-WN`XJG+FJZ!:&:X]L MC6!449:A^(`0IA..<]M9#5-8,:TQ=Q]0T8B^@8#>U\?4T4XP9*>:/ILE1\(6 MSCNOTI`EU^@9>XC(Y7(&,=W[87-^CXIH^KF M(,Y6S]3V3:_,4SQ.;"1"5?:IE[M/];DYFS;AGR2;5Y2!&GFA`0=)&2%V[PG* M0R6V*<5$!2.KQAY29`P4=CW^$\_+NU=%[FBL<_N$5R!,Y].Y8K-ARHP.%6NE MY-A[V@K4_6A3O6*#Q]Z8I&($VD\#JD;?N7ZF0;3GRRM"E#FEA'%C3$<3,7;; MN7=:/1;:PP7%T^2JLD9A`(M"?==+JN'S%CY#?\T[14FDI"*83-01[\4FVE@, MC8ED]3#8R&2*OA*35,#<5E"*HHWUATRSK1INLXS78F$62QFBY`HX"-%P'@+;?3HNW]"Y]*! M.)]^<,F[P/@\IF2+E8,S["O\M>O%ES6$X7H)G7-KY9)34J$5PNP.+/'8:;MB MN230LC7"W==D:FA\`AF`3"_`*I8<*ICN#'3HJ)]1#B3:#4"B'Z`*,C?S*<-! M4CV?'BI'Y`$[<95')*I&8!WAO(+\NFB<@R?.Y/38LB/DNZOO4&F2-4+\*%53 M-[MEQ^0,XR[/T>^5$YN[N>!,YS=#@46([8SY=IK@C1`>\T-_DMC4Q_P@ MGJ-H^O:[HV[XC_FQ71*D^AY^@MERD\1OW%F/NYDCWU82*LP473&P6-.]'4+N(TME M:SMXDA5.DL@RW>VUW>W2Z6?7=R,XO'*?B8A,P[=$H#7='2_>A,_00ROLE'MH M/_G(0X^O;X\@.T]&MQOAT$GO*^3=@=-V+0=*2O4H MO3?Q!MOT1%Y$K0+75F*I1LOPZXJQ4G*$;`F(OF]A+K+M1J%3DYF;WN#DI#!' M=$:V0DUVZ%1\$Y#M#='KC4?N5?`=KD&B;^$->;=4FZJ M(OY$E!S$.X52/0]_9-U2$]!Q=BJ+^@B6^>@0";82^5T1:WD3'1"AIE.F_8S& M*VM3GS2K3!`>2VKS41MO<@:;=S*#MS-0;]?);V/`+HK4%BA/R/V*D!SO[E"A M(G+IINZUC>;8-.?;!V>S\J3?E-V>D?S]&)+OG:P3BA50W.?^2,Y!,^>6\_(% M.OBS=_<:DOW'E[[-O^>M[/&^#Y`IT47X<)#1*+T;]_SLX@4L8W$@C.61O:P] MGP?3FE$4]$0:2,2!1![9BBSSPK;6+-0WS59@X;'\V]H$H+4YVJ7**2UA/=N9 MX,0=^$+1:/\RP__3$Y)@]\DXR3(= ML(CK`*LT8T3Q'8D6K:9W`NG.!QKK@[B&='21U`$V67-R3V1K(%I5[[I87D MPS[11/QDG,V%35ST;S:`R5IHT:JI\*D$[Y*>JE+R896J(AYLIEZ4<[*X`JE0I;K79I;2;C9]G_$*`FBCP"%W MR_H*'9@A&)P",,LY22&<96N2ZC4Z4TX^UC)EZE#[K+(7R^1V`K@5(H>R/3?! M7%.+QQ1VU^LHC"S?(>?Z>AL(8N1MEJ248$\:SS2UN6!":0B\S4K'DLY\;U.? M8;!`O1JKZ>DZ3E!EG602W64>`1K=(%]XQ0 ML;*2")6K4)T(G!>0*F;26#1(9(-4.+CHZJS0.L/JE@PWXYND%K1NL$Q,C0D' ME1Z0)@.)E:'+0V.YMY1%I/@HO5*$:OBL/:QE7F$+PY0L6WN)P/T/Z#WC)Y`? M/2F0'K3K$]IWXB`S54@&6F[N^$A"WU_OS&N2BQYX1BO%3(*3&T*.4Y:G+OW[ M'^B_H!6(O$`0D:(:6V6JB>]0,D;U\PH2UK@F0*M2F*F:^B,EJZG29-6XM2OY MJM!NI?AJ%\JU*6O+?6JRUJ6/D0!#1>=6 M$+RZ_N-OEE$3W1A)/S"B!\"*0"H=4/'=O'.# M@8N<3WY%*M.Z]4;.>L@:#O$7&+JQ9AT:?1=90=2SV1.^V0OXZ/H^:>UNC1?H MJ%HW6\^9;9,/C.UR";H&2^7I6-1+ZI#O#8TJG"4'I!.Y@/'?6F'`$2&=BHOU M$C^28I;M..$R>,),;>A,[G=1.,JZV"]A+/027 MAWHUD$N\*`7/:+ET(YKE$5WIO;^/T+?YET24E>@3K7PUQ"=`YY,4G)FT&*.L M/$F]95L&ZI4&@G=?403!K)!N>H-;=23FT%7A'L7`E-U"6'%P0ST9:@!N5S'A M"!V9\ZD`!',W<4H^[:%#1PA`5=@1"N"6'_2"2.;X4UEL5]VG6U.(:NBN?!KZ3C.9&Z%4'K?M<`3TW9N8N.E7%XMZ6 MQBNVZP.#NR0JXLZ`")>5@@Z>. M<'A-1W-]%RT#@`4#%(!8=/SJB4Q]`BI=.H;:,9M%51B;O<)F/_/>LTG`556@ M*2$':]MJ"`?;V)A,BC`6"P291.FXVL_$ M`CR%L8E6J8D2<,4+0@Z>"OVB!(XNPW`MCJ'D:9GXB540'XC/IP797(J=`8C% M*0*<)K;Q0>-R39,&F'RTE8*%\8420&&V=XLV)UM$)F08/80)>:)IXS+<,#(5 M`4]C*_D(0N5&2H-102R68FG;-9(!5;IH;_LQ.<"IM3S),&>&6006*D69/J:! M3070^`DS9*/1A$Z&XZ^G M8WV@3:?)U\8_6=#1W['0B3'=+C8QL#3#3(LI`D_^0J^B9I`$PQ7TP^2>!(^, M\,Y1&(4WR'/M5X%9<:'2_8)61"7AN->-T6B#Y8UDD(@&5/8`Q-+!M^2O"E/G M[7M!W_'",)D]9+^4#+TZT;R%2&&/R0&J'V)5'*K@)3E?_>S%Y:_3*GRX5Q@6 M:2#^SF9F;J8X&$&`2@+?B"QIR-K?,+V^8?TAJ"S,\H#A.D(-?%P@LG-%N!F3 MQZ5B)-9!_-H8?6Z4H"26I@Q.FAC'1TJ)'9M&-XACS_YQRW0*V9X6H@O1M?-#6K"B&R,H>+H2"(5"(A$20OP6[(P M.XX:V(F=`7R&ONQW455AET=-J2\DXT8,+!(14B=H)J/Y:%8$B^Z04-V%[&%) M>A6LL[9EK_,I#!A.F*L4VQ=P%4#;I5T6AM_9DAQS^6?1W44-!,A#1(E6XB&F M3<8\L`P`6P/M5M@ZE,!2:SZ(-\TSQ:F]#B->(>P)!'0)+*M\)@^QMW&_7MKT MZ3.]XRZIN,;]M9J6A]8M/VWI"SB-C-!9(Y3)O;:"93?@65NEQW3ECJFB9V7% M>.U[7\>C^:@PUA78Z+2W747A?ZI,_)?O2N(9+P\/=Y8'A=_*<`OTCHPB+<3W MQ>GF5I9%Q:GXNJ4=6W7!;J]?Q)2%WBYLN%Z0B)UDXJ"\]=*'^L=(4K-PK,R- M[:%Z*D)J^#Z)+0- M\H%$M,%$-/[J>W*VHKNL?N$48C8=I]R?7`C&'+8' ML#1`Q/4;[^T9IC<9&O79A8-6,Z M8S"129&Z7F1?@_1Z!O6)@^)PVL9`@?'RXS\]W/D6=UGQOK8;B%O>CZQ'WC1J M#0'2\%*F58TE2NFQ=5MAQYR)3BH8I+LYLSI4@%A[/M#C`^L2DY$/'BS[_[O[ MMN6X<63;7\'#1$QW1'EV%>L^YTFV[!['D2V%6MT3^_3##JH*DKB'(FM(EBS- MUQ]<>"=`@B2(A/JAV[9$)G(E3DJ1H# MGBG?W.0`&,+V4MU$]L[?9BRLQ0)@]@HD`WP((W7@G@GC"Q[./Z6K+57ZO=%/Q07EU"G,`L.:!QQ%]#:I0_B,[]S7SZ_TV!G^B`/\ MX,GGJ]O?,LJF5E74%__6RW76_7")B(M$1"9*A:*?4K$3%2$/F>>T]G%&@9U#!""4&.>0NPM%+RT2K%N@T%2;=T+T7[_=22AP'( M5=5`_8R^L]O4.)5*FJ%4%BR/QN!R*K@LV$[9[ELB=@C@6T"*[P1J'UZ4GH>C M1J%$CPH6RZV,'84X*P@R%)V0(S/DYUGY9A]V3W^E]+;/`]K/[1A@@5#`3@J`,QY>--%JDY=@PGMQVJ'NRPYS:7C MZ-)BL=TVG9X=W/*Q\-06ZR)._#BA%?P8!=WN4UL]CVGI/9?E'=PCX\Q\LYPS MQM"?D$:BY\_WKT3^K7LDDH65SMN>U,R08WA@LQDBPK:HH>@FY(_-8O<_2\X0 M)@@128B+FK;VN8C[VA`M,D3()"0IL;7AB_@3!RB-I5(L*S;PB&"NEL85H[P?3S*L$L(6IC5O41 M\]RJM*_XB??S[7JUS=B52C!.KQ&:+RJ:PS)L!`Q''88AE@D=OL2S)EB0X5V^ M\_SZ05;:D!4#OG=C?+QQW_BU71W')L8)-3E('*5IC],*V0V6I8,*X0-J*Q7* MFOW`VD59P_"G-@S:RYG<7L8&JEI(5AG+CO\.5D>;CV6UN\ZQCY5J8[P1JZI> MAW>WW.@)..!GYHV:C&]LH;6*/S!QUE0LUL2<03&DQ;!Z!@=I:DY&]9^#Q$O> MO@8/8?3,)^K$F8;Z>\:'$0I*J?KD9K/;.^G8(A7+)FTP$XR\0K+I$8=VD(L* M2#KAQ@6CDF2P[&O;S88CD7,X'5T+""!P-1"5G0CLH\!QJN)69`U03F_)\S M3UX;1_R<8=^O-*X^F)DO]S7/3T,D7$4<#8BH>WP1OSM_OB-B6 M[\)^;=B[:9OJ1T^VJ_I`@;X/Y\G]M7>4M#?IM66GJ#MKC@]BKO"S&P5>\!AG M=TAWK#E('SLP0DV4'-0;`8KR0 M0H!B0L69VFA0(+:&`Q%*JH)QE+IXLA;`8YE6L16X:" ME?0GZ`.ZS]$>Y6A!B=7TT$Z*UG##-DYT;5F0/P_(B_YKYJMY5F!<-%X!WSJ@"2#CQU76O617M5.!-K&E M=:V_W1(@C'D^^>$;QFEI]&*C07DKPH7/-"!_H]=L',+'@-X7S^?0V/Z$JXYB M?[I;,F(78EFDWP!:V-@=_#X`7')+EA7SYF-[66?T^Q?`^3_\9) M@7*,YP]JS[:X.`2$^K6YF^QBX$R7[%X5)&,V.Q;,->(,CD44)AJA-S*4+72R M.$).;V(6*V\QK5Y'46[P5_A3Q;NNM:')V_TSQ+\!ZSF.J3@( MO_AEE]4=&ZS^[J-NZSJ?D0_^IXK"V4[&*/T1?6YAFD]B)?X,\5F(K,=,5K8K M>/*P,+W!J^!POC_\3>XQ.UL?N"(_<1(UJ![4\9;UL#A)'@ M*_]FH)&8'CB[/DGK(W0_#Q'?ZDKTR6#6]5!$A2$N#:@&@69\CA1?#%J=0-GW MA'P4VD3+(O)/TMBVU=TP?_NM22+58TW*[7*0'_W(7BID+A9E0 MNA:52C5\^$\O2&$O_Q6^U[RE_SM"&=V'C/?:.K]-+CM,3HJD@Q"0A(LK\)G@-B)R^B$QL MC&]UIVR'O!R\,7]GVQ`8]5AZ'%^?DSAQ@Z,7/,J_5MM+9IG0HHGZG5?K]:9* MBW1O!A6;%K2(44DR&$NTH75&HC7((`4'K=&IRTJFN"6\U*OQ:Z-\Z7>KU6J^ M7"PJS("YI6N<_HZB_N9\NGGMEA"A*3_]XODX^N0F^#&,Y!E/]2FC7EMIND^@ MVU:G2IA-]B)_TLM<>,^G>U M[1YWW*[7%0]B^[C&SV/>_'J23>[JKYNZR9.MN6BT!]4&-3, M\218G0%8C4TB]W38RIQR'VO9QT:J7NOEO\JO6\/&0B?U[*;HR6H>RH73VPHS M\;/4:T'O"Y[&`D*.#K*`'\)CQ M):"F#HJ^M-NOMHMENNK#I-";=J@8NCI`Y)A>YQF+9%%"DHI)=X9`+.:,19/N M1B9IHG>@NS5B/M_VA/TC\@*$F?Q9^JG@%G'D3"G6;22FT$/5UP..X^N'SW'B M/=,ZLK\%1R\^A.>`UI1UXZO."Q]]=_RQ>WATHRCCEA^FI M>L'!9KY8[M.PP%I"UP\H;PN5&T.T-<2:0[0]E#6(6(N&XX<)LRQL-4M'-#)A M&Q:Q*G8X4#L\,#N$U`Z'S`XO5#HM$.[&,4Y`R@?JB!Y%B!MA7Y"QQNO!B_%% M?7;S5?.,B<+H0#?-$J99<#-UB]=5\GV)A;3D"U_< M`[W9_NWB,<+LX*O\ABC9HZ;[>XD>RE=K.OO=G/?GF23D9J(,Y_A:H"PJ4')1 MD'=):<'E#,!EI)?LX$S>"[99`:*7^^)Z$>MG+X[_>XX3JM'UPS]=>N@]D?5W M[>\8[/E:%5$_V+K8;#+">!'//U$AD78,F4R8[E`C3,:?7US2[U'?18E]N"COL`=54EJ,4=G,CL($M%=HNUW'2),@H5L_CAX%S#=./?+/$->(C81*.J%,*<2NZ4K5 M8O4;XQDJ:X:8:JBJ&_AI:7L,[MA@-[&$05)%U% M_H9(@HN**NKUV/6V;02[C&/L&CEVMCAO!?UQQ[@%7C%P_V3[\9QZQZ2R9JS(J!P<;BDSJZ+R%=Q?UF-KJ55#6\_UD$8^I\JZ#W0!C3A7H MY,9\7S&N0ES]\:WX8J"QK9QMMAP&DC\/$7?J2O08IZP6@L$;X"D?39B:8R_P MTSR=+B;DE-`,P`S)__H/#T?$`D]O;-9,C2YM+\-PIT6C'@57-O-F=YP+M(52 MVJ`V.DL5J`!,4W!5">VZ3`7,P=)L_Y<(__N,@\.;&@&E;\*P3Z9.C_L=LST_ M)5$HEV4+]?3@=(;@!.!=EWM*2-=J)%#&77KQP0^I7[ MBKO9LU(_'FB=5^5]"K:Q26TE76H34#[Q'0N7Z3FL6S?IG&45O`'!I:8:Z@ZV MWR\:3.+R9BB3B*A(8!J-Q96_V+.U@S[+GE06K[4:P/:'*GJ6% M[!F$L\2>=DR0[%GV8\_2%O:()DC4]CBVO`G!)KDZ/2X"60OZ),GDF!W[$76A M;DR_]T=MG'W=KBMD88?);&'C3>A[AS?^?^7IC,[W@9DI5$HYEUIL%HTUL;*C MSA"7C/Y(_[1GUD.O#5IF0-A9A-)\@FU,;77K+K[*36<+:^/F*E_OWE0N`YB] M4L7Z3#VL&PPNK?1:UZEJ@EPGK!ID2)YV.G(75]LM9PU?RX>6U$:/'6]#<[2I M4H_ZQ6O!GI.V8X!V##!UPF]+A/O`!^6NW*D[62NQGS5\O1U.UOJKT$R]'>BG M)`5L'Z82/[VUF:.C@'<05`TX*#LE+MQ)39'90'CI!5Z"V0'HKT%"/IEW[V-OD-A\XL4\B+.&3K$5O03CQ">)/[_2"K\T1;SV?%Z[Q8V+ MY^D/[CR:8>4_@ZIUJ--BK-8A%49M=63B7!^VA'@OKRYSM-LN4.2,J5J8*/;Y M-2$>=O;B)UZ/\!+?R_9W=[]GF*2MRJB[W38;IC*9G*F8<[4JF'HA%3U)K\C= MXZ6U8]0,>NF4N88;6(]38>W,`#0#+7"RK8(&D;[@Z#XTBG51^:@46`TO9">A M$^=JF/.:["R4HFR]P^BVD98"^;_@`$>N?W%\)HDD/1I!@\\E/D7XD%9,#"KC MN<^O)QS$P@MUAHHR76!_H)ZJMZ-L=_OYCA?@3UM";J4I>N]6WA;+W\J3!,2' M67.&2_4;,:/4-J+G MH#WS'J3\JJP\^NB2=P[3<)B#^#5QHT0_C+4Q&-VA:!``I\N)C$68&BTKH:0, M#3)F7!S^??8B?+P\TQ5HX9V^2J\`Q!:1'LJNLMAGY]0R<711E@M$7"+();GZ M0?(*5U1,.HG^7-I5S$,)Z9:S&U9@)XP5G%+$(JF10)D5-)9^B_W;':5!^LF` MX)Z*8CW**B[G53*R9+&Q;Z*T`1Z\GLB$EG!T6L(X=_NXO9#,R@:UEMU=YWIZ M"K&-WP/NW%CLMKT)#G[*9TIC6)>E]G/HWL2%/];3HF;V*WX"J;\WU-ZW@Z]5 MI92]M1[4\;GQM3*Z+ZGK&:NOLENGZ5^9&#VY^:Z>;"S2]PJ4+6C6* ME([)%0(![J36!J\XL5#_8'#K2]V$*M:0.NP`V4<+*JAUA'K1&P#]L$`-]4M\ M]]E-#47/*JS[!]NICH98YTWX@!XM2H1;?$_47+%IM%?Q6-$;EX`AG3LK\\GET[TELS(?T1S MM:MNI^]^'X`0G4JIGW1>+9=ULF32JV?.B@;0E78R]=CC.)$)5G6N>;DT&]BF M[,8B)JK9"IZEO2@)S[^^GD87U[9BLDU$J[Y]U!A53?FV_VF[NZ@-47&X'"4<9CV<7DQ$`%>$.^F([N;*'SP MI+M12D^8].NBV1[E)K;9'!I]&_'7@?QYJ/[,F7_%CRSS>F0X3A/B"!/7GP3' MIO@.2%%9#;F3\% M[N9V49^(^^`SI/QZ']CISP&LS6-(#X-!),]E]6HZ_0/[QR]A])OT>*/:NP83 M;B6%E%/`_7J]$7&22OY0IB&BPC\\A-&',]2AQPF0UV=0#T]N](A9\05*3U2B M)^B9BUX>7,Z8U6T&3,SH,JV*U-!3[1:&0:)@:*NLG_KLRB[;E%)F<80N2Y6F M&HRV;T?H]#9*R\CD':\\Q0!@=F\*2(C>SW8@O`\.X3.FRR1?B#$^A4'B!6+P^X8@EX/%'3+H:S)^[;OQ+CD36)HHM_CUX"X M%XYELV-3MF@RBDP'0YE(V_ERE08;UDI6!9!5H2I40H5.Z)XIA=+GF5JT$F!) M,;[>P4J\EW1#F7(PEQ2R;N*VCLFI[&E1`W\>>`BX2_)F[" MCOIVG#B5/6T\`C544#^CL1B3:09SA&,7D4<`(Q""1&[:P MJ&$8BYC4>E%:^SOP;.IY*]AZO]]U\@GT-C2-.+LX9<$5:$HNJ<`KX"O.\KQ3 MN8)(VQO&62540]G7=O/EOL(I(LZF2B#:,#I#,9IE4ZL;-KDD-XPE3.J<_VU[ M!99+_8M/[/<;IY5,\%.UVF#6^`1[::Z*XW60QY;956;+&]>3%8JK/P7!$=YT MG_UJJSHM<(RH#&`6#`'"')\C.$D0&'?[JL<(/;T$%=2YTWJN'W&`Y9MB94]# M.'M5!?73V/.L!F*I+TAEH9]2:3\#^_\8;.4.("'83E'XXL7:RTZH'V72\\56 M*;W1/7\=_936-1=^*^-,%]-'R'B!&4"9K[@A0/8X!/>'+EJOYKM=G?P6KMMK M@6EG(JBR]-X&'X@I$79C?(GYGU^#B\,A/`<)Z;K?Z/V`\N_8\9Y9[K0KHWZV M=+Y=YR1BLM!/F=2?D1>@3#!*)8.Q2"?@K)(%1W:2(S-(*36OK'%+P2AVD>P6 M'[#W,HAGI5>MH%JAC_K89K_8J[&M$`Z8Z>D&OJK0+FJ%",^\IJNJD:]F'FOX M%YW)!_?<>\_W$@^W+`UWOPK-OYH^ZON:M_O.WH[*1B7A%G5XHV!G?1[#EPZW MH--(92?M9)[(-'8P[Q(_X"C"QUO\@H.S>K=7?P^4_(2U^_>GZ$J M`)1=,JUZ5$[?M`_:\A90VH0-&SHFL0+KV#X]D2=Q3)&'.7)^#)"?W2W2,/13 M@-F1R>0)(_SP@`_YO]SB/J>?_VX7G[N(T$[N5DO;P?2;"--5U:P[3]_/.11*J.ZU>57C7*\&Y]U.=& M%MOLD'_S@A@B&?V4R\Z+<8#M*-"-NW8?3,K/&4I[;;=4?[AR"SGYW5\6\]EJ M[]"(1SV.D?TOB]5LN]RE/UO!\ES=W:NL5K2QGD)`>6O9W-5;Y_[H'B\:+P.D MHI6BA^[VR_EBD58!*CPT%VQP_[0H%DV%MQZ)(/!V%`#2#[H>A@:`-E,!J`]= MBP)`R@8#R@O8*=_:K?'-KJ?RE-G>OMRT>@F":0S&"009T2.V,*?AF4LX5*>[U^4ACSJ'UO\.BS+ MA#KUJ`:WF;=1CI:KR8;(Y0:LX9\&^'SFVXV?E/I?0`*V>F\'&^5VTC7:+;?X M-:"MX>/7X%,8Q*'O'=E-0-7CRW=T'Y5L.[LNJ0#CY)$J*X^OYNO]/!]$5_R6 MUDEBS=+IFD.IX:R`4IPU;;@\MFGK"",;RIHE?T'EAK-"746Y`-8VX+%3$*,) MDY/":%Z'T2"'\)IB4'E\K\/T%F0_5SB.<3KQ^5MPQ%&ZA'E%US?4NMMV$7!9 M4*M>/:[!7.UDF1!O89:5!#[31O(-`:P9*_(AC89PA-W*(87LRR`#)4=*SMV2 M('4;;HHDZ39\<_WD[?K>]QY5\XGF.\`)3D,AU;YFL9\O'4GZ$G&A*,REPN8I M(T&*LY!4*"JDPN<6(X&*HT;S:]J2(D@9*$L`Q/:![-Y;*UV4'@'HGGN5AECM MB\.*J?]`UK<8BJ#*`%E]B]$(7G!T'TZ%8<%`W+AOV:4(;GJRA.X#.`=L_T\V M4V)#$B`OW5&S`"Q/V;'-3WRW5.[58/%3-(,I;*@&3T< M5YW;%IPL;O,M,14:\,%($?,[!#_[WK,7L,ZT]0K3]G=,4T2FB/*>Z^5B7V9* M*@^5!,;`-YYJQ.D,QVF42UTNV:!4JWE@F)4>H^E1BU/^AE%62=50O^IDN5G%S(R0PC*!-OW1_?7.):GNMW=E&59R&X M65:@1U'6M=,@*9&$,!Q)R6J#T-PHJ*!>EJS7R\;I*"B^"%O)LP.6HS`QWB1@3IQ"58P0^AB0FHT MT4-P@^T"N0B.MW1;A-]^F$K\K$%F"!50#ZB[;#A3%#YA$@D=;MF\[93'K+I8 MH0$;[RPHDFQW`M_,550[87N;0(G2ZF]EGLCMH66[$A-/I'K\EM%+TDE=XO@0 M>2?9WJ".-TQO56I71_TGK#:1H^'FM:(XWQX6^/X57R9_(CTN@CR3&#Q$O>!+=/ MBYXPX,F"9M5WIJRW^\R-B03$18!<*#T:AM,#QM1^W.(LU(EE6$'B+X/AK0C*>I]`_ MDF#S^=]G0K'NCR1^#<;?A;KT\:)U@P1LXSH7!,X'#?#$)&$@XY+HOR(LA0S` MGE;7E%!*;BQ@GK5OXQ<\",.EWMO<5YME@ST3[]SOP9U!<$ILR4K5VM>UM&S= ME^"W@P!=0UOY"Z"$Z#U4W#O.7DX,^`&P)H2\$DZ3):!%W+N]KITN(\;)LH41 M(IX?_Z0=%$X2GQ5^:#_(W?V2\>61+HV4)]?W2V>;KI#D,GD^DDN%.\NM&>:B M!I,(1854V-/-VR\J,`7`^/P^#QRGO! M1Q(QZJ7DA2=75=\RSNQ.E52]9;M;.;N4XB'=*D2ELAZQ<>'"M(=9Y6S7C'4! MC[4C`F@&[-0`N[T!FXD4RN0L0H::I4`&VD2U.QP]LS*ZP;%)=!LP6^K3OC))"AZ0#"U%I69J.;U9Y%(`,Y?;5*VKM=NF2"@_&>3FD M[^33VM#W#$=5ZF**CL7/&6]1UR)R,A$U&K:`848@+\F M^%FZ1T7^@E&6R+3H$UXW6;\1QZ@B#?U!Y2$F$*SOT(/0&8C0'&NZ'+#*G5:K M6,&@N];>1?@P)'/N>L7BY7:YD[.&R;*%,`.`26T*JUHYK/M<=-3["VZJ"[!KO?K73JWGDI#+A.7U],^<8&& ME].U05N4H7%Q>4WT5"#`_+DV>$[WEP.;+5=@5CY-WF40D`Z,Z]3>@56>,=F! ME1OND>RL%E5*`'=@PU$XJBB,=6`B=ZET8`VP.CNPQJ4!]8%\Q\-`G5=3$]4` MN-MOMK6NJWD'1`S3;XU%5:%H\PH/P_5B=")S.KX7=&\EIU&]KY)8`J2G"@/\ M]LV-_H63+^?@*-XHTO&PR;Y+J('Z]):SS#HQ*@AQ28B)@N[/-"!S&L@N#H?P M'`!O@%#SM4I_)S<&!$F^XX1>OWH3A2_>$1\_OOT6TUOUOGB!&QSHE:6'Q'OA M6[K9),J9_"RMXM'L3#4)-4BZ<9JJ%XI<+M/9==(@8O?=9DVB^S?T$VT5><'/ M*&\8%2W/4-$V*AJ'.1)DTF";S&`':K!3V6!G:K"',/H9/>06<_.F(2.!'D*5 M(X8&D[^_R-)QNDF3\'<3:7J?*5ING+GNB`-^U@K"AL4-Y0]^^`-1L@MC#N@Y M+;U;T1E4H?-!1U%2]MYYO'*5@DS?\SM*;20Q636^R MC(;8*;.1U0E-3PHIQ)0^1GY_L6180M-7^+N)+?TKAJVV"]TQQM:$9E(;BA(: M4W9BE\@Y1?@)!['W M@J6@#`:+)B=JG*]AAZ'NCW1)GH04$G\"\M<#J^P3\[H@:G<2]!9C-`#TTTW9 M#YW].I]`_8&*-E"U$?ON.)C6(NF-00=Z6EYJ%%AJ#O/Y*GL'F!"$X$2U+(W@ M\:;]/B[Y\R8I*U-"O:3#9I=QLR0K[\A3<3\#=7MZX+$N\#IYPE%V-Y?T*E9C MU.KRM@J'6LV@94/Q]S/=IW7]P&I;T-R9YLGQQ>'?9R_"1]'>T(XW3&\M;E=' MT5^VV_EBM>3[B[E`%#ZD%4X.F4PRRN)"#6\SUHEP447(J]?D,E$F%&#+L4Z4 M3A4E+5I^8O4E^1<-6PMJ&MF`K$:[?!>R@G%`NLY4K7P8_BM^9#V\+*Q+GS?9 M= M>KX1H2CF4ND,*B[D`F6?>F"6`\'U`Z)"42H5W86H)!K72!ZU;Q_3X?%K4?A)`\;[$W%&O38C)"M MN!3)9BH)^"2<#F!.?V"F.M!V-RMWGBV&L($?LF2S^1P@*]13K]U^M9(0`FBY M;B26TL52Q8PL;D$$Q0!AYB@&;X7?=VSCD3\/R8/>&T6<>7:E5),/X)MF-,&K M=1,9.4"WO72Z6RM+P#>G7%>7&%JVJ(B>A&#(@"T1ZY73Z"LJFU:`.XRAD#9Y M,9:M":N^#4&6=I5Z MU&?>;NH$XJ)GB`M'6:673#PB\H%II1-\D9U9P2TU1Q7R3<$J%G.P_9*2GD+L M8V3?NSE6:ZY^A'0RL3//5)9C'XT+Y=0]=I55'%9F\HQ2&7D!X7'(9M/MYO!0 MHV0TWKX#&C>]>P"3:X:RE9-T;9`WRMAN+]DU&"DC_=IVTK>RH"_YY8:#"0)T,N$KT><5'^_"KW%\ M)M[Q^=]G+WF[(XU?O'KR3ESA5:/4[M9'>2YR-5_E4ZWLLMY4+EVKYY+_&B,N M>X:H=/0'E0\V]ZH;NJ,'NCD6J[MQE;"*AK.1FY\TU(W8*1"[3"HHW92]LD(U-9.` MT>S*<^\]GQ4#4*.7^`73M!)JH3YB-LV:I@H]%@AV^S)E!.=@`>DR%EB)*YX4BU%RR'VK MP0P)>`A:9/,R=V%ZW"X[%87C7R+Y5IG.UPP2I4L7]2"\VZ=GQO.51#*<2(6B M0NH,,;DP[-&+MGH0CIT`CCTVH#JY'BU=Q:K"Z46ZYT@#_.@F^&@.ZV)%P5Z4 M,(8/Z/0 M"X!DI%0K](M3!CSIHW8@U/=9E!0-A4,@..VX"#,;73M5LI MVVXZ+6>#;W!$"V.YC_CZX8OK1;^[_IG\]9

7- M\8<,'SDV8)-%S2;7#XBVA)@H^J^L,92WAK+F^$,`YY,-V,7I\A7L'IY*]0W. M@0=WY_2H4)&?;AYN5>WQ[A;'2>0=2(?VZY-+_.Q>@+`4N_%PI,)D803J-!W(`(G(PE%$=$K"P[]NW.@Z^C6A>3>+ MA41]IJLL_U9[V>3`2$DC]9JNZWUZM#`7C)CD&2U\C<((<>EIKEL9_*@;"IZ3/%A#D$Q)U[J4=8R'4!KZ-`RKF6=H+NJU`8?@F%"`DCZKNU\6ADE'@^2.:I6M[$HPQ?>9, M-JOM>C674(4)FEE$E0'(Q!SY"_K;?%%D=W\O]3QH,9O/Y_2_E$G_!P5A@%,^ M":<180C5F`KJLAD0A>@F@[10S$5P+.V\;#\$K_*F68IUJ:/JF.OY?E>,MM@> MC*Q4'%UTJ>XE_@2YZ5$[:*<,.BM\5"P(HW0#H07[BGLX;HU[2A;3,^\:>6&4 M+FSQW2["ZI'MSQJ?5Y4HHEJ9=+O?SQ?I/"H516NNEO?[3%I&4CYMJ@75`@95 MQZRH%FA.`2T)T:U[I*@NEL0[K0$W\A8&C2 MYA*@UP^?PN?G,&"Y@#3,=[UGM*/M4$8Y_]NO]]N,4EPF+S"62:4S\5PN3WBA M^EBM>!G/R@@/'"%+?.D]OVRS)_@=0LJN6NU<54P%S3RF"3_+%W]^Q='!BULF M7+K>`V*>4!EU3]QGA=:JS&-242H6Y7+AB:!QCRXZHX%02JB[VG(M[--2@3FGH`XN:,/(Z)2ARIAD M"Y%DGB?CD-`40/0YG@_)=?0KCEZ\0UOM$^&C9NG2:%]YJ6FSVNYRFE`Q?)(A M%16#5C(9#\P9`LP@3Z0N5N.'V`R`O(@O@F-FRM;2(_+GS3.DJ42/6ROR?:1B M;P(M)Z()7QM;+*@7TNEZ`M)(3`+$'/%V^H[["KK?,\ND=F64H)(A`V<%.BE MW"%LG:T2/8LVT!^T%<2:L8VKHRWA\)L7@L"CU8LN_5W:"6JRFQE%6NO MO`!_3?!SRYBLZT4;&)IKH[X%=[%?*W6;5#1BLFTCXT#0*CUG!VAP;C;<5HF1 M58-9QX&8K?@SQX7!^/OOL-,<1TTM=/3Y%M,N]^T(0`5ZO0H MQ[Q5Z?UGB,M&5+AE\6@HZE;&?HX3[YD1U7VFAY7_PZZ;]R7HP7G8=&$E.M9, M!\3*%R\F0?!+&%V&Y_N$*'1Q.(3GT@7S34^0OV*6AU(]E/=F+G;;8AZ8BV-; M13*!*),(QCI-&'DI-)?V?/<)K77"Y0+3J=/W:CQJ-P8(@<@W?W)C?'WO>X^B MK9\M#YHD2Z-UY01KLUFG=YYD0E`A!8@6(]$X%31A+H75`8K/IY/O$158('C@ MM[J<^/(#80^=+XIH=P0[6R1UNPICQ';2L@6;;V3]&ASD.Z_KCYC><%UK7[F8 MRG*[7O-]UNEN72\X&*ZB,TKU14EU(@)R"_4H'$X/'$8V2$M\/M\7+4(+T2G= M$N.V[7`I?F^P"\H;53\VO9RO,F@)TY[;*X"1,>YNMZOX+NB&DL$('#4$1CVX&7QE,/4D.IC6]TD'&E[P2(8A M`?GK`?/K'CN7FP<*,9XL]=50T9%V^_DV.[;&VT!%(ZC:BM'59WGN-:TE%M99 MHB.%F]80OQ[$W[KU M#?,QJ4T=53_;;%>;/``Q@2AQ7U&$/Q0RR;^X4-/C/(T(%V6$1"(JBT293)`( MH@^DH_89`0.&"N=*T:'3-""I.#ZEU:.O'R[QO6Q/0.,QDTEYK6WU^M_[U3;C M2B:"+@%3(4#9^2@H3@4*17+4CD2]8/O(S[)*#\L'!^_D^K16<146>O`"E_PR M>`0_R"OC2&5`(K(&-*'IML<['#U_XOKL.NMBAE@Z9]1#`E`8Z%"KQPT! MVY4H0ESEU]:E+?"[WTO+(6#WF4QGAAHCR_8XI%;P<6T9Q19:*GJZC+$JAH0F M\_I%6JI!^T[1VCK&E1I,>I\JP.?2:/ M;;:);+J90A^X!1BXKADB70B=&D*[;IGH=;.$YMLD%&F? M[[*++ZFQO),JY<0O0@<"H5:JVU#('_.=+"(4DE%)-&QDT(!6$B(,HNT7*C1` MEL2,4P'YV`X9)':T$E4:1.3F`LK.,^UHL:WVS1_"9\UFXTT%E+=3.*N-@%RL M:AK,_CR-L.H$ZH9E,-F6.U@MR998`887B4O&,,?/;A2084Q\41Q=N\0/WL&3 MK\ATOFB4,5W:]-BWO=IG].%"4285_522BU+!/T.122]BAU_J7CZXR*3`<'#&M_@0/@:LG/%-Z'N'MZX"(MWO&>5:AS+*(7VY=?*I5B83 ME83.$!>+_DC_!"\2HAFX(P$.RSA%!ZT23L4N>L:0X9OK)V_%VLCW,!#?<='Y MN/'QHEP7U3+OSG:_R4:)7%II+8Q>H?(AO=S!]-XB7=`696B%.$3DP=S2H1>> MT_WEX`9]WRAS+"XP('S78@8K:5[]Q*2_CP\2@ M5,Z,744>`]81&8^J4D42JE2(AH]3Z=A9Z>A3"RA377L;0N['*SSH^]EH(0>.%<+;#*G?#?+2)` M6Q'<-N#0A,AJ8:OUPN6G@0A14D$Y@*Z7DN0Z$V9)+ST86S,UC5-1-O1UPS\9 MOQF(O\ZV8J6U5:S)N`7TD3&_;@40YA^>\/'LX^N'BR#QCIY_3KP7HMGA''D) M,>OGUX-_/N(CO7GE4_A\.O-YK^N';-+]!D=L&?BN9;NPYD9,QAFMFJL?E%_, MTP))F0)T]VY9!53H@#(E.,]+:M"7\B4MH@G?>8'^8,I`]?F`%G4`+&HL!DU" MY$KHTO_EWG?$ZUC+FZ"A=QGY>B^:K?:+S=31#WZ1$=K`?&-[>HL:M57U0DF: M6_V.8U8Y@?RROA7GSQ'JVA8[)_H^L"'OXSGV`AS'I7N6XX]OI7^II7&*8D#" ME9INZG=[+.>"8)0U4KYMFXP9[]^JUV_;D6A-89%&*C7:(N:C1S\RB&-##]O" M,K\>E3ZZL7>@YW]H8*/E(HB:ZAE-/VD@<:"7BLK.OUNOG&8X:*89,\3:X\?B M>(L69AX3VBB](\(_T`UY:39&YYRO0A(C3IF9[`@$@[@AC@?]+0H<%IY/?OB& ML[FH3&=\I"D-#F+V[2Y\I@O+;M+-7__!1P+1"\ES<1*K90TZVX()*?H`J.\@ M=/:B@)-JDLU7\]1;015S"HG^**PD?2+ZT6_ MTXOC+M@UJ21#OO+<>\]G4VO?L$OKEQZO@ULZW4;+;M`\.NXY2-71!DC$U*"X M>DWYS7[>C))4`\14(&&0*<%&LB4U4*8'(LS,-6&C7AMCHG&3\F-V8M/]>/)H MQ9P(%T9TDY+-J4G=NE'M"'L:>2L.=;H^%'!X8W?\?/,"[_G\S*J\W:1%K+Z$ M4;GX6^^8-E0P3"`;J*WZ2M9ZN1)$+W[#4MIN6E(Q:YG=P52IMFAEO#)B.1:D MVJUU#HXXHN>R/AQ<$B=\9JBJ^2R)3",I)PE'8[Z#13'HEIY8]$NZI\EW\#@^ M#/64#1^)^BFLO$-Q.5\L.H,1;[L:C?+FWTD\FM)^RB&I;C0+H]`PTBD$H@$? M0,NI[$*=7W#X&+DGDLBZ_M>`./$S&WE>U6^O3QVJ[]NFSVRKJZ;JS?O5^IS*`H\T`1@Z&]R=W?DZ\ MIP7-Q"+1HF2?-ZV+07V6M7:K]6*_K,4?DHT\EEW0*V0;+B0Q!=8>\09BL7,R MW#W"#-P2Y`#*JD<76Y8'Z2GZ'Y[OJVV'J#X-,BJJJ-!G?E,PSLEDV;*58`2V MQAJ6"C;S8PVANXE'#TUC6,(4Y1F'YANPC.D]X;9>.H*IRIIGV33D'PDUK8%$ MH)'QZ0\W.E;@7AP2[\5+WN@&X5M,RTDP^+_B1^AB^@I.VL$QB^8`OP8OQ)QA M])96;>HYS=?Q.@@#VW7JLUE!L*\_%S[+RI!92$R=%N#;=,/G4QAD]]_DXNU@ MH9H+BRFI8"G-8U$^_Z8X#59_&&[$6=-$U8`3=.@@WWOV0OHZ% M'YB@QR3BQ'MFIRV*'<5L8"\ROM\TOAT13"O)Q8%.WR>%C8?II"F?1O6"Q]+* MV,>W])=JR8NZ))"XIJR>^I:SG;-OQJY4%,H;*J^BLIH6V1.6I#H3&::Q#J;% M,.9C26^"B.-%/RN_@YB@G`OUDV9O;.B])76^%FWI[4L#F_*8">W$P\7Y^9GF M*A4SL7*G\0S]$M'J'V2`\>`EL_SWQ4[>K\$A?"8FCGB9$)J@T$XZ.)`>.,][ M.E]+0O3+Q<4-^\<["D!J24O_[P< MJDKBEH9/I7DQ1Z(2;3/^&B21%\3>@0V?6Z>.=$F%6R8:JK+JI6C+Y6J_:^Y% MYO58.2T.9?ZXK&7D94VC%]HVV!9E,^9I+%%Q\PCJ8/"64=YT>FBMDHR]J2#98C/*OXDA8>IGIS/'2VC?^L MY\R]ED:`\\+AFO>8XEF*QK:R7&56+1`]0[DJJ*2+C2->XT9E02DKI/T+R7#H M9#P_M4H9ZP9O?XU3:Y*A*YUZ?L%L35%J53H2+LWFVY8OCB=S5](X\M/!1KW? M@BA?:BB';%J5Z7L8O."8.`B/WSU#W7#)(/%ML+K*"V>+[5P0U,KM5G,IVO(, MY6UGN95]4CE7/3XGIV1+C1Q!6'M7'?$B26\8G%RY!^)9FO5IXQ&5_* M#?=Q]^P``'^?L)Z+@.+ZXV'QM@"\-T)4`X6A5 M_K3QV1BI*HJNL-VO]]OLQ'>Z1!+F2R0>7R+QB3S3\RB:@)6IVES[D:WU3#W= MH0F6?.TB82M/MK&/[E18*CG M^W1:.CA^@&?]!M+7S!*,ID6RD.RW7:9S_DR86S+2BZN[1Y"$TS2 M@X_1I\!$$<:N#[RUL-/EJO1IM00(9X0[LV5?4ORP2:X(-5#WH\4BNSI0A>Y7^R`XH(*GC``AO5)J8GB;H?",A8)6)E7"@-P<]H2`KB%F^TO@ M(:'W>&F[<];MH0%^E*@1J3,"*2RC6L>'W18"8]A]RTG2]"#I??W<`"UDEKQ] M#8C^;"]>?)T\X>CNR0W2CO2>_&..#C>$LC] M<@>-[<*G?/K`]+B18-.5-:I'[M)UZB7]9BC3$&4J(JJC53DHE.E9_,WM<\SL M\^9A'_9`EBF:*V2_FK_-NTJ@VY#=X>AYH3L#Z6[P/22_G2AZ[(!W'',!DNKV MSE)6S::N!D3?>X"?$YN4MUH22K5O\*=)%W\/?2+&)SFTZ82QUO)[3QFK^JJW-<-9'LP;]M(2K*_B#CD-53Q>&6&7#^&O`*W:QVOZZ/;>EI?<0L>3J M][A98;?0EJ3EZ]5<(Y)II.76TJL9WEE%NB^GY_O<42K!89,;%:X\UV& MK&Z&:HEA'1_@_0>UK$YAFJ2S7UZ2'#+/-8VX=+<6[S88=D+K4SM!WSQ@2Z!L ME*YDCR"J=&D0_&>(I)J_#8NRN?76Q:S"RXO@N/%\>C15UR_J.$C.WQOE6K&BTG:@5OY.O/-9KU* M*U=JB]WEC9>"J)T!X;>GSM@!J`),J;97//5.=5%G^WZ_HN8>^-U\Q8XZH>_Q M4^J9_S'^*K?#O]]Y[?7@F.]8">F//A=5[B7;H2?*R(?K M\XZ&A(-!JA\OV*UV^@>'7&\6J?+-#TG(?CQ#)>U;SH>\SW&BH0_6=1Z$WR?! MI^O>\^AQ=-#1.8X<]VVMC/G2JR7Y_9)$/P*7WK_TW7W&[7=<3-&439%Z@/[J M95OVRST/PNFING1]$/;6#7"+.+TL8DU,&T&J7N%JJ/W?5R12F<2K9.#:W;F_ M!N\B;O6&U>?(U%X]IVR_"+K?BD-UJ/S>XN;$7T2\S(`SDYUD)K,_L`Z.$7KB M[;#O!A*&$Y*X7 M`J[E@E$FV2;.:8+=Y%YOV``<['1?"1?;C0;*27:S=-=GYP]!\(RUK#PR2.W8R*@B3,`1SVED^,PSH2*TPA]OL`+X]WAX5]/H7\DWX=/J4N_3^-!HUY> M;UW]OJC]*N\["B%_S0H57B1)Y-V?^84<28ANW(A\%*!"Q2-1LB+%=[057NXO MQXJ9,%A"R/RL2@JA`>P@1F<")GT!E"@#;F!:+7L3QH+$2P]PIPF5`[<5QS?N-[Q%OLNVYY7E,5F8>)K')_=H+%#I.?+IH\L*6NF>H9AO5DO-_Q0 M$9.-3D0XBKATFNE%M6KBR$M;^)O98SX3(5\4R*EPE$I'=R$JU5'G_6'6@E[@ M>PX\8'M%CZ(P-"G^U8!/#W:>I#>K\Q,?_.<1Q33M_B`_9>\%'R M<86/`H07D1Z*+K7=;G>K?1Y,B/]\*&21?W%AYN/&>$A9E$!E42B3!7!23@LJ MI_U#0;*\C3AE3DN-`)'TY[=1=J3WS><,)O*-QI6'A_OE)NLO\XM2P5/SD7"< M7G!,)=I21RJGU&+D>GJN)QRYIS?AG(W@`>.]5+EUY9"W=)9SWC?=XA/1BVV, M2YXP&7.2#Q*A5"J*^3XST]W4<$R?30#N\ MRXGQX6^/XYL5_0NEY:K4R9`?_<]=Y-(CQ[^^/=^']4_0_+V!3J71 MJ/H4R"*[^C!]'W$!9OUVI/Z.FOY3>ZO4-:BSBB&"I$<12=;.T1L;;K'-\[+- MLZ(G3:9(S>;5*Q8OLX7G3`J?/)CQ4RU`M0-'(W(JB&*.*)8B,I8HR5VJDBI) MX(.SH*TF@N!!*`[T.I2^GL_G*S$%)CC+WSU[I@W1JLD!Y";H$-(Z!HO=>K9; M+E).T'-I]/NSH@>T([>&)-(#\1+S0%#DMR#"A_`Q\/Z#CV2,_Q$'^,&CAZD. MX3,F/[C!@>LG'HXO#H?HW)A1&RS&(+WZZJ:$TI9@.JAI[>$T[)$0Z/=I(Y#<'.KJ9>8.LIW=O`Z.V54$NBC>E&@EVQMJ M*COZ>I&5C>A+?-I'Y;>.O),H,-).+"#DF,,(G7)KE-:_SG0^(G%)7T[#Q2G= MF_Y.XH640L-"A]C@6F8;?S^3UD[?7LX?:0J27.*`&/KMU_`A^4%R*?DDI-)[ MIN_G3]??;M"W#[^?$9>,4M$HDSWMU)]TXE(_X`4' M3,4B(A<&;_M4IW[03OJ5&6C!5[Z)PN/YD,#/BO9A:SY9JFPOB+2D5IR!WW!P M_7#I^6>Z.8`-Z`37RM?ZKKY2#*8?/5537T';9D?%&[57BFLBN/AJ5=.T99@D M8U)K,!JWP#.5)PSTZ7)N,,1.%M&7*5C2[Z,;>P>2QJ3Z]W..+F'P9.[04'U= M8[U>#.(T:Y"-)6QDMU;S,)(7>(]<1C;U=Z9EJ^B8X0FC@^L?SC[?Q$SL%N`$ M^6$HNQ)$J(=.MS]'8YIL\'WS`T MK67$9=6"W#*U&$&SXG-"5X^K80%TF_]0>JA&!*F5;8X%+':-="DNP\(HP!13 M+ZBTFF^&IPAVLWZ`)8ILX#V0MN+'0QA;6$C+Y-__PUX&UL550)``.+J\-5BZO#575X"P`!!"4.```$.0$` M`.U]6W/K-I;N^U3-?_#94W5JIFKV/>GII)*9DF]IU?&V5+;W3O>\I&@2DM&A M2`4D;2N__BR0%"\2<2-!@8+XTIUM`>#"A]NZKY_^YW7EGSTC$N$P^/G-QW^/3H3^\XS^KW<&?_K[^=W-V:=W M'\_.GN)X_>/[]R\O+^\(\;9COG/#U?NSMV^WW_N64?;CV5_>??KT[KO*+W=A M$G@_GE7_=$%0]F$/:/KQ[-.'C]^__?#7MQ_^\O#Q^Q^__^N/WWW\WVKK<+TA M>/D4G_V[^Q_0^,/W;Z''Y[.[=W?O*I/\OV?W81!!Z]7:"39G$]\_NZ.]HK,[ MF"IY1MZ[?%`_G^X90!I$/[^IS/#UD?CO0K)\#Y_Y_'[;\,V__LM9UOC'UPC7 M.KQ\WC;_^/[O7V[NW2>T4F M=%.4)`@\8[:@_WJ[;?:6_NGMQT]O/W]\]QIY;_Z;?O`G$OKH#BW.4AI^C#=K M]/.;"*_6/GJ3_^V)H,7/;[#K>!3Y[S_\Y?,'VO_?+D,W6=%=%'A708SCS318 MA&254OWFC([[]6Y:(Y^.D6Z=.-^([VFK]]R!WGQW1;\P6USB` MQ<&./P\C3#]QX3M1A!<8>4I42PYY2/KG#D%JT"N,&S^A&$;Q]<]H"C?9"K6E M.^^MG:H+)WJZ]L.7:!IXF"`W;DO@_D"=:;W$D>N'44+0N1/A:+:H7NB3P+O' MRP!6SG6">.*Z<`7'\%#,0Q^[&$43STO7U_%;'UC]G]<(R4T817-$X"E8A<'] M$^S="\=W$S_]T&QQB^*\1?I;RXDK?J37Z5V](N+B",T6]W'H_CY;4QHB6(=O M**+(SQ;P!L8$NS'RTA;:YJS^99U;/XEP@*((Z'F$NRO[M/M'@K/K:[;XEE!V MX,NWY!PXCBB^1`'\LIF3T$O<6.LIZ(&2GH&"$^OC%?R+;(!7RGD-.,@)<9^` M5YC#FM'#C;Q9<`5+"40A[]K!Y)OC)PA._"2*4)Q-DB`/5OP&.X_8AXG`"8\B M>,_57E/SU!YR9UXBLKIZ?`5"[AR/WIF'W(QR']<(!_?K]\EJ!/J)%I"TP,A&F&:!L_PAH9D0^^*,(#_CBAWD_^Q MY90%@VI]EX+E`V!ZB1ZU7J[B<7N:Q#2($?`U\=7K&NYK0-+U$P]YT^`"3A0P M,U1\]3+NL^#V-,RQU6=U0@`O%*)O/([IT%K91;FQ>YS,=1+#7[_@`*^25?KC MW-FDOWP-/$2*DY[^%&F:I>)'S4W_-@QB?"&216D'N$I@`?`SFOM.$%&. M*:.6LD4%/U\R4UHAT4U;[V!2#9^7^"#P5&_CBK"?'V;X\0[YZ:E^")N'RN]W MK7CV0%[OD'X-"'+#98#_K/_](HSBE$CD/81?`Y2)FO1F*,7,K\#(1-!@1\J$ M7WY%5/L+O/XS3'@)I*\==,S MIO=&9'Q#X^2JS$8`'T]542C0K0=3_HS&*1;WWQ=X*N'?&169Q%N3=']]PN[3 MA&S;>9.XZ#H+)G?(30BLPC+5Z;7$H1]:>@=+XTY0^$#?TZIJ0*B$<0,/J5&T`XK&8IU:\@ MJ%G:%@ZM<2K;I='.+-%L7776!<<;PYW]RA=4AB^O#? MHV4'+4'KS^ED%K(ALV_`*=4J-DF-W>-D"A5@\<,S"N#.^H50RP<)%SC.?RED M]NS8SPBUC5!5(G""\.K[.-=0\YH_A+],)G/Z7YKP,D:^'MOK;1@C&+6P0Q=B M2]3"ROB`7N-S7]76U1,)0\9G^X5PZAHE1AGM6]6=CC&YO9`WT/ M="VRZ"N][_=]$U=Y*VH_^7(?&\:Q.:QCH=2FE/M7W?,LO4V-!J9/- M-=94>1VECWNJM=V:Z70O>E3POV%TAEIWO.EWXUCJ2-^2.H+D'\KC4.,D/MN&3Z_]Q!^#VOR'?T/NCC? MO?WP,8]"_#?XTV\3^+1'/W_M.\OM<+[SB/R?W^S__KYW>BX20@/>KF$1'/\? MR"%7@7<)"]=`&K.I&I7[VY;^Y;?MLDP:EF7R&,7$H6%I-:+D^_6/XY:,#)W, M<^D:_A8U`,EN>V@ZZ2K*45FV/!R-&3+L#=G<[G#T/<"P'++2G_NG)MOU%_!! M0JW''GK]?VC30%9SNX/1ET724=^X5'"/9DE,0\=I6#^;6%ZG0U%^C7U$+F!G M+=/0%`:I]5:'HNT.+3&]XH+XUEDU[<7&9OU3]T`05?^]H*?Z MWD](G3:'N-N!X#_W'OMZ,H"\Q?MU&LW]UGW"?L$G+$BX4GD[ME2$#:?[+"0> M(FF6BH\?/KPY@PDL$+R2WDTV5R:!*74Q(A%*6]*>."1`P<]O/KTY2R*87+C. M'$*."YX=_J;$Y].(#^=M*W'Z/.+$Y5-*I+X;D1)PGB56WX]8-;Q+)3Y_&?%A M*L&.ML.]A_GE6&:RTI+ISH,<4V MB=XN'6=-Q<7OWR,_CK9_>9MEPRODQOS/O^5ZXFCN;*A:'+8'_(4DJ!I2E5\L M.Y)EFQ':R\+:9J@TF2'03?7Y^)E2H;NQB90Q%H,778'/4VABGDF%EX+AZ+S9B13%\CLV*[:;'FPNEA:@;Y MS<9=@MUF)FB]S'F\/`R,?^TP&@^`;N$)9KFEX%`)Z);J:FA.:;HL*;Z1T=@,W7D8!B#)I+;2Q`2-%=&`06*UA6$*:9@A MO7"?0A]DW8@^??&N:5*ZF^&Y\'?Q0"2V?3($S"*G@Q'ZJXD%*;_4R`@*ED)I M#).S3#W1\GM/,)E:4Q,TS^(G1+)WY@N.7.3[3H#"1,S,2W0T-I_*[I>;1W,' M$_3/M^I"(>/;U-(0Q6L'>WD2,SB9E9W!/]$R/-'Y^X;K)*TN@E8.*QBUDSD>AH8CX\];/@+93J:F9.DCS40+BF?3*$R#,[ MF*#_@:1)KS;"J[6AH0DSE926D)JF%%59MMK3E?'B&Q1L-:QQ-YT$>UJUDJ4[')?U8(2WS)?0F>71VL[ MZ%BJVQ(EN[Q9VZ&DJ*8JP;/+O;4=>"P;6(F274ZN+;<8]ZIJPX\/_RU4D=V9 M+$/9L(3+3KZ\+5Q\M56)6@NV_1F1Q]!6W&14X`5ZG^QDX]MB)V?F+M&S*TJM M*WI-"-G)Z'=[`JKXM.'F[7TB>LB5T=BKB6]]JC8X4)5HCW\]X`ZH@M='.V_M0 MP;?$;.3I&:>1X299(M>&US^&(RIR$]BQHNT[/-F:UJ0=1/N1$+:F-6F'CTQ, MG:T)3MHA)N,=9FNBDW:(-?D.M4MO\D.&4)!6X_1LPHC[V+5*<:+RV`TP&GZ> M`OR$8AC%-Q3+7IYK`,+-JHW!?_LHW4:!-UG1M+!_IG]G6A`8?G+:AC<2>^O[ MX0LM@7X=DLLP>8P7B;_O$":((%8:PW`4)>S&&4DWKI=>8-N24HRYR?0T/*,L M^\8DB9_@:OBS/,7LF>SU&,0,IE&4R%.?MQX$Y>PLFE)=3,P![FL\MQLQ:#&0^HD3Q$I#L;'Y>DE>!H--0YL&]$#@=QLB,'B(%,H1E0@7R MEL>HME+DANQ7T+2$41O#;;^*IQW";9YO^Y4_;3W&Y%@#^U5!.O#;9T%LS7_; M!VY;EL?6G+@Z#)A"0=[VR#X-X/%.Z>A7P`5M_XC:&0&H#3!&7MC1R8!I6=G* M6O8GTTRM/VQ=5?8,KR"+<)L/@3:SYT(NY*$9VV'0/4E M]I.8J9EFM39BYMD6LYYX_TRB.'MT?W4(+2O".J3\/D92G#HXB&[@@0=F,KAZ MI4ZK"8Z>,LIHF#)C)N)^1F:#`D0<6GQXXJUPD!9YB?$SRE-HL.8BZ&5D)I3I MFI-PPB6E)P(%L[[[09!K>#&8+U-):0 M=G_#LJAFM#:30C1"#G%I1L%+$+/],+5,\T\FOX\1]Q3'1U&N)D@5'^PDKHU- M3=,L1^Y`*!7Y^S!:FZ9\JY:1P[K:V@CE*.4ZX8A]<$<$>`BLA85`6&89RQ/;5-%X@*2Y#M26P$"M9:`"Q+&K+=75X!(\9E9;N[ MNP)"'`V=[8[L;5"J:@*[.:H/_TU3P$?"[H"6@)O@79.Z<>4Z4$!JSWK M5SNOK[;7JV]$-V]T"W%N\$-HYX1NZ;VVXTG0 MK3*-5?N'+47;7H-&`21U4XCMI6F$CACUA&U<6[SMY0F4L.+91VVO1*`$E-`= MU_:J!$IHR=EA6M4GL`0I)3=EVZL3*.VM!A?";J4(AL]@"3R'6&KUTH7+^J3= M[0"J^3)U2M)]'$6?VJ&T@XZ=,DQ;]Z,V?/N>Q=1.)5>/D++]W[K5=#B&8'A: ML?S:#U^B*4P9N*P2MSPN_GO*@?+BXND(9^D01O+L%E:#ZY!(!-:RVQO)A%M0 MDZH+`6K[1N#E M^EHYJ]\^#6A>N\]1,LT5CX+A$@.)^:!A\0+O3*C&+-^T-VT./#H=W^ M4!U\0+@T*/"Z[P_908\/AW;[0W7P,:T3L[*1L\FUU!/WCP03=)Y$.$!4`D\C M41F$"[L-8BZ[Q4=D)[/7;Q"S4:W\J#"`F9I:H8N0ESK.TZSUM+#1;%$K"-P\ M+6$_T[-)J9BE5MOHZA41%T><0F&B?J9GDZM#MP0Q#Q&OBZ$Y/.,(L&RHEL6> M`[N+F?1>Z_P0<]6F>\U,TTKUH0^(K'(9_(:*JVQC7)L1C"1URM,.(`]N&RIJ M\^PAC,:&J_\53ASR5?_VNQB90[)>9]99Q]]2-`T6(5DY3<4K=J:/4RO:Q_7=L+]MB`NZZR?=P MM5Y.!V$^@](M>&]$O-&[F/&`VQX#:.2ZEG8@LSV(\)#HR[O#=!1A!R9V MO4I&%Z4-GD,);F8#SX':,<0M@JK^,(/.N2X?@(MDL:>4P7C+K; MR$XN$0F'K7;A^J>,8LT!J5T0_RG#)^<9U"[<_Y1QW?,MM3T/0`\`[KE^VIX9 M0#>&>ZZFW5('V`Z@W@B];BFBAQ]#KM>#;T=%*;+1VYY:^C#@,EP&;`_5/PRX M^QX,AXO6MP5756\:QR*3E_GQ20IT&(/LWMI5K_9J]7 M2:>@PQ+Y-GZ%Y.L7C-.&JS,;87G).$Z[*TKOM1>I4<55+XF9[ M"3L]Z.VE]NM4RVZ=K@501N(3!.^W3VT+W-7@NPH&+OZJ@B<=%M:N_MT177AJ M\7%-M0*S9#VVE\#K!-1.AKUNA?`&F_2;QF;X891D-;:CV6)>7:;`N\?+`"^@ M054MWS\JH`A;1XCY:I,^`%0YY+;*QGW@RCFJAQ.%#3WB5!4.DFSNM4=#8"\< MWTW\/#[P%L5YB_0W$Z4YV-4YF^]_5G,CS]8.,6F1G33`-2T5(SF%W5YCPC(6 ME;SJ/KNUCH3+T'(PD_*+Z*S(&!XM>XC;0--V&]GZZ+;!4'CUG>#3NG4RAJU4 M<>D&4+YEAH_98L=EUD@I+.";/+I(^!G=(S MGEA1SHMQI>H9VTC)HVZ4GV^:!YB\8F:5I!Z_>(0(P@%%J4-'/W"5PP\'FUMG MA2[#E8.95>A$W8;`\QX3O[YS_7Y!].%G$-[8D/STK'0_#`*4>B M^2-F4AT6CRYW9??;&4TBT?_+4W.C$UY%)>-FIX.6[H=*C*XRTT*J3GD5E\H57T&7C?`99`*A\!1NV?P0L0ODO M.3V(Y#!:R@9\2USZ)#S7GX3[2-Y%^18H\(W)0V"[/"-ZK M*G,F`;'M$HK,&]DRV-Q2#8PJ8G*OG^T*&1D^IEG3(/LFV7Y2V[[2H@OOU"1] MK>B-\OF<(!^OX%]D,_%3QBV5U.<)<9^<",T)=K/:(;/@*HKQBN82*;+.1]OT MV_ECXM%*> MA8N$T*N.6YBUO^]9@EXM)_.A(*Q^]-AQW$V4EN9:?WAR@FU-BP/`*J;!'I0/ ML4VK7SMVY&Z1@G*TTU>.'JDP8QR(U^<5[Q*5ER?SGH;(U3"T@JIK+4Q8O%CW:/" MK2O34XLM[,[QX(A/`Y=M]MIM8L27'$XOXN@?RM^-4U;,GZ&MQ,*AKVK%NJ25'H%LJ+SJEIAQA M[ZIC[Y3:TD+XFY"Q,V_E`-ZXYL*F2NDOCZG"R($0%RLZNV7/''X699-;6\(: M4LH:ME;H,[H`M1W^TW*[_6BW@#:ZW;9%<$]970L9 MK^J*3P*)NH*VBL6.%H-C&0"K=T1NU?$^4;PN$EW'][<*&G< MYT^ZNY:]+N6SEZB693Q]G_^&?&\:9,O?M#&D^^JAE(H2.1C9\\N^Y)AM3\K3%*WS M+31;W(8Q+4"WX7A$,IOKP4QQ;_6_GW:_D-;'C2A'=(G@,SB54V5(:^XXYJF6 M]NBE=;_NT#,*$I16L6*'M#0V-4VS'+E#H/0>D6?L(DF`JZU'3^^>YYJ5%N,R MA_4V1JC,*[8@CV:B1$&4ZST)55ZG3\?YIFR3,S"I,JK42`4>M>0*:QCT\BDS MV>7SZL3;W;>M(L<13O$\SX@\AC;C5-/7MHN].8T-U3URQLJ]Q+*8GTJXS!CXT19!51^= M6HEW:1^8TT9QWQN((4:>2C*<,%(5B8\?T;7O^M#Z=-E0J2%L:9"[EWU%[+^J;\W`\L*%0 M.VY8W7VR6CED,UM\#9S$PW&:<"N-KYNMX93&.%C"ODK\N'J7C25QQH`V&P*W M*@3!KK^FNWX:P%%"5$N35<<.X`0D<`CRTT`Y``3'`UT\T=L[FL)FL7#=\NI-.W,%@,WY4F&C>ZT\JNPPS"-3K5"Z`ZL9QA==@>S(H6L.OH#5]@M1>W$Z"#< M`KN&G6>W\_#H=C8PX_?H`72$K@.&S)73`,2A."0;:BT/@\RUO_BC"=-C\?&* M396O@>+U,*'Z*>BA>>FCIZS0!TO#R6ALE&YVPI1:$Z,TWCDO7QPX8=CQA=#6 MVAJE^M>0_#ZE?(.+F#IO1F.35ZW$F:S>JHQ%LEWCTA:EG4UANTJD+4P[MZGM MZH^V,.T$FK711*B4U3'$MU0+-0TF63DE1IIK830V\3Q14J8!$)"DSI!LUZB& MAN;IW?I1W\%+DV4?**/%I>;!'<#\_/94$MS)E*W-4PYO?T(OCTO`5(KX6@?S M]`O3MC&;FZ>=9U1N:JG%4G_MN+3&VV:R)"CU$F:;ZEE-C:1:AB6+J.X.1;/@ MZI4JF1-@-2A5U(?WD76%B_N9$3:RZVSN8):W7:V)Z62]'(#WFIEDR/BO>Y47 M:SR)MBLSV4P$&YI32D`H>-39(-5?4=N%:`68ZA==)['Y*/(A*$"S?[_:+BXK M@"/QW'>2G],40OC9'L!4Y"W;[>TB":&P%S-Y8=NMZAPYA+VI3L1FV0J;T[)( M5C5[VZOFZI5&\J)IX/J)1XL\7X1!%/K8H[=/YGI1!*:J*?X8@NQD%9(8_^EL MPS@?XXLPBG9`XD8X>9N)@7M?'<*9.UMJP%0FBK-139U=H^!S.#JE=X&U"&PLC_DI]/< M?0!SNZ%IG+/R]=%7N$O)A;/&U"*#'-E-QA_"K%5+N!.;1#SQLMLN%RL")_$2 MV&]GED*,_][;+C:W!XGQ?-ON`]_M`A/<[;8+S]W`ZRHZ'X-;`]T'-!$RP'^").S!GL$+3-4*V1V38^U-`N\&_DP54AA% M\%NR0E[U[BGO<`$(/7Y8BXQ9'=O+:#EWR!)VVCPA[A/]8GK2X3$#9JA)W%0< MP4AE[GT2>;5UFL;-HQUCXA)6W?O5V@\W"*5Y*FQK`4I?;9:62"SORP-M[;=<'@M2``JFMFF-!3V,.-G1T'F.7%/^;HPZ?LWV2@LMJUI&C&8[^X;A M62UHW`LM3?ZZG(9#"/S6F.;)TA(/8YHG%;2:WZ1B$S%.C.VH[-WB-3^_ZB5Z M$DC47XPJ%CNL@JV)[N5>LBHP#+[95HNI/$!2[+RM9E+U?<36.MIJ)57<2JJZ M9UMMI8JPB80M6ZVBZB?P$-8?6]V3N]UWC?I^6S-\:8.J:E#HE-)WV"$5BO>= M6"';J4ZPM1M+R1K0J7[PH,/!^@"Q:B"SM[!P3\A5S6Z=:@U;#%ZSCZ!E1=+$ MBMW3SMRHAD]%\65M958Y1$1'[Q2BPG8<(VMWN18TQ`MO>`9\;W#%(<9,#S%'H'J8\SU-FJ>`BU'V^8MC(-.-EJ&=`+ M7J/,9)F10#MBC;*2958#[:"=0CY/-?Z.*A:=P$4^995K0KH)5L\ZEW9Y9^F& M3@.:A\T.[5U_QTK[T\24]L:_T MJX]BPAX9A,V2.(J=@":!_!7AY1.P#1-X%YTENGI%Q,41HK^4'N[%'92^H;JKD9?EVX6?G6`3I1VF M`8VXPL]H[CM!],WQDPQ8&B"9=85UNW8PH3^9<2W)5I$O\-?;&"D]62S$;%%= M@#OD4YU>FDM[[QB)S(<=!S6!0SVR+]U"W`Q'[/9&3! MV,\'K=F-WT)XY=,">H?>CSM?/GI$[W#T^S5!J%JW\1!X-G[WJ-`<+1`26H(= ML3?]D2;1*K;$0:P38BH&B323MRAENL"CTNE^H5%5.-M\ZK@PD]D8-:V,=BC5 M*3"I@VS4+2BI$UMM7]O-/WJ4(4>O"1RSI0X`"?5LJ98I^671J*N^1B-K!P-@ M0]X6>\UX?0*Y\SY;FP1G-$L/9PF&99:65V?8'B)S!`O3K$>V-F4C_"H["JY;5(GRJI2C1\.E@]A\U#;4BPF4E>$$9!Z MAYY1P$XE4VMCU)\*D6>X?1F;WD\IH/Y^B[(:0G93I,I6D1E/]U=,(/4+"F#7 M^:F?Z0H'F"J3J6)F4P#.).H.$\W.>H<7RI>CP'-@&N^X_,H(9\ M&',)R_C%(;^CRH9D39W=83BV;R4S]1BA>0(1FCWQ1;4\%G4&T7;[X`$0%3Q, MMML<#X`P[_JWW4!P`'B%,H;MNOY#;&$&!]!-:3_\Y%,24E\5)H&(9;MOCY2$ MV9AH?$>8L][@T*<8);$A3\X-IF>8M=_`]KIT#$I8XCJU:MTS)QKJ_C4@!2C5 MOU-H9XVAWX8PZM6-:+\:A/)S:;E#\QF2Y)&G" MYFD`/$,083=SO!E3Y+#-DE7FBI]\H['MF(;C2-)P\'DA0:>C2H"194Z8EP3%;&2AY(ID@:TE\8D!2T]1K]E[WO@%=[O(?W352D` MLYXPS3!VIF>0Z!]+XH(QK-X6:<)$J*5U2N$QU'(X2R#%/(YI("R*8NG`D]BN M*QI8&*46P<9VCZY#Q2`Q5">'\^@RI'F[*,NA`TX784`=.%#@8A3U5TGKPO%> MOR`/_MN_WT3T8$T#EUU`B]?<2$E>-F8EL`(-C=H8[6<9(??=,GQ^[R%,)_@= M_0\ZK^\J\X(__78%!,2;1B%J[V%-6T&LB0]BG_[6Y@4?`SU:@0?W4:O21`DCI^?A?S1;=H-O.8ZZ=D[E;OK M*FAL8DWG)/02-YZ1W(K(L2PU-C5([924B*MW8[G6C*51?9^ M0RV[]0Y$:Q)&JZ(/ZW&Q57_#8G>+(GE<\>1P&2D.CPJ# MT:3`[(-FZ_:0YQF+#<.\L6S7J"E@)'K[;%=D*4#%9;)MCS%4QZF)^;<]2E`! M);'2P_9D?0I@2>@\;`]G4[G3>9*#[4GLY'#BR9ZVYX_C:ZUJZ#3J0JSWD!`# MU,B56Y^D6W[C\`ZA_>X=/!5BP_%J4MO9+L4)-9;%8[9CD"J`^7CJP-3T8"4L M?4NTA@SB17[7+R"FPK\SQ1H(K"E4-]AYI+F4X:;Y]0F[3Q.R;>=-XJ+K+)B` M8`N,$%Q+YTZ$S51U3FDN:"IGR`I?8;8WH:MG4B.PJXO[F9A--3_WWD;:;J!9 M4-\T7X/P,8*C2=^^:;!.TC@Q>.1\+!,"TNLG!X!ARRF<;]+N%[X3\4U7O7WN M>+$3&*9YW5^P2A"U;W-,5ZSVQNFOOC/OV%$@'%ZVMS0E'ER4^%U M-CRO"N-R3=`?"0A&37Y#*CV-SBC=_5$*[T=N2"NOA]$9-.$J]_AP>@YE1M'^ M45">&WN,PJ$51!ZIZZ4\*+:;5GL0EQIO%1Y7 M:[V9Z'`@0OMIA+8;M+HN>_MMAT(UCGY\FQB6DV'UI/1- MC9C+R=HG!*1(P25"<4\'QW2&UE;A/,0'94_O M'EH^&F:'8IC])0R]%^S[T]4:II95)HA8U@9&8SWAW<68L\7V.Q3>,%C>T""# M#/"F6"[)GD8*/59(VZ'G;\BGN6*_,BO/R?4=Q.7:LYI2:7_8'K5S:-TPZX(X M,15D[SA+7A76Y[3AO"-'GS'Z,'W6=F#[_/HP3=Z\.F8Y6U(Z]>U=>)KZ&U2V<:= MP$XC/=D`"YDI\*8@NP5+3',)YR\@*TF21"\[O0I/PMUG]"H<\.+TXE4H?16< MF&ZO5Q?.W3O_9"RN`W'=;)'GY1F1Q_`T<-;F5VB_J]4`G&3'UV]TWAPJM*/S MYNB\.5281^?-T7ES./Z';9TWFU1@)Q,)J=-_\_/)^&].`_@5/3BO6@H"Z5&" M7N8@%[3EN4W/48`6F&5/%_4RXMVWI47:/8+7P^@,I-9`#_8,%?5M0L_D;/$/ MY)#[Y/&?R(T?PJM79X4#9KT:81\3F'ZEMW2X#/"?:<+L'*2H`&^.X`Q2E>O$ M=4FR5QJA]3##GFNJ;$Q3&>N:]OZ()A\JB;N@^BRI;Q+;_5H5`12^(K;KL'O; M<`TGU7:=M226DN^4[3RYXLZ3.*%]VUL-<=_4U.97/)5[*\EY]>JB*)HMKJ(8 MP[#(^QIX0$68P$'V+ISHZ=H/7Z+9,R(7#B$;D!]3D:B)I6H[E.71-8HV>Q9^&2G] M87N$U1L8SH`N=TO6JKU+;WS;]=+RU_).*0+.Y6>[A*J&63?&S';IM=W^&UR, MI!GP5-_OVA7(?WFL=^?I@IW,IK7??:&1PRJK:=99"-MU(5*,7.W\U=$[')]A M2`=2I&H8BOEQNU`3%TYOE-*4_B=!B"LTB/N9$"2:J&*+$*S66H2'2Q0CEP[) M%A]VFPP@KNTR9\?NX!R+(HH:>IB,(A+$#QFEK2&X0-I(KC:&R5G*9W?@]3B- MM$]ZZ19I#_?;F:!V:RNZ0^N0Q)2MW+('#+(Y'8PH.[.ZU=%#F#]UVP<$1;\0 M]GX1=M/RWLP1<2GCL@1>OCA696XH*GHC#R1JHIG4F*3YO\+D58. MBE*2^\%*25<@:51E7`F(;=>OM^*#FTT5.U?]J2#'503S&"O;S1!<@+IP1K;; M'*1VECC=I9TV!2EPN+H3VU6]2MOG)!.,2"$DEBD[Q>[;`E.IY"OA^"\KX1`( MM:/QLA543';=^EP""B`UG,13M]_N67'*Z^>O)P@'RYS]T=*],9JSY"%Y<8A7*4<`!^<9B#[?[,FE1C*0EU?_11@Q;0Y[S89BQQZM\EJL\F1U]?@Z M";P[QQ,8YQM;GI)OP#%8U@6T_?;)K-T_.WS>94*S5,P17..L2%]N%RV[;D\8 MG_AI=T8T.:^Y24QYIM9Z&_.>!,B;N&ZR2GSJ[-S"N8#7W_SL1C\)V6)>A@XVMY'V_MH>]\CQ4+;.XM]+05Q.XU\O7LI?+33QC=Z*?1FB=BS MSMAY\EI8B;E,;SNK^@\97@%:TC&/&#&Q(#9:UAMU=:,YG6$%;6$[7Z=*!>`6 M26P1*,VZEM%Z+N7%HV)+M^8R;E`6=K/O90?K*A@H*.JZB-$%<_3(&#TRS($T M>F2H>&38&6DP>F2,'AGR'AGY?#./"^"#!Y-HX"(,HM#'7DI`>I=Q--F,QB84 M\?ND<"T'S.9F\IFG6S;=$5<^WN9DY=;;Y/<9PX9;F'(<'T5WZ!D%"6*G1=QM MI<5T4F$U4+B$A^()_ER]"5@&4=7>AZ&VR<2HTM.@N;&\D/G9'IC-3;ZZ_+N[ M^MRR;TO;I431.U'/`\DDX]TE$#;'M/D*W!C2W>$?[U9;GBIB5> MREOR9+06S'=>'K:#JU4'(JK>)ZN50S:S1?%#>E]E<9!S$BYPG/\R6R/BT"Y9 M,849H>8,ZA13J_)8#-38_"'\93*9IW:0$W+I+DW.WC^3*,YRQ_[J$.*PQ2E^ M'R/NG,!7173I4#0+KE[ITB8X>LHHNT2/S%1JPGYZ'*U1`!O.GWC`V&%Z"\3X M&5TB.$YNMC-AJTY6=-/_F?XSKP32Z(3=4Q;^E1;FZKO1#7`-=S<\ M]K`#$M@$^04!C_\Y@FNX6B<0=@EQX"H&%IULTL?L%JX8Z`F7F9]>*5EQ(*8V MI;\O&M,HP<>;MRRKE0E*9_$3(H!<6+_\&12S6MNJ+]+M!+[[EE?8F?--_J.< M@[C\2#8ZC[,T8XV,3$/LA:BU%1HP@[1+J$Z5N@YL3@U;1G&U)`<;V+PSGJ3; M=!O&&-@L\]>B_11W!Q@#8XZQ5E"'5WOT==(/H]0+`+K7SOG\3J4#Z=PW(4V!MOS M,>B#4,*4VRE)PS,BC^'IP-FKA;-\FV?8:4B3 MAU6\EK5@YD[('4Z7;<'!WO[!3`SC:H7C[,X.O(R[6J*`DB-=SE5M##,1CRLJ M6^9K%*4W"DR*_$9UXV=YF9A:!5)&R'K*3878PZKW[!3ETF]!=E-$E-QWY M_@,KEKS]*2.3Y5TJW=^(YV21>V=&X*"OP\CQ9XN;,%C>X&?D973*+6.KH)5K\OH2BVV[-SK`V\U"V>V1HN!TE!7#;30RMD10Q MS[9[M'3>@@J:!MLK(G9_7)A2L.VI"SM#IZ`2LCWS8660 M`."(YHC]A/J#?Q/7(3V`R8>FVY?@(+F+EYK=9)G.>\43V%/7S( M+%Z[=%%CLPM/YB6=&O+2[2@/BMIHQW)QM4;+=LUF.Q#U'='#*3\'\FQL?>$` MH,<\#6;)SAIEQ20I8_@]R74V68V[0IK(3XW;90CU[7AS:2HZ(5K3D^/>Y(`Q MQ\J=RQ:`9.Q<=C^31Y!1EE%B#J:RX3?0,B?A-77\KF:PE+P=94>QZIKLX@_" MJO^Z[PS":&F6-<]MYG\B;^K!K8,7>&M;VQ9O`WJW9:FHRVT4)2MEEEW/5XSF MMKD1Y9;:;VB47FYJMWJCL22TT4+'EGH`J.,F+*5MJ5%?P'N,):$["1B[-Z+M M^+!?K&9-B28.P'8UE!RLRLRX[:YUS?R(4M5)ZP^J.)_?C9FT

<]]OGN=X8,R^5X<_-@PM[$XNOFF0^3M,@[*,'OT7]7ZNBQ_< M,%8-HP[[>&G#[N0.8L4'>B#2VXTSF1)?FQ2K)( M\.LVJ(EKN^O2=02",:I185++SJC>*9TQ/CG6MB-B!O5$X[6R\XQ>K=9^N$'H M'I%G[*)RU:HSF?@I+6FD3NFN,D>P7;/I*02/:?Z>GEJR98&L9GI>'.)%TR`F M.(BPFV:!$&OM-(QJN(+Q[A%.*;Z/@;)9>B]%E.9L+M0I*?N;HLB@Y2-F8;M7;,'A&$5P#V6HK@M-^9+N>:-U[TG8YJ\\5T/YBV.Z"U^=B=+AZ M;/=_UP>[-A[A<([T`Q$4I/0]H[5J&+-4L%[)#'+4>D95P$Y.!5!DPROA,*LQ M;")(<&ZY78P6,V@$57X2PSB$,BO2F&"Q>?;C$:OB84Z'5E;,3(.4\FR8WBP` M?I/03"_``"W3"R<@WNZ@N@:`?6\(UCNKHT MHVN[>J+URZ!RY9RS'U:BB_PKOY(\#JM1#J,L\:D3W#BQ/U,G#LEM!4G-K1S*;UR MU=.I!M#)G59.CO2!G%AK- MPR-8%5[%EO%5E#QNYI["BN/$#IF5C%SGF_Q'!<=!I=&&<&0[7S=#/YQM5_KD M#NP=`L``00E#@``!#D!``#M7=US MV[@1?^],_P?4#VTZ$UE6'*<73W(=^2.I9YS((]NYZ[W<0"0DH4>!.@"TK?[U MQ8(@"0H41$KR19[R)9$)[&(7OP6P6'Q]^.?3+$(/A`L:LX\'O<.C`T18$(>4 M33X>W-]V^K?G5U<'__SQSW_Z\)=.!PV'Z")FC$016:"?`Q(1CB5!=_@I9O%L M@6Z#*9GAUVB$!0E1S-#/9\-K].:PA]!4ROEIM_OX^'C(>9@Q.0SB61=U.ED! MWU)13M&[PS=O#M]:*<,X8>$ILC^=G/4.^D<_=`Y>G?7.SD] M^>'T;>\7.W<\7W`ZF4KT*OB[RGQTTE$4QVAX.#RTM/HKNHV94+EG<\P6J!]% M:`A4`@V)(/R!A(>&J=#*(E6#3'P\L/1[/#Z,^:2KBNAU?_YRG5;*P9__A-*\ MIT\C'M$2!7S):(Z[E`F)64`LDHBRWSP4D`QU;A?BD!BQ>N_?O^_J5"MW(CH3 MC.=Y_C$6(YW;)'33RNUUCGME*KF8$U%)IE.JZ6B`PY)H\$&;`F0_>G=\9&5F M"IID5JU\*'D7RNFJ3!V5BW`:V*3KZ1P:R!/*G,RNYY-NFFCE#I152KXH9Q/8_*D^0&,\Y7%$[I1-(OAQ/[RJEE":KK8+N;H7<9"`C)B%ETQ2 MN;A2?/E,EW:`J&IDWARY!)D,(1E31K6LO:,>ZJ",W/ZI6*&4%[*8?>@NG>+H)A9:CO,("V&L";`:*H)?:Q+XH3M6>.6,$(Q]+"0,QF3U2\01 MA1$S1&[<);E`(TJ6TN%7B]C661-S%>=]75-\9%E0,QC>60GT6WM()4UUB M@)GL!]J!5E/1&U7[`55\R),\B^+@-POQ9RK`;RO_`'^(BB"*1<*)^D.7!09A MEZ8]):L\5!2(LA);LVEH-I>8,U6!XH;PVZD:VYK9Q&IJ/^`_+`-^'0N!5*<- M@8*9@EIS:\%LV@:=>&*[+8MFVV*C!04:E_;MH,U[#PX_G&P9-@09#%LX6T(:1%=:KI3CR;J^F*UFI( M(IBKG,=""NV8G,%ZS`U>:*IFF&];AM\HCI>-XE8JHH[FA>SB6MO8O+FK68^: MPL*T@S"8<^R@^==AZ4?^[3+R%G<]<2KQ;^%O"/\G3/DW'"6DJ..&#=_/P0_N MR3*XP`QI;NB+ZO;5Q[;'W\R3A@CD'7[:W)/V,/"#^L[UI($7K/ZW#;0QDC<\ MGA,N%S<11*)8>/E[0N>0LBFRC1CZD7;"6^!Z=R+ZH`9E+$2[5M0<[L]Q'#[2 M*%+`7,%J[(2.(M+7=;DIX`U9^B%W`EP9]Q;IADC?D@G\/R3SF(,#LRF\=?CX M,76B688ERGFVX#8$=T@"4EHXX(HL8<'R7*D9U,VY>H%_X\2\T@)*ZP^E(EH[ M^`,7K[(/S[Z(E1?DMQ8GT+;Q8A9ZE?UJ-QKL;%WK#JMAO9ZQK./AMP,W0%>U MQH5>I<8XOM3I?% M&H#JH_>CZ839RDMD+:3/LU;6`-M:C/P@.V$W9]VLQ?D[+:`U,(3=E.2W%"=L MMVHQK3689UE6:6`.=?CXP78"=BN66%JL_YB0;0/P-V+LMP8GU)>5T<+_C''< M!IC7Y^8%^M@)[3DQW1;Q-6?F\MK;(+;6#T,M,([71"):7MN:*TM0:SLAO`T4J8=N?.B$@;CKT2:'#IMV6(:4OOMHF8D9BO`;F!-MK(XJJ]&G$`/, M*!4$?>E\2U`J"S+"("--.V(]B\4IQR&B,_477_0CY9.:\>RRN5))S$:34Y"U3-=4SRBD=)2N3A")+/LJ/OW%\-ON4YD M=97E6J*B0E;MA!EID187G657XN026S-V[;6E4J-,;-VW1H7@R$C>6OC.^M0+ MPF>7HR=E($,<@I>^DVZT'E>__3E!WYH]IRE;VTY:>MM3;FU'7G1OD]E,-?[! M^)[A1-4S"=40I2O9G.EG$^45)9&TC639IIZA!+]].:'B.G9D!('T7!24R8)R M89"1YG6):6MM-:TM7Y$%'RAF$#R"FR?,QV7+69/;;P5.#+E8#=;G,0Q#`-Q: M)VZ!K#LG+-9U:XTLZPG\<#I!X*7EX'8DV"6D5TP2I8B\?()U-=40@R@)27C% M[.M"TB,2>1C8A_A&_+P&\=8)%CL&D16*3*DH*Q915K[WQ!SV*&Y(:8VFKM'` M>KU]=JY67U"+R`^_>X+:V3G0=@F[1O=3(M77+TJF63+3B=EB_CT+"<^]))TD MUL'>D)O?'M:?P(9E9%TB,D6:+%FA*(%2+5UEF>REJ\Q"^`VMPA6],[Q MG$H<[<1P/(S]-N3&C#>T(25!IQ`!&1E:@VIH4#K,KF-+]@:?6D-,$U*_43AQ MWI4;C]KQYGD`-^LQGSE6#EVHF[BYP5IH`N6]*77I`X'3H0)BCBG8$%+,EY&* M$&H]4]EUH7XC,:*;+,<+]39C%J5P^I`5\C7(1D26CCH'8H=K6 M5+;U+46NY7%WC-.@GC"Z'_+WV'3KMF_>Q?? M,Y*NDH,[4RS-W^N+TDFXM#*O4GXB\*P`"?L/"M0)&9(9IG!ZZX9P&CO+9'LD MF=_JZV]"[B!;_'(:*(",!F#B)1U*NP\R-=R]!Y":J8*,+BA7!J7:M&UC2T]S M,N%DHF"Z8JKVF:"!'B5K^IHKB/T6YD2M?=YF5@+*BS![I%O<:^+NN?6IUC2C M,;T??2?([;TWJIUP;(U_[J#;IPK,#HO2SHJ?IC28]GF6+^S+G'3`^D,";YHH M8/0NU64C>9Y"O)9TXD3'5YV@Z&1;,\"\+%G0(PB#8(]<)@["TF8#VV]1+I39 MH-M:WE:65Z?/:4#IMQ$GA.ZQD;:?V3W:]JXN6+RZACNH\GXA.^22M;Y[H4/A M#R0ZOF+S1-;K9K8MPV]!3M!]M04M[0?3EVYI8>S^)S_8DWIP1HCWF@.,J?!OS\4/O!&TMZ*$H9,J"`3I/RHI#HP4J"LR/9K:V43?$M'1( MMMXR9BTB/^INT-(Y5=NV_%VCF^]KSA,>"%.^[V<.)]]X/*;2I.3[35)G:<#A MH!KLCR9!S`(U&S<'1'S9[^+/_?X-_%IG0-]-+K^-NF'/"ANUMF@7R:GXKY%6 M`*4:O,[3B\T\QA6->7H04._]+FEBLUU))F,$&J5__!\U#O@'WF`>DC'2SRN? MP@O#'P\$G$H.NCNK^9E&&LHK@@J%+_( MV;P0O2,\(E%-E57>"I6O@<,+T7:YF==06I%4*%VZ**%"]P]=^ZUF]5?Y+>S:NC\MGX6K5B4WY-":%:WD.U]-YM M(\EF4FPF0N6C]G6M(B.`0D\:&T(.Y_9V`%^:FD'IF7A]#PI?V*_8>\6IHLO^ MZ!1,-A`DX9RP0'-\VT@2FS#_JU.P:2Y+2&AC,3(:^+%5X>0IF-:V#H=(_]K* M(JC>3-+8("PR\WLK?/2 M,R+]:T7Y)$KWTH$`'P_Z,Y@W_==,TN!$E+Z&,9T?@OOPZ\HL#`M#36Y?ZJ?B>S_(#3L)=F7Y-G2YHE,CL*I9&M9%3OHCZ.,?ATQ?%+<#1[4*H M;/#\F6/SWES[9.KV.2VS5GF&^42)E-TUDS99U94G3)8T;$:X-;CII%4^8R^_ M?$F&@^JJ#/L$J)%QE>S[*;(D@:RN\*64O1([#A+X$][%4X.V7%@K.!6C?[WL M>S3,7\[F4;P@Z3[KP2,C7$SI_(9P..&$)\32;7U6`YQ";9Y^W:SM[T(M$?#X M\8+,8S4FV0<&#:A0)/@1I5!^/\TJ][%E*A/4<2GF,Q_13% MCV+P0/@YYGRA3,C:/I\JN2F'%]")?\*PM"07_0DG^KO3J:S,L4^=RV>B&A&. M^N&,,@HEPYE"99:PH0LVR:1[[,L[LFSJ\"7ZR6H M^:\XBB?4=2^7ON^3X5[-YJJVT]./UJ7T2YM@+5WJ$KP$O(JK][,M_=:K2A4^ M0^04;'*CD+X[?NGURDS]K9F5;%]FW[_?Z+RDTS!>X$@NBHC7:O4KLKX$ MF]?6N&Q?#A/HCB#*=U,N_3&&LNP>DK67!DN@US%8ZEE3?72^A9 MC`).ORA<):OR/%NCVV$T\6L"UC48FZN6F!8IOV7:TG-=1EM9JL:5">'?K_%E MPOZ;8'Z;C/Y#`GD77S[AF;EDN$*OU5GW:_)=Q#0&X^*4:.ZXPLQ:&0>;K)IZ M;TB_/^$36P'KF@=XU4'\BT2J_TQ#*"MT]I-LI^9N@59\^5UL+5XXP\;J+/LT M6*2AZJI%"B=EK\1N_'Z]I5ASVGWS7X8D3`(2WN&GH>KQ!1$BW38>$/!32KKZ M,[Z(1;6:'4F=SL/,'W3Z]X2O+*FRP`?51RB_I'IN5#/_/DV1')?K:\S.]6XQ MVPGUYGH)'EIQQ==G$D\XGD]A4==:N[FFC(#0ME?:A&B/@CMKQ=;!ER9Z&H(_ M6,=0GDX7X$$D(UW+Z[1-+PCU`^GDV4O<4BE7PU1*WW-4BJ>+2_<[P4E)4;[< M:66`<1?,]LTSJ#[X51Q"2Q7W9'H1'H'&:^3@Q3EF$YWO;%%D,5$-C::YQVV0 M2!@:8"JU=/5<]O"#2S7]7 M0B3I"96\'AO0O`A+7>^BOVS?_&ZJC'2^<&:/2]_W:>[X+0G@T<&'\J.#M_%8 MJO9('$WJ9=\G!7\A5+AA[-+7[RCNAVZZN5[]_!]02P$"'@,4````"`#2=09' M":Y7_!_G```>WPD`$0`8```````!````I($`````:6-A9"TR,#$U,#8S,"YX M;6Q55`4``XNKPU5U>`L``00E#@``!#D!``!02P$"'@,4````"`#2=09'Z&/- M.)L6``#J/P$`%0`8```````!````I(%JYP``:6-A9"TR,#$U,#8S,%]C86PN M>&UL550%``.+J\-5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`TG4&1UEQ M43X-(@``5$L"`!4`&````````0```*2!5/X``&EC860M,C`Q-3`V,S!?9&5F M+GAM;%54!0`#BZO#575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`-)U!D=> M4J613&(``'][!0`5`!@```````$```"D@;`@`0!I8V%D+3(P,34P-C,P7VQA M8BYX;6Q55`4``XNKPU5U>`L``00E#@``!#D!``!02P$"'@,4````"`#2=09' M#U3$O/XX``!34@0`%0`8```````!````I(%+@P$`:6-A9"TR,#$U,#8S,%]P M&UL550%``.+J\-5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`TG4& M1P,F480/$@``#;8``!$`&````````0```*2!F+P!`&EC860M,C`Q-3`V,S`N M>'-D550%``.+J\-5=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``/+. $`0`````` ` end XML 85 R38.htm IDEA: XBRL DOCUMENT v3.2.0.727
Long Term Debt - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2015
Mar. 31, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Debt Instrument [Line Items]          
Payment of accrued and unpaid interest       $ 471,000 $ 1,068,000
Repayment of debt       11,250,000 4,100,000
Loss on extinguishment of debt   $ (1,700,000) $ (903,000) $ (1,723,000) $ (903,000)
Facility Agreement [Member]          
Debt Instrument [Line Items]          
Debt instrument, maturity date Dec. 29, 2016        
Payment of accrued and unpaid interest $ 162,000        
Repayment of debt $ 11,250,000        
Interest on facility agreement 5.75% 5.75%      

XML 86 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727
Basis of Presentation and Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]  
Revenue Recognition

Revenue Recognition

The Company recognizes revenue primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement.

The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Update No. 2009-13, “Multiple-Deliverable Revenue Arrangements” (“ASU 2009-13”) and ASC Update No. 2009-14, “Certain Arrangements That Contain Software Elements” (“ASU 2009-14”) and ASC 985-605, “Software” (“ASC 985-605”). Revenue for the sale of certain CAD products is recognized in accordance with ASC 840 “Leases” (“ASC 840”). For multiple element arrangements, revenue is allocated to all deliverables based on their relative selling prices. In such circumstances, a hierarchy is used to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value (“VSOE”), (ii) third-party evidence of selling price (“TPE”), and (iii) best estimate of the selling price (“BESP”). VSOE generally exists only when the deliverable is sold separately and is the price actually charged for that deliverable. The process for determining BESP for deliverables without VSOE or TPE considers multiple factors including relative selling prices; competitive prices in the marketplace, and management judgment; however, these may vary depending upon the unique facts and circumstances related to each deliverable.

The Company uses customer purchase orders that are subject to the Company’s terms and conditions or, in the case of an Original Equipment Manufacturer (“OEM”) are governed by distribution agreements. In accordance with the Company’s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references.

If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer’s post-delivery acceptance provisions, if any, and the installation process.

The Company has determined that iCAD’s digital, and film based sales generally follow the guidance of FASB ASC Topic 605 “Revenue Recognition” (“ASC 605”) as the software has been considered essential to the functionality of the product per the guidance of ASU 2009-14. Typically, the responsibility for the installation process lies with the OEM partner. On occasion, when iCAD is responsible for product installation, the installation element is considered a separate unit of accounting because the delivered product has stand-alone value to the customer. In these instances, the Company allocates revenue to the deliverables based on the framework established within ASU 2009-13. Therefore, the installation and training revenue is recognized as the services are performed according to the BESP of the element. Revenue from the digital and film based equipment, when there is installation, is recognized based on the relative selling price allocation of the BESP, when delivered.

Revenue from certain CAD products is recognized in accordance with ASC 985-605. Sales of this product include training, and the Company has established VSOE for this element. Product revenue is determined based on the residual value in the arrangement, and is recognized when delivered. Revenue for training is deferred and recognized when the training has been completed.

The Company recognizes post contract customer support revenue together with the initial licensing fee for certain MRI products in accordance with ASC 985-605-25-71.

Sales of the Company’s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13. Product revenue is generally recognized when the product has been delivered and service and source revenue is typically recognized over the life of the service and source agreement. The Company includes the following in service and supplies revenue: the sale of physics and management services, the lease of electronic brachytherapy equipment, development fees, supplies and the right to use the Company’s AxxentHub software. Physics and management services revenue and development fees are considered to be delivered as the services are performed or over the estimated life of the agreement. The Company typically bills items monthly over the life of the agreement except for development fees, which are generally billed in advance or over a 12 month period and the fee for treatment supplies which is generally billed in advance.

The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20, “Services”. The Company provides for estimated warranty costs on original product warranties at the time of sale.

Cost of Revenue

Cost of Revenue

Cost of revenue consists of the costs of products purchased for resale, costs relating to service including personnel costs for physicists, management services and radiation therapists, costs of service contracts to maintain equipment after the warranty period, product installation, training, customer support, certain warranty repair costs, inbound freight and duty, cost of supplies, manufacturing, warehousing, material movement, inspection, scrap, rework, amortization, depreciation and in-house product warranty repairs.

In September 2014, the Company reclassified depreciation previously included in product and service cost of revenue to amortization and depreciation as a separate component of cost of revenue. For the three and six months ended June 30, 2014, approximately $343,000 and $674,000, respectively was reclassified to conform to current period classification. Medical Device Excise tax included in the cost of revenue is approximately $132,000 and $331,000, for the three and six months ended June 30, 2015, respectively and $200,000 and $379,000 for the three and six months ended June 30, 2014, respectively.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers” (ASU 2014-09), which amends ASC 605 “Revenue Recognition” and creates a new Topic 606 “Revenue from Contracts with Customers.” This update provides guidance on how an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Upon initial application, the provisions of this update are required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this update recognized at the date of initial application. This update also expands the disclosure requirements surrounding revenue recorded from contracts with customers. This update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. In April 2015 the FASB voted to defer effective date of this standard with respect to years, beginning after December 15, 2017. We are currently evaluating the effect of this update on our financial statements and have not yet determined the method of initial application we will use.

Long-lived Assets
Long-lived assets

In accordance with FASB ASC Topic 360, “Property, Plant and Equipment”, (“ASC 360”), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group.

ASC 360-10-35 uses “events and circumstances” criteria to determine when, if at all, an asset (or asset group) is evaluated for recoverability. Thus, there is no set interval or frequency for recoverability evaluation. In accordance with ASC 360-10-35-21 the following factors are examples of events or changes in circumstances that indicate the carrying amount of an asset (asset group) may not be recoverable and thus is to be evaluated for recoverability.

 

    A significant decrease in the market price of a long-lived asset (asset group);

 

    A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition;

 

    A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator;

 

    An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group);

 

    A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group).

As a result of external factors and general uncertainty related to reimbursement for the treatment of non-melanoma skin cancer, the Company evaluated the long-lived assets of the Therapy segment and reviewed them for potential impairment. The Company determined the “Asset Group” to be the assets of the Therapy segment, which the Company considered to be the lowest level for which the identifiable cash flows were largely independent of the cash flows of other assets and liabilities.

In accordance with ASC 360-10-35-17, if the carrying amount of an asset or asset group (in use or under development) is evaluated and found not to be fully recoverable (the carrying amount exceeds the estimated gross, undiscounted cash flows from use and disposition), then an impairment loss must be recognized. The impairment loss is measured as the excess of the carrying amount over the assets (or asset group’s) fair value.

In connection with the preparation of the financial statements for the second quarter ended June 30, 2015, the Company completed its analysis pursuant to ASC 360-10-35-17 and determined that the carrying value of the Asset Group was approximately $36.8 million, which exceeded the undiscounted cash flows by approximately $2.8 million. Accordingly the Company completed the Step 2 analysis to determine the fair value of the asset group. The Company recorded long-lived asset impairment charges of approximately $13.4 million in the second quarter ended June 30, 2015 and as a result the long lived assets in the asset group are recorded at their current fair values.

 

A considerable amount of judgment and assumptions are required in performing the impairment tests, principally in determining the fair value of the asset group and the reporting unit. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair values and, therefore additional impairment charges could be required. Significant negative industry or economic trends, disruptions to the Company’s business, loss of significant customers, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of the assets may adversely impact the assumptions used in the fair value estimates and ultimately result in future impairment charges.

Leases

Under the guidance of ASC Topic 840, “Leases” (“ASC 840”) the Company determined that the lease was a capital lease as it contained a bargain purchase option whereby the Company has the option to buy the equipment for $1 at the end of the lease term. Accordingly, the equipment has been capitalized and a liability has been recorded.

Compensation - Stock Compensation

The Company follows the guidance in ASC Topic 718, “Compensation – Stock Compensation, (“ASC 718”).

Litigation

Litigation

The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

Fair Value Measurement and Disclosures
Fair Value Measurements

The Company follows the provisions of ASC Topic 820, “Fair Value Measurement and Disclosures”, (“ASC 820”). This topic defines fair value, establishes a framework for measuring fair value under US GAAP and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

 

    Level 1 - Quoted prices in active markets for identical assets or liabilities.

 

    Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

    Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value.

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and certain accrued liabilities and our notes payable. The carrying amounts of our cash and cash equivalents (which are composed primarily of deposit and overnight sweep accounts), accounts receivable, accounts payable and certain accrued liabilities approximate fair value due to the short maturity of these instruments. The carrying value of our notes payable approximates fair value due to the market rate of the stated interest rate.

The Company’s assets that are measured at fair value on a recurring basis relate to the Company’s money market accounts.

The Company’s money market funds are included in cash and cash equivalents in the accompanying balance sheets, and are considered a Level 1 investment as they are valued at quoted market prices in active markets.

Income Taxes

The Company recorded an income tax benefit of $107,000 and $28,000, in the three and six months ended June 30, 2015 as compared to a provision of $25,000 and $78,000 in the three and six months ended June 30, 2014, respectively. The income tax net benefit as of June 30, 2015 primarily relates a state tax provision and a benefit from the reversal of a deferred tax liability relating to tax amortizable goodwill. Due to the Company’s goodwill impairment the tax basis in amortizable goodwill is greater than book basis which results in a deferred tax asset that is subject to a valuation allowance. At June 30, 2015, the Company had no material unrecognized tax benefits and no adjustments to liabilities or tax expense were required under ASC 740, “Income Taxes”. The Company does not expect that the unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any interest or penalties related to uncertain tax positions at June 30, 2015. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company’s three preceding tax years remain subject to examination by federal and state taxing authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not under examination by any federal or state jurisdiction for any tax years.

Intangibles - Goodwill and Other

In accordance with FASB ASC Topic 350-20, “Intangibles - Goodwill and Other”, (“ASC 350-20”), the Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the Company is less than the carrying value of the Company.

Segments
In accordance with FASB Topic ASC 280, “Segments”, operating segments, are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker CODM in deciding how to allocate resources and assess performance.